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Ab s t r a c t
Myxoma virus, a poxvirus of the genus Leporipoxvirus, is the causative agent of the disease 
myxomatosis, which is highly lethal in European rabbits. Current vaccines to protect 
domestic rabbits against myxomatosis are not permitted in Australia due to fears the 
vaccine virus could be transmitted to wild rabbit populations.
This thesis has used the myxoma virus/rabbit model to determine the efficacy of novel 
vaccination strategies against a naturally transmitted, lethal poxvirus disease in the species 
at risk. Candidate vaccines were evaluated for their acceptability in domestic rabbits, their 
efficacy against lethal myxoma virus challenge and their non-transmissibility between 
rabbits.
In the first part of this thesis, the protective efficacy of DNA vaccines expressing the 
myxoma virus antigens M055R, M073R, M115L and M121R, and co-expressing rabbit 
interleukin-2 or interleukin-4 was examined. None of the vaccine constructs were able to 
protect rabbits from lethal myxoma virus challenge.
Live, attenuated myxoma virus vaccines were constructed by the targeted deletion of one, 
two or three viral immunomodulatory genes from the genome of the attenuated myxoma 
virus strain Uriarra. Vaccination with TKO, a virus with deletions in the genes coding for 
myxoma growth factor (M010L), the anti-apoptotic factor M011L and the interferon-y- 
binding protein M-T7 conferred complete protection from myxoma virus challenge, and 
caused only a small lesion limited to the inoculation site in mature domestic rabbits. This 
virus was selected for further evaluation.
i i i
The pathogenesis o f TKO was investigated to determine the degree o f tissue damage that 
occurred in domestic rabbits during vaccination and the potential transmissibility o f the 
vaccine virus. TKO caused only transient pathology at the inoculation site and normal skin 
pathology was restored by 20 dpi following an extensive infiltration o f mononuclear cells 
that coincided with the rapid control and clearance o f the virus from the skin. TKO reached 
transmissible titres (>107 pfu/g) in the skin o f some domestic and wild rabbits. Also, 8 and 
12 week old rabbits vaccinated with TKO developed small secondary lesions following 
inoculation. Therefore, TKO was not considered acceptable for use as a myxomatosis 
vaccine in Australia.
In the last section o f the thesis, a replication-deficient myxoma virus vaccine was 
constructed by the deletion o f the host range protein M063R (Uriarra AM063Rg/?/gws). 
Vaccination with Uriarra AM063Rg/?/gzzs resulted in a small lesion at the inoculation site 
only, and conferred complete protection from lethal myxoma virus challenge, although 
some rabbits still developed mild to moderate symptoms o f myxomatosis upon challenge. 
A boost with the same virus conferred protection from disease comparable to replication- 
competent vaccines.
Uriarra AM063Rgp/gws was found to have the best combination o f acceptability, non- 
transmissibility and efficacy o f the tested myxomatosis vaccines, and is a candidate for 
further development for use in protecting Australian domestic rabbits from myxomatosis. 
These results also show that homologous replication-deficient poxvirus vaccines offer a 
safe and effective alternative vaccination method to protect animals and humans from 
poxvirus diseases.
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Chapter 1 
Introduction
Chapter 1 -  Introduction
Ch ap te r  1 -  Int ro du cti on
Poxviruses are the cause of many economically important diseases of domestic animals, as 
well as one of the most damaging human diseases in history, smallpox. Although smallpox 
has been eradicated, its potential use as a bioweapon has renewed interest in the 
development of safer and more effective smallpox and poxvirus vaccines. Currently, all 
commercially available poxvirus vaccines are based on live, attenuated strains of virus. 
These are plagued with problems including a high incidence of side effects such as vaccine- 
induced disease, transmissibility and poor efficacy.
This project has utilised the infection of European rabbits (Oryctolagus cuniculus) with 
myxoma virus as a model to investigate the safety and efficacy of several poxvirus 
vaccination strategies. This model has many advantages over other poxvirus disease 
models as it employs a laboratory animal infected with a virulent, highly lethal and 
naturally transmitted poxvirus. The vaccination strategies investigated include DMA 
vaccines expressing single and multiple antigens, live attenuated poxvirus vaccines 
constructed by the deletion of key viral immunomodulatory genes, and replication- 
defective vaccines. As well as exploring the broader concept of poxvirus vaccination, this 
project has developed candidate myxomatosis vaccines to protect Australian domestic 
rabbits from myxomatosis.
1.1 The  Po x v i r i d a e
The Poxviridae are a large family of highly complex, double-stranded DNA viruses which 
replicate entirely in the cytoplasm of insect (Entomopoxvirinae) or vertebrate 
(Chordopoxvirinae) cells and include a number of important human and animal pathogens
Page 1
Chapter 1 -  Introduction
(Moss, 2002; Table l.l). The most notable poxvirus is variola virus, causative agent of 
smallpox. This virus has now been eradicated from the human population after a concerted 
vaccination campaign (Fenner, 1977; Fenner et al., 1988). However, recent fears of its re- 
emergence as a bioweapon (Tegnell et al., 2002; Whitby et al., 2002) and the emergence of 
the related Orthopoxvirus monkeypox virus in American rodent populations (CDC, 2003) 
has brought to the fore the study of poxvirus biology and the safety and efficacy of the 
current suite of poxvirus vaccines (CDC, 2001; Engler et al., 2002; Fenner, 1989; Roos and 
Eckerman, 2002; Smith and McFadden, 2002).
1.1.1 Poxvirus structure
Poxviruses are the largest and most complex of the animal viruses, and exist in several 
infective forms. Poxvirus particles are large (350 x 270 nm for vaccinia virus; Moss, 
2002), brick-shaped particles, with a nucleocapsid core surrounded by one or two 
membranes. The closed, linear, double stranded genome (between 144 to 288 kb amongst 
different poxvirus species; Gubser et al., 2004) consists of a conserved central region and 
identical inverted terminal repeats (ITRs) that contain genes with host range and 
immunomodulatory functions (Figure 1.1 A; Moss, 2002). The genome is contained within 
the nucleocapsid together with viral proteins required for early transcription of viral genes, 
including RNA polymerase, transcription factors, capping enzyme and poly(A) polymerase 
(Figure 1.1B). This viral core is wrapped in a lipid-protein membrane to form the 
intracellular mature virion (IMV) particle, the most abundant form of poxvirus particle. 
Recent reports suggest that the IMV particle may possess two or more membranes 
(Griffiths et al., 2001; Risco et al., 2002). Extracellular enveloped virions (EEV; Figure 
1.1C) have an extra, Golgi-derived, membrane and are released from an infected cell into 
the surrounding media, or can remain attached to the cell as cell-associated enveloped
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Table 1.1 -  Classification of some important members of the Chordopoxvirinae and poxvirus- 
ir.duced diseases.
G enus S p ec ies H o st D isease
O rthopoxvirus Variola virus Humans Smallpox
Vaccinia virus Humans, mice, rabbits Cutaneous lesion
Ectromelia virus Mice Mousepox
Monkeypox virus Monkeys, humans Monkeypox
Camelpox virus Camels Camelpox
Cowpox virus Rodents, cats, cows, Cutaneous lesion
humans
Parapoxvirus Orf virus Sheep, goats Contagious pustular
dermatitis
Human Milker’s nodule
Pseudocowpoxvirus Cattle Udderpox
Human Milker’s nodule
Bovine papular stomatisis Cattle Bovine papular
virus stomatisis
Humans Milker’s nodule
Capripoxvirus Goatpox virus Goats Goatpox
Sheeppox virus Sheep Sheeppox
Lumpy skin disease virus Cattle Lumpy skin disease
Suipoxvirus Swinepox virus Pigs Swinepox
A vipoxvirus Fowlpox virus Chicken Fowlpox
Turkeypox virus T urkey Turkeypox
Canarypox virus Canary Canarypox
Mioil uscipoxvirus Molluseum contagiosum Humans Molluseum
virus contagiosum
Yatapoxvirus Tanapox virus ?Rodents, Humans Cutaneous lesion
Yaba monkey tumor virus ?Monkeys, Humans Cutaneous lesion
Leporipoxvirus Myxoma virus Tapeti Cutaneous fibroma
Brush rabbit Cutaneous fibroma
European Rabbit Myxomatosis
Rabbit fibroma virus Eastern cottontail Cutaneous fibroma
European Rabbit Cutaneous fibroma
Figure 1.1 - Schematic of the poxvirus genome and morphology of vaccinia virus 
virions. A: The poxvirus genome is a linear, double-stranded DNA molecule, 144-224 
kb in size, with 0.6-15 kb inverted terminal repeats (red) at each end. The central 
region of the genome is conserved and encodes the structural and enzymatic genes 
required for virus replication. The inverted terminal repeats are less conserved and 
primarily encode immunomodulatory genes.
VV particles exist in two infectious forms, intracellular mature virions (IMV; B) and 
extracellular enveloped virions (EEV; C). IMV particles contain the dsDNA genome 
of the virus associated with nucleoproteins, and the viral enzymes required for early 
gene synthesis (such as RNA polymerase, poly(A) polymerase, capping enzyme and 
transcription factors) inside a protein nucleocapsid. This is then wrapped in a protein- 
lipid membrane containing 13 viral transmembrane, membrane-bound or membrane- 
associated antigens (A9L, A13L, A14L, A14.5L, A17L, A27L, A28L, D8L, D13L, 
El OR, A28L, H3L, I5L and L1R). EEV particles are IMV particles wrapped in another 
lipid membrane containing 4 glycoprotein antigens on the outer surface (A33R, B5R, 
A56R and A34R) and one on the inner surface (F13L).
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virions (CEV) and play an important role in infecting adjacent cells. The EEV and IMV 
membranes of vaccinia virus (VV) have different membrane-bound and associated proteins, 
as shown in Figure l . I.
1.1.2 Poxvirus replication cycle
Poxviruses replicate entirely within the cytoplasm of infected cells (Figure 1.2). To enter 
the cell, IMV and EEV particles may utilise different receptors, both on the surface of the 
virus particle and on the host cell (Moss, 2002). The cellular receptors for poxviruses are 
unknown, and reports suggesting that poxvirus particles bound to the epidermal growth 
factor receptor (EGFR) (Eppstein et al., 1985) or to chemokine receptors (Lalani et al., 
1999b) have not been supported by other groups (Hugin and Hauser, 1994; Masters et al., 
2001). VV IMV particles attach to and penetrate the host cell via a number of viral 
membrane proteins including L1R (Ichihashi et al., 1994; Wolffe et al., 1995), A27L 
(Rodriguez et al., 1996; Rodriguez et al., 1993; Rodriguez and Esteban, 1987), D8L (Hsiao 
et al., 1999; Lai et al., 1991a), A28L (Senkevich et al., 2004a; Senkevich et al., 2004b) and 
H3L (Lin et al., 2000). B5R and A34R may have a role in binding of EEV virions 
(Galmiche et al., 1999; McIntosh and Smith, 1996). After fusion of the IMV and plasma 
membranes, the nucleocapsid is released into the cytoplasm. EEV entry is a more complex 
process due to the extra viral membrane. It is believed that following binding, the EEV is 
endocytosed, the EEV membrane disrupted due to the low pH of the endosome and the 
resulting IMV particle fuses with the endosomal membrane to release the viral core into the 
cytoplasm (Vanderplasschen et al., 1998).
Once inside the cell, the virus core immediately begins transcription of early viral genes 
using transcription machinery carried within the nucleocapsid. The nucleocapsid is
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degraded by a viral protease (Pedley and Cooper, 1987), releasing the viral genomic DNA 
and early transcripts into the cytoplasm. Early viral genes encode the proteins required for 
viral DNA replication and the expression o f intermediate viral genes, as well as those 
responsible for immune modulation and suppression. The immunomodulatory genes o f 
myxoma virus w ill be discussed in detail in Section 1.2.4. The poxvirus genome is 
replicated entirely within the cytoplasm in discrete regions known as factory areas or 
viriosomes (Moss, 2002). The genome is replicated as concatemers and resolved into 
individual genomic units, in a process not fully understood (Moss, 2002).
Expression o f intermediate and late genes follow DNA replication (Moss, 1990). Late 
genes include the structural proteins, which go on to make progeny virus as well as those 
required for assembly o f new virus particles. Virus assembly occurs at discrete cytoplasmic 
sites visible as membrane crescents, which go on to form the IM V membrane. These 
membranes become spherical, enclosing viral nucleoprotein, DNA and all o f the required 
structural proteins and enzymes. This structure eventually matures into an infectious IM V 
particle. These can then be transported along microtubule networks to regions where they 
are wrapped in two more lipid membranes derived from the trans-Golgi or endosomal 
network (Smith et a l., 2002), to form intracellular enveloped virions (IEV). These particles 
are moved on actin tails that form on viral protein complexes on the outer surface o f IEV 
particles, which move them to the plasma membrane. Fusion o f the outer IEV membrane 
with the plasma membrane releases a mature EEV particle, which can be forced away from 
the cell on the actin tail or enter adjacent cells (Smith et al.,  2002).
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1.2 My x o m a  v i r u s  a n d  m y x o m a t o s i s
Myxoma virus is the prototype member of the Leporipoxvirus genus, which also includes 
the antigenically related rabbit (or Shope) fibroma virus (RFV), squirrel fibroma virus and 
hare fibroma virus (Esposito and Fenner, 2002; Moss, 2002). Myxoma virus infects 
members of the family Leporidae including rabbits and hares. The virus released in 
Australia and Europe originated in the South American jungle rabbit, also known as the 
tapeti (Sylvilagus brasiliensis), in which it induces a benign cutaneous lesion at the site of 
inoculation. However, in the European rabbit (Oryctolagus cuniculus), the virus causes 
myxomatosis, a systemic disease characterised by large mucoid cutaneous swellings 
(myxomas) with virus replication occurring in many tissues within the host, and which is 
highly lethal in susceptible rabbits (Kerr and McFadden, 2002). There are also strains of 
myxoma virus which are found in the Californian brush rabbit, Sylvilagus bachmani, and 
referred to as Californian myxoma virus. These strains are highly lethal in domestic 
European rabbits, more so than South American strains, but do not induce florid clinical 
myxomatosis before death except in occasional rabbits which survive for more than 12 days 
(Fenner and Ratcliffe, 1965).
1.2.1 History of myxomatosis in Australian wild rabbits
Wild European rabbits were first successfully to mainland Australia in 1859 near Geelong. 
Over the next 60 years, rabbits rapidly spread over most of the continent, causing extensive 
environmental and agricultural damage (Fenner and Ratcliffe, 1965; Myers et al., 1994). 
The use of myxomatosis as a biological control against rabbits was suggested in 1919 
(Fenner and Ratcliffe, 1965). This was followed by experimental trials in the 1930's and 
40's. However, successful spread of the virus did not occur until summer 1950 following 
experimental release at Gunbower, Victoria (Fenner and Ratcliffe, 1965). The virus rapidly
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spread throughout the Murray-Darling basin over the next few months, and to the rest o f the 
continent following a widespread inoculation campaign. The originally released virus (the 
Standard Laboratory Strain, SLS) was 99.8% lethal in infected rabbits (Fenner and 
Ratcliffe, 1965). The rabbit population dropped significantly during the original epizootics, 
reducing rabbit numbers to about 5% o f the pre-myxoma virus levels (Williams et al., 
1995). Myxoma virus was later deliberately released into France where it spread to the rest 
o f Europe and the United Kingdom (Fenner and Ratcliffe, 1965).
Since the release o f myxoma virus in Australia and Europe, the virus and rabbit have co-
evolved. Attenuated strains o f the virus have become dominant in the field, and wild rabbit 
populations have developed resistance to the virus (reviewed in detail in Fenner and 
Rattcliffe, 1965; Kerr and Best, 1998). Moderately attenuated strains o f the virus 
transmitted more effectively than the highly virulent SLS strain due to longer survival times 
o f infected animals, allowing a greater period o f time during which the virus could be 
transmitted by insect vectors. The emergence of attenuated viruses may have allowed for 
the survival and reproduction o f genetically resistant rabbits. Myxoma virus is now 
endemic in w ild rabbit populations and is still responsible for killing 50-60% o f infected 
wild rabbits in Australia (Kerr and Best, 1998).
1.2.2 Domestic rabbits and myxomatosis in Australia
Since the release o f rabbit haemorrhagic disease virus (RHDV) in Australia in 1996, wild 
rabbit numbers have dropped significantly in many parts o f the country (Kovaliski, 1998; 
Mutze et al., 2002), including areas in which wild rabbit harvesting operations for meat and 
fur was an important industry. Since this time, the raising o f rabbits as farmed animals for 
meat and fur production has been legalised by most State governments, and a shift toward
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domestic rabbit farming from wild rabbit harvesting has occurred. In 1999, the Australian 
farmed rabbit industry was estimated to be worth A$620,000 with an annual domestic 
growth rate o f 31% (Foster, 1999).
Myxomatosis has the potential to cause devastating losses to rabbit farms following 
transmission to domestic populations from wild rabbit populations where the virus is 
endemic (Frolich et al., 2002). Moreover, myxomatosis vaccines are not permitted in 
Australia due to fears that vaccine virus could be transmitted from recently vaccinated 
animals to w ild rabbit populations (Fenner and Ross, 1994). There are fears that a live 
vaccine virus could become established amongst w ild rabbits and reduce the efficacy o f 
myxoma virus as a population control (Fenner and Ross, 1994). In the absence o f a 
vaccine, the only control mechanisms for myxomatosis are to exclude insect vectors by 
maintaining insect proof facilities, and through the culling o f infected rabbits (Foster, 
1999).
1.2.3 Pathogenesis of myxoma virus in domestic European rabbits
The pathogenesis o f virulent and attenuated strains o f myxoma virus in susceptible 
(domestic) and genetically resistant (wild) rabbits has been previously studied (Best et al., 
2000; Best and Kerr, 2000). The current model for myxoma virus pathogenesis is 
displayed in Figure 1.3 and is based on the following experimental data. After inoculation 
o f the virus into the epidermis by an arthropod vector, the virus initially replicated in MHC- 
II dendritic-like cells in the dermis and in endothelial cells (Best et al., 2000). Dramatic 
histological changes were observed in the skin, both at the primary inoculation site and 
secondary skin lesions. There was proliferation o f the epithelial cells, and associated 
thickening o f the epidermis, followed by degradation o f the collagen structure in the dermis
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Figure 1.3 - Pathogenesis of myxoma virus in European rabbits. The virus is deposited 
in the skin by biting insects, and replication is first seen in MHC-II+ dendritic-like cells 
(DC) in the dermis. Within 24 hours the virus reaches the draining lymph node where 
it replicates within lymphocytes within the T cell zone. The virus disseminates in 
infected lymphocytes, monocytes and macrophages to other tissues including the 
spleen, testis, lung, distal skin and mucocutaneous sites including the nose and 
conjunctivae. At the inoculation site and distal skin sites, virus replication shifts to the 
epidermal layer, where it replicates to high titres, and can be transmitted by biting 
insects. Figure adapted from Kerr and McFadden (2002).
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and epidermis, vesicle formation and scabbing (Hurst, 1937). A limited inflammatory 
response was seen in the skin, usually taking the form of an influx of polymorphonuclear 
cells into the dermis and subdermis. Endothelial cells surrounding the blood vessels of the 
epidermis and dermis proliferated, and large stellate cells called myxoma cells were often 
associated with small blood vessels, and believed to be derived from infected endothelial 
cells (Best et al., 2000; Hurst, 1937).
Within 24 hours, virus was detected in the draining lymph node, replicating in the T cell 
zone. Infection of lymphocytes resulted in an extensive reduction in the lymphocyte 
population initially within the paracortex, and later in the follicles (Best et al., 2000). The 
virus disseminated to other lymphoid tissues (distal lymph nodes, spleen), the lungs, testes, 
secondary skin sites and mucocutaneous surfaces of the eyelids and nose. As virus was not 
detectable as free virions in the serum, it is believed that it disseminated to distal sites 
within infected leukocytes (Fenner and Woodroofe, 1953). The infection and widespread 
dysfunction of these cells are believed to play a key role in the development of systemic 
immune suppression and poor innate and adaptive immune responses to the virus and 
secondary infections. The virus can be transmitted to other animals from primary and 
secondary skin lesions by biting arthropods due to high titres of virus in the epidermis 
(Fenner and Ratcliffe, 1965; Joubert et al., 1967; Mead-Briggs and Vaughan, 1975; 
Shepherd and Edmonds, 1977). The virus does not replicate in the insect vector, but is 
passively transferred on the mouthparts of the insect (Day et al., 1956).
1.2.3.1 Clinical manifestations o f myxomatosis
The first clinical sign of infection is a lesion developing at the cutaneous inoculation site 
within 2-4 days post inoculation. This lesion begins as a small red swelling, grows up to 60
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mm in diameter and can be highly protuberant (20 mm high) depending on the strain o f 
virus (Fenner and Ratcliffe, 1965). Between 6 and 8 days, secondary signs o f myxomatosis 
can be observed as swellings on the mucocutaneous surfaces o f the conjunctivae and nose 
that develop into distinct secondary lesions. The eyelids can swell considerably, and 
secondary bacterial infections result in mucopurulent discharge that can completely block 
the eyes. Mucopurulent discharge in the nasal passages can obstruct the airways resulting 
in laboured, ‘ snuffly’ breathing. Secondary skin lesions develop over the entire body, but 
are most prominent on the face, ears and eyelids. In rabbits that survive infection, the 
clearance o f these secondary lesions can result in scarring, loss o f fur and a 'moth-eaten' 
appearance, most obvious on the thin tissue o f the ears, which is a major concern to owners 
o f show animals and pets (NSW Rabbit Fanciers Association, personal communication).
In male rabbits, the virus replicates to high titres in the testes resulting in oedematous 
swelling o f the scrotum, an acute inflammatory response in the interstitium, necrosis o f 
tubular cells and epididmytitis (Fenner and Woodroofe, 1953; Hurst, 1937). Infection with 
attenuated strains o f myxoma virus can result in long term infertility  in male rabbits 
(Fountain et al., 1997; Sobey and Turnbull, 1956), or transmission o f the virus in semen 
during artificial insemination (Marlier et a l., 2000), both major concerns for rabbit 
breeders.
The cause o f death in myxoma virus-infected rabbits is unclear. There is no obvious 
pathology in any key organ in which virus can be detected that would be expected to lead to 
death (Mims, 1964). Generalised immunosuppression caused by the virus may allow 
secondary bacterial infections to occur in the upper respiratory tract, with resultant 
respiratory difficulties. This has been considered the primary cause o f fatality through
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obstruction of the respiratory tract by mucopurulent discharge (Hobbs, 1928), however in 
acute infections, rabbits succumb to the virus with little pathology in the lungs or evidence 
of significant secondary infections (Fenner and Ratcliffe, 1965), indicating that there are 
other casues of death.
1.2.3.2 Genetic resistance o f Australian wild rabbits
The mechanisms underlying the genetic resistance of wild rabbits have not been 
characterised and are currently under investigation (Best et al., 2000; Best and Kerr, 2000; 
Kerr and McFadden, 2002; Kerr et al., 2004). In genetically resistant rabbits, the extent of 
pathology in the draining lymph node observed 4 days post inoculation was reduced 
compared to susceptible rabbits, and there was less virus detected at distal tissues (Best and 
Kerr, 2000). It appears that resistant rabbits are able to control the replication of myxoma 
virus early in infection through enhanced innate immune mechanisms, before generalised 
virus-induced immunosuppression sets in. This allows them to develop a virus-specific 
cell-mediated response sufficient to control and clear the virus (Best et al., 2000; Best and 
Kerr, 2000).
1.2.4 Immunomodulatory proteins of myxoma virus
Of the 156 predicted open reading frames in myxoma virus, 31 have demonstrated or 
predicted immunoregulatory or host range functions (Barrett et al., 2001; Cameron et al., 
1999). Many of these have been intensively studied both in vivo and in vitro as a model 
system for poxvirus immunomodulatory strategies and have been reviewed in detail (Nash 
et al., 1999; Zuniga, 2002).
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Poxvirus immunomodulatory proteins have distinct functions and benefits for the virus 
(Table 1.2). These can be classed into three broad groups including viroceptors, which are 
secreted from infected cells and mimic host cellular receptors, binding to and neutralising 
specific immune modulators (M -T l, M-T2, M-T7); virokines, which are secreted from 
infected cells and mimic the structure o f host cytokines, immune system inhibitors or 
growth factors (MGF); and viromitigators, intracellular proteins which play a role in virus 
host range (both species host range and cell types within the host) and regulation o f 
apoptosis (M-T4, M-T5, MO11L, M029R, M063R, M 151R, M 153R and M 152R).
During the course o f this project, four live, attenuated myxoma virus vaccine candidates 
were constructed by inactivating key viral immunomodulatory and host range genes. The 
functions o f myxoma virus immunomodulatory proteins that are o f importance to this 
project (M-T7, M010L, M011L and M063R) are described in detail below.
1.2.4.1 The interferon-y binding protein -  M-T7
A ll Chordopoxviruses encode an interferon-y (IFN-y) binding protein (Smith et al., 1998). 
Inhibition o f IFN-y action is advantageous to poxviruses due to the central role o f the 
cytokine in innate and cell-mediated adaptive immune responses (Boehm et al., 1997). 
IFN-y is a pleiotropic cytokine secreted by activated T cells and NK cells. It is active as a 
34 kDa homodimer, and binds to a specific IFN-y receptor ubiquitously expressed on all 
nucleated cells, leading to the phosphorylation o f S TA T la  transcriptionally active subunits 
and the transcription o f specific interferon response genes (Boehm et al., 1997). IFN-y has 
many effects on host cells including the upregulation o f MHC-I and MHC-II expression, 
the promotion o f Thl differentiation and inhibition o f Th2 differentiation o f CD4 T helper 
cells, the activation o f macrophages and the induction o f inducible nitric oxide synthetase
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Table 1.2 -  Selected immunomodulatory proteins of myxoma virus.
O pen
R ead in g
F ram e
S ize
(aa)
Fun ction V iru len ce  o f  
kn o ckou t 
virus
R eferen ces
M001R/L 260 Secreted chemokine 
binding protein (MT1)
virulent Graham et al. (1997) 
Lalani et al. (1998) 
Lalani et al. (1999a) 
Seet et al. (2001)
M002R/L 326 Soluble TNF receptor 
homologue/apoptosis 
regulator (MT2). 
Intracellular and 
secreted
attenuated Schreiber et al. (1996)
Schreiber and McFadden (1996) 
Schreiber et al. (1997)
M004R/L 237 ER localised apoptosis 
regulator (MT4)
attenuated Barry et al. (1997) 
Hnatiuk et al. (1999)
M005R/L 483 Cytoplasmic apoptosis 
regulator
attenuated Mossman et al. (1996a)
M007R/L 263 Secreted y-interferon 
receptor homologue 
(MT7); chemokine 
binding protein
attenuated Lalani et al. (1997) 
Mossman et al. (1995b) 
Upton et al. (1992) 
Mossman et al. (1996b)
M008.1R/L 369 Secreted anti-
inflammatory serpin 
(Serp 1)
attenuated Macen et al. (1993) 
Upton et al. (1990) 
Nash et al. (1998) 
Hatton et al. (2000)
M010L 85 EGF-like growth factor 
(MGF)
attenuated Opgenorth et al. (1992) 
Lin et al. (1991) 
Opgenorth et al. (1993)
M011L 166 Anti-apoptotic integral 
mitochondrial 
membrane protein
attenuated Everett et al. (2000) 
Macen et al. (1996) 
Opgenorth et al. (1992)
M151R 326 Cytoplasmic serpin 
(Serp 2)
attenuated Messud-Petit et al. (1998) 
Turner et al. (1999)
M152R 266 Cytoplasmic serpin 
(Serp 3)
attenuated Guerin et al. (2001)
M153R 206 Myxoma virus 
leukemia-associated 
protein, MFIC-I down- 
regulation
attenuated Guerin et al. (2002)
Table 1.2 continued
M 029L 115 PKR inhibition, 
interferon
resistance/host range. 
Cytoplasmic
N/D* Uncharacterised in myxoma virus
M 062R 158 Virulence factor/host 
range
N/D* Uncharacterised in myxoma virus
M 063R 215 FAS binding death 
associated protein 
domain/apoptosis 
regulator/interferon 
resistance
Attenuated Grant McFadden, personal 
communication
M 064R 203 Virulence factor/host 
range. Cytoplasmic
N/D* Uncharacterised in myxoma virus
M 156R 102 Structural mimic of 
eIF2a; cytoplasmic; 
inhibition of PKR; 
interferon resistance
N/D* Ramelot et al. (2002)
* - Not done
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(iNOS) (Boehm et a/., 1997; Goodbum et al., 2000; Revel and Chebath, 1986). IFN-y also 
establishes an ‘antiviral’ state within cells through the transcriptional induction of dsRNA- 
activated protein kinase (PK.R) (Hovanessian, 1993), 2’-5’ oligoadenylate synthetase (2-5A 
synthetase) (Graham et al., 1993) and dsRNA-specific adenosine deaminase (dsRAD) 
(Patterson et a l ,  1995). These proteins recognise and are activated by dsRNA molecules 
produced during viral infection, and lead to the inhibition of protein synthesis and non-
specific degradation of mRNA, inhibiting viral replication (Boehm et al., 1997; Goodbum 
et al., 2000). Mice with deleted IFN-y or IFN-y receptor genes show increased 
susceptibility to many pathogens including the poxviruses VV and ectromelia virus (Huang 
et al., 1993; Karupiah et al., 1993; Muller et al., 1994).
The first viral IFN-y receptor homologue was discovered in myxoma virus as a secreted 
protein with a high degree of homology to the extracellular domains of the cellular IFN-y 
receptor (Upton et al., 1992). This protein (M-T7) is encoded by the gene M007, which is 
present as two copies, one in each of the inverted terminal repeats of the myxoma virus 
genome. M-T7 is a 37 kDa glycoprotein and is the major protein secreted from cells 
infected with myxoma virus (Upton et al., 1992). It specifically binds rabbit IFN-y and 
prevents its binding to cellular IFN-y receptors (Mossman et al., 1995b).
M-T7 is a key virulence factor of myxoma virus (Mossman et al., 1996b). Disruption of 
both M007 reading frames resulted in a highly attenuated virus with mortality in domestic 
rabbits reduced to 8% compared to 100% for wild type virus (Mossman et al., 1996b). The 
infection was characterised by reduced symptoms of disease including fewer and less 
severe secondary lesions. Lesions were characterised by a massive increase in cellular 
infiltrate into the sites of infection, including active lymphocytes and macrophages
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(Mossman et a/., 1996b). The effects of M-T7 deletion were systemic, in that secondary 
lymphoid organs such lymph nodes and spleens contained much greater levels of reactive 
lymphocytes and a generally more vigorous cellular immune response compared to wild 
type myxoma virus-infected rabbits (Mossman et al., 1996b).
M-T7 also binds to a range of host C, CC and CXC chemokines through their heparin-
binding domains (Lalani et al., 1997). Chemokines are a large family of small proteins 
which form the communication system of the immune system (Laing and Secombes, 2004; 
Rot and von Andrian, 2004). They are released at sites of infection or by specific immune 
cells and establish chemoattractant gradients used by leukocytes to migrate to the 
appropriate regions. The release of M-T7 by virus-infected cells has a dramatic effect on 
leukocyte migration in myxoma virus-infected tissues, preventing the influx of 
lymphocytes to the site of infection (Lalani et al., 1997; Mossman et al., 1996b). Myxoma 
virus also encodes M-Tl, which binds to CC chemokines (Lalani et al., 1999a; Seet et al., 
2001), and two uncharacterised proteins (M144R, M118L) with postulated chemokine- 
modulating properties (Barrett et al., 2001; Cao and McFadden, 2001). The overall result 
of M-T7 secretion from infected cells is an abrogation of innate antiviral responses induced 
by IFN-y, and the disruption of chemokine gradients, inhibiting the directional infiltration 
of leukocytes (Lalani et al., 1997; Mossman et al., 1996b).
1.2.4.2 Myxoma growth factor -  M010L
The myxoma growth factor (MGF) is an 85 amino acid (aa) polypeptide encoded by the 
gene M010L (Lin et al., 1991). This highly glycosylated protein is secreted early during 
infection and plays a role in the proliferation of cells at primary and secondary sites of 
infection including the skin, conjunctiva and respiratory tract (Opgenorth et al., 1992). It
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has been postulated that the mitogenic action o f EGF homologues encoded by poxviruses 
stimulate higher levels o f biosynthetic activity in infected and adjacent cells, providing a 
local environment allowing for enhanced replication o f the virus (McFadden et al., 1995).
Deletion o f MGF from virulent strains o f myxoma virus results in attenuation o f the 
infection (Opgenorth et a l., 1992). Secondary lesions on the body and conjunctiva were 
observed, but the disease was milder than in rabbits infected with wild type myxoma virus, 
and resulted in only 25% mortality in domestic rabbits. Epithelial cell layers over the 
primary lesion and secondary lesions o f the conjunctiva and lungs contained fewer 
proliferating cells. Attenuation was suggested to be due to less proliferation-induced 
damage to epithelial cell layers at sites o f infection, especially in the lungs, resulting in a 
reduced level o f bacterial infections (Opgenorth et al., 1992).
1.2.4.3 M011L
M011L encodes a 166 aa protein that plays an important role in myxoma virus 
pathogenesis. The protein is synthesised early in infection and possesses a C-terminal 
hydrophobic helix and an N-terminal signal sequence which localises the protein to the 
outer mitochondrial membrane (Everett et al., 2000; Graham et al., 1992). Domestic 
rabbits infected with a strain o f myxoma virus with an inactivated M011L open reading 
frame (AM011L) survived infection with only mild signs o f myxomatosis (Opgenorth et 
al., 1992). Lesions were characterised by a more intense inflammatory response with an 
increased polymorphonuclear cell infiltrate (Opgenorth et al., 1992). There was also less 
lymphocyte depletion in the spleen (Opgenorth et al., 1992).
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In vitro, AMOl lL viruses exhibited normal growth characteristics in rabbit fibroblast cell 
lines. However, in the rabbit CD4 T lymphocyte cell line RL-5, apoptosis was induced 
resulting in a non-productive infection of these cells (Macen et al., 1996). MOllL 
expression was also required to inhibit apoptotic responses in infected monocytes and 
macrophages (Everett et al., 2000), and its anti-inflammatory properties were mediated by 
the prevention of inflammatory responses induced by apoptotic monocytes (Savill, 1997). 
MOl 1L prevented the loss of mitochondrial membrane potential which otherwise led to the 
activation of caspase-9 and the apoptosis of infected cells (Everett et al., 2002; Saelens et 
al., 2004).
1.2.4.4 Host range genes - intracellular inhibitors o f interferons
A host range protein is one that allows the infecting virus to productively infect a cell. The 
deletion of any single host range protein usually has lethal effects on poxvirus replication in 
many cell lines, resulting in a non-productive infection, and/or attenuation of the virus in 
vivo. Poxvirus host range genes (viromitigators) can be classified into two groups. The 
first are proteins that interrupt specific cellular pathways leading to apoptosis. In myxoma 
virus, these include M-T2, M-T4, M-T5, M011L, M143R and M151R (Barrett et al., 2001). 
The second are proteins that play a role in preventing the action of interferon within 
infected cells, through the interruption of pathways and intermediates that lead to the 
activation of interferon response genes (Smith et al., 1998).
During this project, a myxoma virus vaccine that was replication-deficient in rabbit cells 
was constructed by deleting M063R, a gene that plays an unidentified role in the 
interruption of host cell responses to interferons (Grant McFadden, personal 
communication). M063R belongs to a class of poxvirus proteins containing the conserved
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Pox_C7_F8A domain. There are 24 proteins containing this m otif amongst the 
Chordopoxviruses, including 3 myxoma virus proteins (M062R, M063R and M064R) 
(Cameron et al., 1999), the VV protein C7L (Oguiura et a l., 1993) and the capripoxvirus 
protein CF8A (Gershon and Black, 1989). Deletion o f C7L from the genome o f VV 
resulted in a virus with reduced replication ability in hamster Dede cells, but normal 
replication in most human cell lines (Oguiura et al., 1993). The myxoma virus genes 
homologous to C7L and their mechanism o f action have not been fu lly  characterised, 
although are believed to be through the impediment o f the infected cell’s response to 
interferons (Grant McFadden, personal communication). Deletion o f M063R from the 
genome o f myxoma virus resulted in a virus unable to replicate in rabbit cells, but able to 
replicate in several primate cell lines (Grant McFadden, personal communication).
Several other poxvirus proteins have well-defined roles in inhibiting host cell responses to 
interferons. M156R is a structural mimic o f the eukaryotic translation initiation factor l a  
(elF2a) (Ramelot et al., 2002). M156R competes with elF2a as a substrate for
phosphorylation by the interferon-inducible protein kinase PKR, thereby preventing the 
phosphorylation o f eIF2a and the resultant inhibition o f translation. Homologues o f 
M156R are present in many other poxviruses including the well-characterised VV protein 
K3L (Beattie et al., 1991; Carroll et al., 1993; Davies et al., 1992; Kawagishi-Kobayashi et 
al., 1997) and swinepox C8L (Kawagishi-Kobayashi et al., 2000).
M029R is a homologue o f the VV protein E3L (Barrett et al., 2001), a well-characterised 
protein that prevents the activation o f IFN-activated genes. E3L has been shown to bind to 
dsRNA produced during viral infection and thereby preventing the activation o f PKR (and 
protein translation inhibition through eIF2cx) and 2-5A synthetase (and the subsequent
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activation of RNAseL) (Garcia et a/., 2002; Langland and Jacobs, 2002; Rivas et al., 1998; 
Sharp et al., 1998; Smith et al., 2001; Xiang et al., 2002). Together, E3L and K3L directly 
block the intracellular antiviral activity of interferons, preventing the interferon-mediated 
cessation of biosynthetic activity within VV-infected cells.
1.3 Im m u n e  r e s po n s e s  to  po x v ir u s  i n f e c t i o n s
When considering vaccine design, it is imperative to distinguish between immune 
responses that are responsible for clearance o f an infection, and the long-term memory 
responses that are critical for protection from further challenge. Knowledge of the virus- 
specific memory responses required for long-term protection are essential to the rational 
design of a poxvirus vaccine that must induce these responses. However, consideration of 
virus clearance is also important as the majority of poxvirus vaccines are live viruses that 
must be cleared from the vaccinated host, and in the process induce virus-specific 
circulating antibody and memory T and B cells that can confer the desired level of 
protection from challenge.
1.3.1 Poxvirus disease models - why use the myxoma virus/rabbit model?
The majority of research into the immunological responses to poxvirus infection has been 
undertaken in two mouse models - vaccinia virus (VV) and ectromelia virus (EV). The 
diversity of immunological tools available for mice has resulted in the elegant dissection of 
the specific immune responses involved in virus clearance and protection. The EV/mouse 
model is a natural poxvirus model, and the virus is a naturally transmitted pathogen (Turner 
and Moyer, 2002). A low dose of virus (<10 pfu) delivered subcutaneously can replicate, 
disseminate and induce a fatal systemic disease (Fenner, 1981). EV has been used to 
determine the host immune responses critical for control, clearance and recovery from a
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virulent poxvirus infection (Atrasheuskaya et al., 2004; Chaudhri et a/., 2004; Karupiah, 
1998; Karupiah et al., 1996; Karupiah et al., 1993). However, the EV/mouse model has not 
been used to elucidate the specific immune responses required for protection from re-
challenge.
The VV/mouse model has been used extensively in recent years to determine the host 
factors that can confer immunity to challenge with poxviruses (Belyakov et al., 2003; 
Wyatt et al., 2004; Xu et al., 2004). However, it is important to note that the VV/mouse 
model is not a natural disease model, and the results obtained cannot be directly 
extrapolated to natural poxvirus disease models (Turner and Moyer, 2002). VV is only 
lethal in mice at very high doses (>106 pfu) delivered by intracranial, intranasal or 
intraperitoneal routes. Intraperitoneal challenge is an artificial mode o f infection as the 
virus is immediately disseminated to all internal organs, and intranasal infection is only 
lethal with certain strains o f VV such as Western Reserve (WR), and lethality is dose- 
dependant (Turner, 1967). 'Natural' infection via the skin results in a non-disseminating, 
non-lethal disease in immunocompetent mice (Tscharke and Smith, 1999; Turner, 1967). 
The deletion o f many key VV genes only alters the pathogenicity o f VV in mice during 
intradermal infection, not intranasal challenge (Tscharke et al., 2002). Other key 
immunomodulatory proteins do not affect VV virulence as they do not interact with murine 
substrates. For instance, the VV IFN-y-binding protein B8R binds to murine IFN-y with a 
much lower affinity than to IFN-y o f other species, and deletion o f B8R does not alter the 
pathogenesis o f intranasal VV infection in mice (Mossman et al., 1995a; Symons et al., 
2002).
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Outside of the Orthopoxviruses, there is no mouse model for poxvirus diseases. The lack 
of immunological tools and in-bred strains available for non-mouse species makes it 
difficult to elucidate the immune mechanisms that are responsible for poxvirus clearance 
and protection.
This study has utilised the rabbit/myxoma virus model to evaluate the protective efficacy of 
various vaccination strategies in a natural disease model. This model utilises a laboratory 
animal and a well-characterised virus with defined pathogenesis. Infection with a small, 
naturally delivered (intradermal incoulation) dose of virulent virus results in dissemination 
of the virus and a 100% lethal disease. The protective efficacy of vaccines in this model 
can be extrapolated to other natural poxvirus disease models including capripoxvirus 
infections and smallpox because a vaccine design that protects rabbits from myxomatosis is 
likely provide a model for vaccines to protect other hosts from diseases with a similar 
disseminating, lethal pathology.
1.3.2 Immune mechanisms responsible for clearance of poxvirus infections
1.3.2.1 Antibody
Anti-poxvirus antibody does not appear to play an important role in the clearance of, and 
survival from, many primary poxvirus infections, although anti-virus antibody develops 
quickly following infection. Antibody is detected as soon as 6 days after infection in VV- 
infected mice (Hutt, 1975; Novembre et al., 1989) and myxoma virus-infected rabbits (Best 
and Kerr, 2000), and by 7 days post infection in EV-infected mice (Chaudhri et al., 2004).
In VV-infected mice, cell-mediated immune mechanisms (cytotoxic T lymphocytes [CTL] 
and natural killer [NK] cells) peak and contract before significant neutralising antibodies
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are detected, suggesting that antibodies play a relatively minor role in clearance of the 
primary VV infection (Novembre et a/., 1989). This is further supported by the fact that 
humans with Burton’s agammaglobulinemia, a genetic defect that renders them incapable 
of generating antibody, generally do not display adverse reactions to VV vaccination and 
are still capable of developing protective immunity to smallpox in the complete absence of 
antibody (Fulginiti et al., 1968; Kempe, I960).
However, other studies have suggested that antibodies are required in the clearance of 
poxviruses. IgH" (antibody-deficient) mice infected with VV retained higher titres of VV 
at 14 dpi than wild type mice did (Xu et al., 2004). Similarly, B cell deficient mice develop 
a persistent EV infection despite the generation of potent anti-EV cell-mediated immunity 
(Karupiah, 1998). The infection is resolved following transfer of immune serum or naive B 
cells (Karupiah, 1998).
1.3.2.2 Cell-mediated immune responses - cytotoxic T lymphocytes (CDS T cells) and 
helper T cells (CD4 T cells)
Infection with poxviruses induces high levels of virus-specific T lymphocytes which are 
principally responsible for clearance of the primary infection (Blanden, 1974; Buller and 
Palumbo, 1991). Virus-specific T cell responses have been identified in mice infected with 
EV (Karupiah et al., 1996) or VV (Demkowicz et al., 1992; Xu et al., 2004), humans 
infected with VV (Demkowicz and Ennis, 1993; Demkowicz et al., 1996; Hammarlund et 
al., 2003), sheep infected with VV (Issekutz, 1984; Issekutz, 1985), pigs infected with 
swinepox virus (Williams et al., 1989), and chickens infected with fowlpox virus (Singh 
and Tripathy, 2003). The anti-poxviral activity of virus-specific T cells in vivo is primarily 
through their direct cytotoxic action on infected cells, and through the antiviral activity of
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IFN-y secreted from active CD8 and CD4 T cells. CD4 T cells also have a role in the 
development of humoral responses in mice infected with Orthopoxviruses (Belyakov et al., 
2003; Ennis et al., 2002; Karupiah, 1998; Karupiah et al., 1996; Karupiah et al., 1993; 
Mullbacher, 2003).
The critical importance of CD8 T cells in the recovery of mice infected with EV has been 
well established (Blanden, 1970; O'Neill and Blanden, 1983; O'Neill and Brenan, 1987). 
Depletion of all T cells prevented the recovery of EV-infected mice (Blanden, 1970; 
Blanden, 1971; Blanden, 1974). C57BL/6 mice depleted of, or lacking, CD8 T cells 
succumbed to EV with significantly higher titres of virus detected in the spleen and liver 
than in normal mice (Karupiah et al., 1996). Mice depleted of CD4 cells did not succumb 
to infection, although they had higher virus titres, lower virus-specific CTL activity and 
became persistently infected with virus (Karupiah et al., 1996).
The relative importance of CD8 and CD4 T cells appears to be reversed in VV-infected 
mice. CD8 knockout mice were able to overcome even high doses of intradermally 
delivered VV with little pathology (Spriggs et al., 1992). Similarly, CD8 T cell-depleted 
mice challenged intraperitoneally with VV showed a similar pathology to VV-infected 
control mice (Xu et al., 2004). However, depletion of CD4 T cells before VV challenge 
prevented mice from clearing VV effectively, with reduced virus-specific CTL and 
antibody responses (Xu et al., 2004). In a separate non-lethal VV infection study, it was 
found that compared to untreated mice, CD4 T cell-depleted mice displayed normal 
pathology, CD84 T cell depleted mice had slightly increased weight loss and mice with 
both CD4 and CD8 T cells depleted succumbed to the infection (Belyakov et al., 2003). 
Although CD4 -deficient mice appear to mount normal CD8" CTL responses, the
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importance of CD4 T cells in recovery seems to be their crucial role in the development of 
early antibody responses (Karupiah et al., 1996; Mullbacher, 2003).
There is little information on the importance of cell-mediated immune responses outside of 
inbred mouse model studies. However, the importance of cell-mediated immunity in the 
clearance of VV in humans has been well-documented, as it was found that individuals 
with deficient T lymphocyte responses were more prone to develop disseminated VV 
disease following vaccination, indicating poor control of the VV infection (Fenner, 1993; 
Fulginiti et al., 1968; O'Connell et al., 1964).
1.3.2.3 Cytokines in the clearance o f poxvirus infections
The importance of Thl responses, and especially Thl cytokines, in the control and 
clearance of poxvirus infections has been established through studies involving strains of 
mice that are genetically resistant or genetically susceptible to EV infection. BALB/c mice 
succumbed to EV infection following inoculation with very small doses (<10 pfu) of virus, 
whilst C57BL/6 mice cleared and recover from high doses of virus (>106 pfu) (Karupiah, 
1998). Following infection with EV, genetically resistant mice generated a Thl cytokine 
profile (IFN-y, tumour necrosis factor-a [TNF-a] and interleukin-2 [IL-2]) in the draining 
lymph node and spleen, whilst susceptible mice generated a Th2 cytokine profile, 
dominated by interleukin-4 (IL-4), with no IFN-y, TNF-a or IL-2 (Chaudhri et al., 2004). 
The cytokine profile in resistant mice promoted the development of a potent cell-mediated 
adaptive immune response against the infection coupled with enhanced innate immune 
responses including increased NK cell activity. The development of a Thl-dominant 
response was responsible for the rapid control of virus replication in distal tissue and the 
subsequent survival of the mice.
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The importance o f cytokines in the control o f poxvirus infections has also been investigated 
by systemically delivering or inhibiting cytokines during poxvirus infections, or using 
recombinant viruses expressing Thl or Th2 cytokines. Expression o f IL-4 (a key Th2 
cytokine) in myxoma virus or EV enhanced the virulence o f the recombinant virus and was 
able to overcome genetic resistance in rabbits and mice respectively, by suppressing CTL 
and innate immune responses (Jackson et al., 2001; Kerr et al., 2004). IL-4 expression in 
EV was also able to overcome pre-existing immunity to EV (Jackson et a l., 2001). VV 
expressing IL-4 also demonstrated increased virulence in mouse models, although infection 
was not lethal in immunocompetent mice (Andrew and Coupar, 1992; Sharma et al., 1996). 
In contrast, VV recombinants expressing the Thl cytokines IFN-y, TNF-a, IL-2, IL-12 or 
IL-18 had reduced virulence and were cleared more rapidly than control viruses (Gherardi 
et al., 2003; Hugin et al., 1993; Karupiah et al., 1990; Karupiah et al., 1991; Kohonen- 
Corish et al., 1990; Perera et al., 2001; van Den Broek et al., 2000). Similarly, systemic 
delivery o f IFN-y or TNF-a enhanced innate and cell-mediated immune responses against 
EV (Atrasheuskaya et al., 2004), whilst depletion o f IFN-y resulted in a lethal infection in 
genetically resistant mice (Karupiah, 1998; Karupiah et al., 1993).
1.3.2.4 Summary
Current knowledge suggests that a Thl cell-mediated immune response is critical for the 
rapid clearance o f poxvirus infections in mice. Antibody plays an important role in the 
clearance o f persistent poxvirus infections, but is not essential for survival from lethal 
challenge. The relative importance o f CD8 and CD4 T cell responses differs significantly 
between the closely related VV  and EV infections. This suggests that each poxvirus 
disease may have different requirements for cell-mediated control o f the infection. The 
importance o f Thl cell-mediated immunity in the control o f poxviruses is further supported
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by the fact that all Chordopoxviruses have evolved strategies to interfere with Thl 
cytokines and cell-mediated immune responses including the secretion of anti-
inflammatory proteins, down-regulation of host cell MHC-I expression, and cytokine and 
chemokine-binding proteins including those that that disrupt the function of IFN-a/ß, IFN- 
Y, TNF-a, IL-18 and IL-lß (Johnston and McFadden, 2003; Sect et al., 2003; Smith et a/., 
1998; Zuniga, 2002). Interference with Thl cytokines and cell-mediated immunity is 
clearly advantageous to the in vivo replication of poxviruses.
1.3.3 Immunological memory and immune responses responsible for protection from 
poxvirus challenge
A successful vaccine is capable of priming the adaptive immune system against specific 
components and molecules of a pathogenic organism to establish adequate levels of 
circulating antibody and antigen-specific memory cells that can prevent the induction of 
disease upon re-exposure to the pathogen. For a vaccine to be effective, it must induce 
adaptive immune responses that are able to quickly eliminate the invading pathogen before 
the induction of disease. These responses must be induced at the relevant site, be of the 
appropriate nature (antibodies, CTLs, Thl, Th2) and be of sufficient longevity to provide 
adequate protection from disease (Roitt, 1997; Zinkemagel, 2002).
The success of the smallpox eradication campaign is testament to the ability of poxvirus 
infections and vaccines to induce long-term protective memory responses. Following 
vaccination of humans with live VV vaccine, VV-specific antibody, CTL activity, 
lymphoproliferative activity and IFN-y production are detected within 10-14 days, with a 
predominant Thl cytokine profile in VV-specific CD4 T cells (Amara et al., 2004; 
Demkowicz and Ennis, 1993; Ennis et al., 2002; Henderson and Moss, 1999). Immunity to
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variola virus infection and smallpox is robust 50 years after vaccination with a single dose 
of live VV vaccine in infancy (Baxby, 2002; Cohen, 2001). Virus-specific CD4 and CD8 
T cell responses are readily detectable 4 months after vaccination and for up to 70 years 
following vaccination (Demkowicz and Ennis, 1993; Demkowicz et al., 1996; Hammarlund 
et al., 2003). Similarly, following recovery from myxomatosis, rabbits are considered to 
have lifelong protection from further challenge, although they can become re-infected, 
albeit with drastically reduced symptoms usually limited to a lesion at the inoculation site 
(Fenner et al., 1953; Kerr, 1997). However, not all poxvirus infections confer protection 
from re-infection. Most notably, immunity to orf virus is only transient in sheep and 
repeated re-infections are common, although with milder disease (Haig and Mercer, 1998).
Understanding of the specific immune mechanisms which are capable of conferring 
protection against challenge with a poxvirus is critical to the development of an effective 
poxvirus vaccine. Again, most data has been acquired from the VV/mouse and EV/mouse 
models that have permitted an elegant dissection of the immune mechanisms required for 
immunity. However, there is a great deal of conflicting data on the requirements for 
protection from challenge, and a definitive 'mechanism of immunity' has yet to be 
described.
1.3.3.1 Antibody
The importance of virus-specific antibody in protecting immunocompetent hosts from 
poxvirus infections has been demonstrated in many different poxvirus disease models. 
Humans with high levels of anti-VV antibodies were resistant to challenge with smallpox 
and low levels of VV neutralising antibody correlated with higher susceptibility to 
smallpox infection (Mack et al., 1972; Sarkar et al., 1975). Vaccinia immune globulin
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(VIG) isolated from VV-immune individuals was of therapeutic benefit when administered 
to smallpox infected individuals and those suffering VV-induced disease after vaccination 
and is currently the only therapy available following Orthopoxvirus infection (CDC, 2001; 
Kempe, I960; Kempe e ta /., 1961).
Passive immunisation of mice with VV-immune serum confers complete protection from 
lethal VV infection, and a reduction in viral load (Boulter and Appleyard, 1973; Xu et al., 
2004). Passive immunisation with polyclonal or monoclonal antibodies directed against 
individual VV IMV or EEV antigens can also protect mice from lethal VV challenge 
(Galmiche et a l., 1999; Hooper et a l., 2000; Ramirez et al., 2002) Transfer of EV-immune 
serum partially protects from EV challenge, though virus replication in the liver and spleen 
still occurs (Blanden, 1971) and passive immunisation of sheep with capripox-immune 
serum offers protection from capripox-induced disease (Kitching, 1986).
However, virus-specific antibody confers only limited or no protection in other poxvirus 
disease models. Passive transfer o f orf-immune serum to sheep did not offer any 
significant protection from challenge (Buddie and Pulford, 1984; Mercer et al., 1994). 
Similarly, passive immunisation of rabbits with immune serum protected only 15% of 
rabbits from lethal challenge with myxoma virus (Fenner and Marshall, 1954) and 
maternally-transferred antibody was unable to consistently protect young rabbits from 
infection or death from myxomatosis (Fenner and Marshall, 1954; Sobey and Conolly, 
1975).
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1.3.3.2 Cell-mediated immune mechanisms involved in immunity to poxvirus challenge 
Although the importance of virus-specific CD4 and CD8 T lymphocytes in recovery from 
poxvirus infections has been well established, the relative importance of virus-specific cell- 
mediated immune responses in preventing or ameliorating subsequent infections is not well 
understood and there are conflicting results in the literature.
Transfer of spleen cells from EV immune mice to naive mice conferred significant 
protection from challenge, far in excess of that conferred by hyperimmune serum (Blanden, 
1971; Blanden, 1974), indicating that virus specific cells alone, in the absence of anti-EV 
antibody, are capable of conferring protection from poxvirus challenge. However, 
depletion of CD4 or CD8 T cells in VV-immune mice did not alter disease pathogenesis 
upon challenge, and were only required for protection in the absence of VV-specific 
antibody (Belyakov et al., 2003). In another study, VV-vaccinated CD4+ T cell-deficient 
mice were not effectively protected from VV challenge (Wyatt et ah, 2004). In the absence 
of antibody, VV-immunised mice developed disease following lethal VV challenge (as 
measured by weight loss) but did not die, suggesting that memory T cell responses alone 
can protect from VV-induced death, but not disease, due to the time required for cell- 
mediated effector mechanisms to respond to infection (Belyakov et al., 2003). Similarly, 
transfer of CD8 memory T cells from VV immune mice conferred high levels of 
protection from VV challenge, as seen by a 100-fold reduction in virus load (Xu et ah, 
2004), indicating that CD8 memory responses are highly effective mediators of protection.
Outside of mouse models, the importance of cellular immune mechanisms in protection 
from poxviruses is uncertain due to the lack of inbred animal strains required for cellular 
transfer experiments. The only model studied in any detail is orf virus infection of sheep.
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CD4 T cells are the predominant lymphocyte in orf lesions during primary and secondary 
infections (Jenkinson et al., 1992; Jenkinson et al., 1990), and depletion of CD4 cells in 
the early stages of re-infection resulted in increased lesion size and increased time to lesion 
resolution (Lloyd et al., 2000). A similar, though smaller effect was noted upon depletion 
of CD8+ T cells (Lloyd et al., 2000).
The specific antigens against which cell-mediated responses are generated in animals 
following poxvirus infection have not been well studied. Responses against specific HLA- 
A2- or HLA-Db-restricted epitopes within five VV antigens have been measured in VV- 
infected mice and humans (VV Copenhagen ORFs H3L, B22R/C16L (common epitope), 
C7L, D6R and A26L) (Drexler et al., 2003; Snyder et al., 2004; Terajima et al., 2003). 
Vaccination of mice with the H3L peptide did not confer protection from lethal VV 
challenge (Drexler et al., 2003). However, vaccination of mice with the C7L or A26L 
peptides did confer CD8 T cell-dependant protection from VV-induced death, but not 
disease (Snyder et al., 2004), indicating that memory CTL responses directed against a 
single VV epitope can confer protection in mice.
1.3.2.3 Summary
These results suggest that virus-specific CD4 and CD8+ T cells are not absolutely required 
for protection from lethal Orthopoxvirus challenge of mice if there is anti-Orthopoxvirus 
antibody present, but are essential in the absence of antibody. Cell-mediated immune 
responses alone are capable of preventing death but not virus-induced disease, presumably 
due to the time required for the proliferation and differentiation of memory T cells to 
effector CTLs (Esser et al., 2003; Kaech et al., 2002). The relative importance of cell- 
mediated versus antibody-mediated protection in animals other than in the VV/mouse and
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EV/mouse models is unknown. However, the absence o f protection following passive 
transfer o f antibody strongly suggests that cell-mediated immunity is critical in protecting 
sheep and rabbits from o rf and myxoma viruses respectively. The importance o f 
neutralising antibody in the VV/mouse model is most likely due to its ability to neutralise 
enough challenge virus, lowering the effective dose below lethal limits (Hooper et al., 
2000).
1.4 Po x v ir u s  v a c c in a t io n  st r a t eg ies
Recovery from a poxvirus infection results in complete clearance o f the pathogen and life-
long immunity to disease caused by the virus (Esposito and Fenner, 2002). These 
characteristics make most poxvirus diseases readily preventable by vaccination, as 
clearance and recovery from the vaccine infection can confer the same life-long immunity.
Commercially available poxvirus vaccines are all live viruses. These take two forms -  
antigenicaUy related poxviruses which are non-pathogenie but which confer cross-
protection (heterologous vaccines), or pathogenic virus strains that have been attenuated by 
multiple passage in tissue culture resulting in random mutations and gene inactivation until 
a suitably safe but protective vaccine has been generated (homologous vaccines). 
Inactivated poxvirus vaccines are not effective in natural poxvirus disease models, even 
though high titres o f neutralising antibody are generated (Fenner et a l., 1988).
Other experimental vaccination strategies that have proven effective in protecting mice 
from poxvirus challenge include subunit formulations consisting o f individual poxvirus 
antigens or combinations o f antigens delivered as protein or DNA vaccines, and non-
replicating poxvirus strains. The characteristics, benefits and disadvantages o f these
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different vaccination strategies are described below. Vaccines against myxomatosis will be 
described in more detail in Section 1.5.
1.4.1 Live attenuated poxvirus vaccines
As live vaccine viruses can infect antigen presenting cells and produce antigens 
endogenously, they are proficient at inducing Thl -dominant cell mediated immune 
responses as well as neutralising antibodies against key viral antigens (Ahmed and Gray, 
1996; Plotkin, 2003). For this reason, live attenuated poxvirus vaccines have proven 
successful in many poxvirus disease models because they are capable of inducing virus- 
specific cell-mediated immune responses that are critical for protection from poxvirus- 
induced disease (Section 1.3.3.2).
Some of the commercially available and experimental live, attenuated poxvirus vaccines 
are summarised in Table 1.3. Vaccines are available to prevent smallpox (Fenner et al., 
1988), fowlpox (Laidlaw and Skinner, 2004; Sarma and Sharma, 1988; Tripathy and Reed, 
1997), orf (Buttner and Rziha, 2002; Mclnnes et al., 2001; Nettleton et al., 1996), lumpy 
skin disease (Capstick and Coakley, 1961; Davies, 1991; Kitching, 2003; Weiss, 1968), 
goatpox and sheeppox (Carn, 1993; Kitching, 2003) and myxomatosis (Section 1.5). The 
majority of these vaccines are homologous virus strains, except for VV-based smallpox 
vaccines (Fenner et al., 1988) and the capripoxviruses, which are all antigenically related 
and cross protective (Cam, 1993).
Although most live poxvirus vaccines confer excellent protection, many have high 
complication rates. The best documented is VV vaccines in humans, as billions of doses 
were used during the smallpox eradication campaign (Fenner et a l, 1988). Following
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Chapter 1 -  Introduction
vaccination, most recipients developed very mild complications including fever and 
swollen and tender lymph nodes (Henderson and Moss, 1999). More serious, potentially 
lethal complications included generalised vaccinia, progressive vaccinia, postvaccinal 
encephalitis, myopericarditis and transmission of the vaccine virus to naive contacts (CDC, 
2001; Henderson and Moss, 1999; Lane eta/., 1969; Maurer et al., 2003). Fatalities, 
primarily due to progressive vaccinia and nervous system complications were responsible 
for approximately 1 death per million vaccinees during the 1960’s (CDC, 2001). The recent 
vaccination campaign in the US highlighted that adverse effects of VV vaccination, 
especially myopericarditis, are still common (Cassimatis et al., 2004; CDC, 2004; Check, 
2004). Today, the use of traditional live VV vaccines poses a significant risk to 
immunosuppressed individuals (Bartlett et al., 2003; Bartlett, 2003a; Bartlett, 2003b; 
Redfield et al., 1987), and immunosuppression due to HIV infection is much more 
widespread than when smallpox vaccination was discontinued in the early 1970's.
Other live poxvirus vaccines have similar problems. Orf virus vaccine strains have been 
responsible for outbreaks of scabby mouth disease (Gilray et al., 1998). Capripoxvirus 
vaccines can induce disease and severe reactions at the inoculation site, and many are not 
considered suitable for animals of show quality (Carn, 1993; Yeruham et al., 1994). 
Transmission of the vaccines have been reported, especially where sheeppox virus has been 
utilised as a heterologous LSDV vaccine, as this vaccine virus is still pathogenic for naive 
sheep (Capstick and Coakley, 1961; Davies, 1991).
1.4.2 Subunit poxvirus vaccines
Vaccines consisting of whole inactivated viruses or components of viruses are highly 
effective in many different disease models. Subunit vaccines are considered much safer
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than live vaccines due to their non-replicating nature (Plotkin, 2003). The parenteral 
delivery o f these vaccines tend to generate Th2 and potent neutralising antibody responses, 
and are highly effective against viruses where neutralising antibody is protective. 
However, non-live vaccines, especially protein vaccines, generate no or poor CTL 
responses, and are not effective for viruses where CTL responses are critical for protection 
(Zinkemagel, 2002).
Protein subunit poxvirus vaccines, consisting o f individual poxvirus antigens delivered as a 
protein vaccine have had some success in experimental animal models (Table 1.4). The 14 
kDa IM V  fusion protein A27L confers complete protection from lethal VV challenge in 
mice when delivered as a protein vaccine (Demkowicz et al., 1992; Lai et al., 1991 b). The 
VV core antigens A4L and A10L were also able to confer partial protection (Demkowicz et 
a l., 1992). Goats have been partially protected from challenge with virulent goatpox virus 
fo llow ing vaccination with the P32 protein (homologous to VV  H3L), although all 
challenged animals still developed symptoms o f disease (Cam et al., 1994).
DNA vaccines have proven an effective means o f identifying the protective antigens o f 
Orthopoxviruses (Table 1.4). In its most basic form, a DNA vaccine consists o f a bacterial 
plasmid expressing a protein antigen under the control o f a constitutive mammalian 
promoter (Lai and Bennet, 1998). When delivered to the host, the plasmid is taken up by 
host cells, the antigen gene transcribed and translated and the resultant foreign protein is 
processed via cellular proteosomic pathways and presented to immune cells in the context 
o f MHC-I (Gurunathan et al., 2000; Weiner and Kennedy, 1999). As the antigenic protein 
is synthesised and processed within host cells, DNA vaccines are one o f the few non-live 
vaccination methods capable o f inducing potent Thl/cell-mediated immune responses as
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Table 1.4 - Subunit poxvirus vaccines. The protective efficacy of subunit vaccines have been 
evaluated in mice challenged with VV, monkeys challenged with monkeypox and goats 
challenged with goatpox.
Antigen and Delivery 
System
Efficacy 
(% survival)3
Comments References
Lethal vaccinia virus challenge of BALB/c mice
A4L protein 50 Demkowicz et al. (1992)
A10L protein 75 Demkowicz et al. (1992)
A27L protein 100 Lai et al. (1991b) 
Demkowicz et al. (1992)
A27L DNA vaccine 80, 10 Pulford et al. (2004) 
Hooper et al. (2003)
B5R DNA vaccine 85, 100 Galmiche et al. (1999) 
Pulford et al. (2004)
A33R DNA vaccine 100, 67, 70 Galmiche et al. (1999) 
Pulford et al. (2004) 
Hooper et al. (2000)
A36R DNA vaccine 50, 60 Galmiche et al. (1999) 
Pulford et al. (2004)
A34R DNA vaccine 15,0 Galmiche et al. (1999) 
Pulford et al. (2004)
A13L DNA vaccine 0 Pulford et al. (2004)
D8L DNA vaccine 50 Pulford et al. (2004)
H3L DNA vaccine 33 Pulford et al. (2004)
L1R DNA vaccine 0, 80 Pulford et al. (2004) 
Hooper et al. (2000)
L1R + A33R DNA vaccine 90 Weight loss profile 
and survival rate 
identical to Dryvax- 
vaccinated mice
Hooper et al. (2000)
A27L + B5R DNA vaccine 70 Hooper et al. (2003)
B5R + L1R DNA vaccine 100 Hooper et al. (2003)
B5R + A33R DNA vaccine 80 Hooper et al. (2003)
A33R + B5R +A27L + 
L1R DNA vaccine
100 Less weight loss than
Dryvax-vaccinated
mice
Hooper et al. (2003)
CD8+ HLA-A2-restricted 
epitope from VV C7L
80 Snyder et al. (2004)
Monkeypox virus challenge of rhesus macaques
VV A33R,+ B5R +A27L 
+ L1R DNA vaccine
100 Some secondary signs 
of disease
Hooper et al. (2004)
VVL1RDNA vaccine 100 More severe disease 
than seen in monkeys 
which received four- 
antigen combination
Hooper et al. (2004)
Goatpox virus challenge of British white cross goats
P32 (VV H3L) protein 100 All animals developed 
disease, but survived
Cam et al. (1994)
a - Each number represents the result of a separate experiment
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well as humoral immune responses (Gurunathan et al., 2000; Shedlock and Weiner, 2000; 
Takashimaand Morita, 1999; Weinerand Kennedy, 1999).
DNA vaccines expressing EEV or IM V antigens have proven highly effective at protecting 
mice from VV challenge, although with varying results between antigens and experiments 
(Table 1.4; Galmiche et a l., 1999; Hooper et al., 2000; Hooper et al., 2003; Pulford et al., 
2004) The four-gene combination o f the VV genes L1R, A33R, B5R and A27L has proven 
effective at protecting monkeys from lethal monkeypox challenge (Hooper et al., 2004), 
and in mice, this combination proved more effective than vaccination with live VV (Hooper 
et al., 2003).
It is important to note that the majority o f research on poxvirus subunit vaccines has been 
conducted in the VV/mouse model, which as discussed previously, is not a natural poxvirus 
disease model. Mice are very well protected from lethal VV challenge by VV-neutralising 
antibodies (Boulter and Appleyard, 1973; Xu et al., 2004), which is not the case with most 
other poxvirus diseases (Buddie and Pulford, 1984; Cohen, 2001; Fenner and Marshall, 
1954; Mercer et al., 1994). High titres o f neutralising antibody directed against these IM V 
and EEV antigens would be capable o f neutralising enough challenge virus to lower the 
effective dose below lethal limits (Hooper et al., 2000). However, many o f these DNA 
vaccines had protective efficacy despite no V V  neutralising antibody activity after 
vaccination (Galmiche et al., 1999; Pulford et al., 2004). This suggests antigen-specific 
cell-mediated mechanisms are conferring protection for at least some o f these antigens, 
although the magnitude and phenotype o f cell-mediated responses induced by DNA 
vaccines have not been reported. It is unknown whether DNA vaccines expressing IM V,
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EEV, structural or enzymatic antigens will be protective in natural poxvirus disease models 
where virus-specific cell-mediated immunity is critical for protection.
1.4.3 Replication-deficient poxvirus vaccines
Replication-deficient smallpox vaccines have been investigated due to the increased safety 
of these vaccines in immunocompromised individuals. These viruses are unable to 
replicate in host cells due to the deletion of key viral host range genes, with viral replication 
terminating before the assembly of new virion particles (Blanchard et al., 1998). As these 
viruses are incapable of productive infection in vivo, they cannot disseminate beyond the 
inoculation site and induce disease. However, their ability to express a large number of 
viral antigens in vivo before termination of the replication cycle results in the effective 
delivery of a wide variety of poxvirus antigens and epitopes (McCurdy et al., 2004).
Only two replication-deficient poxvirus vaccines have been evaluated as protective 
vaccines, the VV strains modified vaccinia virus Ankara (MVA) and NYVAC (Table 1.5). 
MVA was attained after 570 passages of the VV strain Ankara in chicken embryo 
fibroblasts (Antoine et al., 1998). This resulted in the splitting or deletion of 25 open 
reading frames including the important immunomodulatory genes C23L (chemokine 
binding protein), C19L (TNF-a receptor homologue), Serp-1, B4R (homologous to 
myxoma virus anti-apoptotic factor M-T5) and host-range genes including K1L (Antoine et 
al., 1998). Expression of the interferon-y binding protein and interferon-a/ß binding 
proteins was not detected (Blanchard et al., 1998). NYVAC was constructed by the 
targeted deletion of 18 host range, immunomodulatory and enzymatic genes (Tartaglia et 
al., 1992). The effect of these mutations and deletions in both viruses is a highly restricted 
host cell range. MVA and NYVAC cannot productively infect most mammalian cell lines
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in vitro, but can grow to high titres in some avian cell lines such as chick embryo 
fibroblasts (Blanchard et al., 1998).
MVA is effective in preventing lethal VV in mice (Belyakov et al., 2003; Wyatt et al., 
2004), cowpox infection in rabbits (Munz et al., 1993) and monkeypox in cynomolgous 
monkeys (Earl et al., 2004). The range of anti-VV immune responses induced by two 
doses of MVA in mice and monkeys was comparable to that induced by standard 
replication-competent VV vaccines (Belyakov et al., 2003; Earl et al., 2004; Wyatt et al., 
2004). Two doses of MVA were capable of protecting monkeys from lethal monkeypox, 
although most animals developed very mild disease (Earl et al., 2004). A single dose of 
MVA followed by DryVax significantly reduced the size of the lesion induced by DryVax, 
and offered complete protection from disease, comparable to a single DryVax inoculation 
(Earl et al., 2004). However, their efficacy in protecting humans from smallpox has not 
been evaluated (Rosenthal et al., 2001; Smith and McFadden, 2002).
MVA and NYVAC have proven safe and effective at inducing protective immunity against 
poxvirus challenge in immunocompromised mice, rabbits and monkeys, even at very high 
doses (Edghill Smith et al., 2003; Wyatt et al., 2004). MVA was used extensively in 
Germany during the smallpox eradication campaign with no reported side effects, even 
amongst susceptible populations (Mayr et al., 1978). Taken together, these data suggest 
that replication-deficient vaccines would be safe to use in immunocompromised humans.
1.5 My x o m a t o s i s  v a c c i n e s
Currently available myxomatosis vaccines are all attenuated live viruses. In Europe, there 
are several widely used myxomatosis vaccines of two forms -  heterologous vaccines using
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the antigenically related poxvirus, rabbit fibroma virus (RFV), or homologous vaccines 
using tissue culture-attenuated strains of myxoma virus (Marlier et a/., 2000; Vautherot et 
al., 1997). The details of myxomatosis vaccines and their protective efficacy are 
summarised in Table 1.6.
RFV-based vaccines are widely used in the United Kingdom. Protection from 
myxomatosis is generally limited and short-lived, and dependent on the RFV strain used. 
Vaccination with RFV strain OA induced only a small lesion on rabbits and the protection 
conferred was extremely limited and short-lived. When challenged with virulent myxoma 
virus 3 or 5 months after vaccinations, seven of nine of rabbits developed severe 
myxomatosis and two died (Fenner and Woodroofe, 1954). The Boerlage strain of RFV 
induced a more severe primary lesion following vaccination (up to 40 mm in diameter) 
although no vaccine-induced disease was noted in rabbits as young as 14 days. Following 
challenge with high doses of virulent myxoma virus, a significant level of protection was 
observed up to 12 months following vaccination (Fenner and Woodroofe, 1954). However, 
commercially available RFV vaccines appear to offer only poor protection against myxoma 
virus challenge (Marlier et al., 2000).
Several homologous myxomatosis vaccines have been developed which are widely used in 
Continental Europe (Gorski et al., 1994; Vautherot et al., 1997). These vaccines are field 
strains of virus that were passaged in vitro until a suitably attenuated strain of virus was 
obtained (Brun et al., 1981; Jacotot et al., 1967; McKercher and Saito, 1964; Saurat et al., 
1978). The widely used French vaccine SG33 was very effective at preventing lethal 
myxomatosis, but protection was relatively short lived. By 12 months after vaccination, 
50% of rabbits succumbed to lethal infection (Picavet et al., 1989; Saurat et al., 1978). At
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Chapter 1 -  Introduction
higher doses (>2000 pfu), SG33 is capable of inducing mild secondary signs of 
myxomatosis in 8-12 week old rabbits. Similarly, other myxoma virus vaccines can cause 
side effects such as fever (McKercher and Saito, 1964), and can disseminate to distal 
tissues (Gorski et a/., 1994).
Current attenuated myxoma virus vaccine strains can induce mild myxomatosis and an 
immunosuppressed state, especially in younger animals, which can result in the 
establishment of lethal secondary bacterial infections (Brun et al., 1981; Vautherot et al., 
1997), and reversion to virulence has been reported (Jacotot et al., 1967). A 
‘recommended’ myxomatosis vaccination regime to reduce the incidence of vaccine- 
induced disease involves vaccination with the heterologous RFV vaccine first, followed by 
a boost with a homologous myxoma virus vaccine (Marlier et al., 2000; Vautherot et al., 
1997). However, this vaccination regime only offers moderate protection from disease 
(Marlier et al., 2000).
Another field of myxomatosis vaccine research is transmissible myxomatosis vaccines for 
use in wildlife conservation. Researchers in Spain have been developing a transmissible 
myxoma virus/rabbit haemorrhagic disease virus (RHDV) vaccine to protect wild rabbit 
populations from both viruses (Bertagnoli et al., 1996). In some parts of Europe, rabbits 
form the primary food source for several highly endangered predators including the lynx 
and imperial eagle. Since the outbreak of RHDV, rabbit populations have dropped to very 
low levels, adversely affecting the populations of the predators (Ferrer and Negro, 2004; 
Rodriguez and Delibes, 2002). A myxoma virus strain isolated from the wild in Spain has 
been modified to encode the RHDV capsid protein VP60, and confers complete protection 
from both myxoma virus and RHDV challenge (Bertagnoli et al., 1996). This recombinant
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vaccine has proven to be very safe in wild rabbits under laboratory conditions (Torres et al., 
2000), and has at least limited horizontal transmissibility of protection in laboratory and 
field trials (Barcena e t a l ., 2000; Torres et a l ., 2001).
1.6 Su m m a r y  a n d  A i ms  o f  Th i s  pr o j e c t
Despite the need for more effective poxvirus vaccines to combat diseases such as goatpox, 
sheeppox, scabby mouth disease, lumpy skin disease, myxomatosis and the potential re- 
emergence of smallpox, the currently available poxvirus vaccines are all live, attenuated 
vaccines that have an unacceptably high incidence of side-effects or poor efficacy. This 
project has evaluated the efficacy of novel poxvirus vaccine designs in protecting rabbits 
from challenge with myxoma virus - a natural host/pathogen model. This model allows us 
to determine the characteristics of a vaccine that is capable of protecting a host from a 
highly lethal, naturally transmissible poxvirus, whilst causing minimal side effects.
The vaccine candidates were evaluated using the following criteria for an ‘ideal’ myxoma 
virus vaccine or vaccination strategy:
1. The vaccine itself would cause no illness or distress in vaccinated animals, especially 
younger (8-12 week old) animals, including any long-term scarring caused by vaccine- 
induced clinical manifestations (vaccine acceptability).
2. The vaccine would confer complete protection (total absence of any clinical 
manifestations of disease) from challenge with virulent strains of myxoma virus 
(vaccine efficacy).
3. The vaccine would be unable to transmit between a recently vaccinated animal and 
other animals, either by direct contact or via arthropod vectors (non-transmissibility).
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In Chapter 3, the protective efficacy o f DNA vaccines expressing single and multiple 
myxoma virus antigens and rabbit cytokines is evaluated. Chapter 4 describes the 
construction o f three live, attenuated myxoma virus vaccines by the deletion o f key viral 
immunomodulatory genes. These vaccines were evaluated for their safety and efficacy. 
This poses the question: can a live, attenuated vaccine be constructed such that it is 
completely safe, but still be capable o f conferring complete protection from challenge? 
One o f these vaccine strains proved to be highly efficacious and safe in rabbits, and it was 
studied in greater detail. In Chapter 5, the pathogenesis o f this vaccine was studied to 
determine the following: the potential transmissibility o f this vaccine between animals; the 
degree o f dissemination o f the vaccine virus that occurred in vivo; and the degree o f tissue 
damage that occurred at the site o f inoculation and the draining lymph node. In Chapter 6, 
the safety and efficacy o f this live, attenuated virus was evaluated in 8 and 12 week old 
rabbits. Finally, a replication-deficient myxoma virus vaccine was constructed by the 
deletion o f a key host-range gene, and the virus evaluated for its protective efficacy and 
safety, both atone and as part o f a prime-boost regimen (Chapter 7).
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Chap ter  2 - Mate rials  a n d  Me t h o d s
2.1 Mo l e c u l a r  Bi o l o g y  Me t h o d s
2.1.1 Growth and storage of bacterial cultures
Unless otherwise indicated, bacterial cultures were grown overnight at 37°C. Luria-Bertani 
(LB) broth (1% tryptone [Bacto, Australia], 0.5% yeast extract [Bacto, Australia] and 1% 
NaCl [BDH, Australia]) was used for liquid cultures and LB agar (LB broth with 1.5% agar 
[Bacto, Australia]) was used for the plating of bacteria. Liquid cultures were incubated in a 
shaking incubator at approximately 200 rpm. Media was supplemented with 100 pg/mL of 
ampicillin (Sigma, Australia) or 30 pg/mL of kanamycin (Sigma, Australia) if required. 
Cultures were stored at 4°C for the short term. For long term storage, bacterial cultures 
were grown overnight in LB broth, mixed with an equal volume of glycerol (BDH, 
Australia) and stored at -80°C.
2.1.2 Cloning into plasmids
2.1.2.1 Restriction endonuclease digestion o f DNA
DNA was digested with appropriate restriction endonucleases for analytical purposes and to 
generate cohesive ends for cloning. For cloning purposes, a reaction was prepared 
containing 10-20 units of the appropriate restriction endonuclease, 5 pL of the 
corresponding lOx incubation buffer, 20 pL plasmid miniprep DNA or PCR product DNA 
(concentration not determined) and MilliQ water to a final volume of 50 pL. The mixture 
was incubated at 37°C for 2-4 h. The required fragments were isolated by agarose gel 
electrophoresis (Section 2.1.5), and purified (Section 2.1.6).
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2.1.2.2 Dephosphorylation o f linearised vector
To prevent self-ligation, linearised plasmids used during cloning were dephosphorylated. 
Following digestion with the appropriate restriction endonuclease, 2 units of shrimp 
alkaline phosphatase (Roche, Germany) was added to the restriction reaction and the 
mixture incubated for a further 30 min at 37°C. Dephosphorylated, linear vector was 
isolated by agarose gel electrophoresis (Section 2.1.5) and purified (Section 2.1.6).
2.1.2.3 Ligations
Ligation reactions contained 1 pL of lOx T4 DNA ligase buffer (MB1, USA), 1 unit of T4 
DNA ligase (MBI, USA), 1 pg of dephosphorylated vector DNA, insert DNA and MilliQ 
water to a final volume of 10 pL. An approximate insert DNA : vector DNA molar ratio of 
5 was used for all ligation reactions. The reaction was incubated at 16°C overnight. If not 
used immediately for transformation, ligation reactions were stored at -20°C.
2.1.2.4 TA cloning
The pGEM-T Easy Cloning Kit (Promega, USA) was used for the direct cloning of Taq 
DNA polymerase-amplified PCR products. This enzyme adds a single 3’-A residue to the 
PCR product regardless of the template’s sequence. The linear vector possesses 3’ single T 
overhangs that allow for the efficient cloning of these PCR products.
Ligation reactions were set up according to the manufacturer’s instructions with 
modifications. To 7 pL of agarose gel electrophoresis-purified PCR product (Section 2.1.6) 
was added 1 pL of lOx T4 ligase buffer, 1 pL T4 ligase and 1 pL of pGEM-T Easy vector. 
This mixture was incubated at 16°C overnight, and transformed into E. coli as described in 
Section 2.1.2.6. If not used immediately, the ligation reaction was stored at -20°C.
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2.1.2.5 Preparation o f electrocompetent cells
To prepare electrocompetent cells, a glycerol stock of the required E. coli strain was 
streaked onto LB agar and grown overnight at 37°C. A single colony was selected and 
grown overnight in LB broth at 37°C. The next morning, this culture was diluted 1:20 in 
200 mL of fresh LB broth in a 500 mL conical flask and incubated with shaking at 37°C 
until mid-log phase (3 h). The bacteria were pelleted by centrifugation at 5000 rpm for 10 
min at 4°C (Sorvall RC5+ centrifuge, GSA rotor). The supernatant was discarded and the 
bacteria gently resuspended in 200 mL of ice-cold (1°C) sterile MilliQ water. The bacteria 
were pelleted at 5000 rpm for 10 min, and the supernatant discarded. The pellet was again 
resuspended in 100 mL of cold sterile MilliQ water and pelleted by centrifugation. The 
supernatant was discarded, and the bacteria suspended in 4 mL of cold sterile 10% glycerol. 
The bacteria were pelleted once more, the supernatant discarded and the bacteria suspended 
in 400 pL of cold sterile 10% glycerol. The bacterial suspension was divided up into 40 pL 
aliquots on ice in mierofuge tubes, and stored at -80°C.
2.1.2.6 Transformation o f electrocompetent cells
Electrocompetent E. coli was transformed by electroporation using a BioRad GenePulser II. 
The competent bacterial cells were thawed on ice. The DNA to be transformed into the 
cells (1-2 pL of plasmid miniprep or ligation reaction) was mixed with the cells, and the 
entire contents transferred to a BioRad GenePulser 0.2 cm electroporation cuvette that had 
been chilled on ice. The suspension was subjected to electroporation at 2.5 kV, 200 ohms 
and 25 pFd. Immediately following this, 1 mL of chilled LB broth was added, and the 
suspension transferred back into the original tube. The cell suspension was incubated at 
37°C for 1 h. After incubation, 50 pL of the cells were plated onto LB agar plates
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supplemented with 100 pg/mL of ampicillin or 30 pg/mL of kanamycin. 1PTG and X-gal 
were added to the agar plates if a-complementation was being carried out (Section 2.1.2.7).
2.1.2.7 a-complementation
The vectors used in this project often allowed the use of a-complementation to isolate those 
clones that contained insert DNA. a-complementation selection plates were prepared by 
spreading 20 pL each of isopropyl-ß-D-thiogalactopyranoside (IPTG; 20 mg/mL [Sigma, 
Australia]) and 5-bromo-4-chloro-3-indolyl-ß-D-galactoside (X-Gal; 20 pg/mL [Sigma, 
Australia]) onto LB agar plates containing ampicillin (100 pg/mL). The transformed 
bacteria (50 pL) were spread on the surface of these plates and incubated for 16-20 h at 
37°C. White colonies were selected for further analysis by transfer to a fresh LB-ampicillin 
agar plate or broth. These cultures underwent miniprep (Section 2.1.3.1) and restriction 
analysis (Section 2.1.2.1).
2.1.3 Plasmid DNA preparation
The plasmids used in this study are listed in Table 2.1.
2.1.3.1 Small scale plasmid DNA preparation (Miniprep)
Plasmid DNA was prepared using the Qiagen Spin Miniprep Kit according to the 
manufacturer’s instructions. Briefly, the bacterial strain containing the plasmid of interest 
was streaked onto an LB agar plate supplemented with the appropriate antibiotic and 
incubated overnight at 37°C. A single colony was selected, placed into 5 mL of LB broth 
supplemented with the appropriate antibiotic and incubated overnight at 37°C. The next 
morning, 1.5 mL of this culture was poured into a microfuge tube and the bacteria pelleted 
in a microcentrifuge at 13,000 rpm for 60 sec (Eppendorf 5415C centrifuge). The
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Table 2.1 -  Cloning vectors and plasmids used in this study.
P lasm id  / V e c to r C o m m en ts S o urce  / 
R eferen ce
V e c to rs
pDual2+ DNA vaccine vector containing two 
expression cassettes controlled by 
CMV-IE promoters and BGH-pA 
terminators, derived from pcDNA3.1+; 
AmpR
Scott
Thompson,
JCSMR
Figure 3.1
pGEM-T Easy TA-cloning vector for the cloning of 
Taq DNA polymerase amplified PCR 
products; AmpR, LacZ^
Promega
pET30a+ Cloning vector for the production of 
recombinant protein in X, phage 
lysogenic E. coli, under the Tl-lac  
promoter system; KanR
No vagen
pKS+Bluescript Cloning vector containing extensive 
multiple cloning site; AmpR, LacZ^
D N A  V a c c in e  P lasm ids
pDual-HA pDual2+ containing the haemagglutinin 
gene from influenza A/Peurto Rico/8 in 
the first expression cassette
This study 
(Chapter 3)
pDual-IL2 pDual2+ containing the rabbit 
interleukin-2 cDNA cloned into the 
second expression cassette
This study 
(Chapter 3)
pDual-lL4 pDual2+ containing the rabbit 
interleukin-4 cDNA cloned into the 
second expression cassette
This study 
(Chapter 3)
pDual-55R pDual2+ containing the myxoma virus 
antigen gene, M055R in the first 
expression cassette
This study 
(Chapter 3)
pDual-55R-IL2 pDual-55R containing the rabbit 
interleukin-2 cDNA cloned into the 
second expression cassette.
This study 
(Chapter 3)
pDual-55R-IL4 pDual-55R containing the rabbit 
interleukin-4 cDNA cloned into the 
second expression cassette
This study 
(Chapter 3)
pDual-73R pDual2+ containing the myxoma virus 
antigen gene, M073R in the first 
expression cassette
This study 
(Chapter 3)
Table 2.1 continued
p D u a l- 7 3 R - I L 2 p D u a l- 7 3 R  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 2  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 7 3 R - I L 4 p D u a l- 7 3 R  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 4  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 1 0 7 L p D u a l2 +  c o n ta in in g  th e  m y x o m a  v iru s  
a n t ig e n  g e n e ,  M 1 0 7 L  in  th e  f i r s t  
e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 1 0 7 L - I L 2 p D u a l- 1 0 7 L  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 2  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a I - 1 0 7 L - I L 4 p D u a l- 1 0 7 L  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 4  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 1 1 5 L p D u a l2 +  c o n ta in in g  th e  m y x o m a  v iru s  
a n t ig e n  g e n e ,  M 1 1 5 L  in  th e  f i r s t  
e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 1 1 5 L - I L 2 p D u a l - 1 15 L  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 2  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 1 1 5 L - I L 4 p D u a l- 1 1 5 L  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 4  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te .
T h is  s tu d y  
( C h a p te r  3 )
p D u a l-1 2 1  R p D u a l2 +  c o n ta in in g  th e  m y x o m a  v iru s  
a n t ig e n  g e n e ,  M 1 2 1 R  in  th e  f ir s t  
e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 1 2 1 R - I L 2 p D u a l- 1 2 1 R  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 2  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
p D u a l- 1 2 1 R - I L 4 p D u a l- 1 2 1 R  c o n ta in in g  th e  r a b b i t  
in te r le u k in - 4  c D N A  c lo n e d  in to  th e  
s e c o n d  e x p r e s s io n  c a s s e t te
T h is  s tu d y  
( C h a p te r  3 )
Recombinant Protein 
Synthesis Plasmids
p E T - 5 5 R p E T 3 0 a +  c o n ta in in g  th e  m y x o m a  v iru s  
a n t ig e n  g e n e  M 0 5 5 R , c lo n e d  in  f r a m e  
w i th  th e  5 ’ p u r i f ic a t io n  ta g s ,  b e tw e e n  
th e  E c o R \ a n d X h o l  s i te s
T h is  s tu d y  
( C h a p te r  3 )
p E T - 7 3 R p E T 3 0 a +  c o n ta in in g  th e  m y x o m a  v iru s  
a n t ig e n  g e n e  M 0 7 3 R , c lo n e d  in  f r a m e  
w i th  th e  5 ’ p u r i f ic a t io n  ta g s ,  b e tw e e n  
th e  E c o R l  a n d  X h o \  s i te s
T h is  s tu d y  
( C h a p te r  3 )
Table 2.1 continued
p E T -1 1 5 L p E T 3 0 a +  c o n ta in in g  th e  m y x o m a  v iru s  
a n t ig e n  g e n e  M l  1 5 L , c lo n e d  in  f r a m e  
w i th  th e  5 ’ p u r i f ic a t io n  ta g s ,  b e tw e e n  
th e  E c o R I a n d  X h o \  s i te s
T h is  s tu d y  
( C h a p te r  3 )
p E T -1 2 1 R p E T 3 0 a +  c o n ta in in g  th e  m y x o m a  v iru s  
a n t ig e n  g e n e  M 1 2 1 R , c lo n e d  in  f r a m e  
w i th  th e  5 ’ p u r i f ic a t io n  ta g s ,  b e tw e e n  
th e  E c o R \  a n d  X h o \  s i te s
T h is  s tu d y  
( C h a p te r  3 )
Plasmids used in the 
construction of 
recombinant myxoma 
viruses
p K S +AM 1O L/M 11 L g p t p K S +B lu e s c r ip t  c o n ta in in g  tw o  re g io n s  
o f  th e  M 1 O L /M  11L  lo c u s  o f  th e  
m y x o m a  v ir u s  s t r a in ,  U r ia r r a  b e tw e e n  
w h ic h  is  c lo n e d  th e  g p t  g e n e  o f  E . c o l i  
u n d e r  th e  c o n tr o l  o f  th e  p o x v ir u s  
p r o m o te r  p 7 .5
T h is  s tu d y  
( C h a p te r  4 )
F ig u r e  4.1
p K S +A M - T l g p t p K S +B lu e s c r ip t  c o n ta in in g  tw o  r e g io n s  
o f  th e  M T -7  lo c u s  o f  th e  m y x o m a  v iru s  
s t r a in ,  U r ia r r a  b e tw e e n  w h ic h  is  c lo n e d  
th e  g p t  g e n e  o f  E . c o l i  u n d e r  th e  c o n tr o l  
o f  th e  p o x v ir u s  p r o m o te r  p 7 .5
T h is  s tu d y  
( C h a p te r  4 )
F ig u r e  4 .3
p K S +A M -T7#w s p K S +B lu e s c r ip t  c o n ta in in g  tw o  re g io n s  
o f  th e  M T -7  lo c u s  o f  th e  m y x o m a  v iru s  
s t r a in ,  U r ia r r a  ( id e n t ic a l  to  p K S A M T -  
7g p t )  b e tw e e n  w h ic h  is  c lo n e d  th e  E . 
c o l i  g e n e  g u s  u n d e r  c o n tro l  o f  th e  
p o x v i r u s  p r o m o te r  p E /L
T h is  s tu d y  
( C h a p te r  4 )
F ig u r e  4 .3
p K S +A M 063R g p tg u s p K S  B lu e s c r ip t  c o n ta in in g  tw o  r e g io n s  
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supernatant was discarded, another 1.5 mL of culture added to the tube, the tube 
centrifuged again and the supernatant discarded. The bacterial cell pellet was resuspended 
in 250 pL of Buffer PI. Buffer P2 (250 pL) was then added and the tube inverted several 
times before addition of 350 pL of Buffer N3. After 5 min incubation at room temperature, 
the tube was centrifuged at 13,000 rpm for 10 min. The supernatant was transferred to a 
Qiagen Spin Column that was centrifuged for 60 sec at 13,000 rpm and the eluent 
discarded. The column was washed with 500 pL of Buffer PB and then 750 pL of Buffer 
PE, and the eluent discarded after each centrifugation. To elute plasmid DNA, 50 pL of 
Buffer EB was placed in the spin column that was incubated at room temperature for 5 min 
before centrifuging for 1 min into a clean microfuge tube. The plasmid DNA solution was 
then stored at -20°C.
2.1.3.2 Large scale preparation o f plasmid DNA and purification by CsCl-gradient 
Plasmid DNA for injection into rabbits was purified by two rounds of CsCl gradient 
ultracentrifugation as described in Sambrook and Russell (2001). To prepare plasmid 
DNA, 1 L of £. coli DH5a culture containing the vaccine plasmid (Table 2.1) was 
centrifuged in 500 mL Dryspin bottles (Nalgene, USA) at 5000 rpm in an SLA-3000 rotor 
(Sorvall RC5+ centrifuge) to collect bacteria. The medium was poured off, the pellet 
resuspended in 200 mL of STE buffer (100 mM NaCl, 100 mM Tris.ElCl [Progen, 
Australia], 10 mM EDTA [BDH, Australia], pH 8.0), and then recentrifuged. After pouring 
off the supernatant, the pellet was resuspended in 72 mL of ice-cold Solution I (50 mM 
glucose, 25 mM Tris.HCl, 10 mM EDTA, pH 8.0), then 160 mL of Solution II (200 mM 
NaOH [BDH, Australia], 1% SDS [BDH, Australia]) was added. The tube was inverted 
several times to thoroughly mix the bacteria with Solution II, then incubated at room 
temperature for 10 min. Ice-cold Solution III (40mL; 3 M potassium acetate [Ajax,
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Australia], 11.5% glacial acetic acid [BDH, Australia]) was then added, and the mixture 
gently shaken. After incubating on ice for a further 10 min, the precipitate was removed by 
centrifugation at 5000 rpm in an SLA 3000 rotor for 20 min. The supernatant was poured 
o ff into a clean 500 mL Dryspin bottle, ensuring no precipitate followed. Isopropanol (105 
mL; BDH, Australia) was added to precipitate plasmid DNA, and the mixture incubated at 
room temperature for 15 min. Plasmid was pelleted by centrifugation (6000 rpm for 20 
min) at 25°C. The pellet was washed twice with lOOmL o f 70% ethanol (BDH, Australia) 
and allowed to dry in air. The plasmid DNA was then dissolved in 6 mL o f TE buffer (2 
mM Tris.HCl, 5 mM EDTA, pH 8.0).
To further purify the plasmid DNA and remove any endotoxin, caesium chloride (CsCl) 
gradient ultracentrifugation was performed. Briefly, 1 g o f CsCl (Sigma, Australia) was 
added per m illilitre  o f plasmid DNA solution. This resulted in a final CsCl concentration 
o f approximately 0.8 g/mL. Ethidium bromide solution (10 mg/mL; Sigma, Australia) was 
added at 800 ^L  per 10 mL o f plasmid/CsCl solution. Beckman 342413 Quickseal 
ultracentrifuge tubes (13.5 mL) were filled with the resulting solution. The tubes were 
sealed and centrifuged in an 80Ti rotor at 60,000 rpm for 21 h. The plasmid DNA band 
was removed using an 18G needle and syringe, and diluted with TE buffer containing 1 
g/mL o f CsCl to a final volume o f 13.5 mL. The ultracentrifugation step was repeated, and 
the plasmid DNA band again removed. Ethidium bromide was extracted using water- 
saturated butanol (BDH, Australia), and CsCl removed by at least three rounds o f dialysis 
against TE buffer, until there was no butanol odour in the dialysis buffer. The purified 
plasmid DNA solution was stored at -20°C.
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2.1.4 Determination of DNA concentration
The concentration o f DNA in a solution was measured using spectrophotometry. The DNA 
solution was diluted 1:200 with M illiQ  water, and the absorbance at 260 nm measured 
using a Varian Cary Bio UV-Visible Spectrophotometer. The concentration was calculated 
by multiplying the absorbance by the dilution factor (200) and by the absorptivity o f 
double-stranded DNA (50 m L.cm 'pg '1) to obtain a DNA concentration in pg/mL.
2.1.5 Agarose gel electrophoresis
Agarose gel electrophoresis was performed using 0.6-1.5% agarose (Progen, Australia) in 
IX  TAE buffer (40 mM Tris.HCl, 0.9 mM EDTA, pH adjusted to 8.0 with glacial acetic 
acid). Agarose gel loading buffer (1/6 o f sample volume; 25% glycerol, 5.6 pg/mL 
bromophenol blue [Sigma, Australia]) was added to samples before loading onto the gel. 
The electrophoresis was carried out with IX  TAE buffer as the running buffer at a constant 
voltage o f 90 V until the blue dye front was about 80% down the gel. A fter 
electrophoresis, the gel was stained for 20 min in 1 pg/mL ethidium bromide solution, then 
destained in M illiQ  water for 30 min. DNA bands were visualised using a UV 
transilluminator, and recorded using a CCD camera and NIH Image software.
2.1.6 Purification of DNA from agarose gels
To purify DNA after gel electrophoresis (plasmids, PCR products and restriction 
fragments), the band containing the DNA o f interest was excised from the gel and 
transferred to a microfuge tube. The DNA was purified using the Qiagen Gel Extraction 
Kit, according to the manufacturer’s instructions. Briefly, the gel slice was weighed and 
three volumes o f Buffer QC added. The tube was incubated at 50°C until the gel had 
dissolved completely. One gel volume o f isopropanol was added to the tube and the
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mixture vortexed. The mixture was then transferred to a QIAquik spin column and 
centrifuged at 13,000 rpm for 1 min and the eluent discarded. The column was washed 
with 750 pL o f Buffer PE and the eluent discarded. To elute the DNA, 30 pL o f Buffer EB 
was added to the column that was incubated at room temperature for 5 min before 
centrifuging at 13,000 rpm for 1 min into a clean microfuge tube. The DNA solution was 
stored at -20°C until required.
2.1.7 Northern analysis
2.1.7.1 RNA gel electrophoresis and blotting
To detect the presence o f RNA transcripts, Northern blot analysis was used. RNA from 
cells was prepared as described in Section 2.4.4. A 1.1% agarose/formaldehyde gel was 
prepared by dissolving 0.55 g o f agarose in 36 mL o f diethylpyrocarbonate (DEPC; Sigma, 
Australia)-treated M illiQ  water and cooling to 60°C. RNA gel buffer (5 mL o f a 10X 
solution; 200 mM triethanolamine [BDH, Australia], 50 mM EDTA, pH 7.4) was added 
with 9 mL of 36% formaldehyde (BDH, Australia), giving a final concentration o f 2 M 
formaldehyde. The gel was allowed to set in an RNAse-free electrophoresis tank and 
covered with RNA running buffer (20 mM triethanolamine, 5 mM EDTA, 1.8 M 
formaldehyde, pH 7.4). RNA samples were prepared by adding 6 pL o f RNA to 14.4 pL o f 
RNA sample buffer (66% deionised formamide [BDH, Australia], 2.2 M formaldehyde, 27 
mM triethanolamine, 6.7 mM EDTA, pH 7.4) and denaturing at 60°C for 15 min. After 
adding 2 pL o f 6X agarose gel loading buffer, the RNA samples were loaded onto the gel 
and electrophoresed at a constant voltage o f 90 V for 2 h. The gel was stained in 1 pg/mL 
ethidium bromide solution for 20 min, destained in DEPC-treated water for 2-3 h and 
visualised as described in Section 2.1.5. The gel was then submerged in 20X SSC (300 
mM NaCl, 3 M citric acid [BDH, Australia]) for 30 min and then RNA transferred onto a
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Hybond N+ membrane (Amersham, USA) using the apparatus shown in Figure 2.1. 
Following overnight transfer at room temperature, the membrane was removed and baked 
at 120°C for 2 h to bind the RNA to the membrane.
2.1.7.2 Probe preparation
The membrane was probed with digoxigenin (DIG)-labelled DNA prepared using the DIG 
Fligh-Prime DNA Labelling and Detection Kit (Roche, Germany) according to the 
manufacturer’s instructions. The probe DNA required for each Northern blot corresponded 
to the gene whose transcripts were under investigation. This DNA was purified by gel 
electrophoresis following restriction endonuclease reaction or PCR amplification, and 
purified as described in Section 2.1.6. For the labelling reaction, 1 pg of probe DNA was 
suspended in 16 pL of DEPC-treated water and boiled for 10 min to denature the DNA. 
The tube was then placed on ice and 4 pL of DIG-High Prime Solution added to the probe 
DNA solution. The reaction was vortexed briefly, incubated at 37°C for 3-5 h, and then 
boiled for 10 min before placing on ice. The labelled probe solution was then ready to be 
added to the hybridisation reaction.
2.1.7.3 Membrane hybridisation
The fixed nylon membrane carrying the RNA was prehybidised in a Hybaid bottle with 50 
mL of high-SDS hybridisation solution (50% deionised formamide, 50 mM NaßPCL [BDH, 
Australia], 7% SDS, 0.1% N-laurylsarcosine [Sigma, Australia], 10% Blocking Solution 
[DIG Fligh-Prime Kit, Roche, Germany], 750 mM sodium citrate, 75 mM NaCl, pH 7.0) 
for 2 h at 65°C. After prehybridisation, the denatured, labelled probe DNA (Section 
2.1.7.2) was added and the tube incubated overnight at 65°C. In the morning, the 
hybridisation solution was poured off and the membrane washed at 70°C for 15 min, twice
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with 50 mL of 2X wash solution (300 mM sodium citrate, 30 mM NaCl, 0.1% SDS, pH 
7.0), twice with 50 mL of 0.5X wash solution (75 mM sodium citrate, 7.5 mM NaCl, 0.1% 
SDS, pH 7.0) and once with 0.2X wash solution (30 mM sodium citrate, 3 mM NaCl, 0.1% 
SDS, pH 7.0). The membrane was then removed from the Hybaid bottle and washed once 
with maleic acid buffer (100 mM maleic acid [Ajax, Australia], 150 mM NaCl, pH 7.5).
2.1.7.4 Visualisation o f probe binding
After washing, the membrane was probed with a monoclonal antibody against DIG, and 
binding of the antibody was detected by enhanced chemiluminescence (ECL). All steps 
were performed at room temperature using the DIG High-Prime DNA Labelling and 
Visualisation Kit (Roche, Germany) according to the manufacturer's instructions. Briefly, 
the membrane was transferred to a hybridisation bag and blocked with 20 mL of antibody 
blocking solution (90 mM maleic acid, 135 mM NaCl, 10% Blocking Solution [Roche, 
Germany], pH 7.5) for 30 min. The antibody blocking solution was poured off and 
replaced with 20 mL of antibody blocking solution containing 2 pL of alkaline 
phosphatase-conjugated anti-DIG antibody (Roche, Germany). After incubating for 30 
min, the membrane was washed twice with 20 mL of antibody wash buffer (100 mM 
maleic acid, 150 mM NaCl, 0.3% Tween 20 [Sigma, Australia], pH 7.5), 15 min each wash. 
Finally, all buffer was removed, the membrane covered with CSPD Ready-to-Use Reagent 
(Roche, Germany), sealed in a clean hybridisation bag and exposed to Hyperfilm ECL 
(Amersham, USA), which was developed using a Kodak X-OMAT automated x-ray film 
processor.
Page 49
Chapter 2 -  Materials and Methods
2.1.8 Polymerase Chain Reaction (PCR) methods
2.1.8.1 Standard PCR
PCR was used for several purposes in this study. Oligonucleotide primers (Tables 2.2 and 
2.3) were designed based on published sequences obtained from Genbank databases to 
amplify specific sequences under investigation. Primers were commercially manufactured 
by Proligo Australia as a stock solution o f 100 mM in water. Primers were diluted to a 
working concentration o f 10 mM with M illiQ  water. The standard PCR method used the 
following reaction mix, time and conditions:
1 pL o f forward primer (10 mM stock solution)
1 pL o f reverse primer (10 mM stock solution)
• 2 pL 10X Taq DNA polymerase buffer (Fischer Biotech, USA)
1.5 pL MgCb(25 mM stock solution; Fischer Biotech, USA)
1.5 pL dNTPs (10 mM each stock solution; Fischer Biotech, USA) 
i unit o f Taq DNA polymerase (Fischer Biotech, USA)
• Template DNA (generally 2-5 pL)
• sterile M illiQ  water to 20pL
Following careful mixing o f the reaction, it was placed in a capillary tube in a Corbett 
Research FTS-IS Capillary Thermal Sequencer and subjected to the following temperature 
program:
1 X
30-45 X
1 X
rapid ramp to 95°C for 2.5 min 
rapid ramp to 95°C for 30 sec
rapid ramp to annealing temperature (50-60°C) for 30 sec 
rapid ramp to 72°C for 1-4 min (extension)
72°C for 4 min.
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Table 2.2 - PCR primers used in the amplification and cloning of myxoma virus genes 
and rabbit cytokines. The restriction sites incorporated in the primers are underlined, and 
the start or stop codons included in the primer are in bold.
M055R Fwd (£c«RI)
5’ TTG GAA TTC ATG GGT GCC GCC GCG AG 3’
M055R Rev (XhoI)
5’ CGT CTCGAG CAG TTT TTA A AC ACT GTG TAC C 3’
M073R Fwd (£coRI)
5’ CGT GAA TTC ATG TCT TGG TCC ATA AAC CTA G 3’
M073R Rev (Xhol)
5’ CTG CTCGAG GAG TTA TTT TTT GGT TGT CTG 3’
M107L Fwd (£c«RI)
5’ CTG GAA TTC ATG AGT TAT TTA AGT TAT TAC AAT ATG 3’
M107L Rev (XhoI)
5’ CGT CTCGAG AT A ATT ATT AAT CTT CGT AG A AGC 3’
M115L Fwd (£cöRI)
5’ CGT GAA TTC ATG GAT AGA GTG TTG TCG ATA TAC 3’
M115L Rev (Xhol)
5’ CGT CTCGAG GTT TCT GTA ACG ATT ATA GAG C 3’
M121R Fwd (£ c ö RI)
5’ CGT GAA TTC ATG TCG TTA CAC GCC AAC G 5’
M121R Rev (Xho\)
5’ CGT CTC GAG TTT TCA TTT ATA ACT ATA AAG TAA ATG 3’
IL2 Fwd (Nhel)
5’ CGT GCT AGC ATG TAC AAA GTA CAA CTC TTG 3’
IL2 Rev (///«d ill)
5’ CGT AAG CTT TTA TGA ACT CGA TGC TCA G 3’
IL4 Fwd (ATi I^)
5’ CGT GCT AGC ATG GGG CTC CCT GCC 3’
IL4 Rev (HindlU)
5’ CTG AAG CTT TCA GCT CTG ACG CTT TG 3’
Table 2.3 -  Primers used in the construction and screening of recombinant myxoma 
viruses. Restriction sites incorporated into the primers are underlined.
M007L-R2 (XhoY)
TCCTCGAGACGTTCAAACATGGAG
M007-RI
TCCGTAGACGGACACTTCC 
M007L-F2 (///«dill)
CGAAGCTTAAACGAGCGGAGTACGTC
M007L-R1 (EcoRl)
AAGAATTCTACGCTGGTACCTGTTC
M007L-F1 (BamHl)
GTGGATCCTCGCGTCGCTCGCTATC
M008L-F1 (BamHl)
ACGGATCCTGTCACTTCGCCACCATG
M009L-R1 (Xhol)
GACTCGAGCGTCGCTCATTGCACCATC
M010L-F1 (///«dill) 
CTACGTGGGAAGCTTATGTCAG
M010L-R1
TAGAATTCCAACGAAGGCATCGTTGC
M011L-R1 (£coRI) 
CTATGAATTCCGAGAACATAGC
M012L-F1 (BamHl)
ACGGATCCATAACGGATTCGGTTCAAG
M062R-R1 (Bam HI) 
CAGGATCCGTGATCAACCTGTTCAG
M063R-R1 (£coRI)
GTGAATTCGCAACTGTGCCCGTGAC
M063R-F1
GAGAAGGAGTACTGCTTCAC
M063R-F2 (///«dill)
CGAAGCTTATACCAGCAGTGAGGAAG
M064R-R1 (XhoX)
CCCTCGAGATAACGACTTTATAAATAAGTG
gpt-Rl
CAACATGTCCCAGGTGACG
gus-Fl
GGACTGGCATGAACTTCG
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I f  not analysed immediately by agarose gel electrophoresis (Section 2.1.5), PCR products 
were stored at -20°C.
2.1.8.2 Colony PCR
Colony PCR was used to screen transformed E. coli colonies for the presence o f the 
required insert DNA. Template DNA was prepared by suspending a colony o f bacteria in 
50 pL o f M illiQ  water, and incubating at room temperature for 10 min. After vortexing 
vigorously, 5 pL o f this suspension was used immediately in a PCR as described in Section 
2.1.8.1, and the remainder stored at 4°C. I f  the colony was found to contain the required 
insert DNA, the colony preparation was restreaked from the 50 pL aliquot onto an LB agar 
plate supplemented with the appropriate antibiotic and incubated at 37°C overnight.
2.1.9 DNA Sequencing
DNA was sequenced using the ABI Prism BigDye Terminator Cycle Sequencing Ready 
Reaction K it (Perkin Elmer, USA). To 4 pL o f the Ready Reaction Mixture was added 
300 ng o f template DNA, 3.75 pmol o f sequencing primer and M illiQ  water to a final 
volume o f 10 pL. The reaction was subjected to the following temperature program in a 
Corbett Research FTS-IS Capillary Thermal Sequencer:
25 cycles o f [95°C for 10 sec; 50°C for 5 sec; 60°C for 4 min]
Once completed, excess dye terminators were removed by adding water (10 pL), 2 pL o f 3 
M sodium acetate [BDH, Australia] and 50 pL o f ethanol. The mixture was placed on ice 
for 20 min, followed by 20 min o f centrifugation at 13,000 rpm. The supernatant was 
removed and the DNA pellet washed three times with 500 pL o f ice-cold 70% ethanol. The 
tube was centrifuged for 5 min and the wash solution removed. The pellet was then air- 
dried. Once dried, the reactions were electrophoresed and the sequence recorded using an
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ABI 3730 Sequencer (Applied Biosystems, Australia) at the John Curtin School o f Medical 
Research Biomolecular Resources Facility at the Australian National University.
2.2 SDS-PAGE a nd  Immu n o b l o t t in g
2.2.1 Preparation and electrophoresis of SDS-PAGE gels
During this project, size-separation o f proteins was performed prior to immunoblotting or 
other forms o f analysis. This was accomplished using the BioRad M ini Protean II system. 
A ll experiments used 1 mm thick, 12% SDS-PAGE resolving gels topped with a 4.7% 
stacking gel and were prepared in duplicate. The resolving gel solution was prepared by 
mixing 1.5 mL o f 40% acrylamide solution (29 parts acrylamide, 1 part bis-acrylamide; 
Amresco, USA), 2.25 mL o f M illiQ  water and 1.25 mL o f resolving gel buffer (500 mM 
Tris.HCl, 0.4% SDS, pH 6.8). The gel was polymerised by adding 5 pL o f N,N,N',N'- 
tetramethylethylenediamine (TEMED; BioRad, Australia) and 50 pL o f a 10% ammonium 
persulfate solution (APS; Biorad, Australia), and the solution immediately transferred to the 
gel housing for setting. Once the resolving gel had set, a stacking gel was prepared by 
mixing 625 pL o f stacking gel buffer (1.5 M Tris.HCl, 0.4% SDS, pH 8.8), 300 pL o f 40% 
acrylamide and 1.63 mL o f M illiQ  water. TEMED (5 pL) and 10% APS (50 pL) were 
added and solution layered on top o f the resolving gel. A teflon comb with the required 
number o f wells was immediately inserted and the stacking gel was set at room temperature 
for 30 min. Once set, the comb was removed, the gels were placed into the gel tank and 
covered with SDS-PAGE running buffer (0.1% SDS, 24 mM Tris.HCl, 192 mM glycine 
[BDH, Australia]).
Samples were prepared by mixing equal volumes o f protein sample and 2X sample loading 
buffer (SLB; 62.5 mM Tris.HCl, 10% glycerol, 2% SDS, 0.4 mg/mL bromophenol blue,
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pH 6.8). I f  denaturing conditions were required, 2X SLB was supplemented with 
dithiothreitol (DTT; Sigma, Australia) to a final concentration o f 100 mM. Samples were 
then boiled for 3 min and cooled on ice. Samples (20 pL) were added to each well and 
electrophoresed at a constant 100 V for 90 min. Protein molecular weight markers 
(Benchmark Pre-Stained Markers [GibcoBRL, USA]) were run on each gel, to allow 
determination o f the molecular weight o f proteins under analysis. After electrophoresis, the 
gels were removed from the apparatus and the stacking gel removed and discarded.
2.2.2 Coomassie blue staining of SDS-PAGE gels
To visualise proteins in the SDS-PAGE gels, the resolving gel was placed in 50 mL o f 
Coomassie Blue staining solution (45% methanol, 9% glacial acetic acid, 1.8 g/L 
Coomassie brilliant blue [Sigma, Australia]) and gently agitated for 60 min on a rocking 
table. The gel was then removed and destained in 100 mL o f destaining solution (23% 
ethanol, 9.6% glacial acetic acid) for 60 min. The destaining solution was replaced and the 
gel destained overnight. Destaining solution replacement was continued until the 
background o f the gel was completely destained.
2.2.3 Silver staining of SDS-PAGE gels
Silver staining was performed using the Bio-Rad Silver Stain K it according to the 
manufacturer’s instructions. A fter electrophoresis, the gel was removed from the 
apparatus, placed in 100 mL o f Fixative-1 (40% methanol, 10% glacial acetic acid) and 
gently agitated for 30 min. The gel was then transferred to 100 mL o f Fixative-2 (40% 
methanol, 5% glacial acetic acid) for 15 min, and then to a fresh aliquot o f Fixative-2 for 15 
min. The gel was then placed in 50 mL o f Oxidiser Solution (Biorad, Australia), gently 
agitated for 5 min, then washed twice in 100 mL o f M illiQ  water. The gel was transferred
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to 50 mL o f Silver Reagent (10% Silver Reagent Concentrate in M illiQ  water [Biorad, 
Australia]) for 20 min with shaking, and then washed in 100 mL o f M illiQ  water for 1 min. 
Developer Solution (50 mL; 32 g/L Developer Powder [Biorad, Australia]) was added to 
the gel until a smoky precipitate formed (approximately 1 min), when it was replaced with 
a further 50 mL o f Developer Solution. The gel was left in the Developer Solution until 
bands were clearly visible, at which point the gel was placed in Stop Solution (5% glacial 
acetic acid) for 5 min.
2.2.4 Transfer of proteins from SDS-PAGE gels to PVDF membranes 
(immunoblotting)
To perform immunoblot analysis, proteins were transferred from the SDS-PAGE gel to 
PVDF membranes using the Hoefer SemiPhor transfer apparatus. After electrophoresis, 
gels were placed in Electrotransfer Buffer (25 mM Tris.HCl, 192 mM glycine, 0.1% SDS, 
15% methanol) for 20 min. Ten sheets o f 3MM paper o f the same size as the gel were 
soaked in Electrotransfer Buffer. An lmmobilon-P PVDF membrane (Millipore, Australia) 
o f the same size as the gel was wet with methanol, and then soaked in Electrotransfer 
Buffer for 5 min. The apparatus was assembled as shown in Figure 2.2. The proteins were 
transferred by applying a constant current o f 0.8 mA per cm“ o f gel area for 45 min. After 
transfer, the membrane was removed and washed in Tris-buffered saline (TBS; 137 mM 
NaCl, 25 mM Tris.HCl, 2.7 mM KC1 [Ajax, Australia], pH 8.0). The membrane was then 
used in immunostaining immediately, or blotted dry and used within a few days.
2.2.5 Immunostaining of membranes
PVDF membranes were probed with antibodies for the presence o f specific proteins. 
Membranes were first blocked using 50 mL o f blocking buffer (10% skim m ilk powder
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[Diploma, Australia] in TBS) overnight at 4°C, or for 1 h at room temperature. The 
membrane was then washed three times in 50 mL o f TTBS (0.1% Tween 20 in TBS) with 
agitation at room temperature. The primary antibody was then diluted in 20 mL o f 
antibody buffer (2% skim milk powder, 0.05% Tween 20 in TBS) to the required dilution 
factor (1/100 to 1/5000), and incubated with the membrane with agitation at room 
temperature for 2 h. The membrane was then washed three times with 50 mL TTBS with 
agitation. The secondary antibody conjugated to horseradish peroxidase (HRP; Silenus 
Labs, Australia) was then diluted 1/1000 with 20 mL o f antibody buffer and incubated at 
room temperature with the membrane for 1 h. The membrane was then washed twice with 
50 mL o f TTBS with agitation, and then once with 50 mL o f TBS. The membrane was 
now ready to visualise specific binding o f the primary antibody.
2.2.6 Visualisation of antibody binding
Chemiluminescent detection o f specific antibody binding to the membrane was done using 
the ECL Western Blotting Analysis System (Amersham Biosciences, United Kingdom), 
according to the manufacturer’s instructions. Equal volumes o f the two kit reagents 
(Detection Reagents 1 and 2) were mixed and allowed to reach room temperature. Enough 
o f the reagents were prepared such that there was 0.125 mL/cm" o f membrane. The 
solution was placed on the immunostained membrane (Section 2.2.5) such that the entire 
surface was in contact with the Detection Reagent and incubated at room temperature for 1 
min. Excess reagent was poured off, and the membrane wrapped in plastic film and placed 
into an autoradiography cassette. The membrane was exposed to Hyperfilm ECL which 
was developed using a Kodak X-OMAT automated x-ray film  processor.
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2.3 Pr e p a r a t io n  o f  r e c o mb in a n t  my x o ma  v ir u s  a n t ig e n s  as  6XH is -T a g g e d
FUSION PROTEINS
Recombinant proteins were produced in an E. co//-based pET system (Novagen, Germany), 
utilising the T l-Iac  promoter system for high production levels o f recombinant proteins 
(Novagen, 2003; Studier et al., 1990). Proteins were purified using TALON Metal A ffin ity 
Resin (Clontech, USA). These recombinant proteins were used in Western blot analysis 
and lymphocyte proliferation assays described in Section 2.7.
2.3.1 Preparation of producer strain of bacteria and production of protein
Myxoma virus genes were amplified by PCR (Section 2.1.8) using primers described in 
Table 2.2. The primers contained an EcoR\ site immediately before the start codon, and a 
Xho\ site a few bases downstream o f the stop codon. Purified PCR amplified fragments o f 
myxoma virus open reading frames were digested with EcoR\ and Xho\, and were inserted 
into the pET30a+ vector (Novagen, Germany) between the EcoRA and Xho\ sites, in frame 
with the 5’ purification tag sequences. The recombinant plasmids were transfected into E. 
coli BL21(DE3), a producer strain o f bacteria containing a lysogenic T7-type 
bacteriophage, DE3. Bacteria were grown overnight at 37°C in LB-kanamycin broth, sub-
cultured 1:50 into fresh LB-kanamycin broth and incubated with shaking for 2.5 h at 37°C. 
Inducer (IPTG to a final concentration o f 1 mM) was added and shaking at 37°C continued 
for a further 3 h.
2.3.2 Harvesting of soluble protein from culture
Cells were collected by centrifugation in 40 mL Oak Ridge Tubes at 5000 rpm in a SS-34 
rotor for 20 minutes (Sorvall RC5+ centrifuge), and media poured off. The cell pellet was 
resuspended in Extraction/Wash Buffer (50 mM Na3P0 4 , 300 mM NaCl) such that the
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bacteria were concentrated 10-fold from the original culture. Lysozyme (final 
concentration of 100 jig/mL; Sigma, Australia) was added and the bacteria incubated on ice 
for 30 min with occasional shaking. The cells were then lysed by sonication on ice (4 
pulses of 15 sec, maximum power). The bacterial cell lysate was then centrifuged in 40 mL 
Oak Ridge Tubes at 10,000 rpm in an SS-34 rotor at 4°C for 30 min (Sorvall RC5C+ 
centrifuge) to pellet insoluble material. The clarified supernatant was transferred to a clean 
tube and was used immediately, or stored at -80°C overnight.
2.3.3 Purification of recombinant protein on TALON-IMAC resin
Recombinant protein was purified on TALON IMAC resin (Clontech, USA). A gravity 
flow column containing 5 mL of TALON resin was washed with 25 mL of 
Extraction/Wash Buffer. Clarified cell lysate (20 mL) was added to the column and 
allowed to flow through. The resin was then washed with 25 mL of Extraction/Wash 
buffer, followed by 25 mL of Imidazole Wash Buffer (50 inM NasPCL, 300 mM NaCl, 15 
mM imidazole [Sigma, Australia]) to remove non-specifically bound proteins. To elute 
recombinant proteins, 25 mL of Extraction Buffer (50 mM NasPCL, 300 mM NaCl, 150 
mM imidazole) was added to the column, and 1 mL fractions of flow-through eluent 
collected and stored at -80°C.
Individual fractions were analysed by SDS-PAGE. Fractions containing the recombinant 
protein were pooled and protein precipitated by the addition of 1/10 volume of 1 g/mL 
trichloroacetic acid (BDH, Australia). The tubes were incubated on ice for 20 min and then 
centrifuged at 13,000 rpm for 15 min at 4°C (Eppendorf 5415C centrifuge). The protein 
pellet was washed three times with acetone and then air-dried. Recombinant proteins were
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resuspended in phosphate buffered saline (PBS; 137 inM NaCl, 1.76 mM KH 2PO4, 10.2 
mM Na2HPC>4, 3 mM KC1, pH 7.4) and stored at -80°C.
A negative control antigen was prepared as follows: E. coli BL21(DE3) containing the 
pET30a+ vector only was subjected to the same treatment and protein purified. The 
resulting 10 kDa protein contained all o f the N-terminal purification tags, and bacterial 
products found in the antigen preparations, but no myxoma virus-specific sequences.
2.4. Cel l  c u l t u r e  Me t h o d s
2.4.1 Maintenance and sub-culturing of RK-13, Vero, CV-1 and BSC-1 cell lines
RK-13 and Vero cells (obtained from laboratory stocks), and CV-1 and BSC-1 cells 
(obtained from Ron Jackson, CS1RO Sustainable Ecosystems) were maintained in Minimal 
Essential Medium (MEM; Gibco, USA), supplemented with 10% foetal calf serum (Gibco, 
USA), 2 mM L-glutamine (Gibco, USA), 500 pg/mL amphotericin B (Gibco, USA), 60 
pg/mL penicillin (CSL, Australia) and 100 pg/mL streptomycin (Sigma, Australia). 
Medium with all o f the above additives w ill be called MEM(Complete). MEM(Complete) 
without foetal calf serum w ill be called MEM(F‘A ). MEM(Complete) without antibiotics 
(includes penicillin, streptomycin and amphotericin) w ill be called MEM(F A'). 
MEM(Complete) without foetal calf serum or antibiotics w ill be called MEM(F'A'). Each 
o f these media was required for specific protocols.
Cells were sub-cultured every 3-4 days. For a confluent cell monolayer in a T180 cell 
culture flask (Nunc, USA), the monolayer was washed twice with 20 mL o f trypsin diluent 
(140 mM NaCl, 5 mM KC1, 400 pM Na2HP04, 400 pM KH2P04, 6 mM NaHC03, 300 pM 
Na3EDTA, pH 7.3). Trypsin (15 mL o f 0.1% solution in trypsin diluent; Gibco, USA) was
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added to the flask and incubated at 37°C for 3-5 min. The cells were dislodged and poured 
into a tube containing 20 mL o f MEM(Complete) and the concentration o f cells determined 
by counting with a haemocytometer. Approximately 3 mL o f the cells were transferred to a 
fresh T180 flask with 40 mL o f MEM(Complete) and incubated for 3-4 days at 37°C before 
sub-culturing again. These cells could also be plated out into 6-well, 24-well or 96-well 
plates as required. Unless otherwise indicated, all incubations during cell culture were 
performed at 37°C in a humidified, water-jacketed incubator in an atmosphere o f 5% 
C 02/95% air.
2.4.2 Transfection of RK13 and Vero cells
Twenty-four (24)-well plates were seeded with 1.5x10s cells in 1 mL o f MEM(F A') per 
well. These were grown to 90-95% confluency. Monolayers were washed twice with 
MEM(F’A ’ ) and then 500 pL o f MEM(F A ) was added to each well. In a microfuge tube, 
50 pL o f MEM (F A  ) and 3 pL o f Lipofectamine 2000 (Gibco Life Technologies, USA) 
were mixed by gently flicking the tube. This was incubated at room temperature for 5 min 
and then added to 50 pL o f MEM(F'A') containing 2 pg o f the plasmid to be transfected 
into cells, and mixed by gently flicking the tube. This mixture was then incubated at room 
temperature for 20 min and added to 1 well o f washed cells. Cells were then incubated at 
37°C until required (usually 24 or 48 h).
2.4.3 Protein extraction from plasmid-transfected RK13 cells
Transfected monolayers were washed twice with 1 mL o f PBS, and then 150 pL o f IX  
SDS-PAGE sample loading buffer was added to each well. A ll cellular material was 
scraped from the well using a pipette tip, and the contents transferred to a microfuge tube.
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Samples for SDS-PAGE analysis were boiled for 10 min with 15 pL o f 1 M DTT (reducing 
conditions) or with no additional DTT (non-reducing conditions).
2.4.4 RNA Extraction from plasmid-transfected RK13 cells
Twenty-four hours following transfection, the media was removed, and the monolayer 
washed with 1 mL o f PBS. To each well was then added 200 pL o f RNAZol B (Tel-Test, 
USA). A ll cellular material was scraped from the well using a pipette tip, and the solution 
transferred to a 1.5 mL microfuge tube. Chloroform (20 pL) was added and the tube 
shaken vigorously for 15 sec. The tube was placed on ice for 5 min and then centrifuged at 
13,000 rpm (Eppendorf 5415 D centrifuge) at 5°C for 15 min. The top (aqueous) layer was 
then removed to a fresh microfuge tube containing 150 pL o f isopropanol. This was mixed 
and placed on ice for 15 min to precipitate the RNA. The tube was centrifuged at 13,000 
rpm for 15 min at 4°C, and the supernatant removed. The RNA pellet was washed with 1 
mL o f 75% ethanol by vortexing briefly, and then centrifuging at 13,000 rpm for 5 min. 
A fter removing the supernatant, the pellet was dried briefly under vacuum at room 
temperature. The pellet was resuspended in 20 pL o f DEPC-treated water with 1 U/pL o f 
DNAse (Sigma, Australia), and stored at -80°C.
2.4.5 Immunofluorescent detection of protein production in transfected cells
After transfection, cells were incubated for 24 h. Monolayers were washed twice with 500 
pL o f PBS, then fixed with 250 pL o f methanol:acetone (1:1) for 10 min. After removing 
the methanokacetone, monolayers were then washed twice with PBS. Polyclonal anti-
myxoma virus serum from a hyperimmune rabbit was utilised to detect myxoma virus 
antigens. Serum was diluted 1:400 with PBS containing 3% bovine serum albumin (BSA; 
Amersham, UK) and incubated with cell monolayers for 90 min. Monolayers were washed
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twice with PBS containing 3% BSA and then incubated with fluorescein isothiocyanate 
(FITC)-conjugated anti-rabbit Ig (Silenus Labs, Australia) for 60 min. After washing twice 
with PBS, specific binding o f antibody was observed using a Leitz Fluovert FS microscope 
and recorded with a Spot RT digital camera (Diagnostic Instruments, Australia).
2.4.6 In vitro confirmation of rabbit interleukin-4 expression
Expression o f rabbit interleukin-4 (IL-4) was detected using immunofluorescence. RK13 
monolayers transfected with IL-4-expressing plasmids were fixed as described in Section
2.4.5. Anti-rabbit IL-4 antiserum had previously been raised in rats immunised with a 
synthetic peptide based on Helix A o f rabbit IL-4. This serum binds specifically to rabbit 
IL-4 on both immunoblots and transfected cells (Kerr et al., 2004). The serum was diluted 
1/100 in PBS containing 3% BSA, added to fixed monolayers and incubated at room 
temperature for 90 min. Antibody binding was detected using FITC-conjugated anti-rat 
IgG secondary antibody (Silenus Labs, Australia) and observed as described in Section
2.4.5.
2.4.7 Concentration of supernatants from tissue culture cells
For the analysis o f proteins secreted from transfected or virus-infected cells, supernatants 
were concentrated. This was achieved using Centricon Centrifugal Filter Devices (Amicon 
Bioseparations, USA) according to the manufacturer’s instructions. After 24-48 h 
incubation, supernatants from transfected or infected RK13 cell monolayers were collected 
without disturbing the cell monolayer. Supernatant (2 mL) was placed into the sample 
reservoir o f a Centricon YM-10 tube and the device assembled according to the 
manufacturer’s instructions. The tubes were centrifuged at 5000 rpm in an SS-34 rotor at 
25°C for 1 h. This resulted in the 50-fold concentration o f supernatants (retentate volume
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of 40 pL). The retentate was collected by removing the filtrate vial, capping the sample 
reservoir and inverting the tube. The tube was centrifuged at 5000 rpm in an SS-34 rotor 
for 10 min to collect the concentrated retentate. This was stored at -80°C until required for 
further analysis.
2.4.8 HT-2 bioassay for in vitro confirmation of interleukin-2 expression
The production of rabbit interleukin-2 (IL-2) from IL-2-expressing plasmid-transfected 
cells was detected using the mouse lymphocyte cell line HT-2, which has an absolute 
dependence on IL-2 for proliferation (Wadhwa et a/., 1995). Rabbit IL-2 is able to induce 
proliferation of this cell line (Peter Kerr, personal communication). HT-2 cells were 
cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% foetal calf serum, 2 
mM L-glutamine, 500 pg/mL amphotericin B, 60 pg/mL penicillin, 100 pg/mL 
streptomycin, 1 mM sodium pyruvate (Sigma, Australia), 10 mM NaCl and 6.2 pL/L 
monothioglycerol (Sigma, Australia). This media was called RPMI(HT-2). This was 
supplemented with 0.1% recombinant mouse IL-2 solution produced in Hi5 cells (obtained 
from Barbara van Leeuwen, School of Biochemistry and Molecular Biology) for the growth 
and passaging of HT-2 cells. For use in the bioassay, cells were collected by centrifugation 
at 1200 rpm in a Beckman Allegra 6R centrifuge for 10 min, and the supernatant removed. 
The cells were washed 3 times with 30 mL of RPMI(H-T2) without supplemental IL-2 to 
remove residual IL-2. All following steps used media without supplemental IL-2 Cells 
were then counted using a haemocytometer.
To measure the production of rabbit IL-2 from IL-2-expressing plasmid-transfected RK13 
cells, cells were incubated for 48 h following transfection and the supernatant collected and 
concentrated by a factor of ten (Section 2.4.7). Two-fold serial dilutions of the
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concentrated supernatants were performed using RPMl(HT-2), from 0 to 1/1024 and 50 pL 
o f each dilution added to quadruplicate wells in round bottom 96-well plates. As a positive 
control, recombinant mouse IL-2 was diluted 1/100 and then serially diluted as described 
above. Concentrated supernatants from cells transfected without plasmid (mock- 
transfected) was used as negative controls. To each well, 5 x 104 cells o f HT-2 were added 
in 50 pL o f RPMI(HT-2). Plates were incubated for 24 h at 37°C in humidified air with 
5% CO2. To measure IL-2 induced proliferation, 0.5 pCi o f 1H-thymidine (Amersham, 
UK) was added in 10 pL o f RPMI(HT-2) to each well and the plates incubated for a further 
6 h. The plates were then stored at -80°C. Cells were harvested using a Packard Filtennate 
96 onto an EasyTab-C Self-Aligning Glass Filter (Packard, Australia). The glass filter was 
dried at 37°C for 20 min and loaded into an OmniFilter cassette (Packard, Australia). 
Microscint O scintillant fluid (20 pL; Packard, Australia) was added to each well o f the 
glass filter, and ’ H-thymidine incorporation counted on a Packard Topcount NXT 
scintillation counter (Packard, Australia).
2.5 VIRUS CULTURE METHODS 
2.5.1 Virus strains
The Standard Laboratory Strain o f myxoma virus (SLS) used in this study is derived from a 
freeze-dried rabbit tissue stock prepared by Professor Frank Fenner (John Curtin School o f 
Medical Research, Canberra, Australia) in 1953. This virus is o f Grade I virulence (Fenner 
and Marshall, 1957), killing 100% o f infected laboratory rabbits with an average survival 
time o f less than 13 days (Robinson et al., 1999). The Lausanne strain o f myxoma virus 
has been completely sequenced (Cameron et al., 1999) and was used as the template for 
primer design in the cloning o f viral antigen genes (Tables 2.2 and 2.3). The Uriarra strain 
o f myxoma virus was derived by plaque purification by Russell and Robbins (1989) from
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the Uriarra/2/53-1 isolate (Mykytowycz, 1953). This virus is o f Grade 5 virulence and 
more than 95% o f infected laboratory rabbits recover from infection although they do 
develop moderate to severe clinical myxomatosis (Fountain et a l., 1997; Best and Kerr, 
2000). Viruses used in this study were prepared in RK13 cell monolayers that had been 
infected with testis samples taken from infected laboratory rabbits 8-9 days after infection 
with the viruses. Virus stocks used were then concentrated (Section 2.5.4) and the titre 
determined as described in Section 2.5.5.
2.5.2 Preparation of viral DNA
For PCR amplification o f viral DNA sequences, myxoma virus DNA was purified using the 
Qiagen DNAeasy Tissue K it according to the manufacturer’s instructions. Briefly, a T75 
flask o f cells was infected with virus at a multiplicity o f infection (MOI) o f 1 and incubated 
at 37°C for 4-5 days, until complete cytopathic effect (CPE) was observed. The flask was 
freeze/thawed twice (-80°C to 37°C) and the virus/cell lysate collected into a 40 mL Oak 
Ridge tube. The tube was centrifuged at 12,000 rpm in an SS-34 rotor for 2 h at 4°C, and 
the supernatant poured off. The cell pellet was resuspended in 200 pL o f PBS and 
transferred to a microfuge tube. Buffer AL (200 pL) and 20 pL o f proteinase K solution 
was added and the mixture incubated at 70°C for 15 min. Ethanol (200 pL) was added to 
the tube and then vortexed briefly to ensure mixing. The mixture was transferred to a 
DNAeasy Spin Column, centrifuged at 8000 rpm for 1 min (Eppendorf 5415C centrifuge) 
and the eluent discarded. The column was washed with 500 pL o f Buffer AW1, and then 
500 pL o f Buffer AW2. After discarding the eluent, the column was centrifuged at 13,000 
rpm for 3 min to remove residual wash buffer. The column was transferred to a clean 
microfuge tube and 100 pL o f Buffer AE added to the column, which was incubated at
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room temperature for 5 min. Viral DNA was eluted by centrifugation at 13,000 rpm for 1 
min, and the DNA stored at -20°C until required.
2.5.3 Preparation of recombinant viruses
2.5.3.1 Infection o f cells with virus and transfection with homologous plasmid 
To prepare deletion mutants of the Uriarra strain of myxoma virus, a monolayer of RK13 
cells was grown in a 6-well plate until 90-95% confluent. The monolayer was washed 
twice with 1 mL of MEM(F'A'), and then infected with 1 x 106 pfu of Uriarra (MOI=l) in 
400 pL of MEM (FA)  and incubated at 37°C for 1 h, rocking every 10 min. The virus 
dilution was removed and the monolayer washed twice with 1 mL of MEM(F'A') to remove 
residual virus, and then 2.5 mL of MEM(F'A') added.
Plasmids used for the preparation of recombinant viruses are described in Table 2.1. To 
prepare the plasmid DNA for transfection, 5 pg of the required plasmid was added to 250 
pL of MEM(FA'). In a separate tube, 15 pL of Lipofectamine 2000 was added to 250 pL 
of MEM(F'A') and incubated at room temperature for 5 min. The plasmid DNA and 
Lipofectamine solutions were mixed by flicking the tube and incubated at room 
temperature for 20 min, then the entire mixture was added to the well containing the 
Uriarra-infected RK13 monolayer. The cells were incubated at 37°C for 5 h, and the 
monolayer washed twice with 1 mL of MEM(F'A’). Finally, 3 mL of MEM(F‘A ) 
supplemented with 250 pg/mL of xanthine (Sigma, Australia), 10 pg/mL of mycophenolic 
acid (Sigma, Australia) and IX HAT supplement (Gibco, USA) was added to the well if 
using gpt selection (this media will be called MEM[Selective]) or 3 mL of MEM(F'AT) if 
using gus selection, and the cells returned to the 37°C incubator for 2-4 days, until 
complete CPE was observed on the monolayer. The plate was then freeze/thawed twice to
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disrupt cells and release virus, and the cell lysate collected. This was called the 
recombinant virus preparation, and was stored at -80°C.
2.53.2 Purification o f recombinant virus using guanine phosphorybosyl transferase (gpt) 
selection
To isolate pure recombinant virus, several rounds of plaque purification were performed. 
The recombinant virus preparation was sonicated using a Branson Sonifier 450 Cup 
Sonicator (50% Duty, Output 5) for 40 sec. The sonicated preparation was then serially 
diluted in tenfold steps using MEM(F'A ) down to 10‘6. RK13 monolayers in 6-well plates 
were washed twice with MEM(F'A ), infected with 400 pL of serially diluted virus (10~' to 
10‘6 in separate wells) and incubated at 37°C for 1 h. After infection, 2.5 mL of 
MEM(Selective) was added to each well and the plate returned to the 37°C incubator.
After 3-4 days of growth, the location of single, isolated plaques on the cell monolayer 
were marked on the underside of the tissue culture plate. The medium was removed, and 
the monolayer air-dried briefly. Using a 20 pL pipette tip containing 3 pL of MEM(F‘A ), 
the plaque was gently scraped off the plate and transferred to a microfuge tube containing 
50 pL of MEM(F'A ). The plaque preparation was freeze/thawed twice and stored at 
-80°C.
To amplify virus in isolated plaques, RK.13 monolayers were prepared in a flat-bottomed 
96-well plate. The monolayers were washed twice with MEM(F'A'). The plaque 
preparation was vortexed for 30 sec and added to the RK13 monolayers and incubated for 1 
h at 37°C. The media was removed from the wells and 100 pL of MEM(Selective) added
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to each well. The plate was incubated for 5-7 days, or until CPE was evident on the 
monolayer. The plate was then stored at -80°C.
2.5.3.3 PCR screening o f single isolated plaques
To determine the purity of virus isolated from amplified plaques, PCR screening was used. 
A combination of two or three primers (Table 2.4) was used to identify recombinant and 
wild type (Uriarra) virus in each amplified virus preparation. The amplified virus in the 96- 
well plate was freeze/thawed twice, collected into a microfuge tube and vortexed for 30 sec. 
A 10 pL aliquot was transferred to a separate tube, microwaved for 2 min on high using a 
Sharp Carousel R-3C57 Microwave, cooled on ice and then vortexed for 30 sec. This 
plaque preparation (4 pL) was used as template in a 20 pL PCR as described in Section 
2.1.8, and the PCRs separated by agarose gel electrophoresis as described in Section 2.1.5. 
Samples from which only PCR products indicative of recombinant virus, or predominantly 
PCR products from recombinant virus were amplified, were selected for further purification 
as described in Section 2.5.3.2. The process was repeated until only pure recombinant virus 
was present -  a process that took between 3 and 7 rounds of plaque purification.
2.5.3.4 Purification o f recombinant virus using ß-glucuronidase fgusj selection 
Selection of recombinant virus using gus selection is reliant upon production of the gus 
gene product (ß-glucuronidase) in cells and plaques formed from cells infected with 
recombinant virus staining blue in the presence of 5-bromo-4-chloro-3-indolyl-ß-D- 
glucuronic acid (X-gluc). To isolate single recombinant plaques, the recombinant virus 
preparation was diluted and plated out on RK13 cell monolayers as described in Section 
2.5.3.2, but without the use of selective reagents in the media (MEM[F'A ] only). After 4-5 
days of growth, 10 pL of X-Gluc (10 mg/mL; Sigma, Australia) in 100 pL of MEM(F'A )
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Table 2.4 -  Primer combinations used in screening virus preparations for wild-type 
(Uriarra) and recombinant virus during purification. A blank space indicates no product 
would be obtained for that virus type.
V iru s P rim ers W ild  Type  
P ro d u ct 
S ize (bp)
R ecom . 
P rodu ct 
S ize  (bp)
Uriarra AM 1OL/M11Lgpt M009L-R1 x M012L-F1 xgpt-R l 1092 645
M012L-F1 x M010L-R1 684
M012L-F1 xgpt-R l 645
Uriarra AMT-7gp/ M007-R2 x M007-F1 x gpt-Rl 747 603
M007-F1 x M007-RI 380
M007-F1 xgpt-R l 603
Uriarra AMT-7gws M007-R2 x M007-F1 x gus-Fl 747 411
M007-F1 x M007-RI 380
M007-F1 xgpt-R l 411
Uriarra AM063Rg/?/gws M062R-F1 x M064R-R1 x gpt-Rl 1223 440
M064R-R1 x M063R-F1 660
M062R-F1 xgpt-R l 440
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was added to each well. After 4-8 h further incubation, isolated blue plaques were marked, 
picked, amplified and screened by PCR as described previously for gpt selection.
2.5.4 Preparation of concentrated virus
Virus was grown in monolayers of RK13 or Vero cells in T180 cell culture flasks as 
described previously (Section 2.5.1) and collected into 40 mL Oak Ridge Tubes after 
freeze/thawing twice. The infected cell lysate was centrifuged for 2 h at 12,000 rpm in an 
SS-34 rotor (Sorvall RC5+ centrifuge) at 4°C. After centrifugation, the supernatant was 
poured off and the cell debris pellet resuspended in 1 mL of MEM(Complete). After 
vortexing for 60 sec, the concentrated virus preparation was sonicated (4 x 20 sec pulses, 
maximum power). The concentrated virus stock was then titred (Section 2.5.5) and stored 
at -80°C.
2.5.5 Plaque assay to determine virus titre
Vims stocks were titrated by plaque assay in duplicate on Vero cell monolayers and titres 
expressed as plaque forming units/mL (pfu/mL). Briefly, monolayers of Vero cells were 
prepared in 6-well plates and washed twice with 1 mL of MEM(F’A ). Ten-fold serial 
dilutions of the virus stocks were prepared, vortexing the virus for 20 sec between each 
dilution. Diluted virus (100 pL) was added to wells in duplicate, followed by 200 pL of 
MEM(F'A). Plates were incubated for 1 hr at 37°C, rocking every 10 min, after which 2.5 
mL of MEM(Complete) was added to each well. The plates were returned to the incubator 
at 37°C for 5-8 days. To visualise plaques, the media was poured off and replaced with 2 
mL of 10% formalin in water and incubated at room temperature for 1 h. The formalin was 
then poured off and replaced with 1 mL of 0.1% crystal violet (Sigma, Australia) in water 
for 30 min. After staining, the fixed monolayers were washed liberally with water and left
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to dry. Plaques could be observed, using a light box, as clear areas on a purple-stained cell 
monolayer. Plaques were counted and the concentration determined using the following 
equation:
Virus titre (pfu/mL) = average number of plaques per well x 10 x dilution factor
2.5.6 Virus growth curves in RK13 and Vero cells
To measure the in vitro growth characteristics of recombinant viruses with respect to 
parental viruses, cells were infected in vitro and the titre of virus at specific times post-
infection determined. Confluent monolayers of RK13 or Vero cells were prepared in 24- 
well plates (2 x 10^  cells/well). Monolayers were washed twice with 1 mL of MEM(F'A ). 
Growth curves were performed at two MOIs: 0.1 and 3.0. To achieve this, concentrated 
virus stocks were diluted in MEM(F'A) such that the concentration was 2 x 10^  pfu/mL 
(for MOI=0.1) and 6 x 106 pfu/mL (for MOI=3), and 100 pL was plated onto duplicate 
wells. Seven identical plates were prepared simultaneously to obtain separate plates for 
each time point. Plates were incubated at 37°C for 1 h, rocking every 20 min, and then 400 
pL of MEM(F'A ) added to each well. The final volume in each well was 500 pL. One 
plate was immediately stored at -80°C (Time 0 sample). The other plates were incubated at 
37°C for 12, 24, 36, 48, 72 or 96 h, and one plate stored at -80 °C at each time point. The 
titre of virus in each sample was determined by plaque assay as described in Section 2.5.5.
2.5.7 Virus growth curves in RL-5 cells
The in vitro growth characteristics of recombinant viruses with respect to parental viruses 
were also measured in the rabbit CD4 T lymphocyte cell line RL-5. RL-5 cells were 
infected in vitro and the titre of virus at specific times post-infection determined.
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RL-5 cells were grown in RPMI medium supplemented with 10% foetal calf serum, 2 mM 
L-glutamine, 500 pg/mL amphotericin B, 60 pg/mL penicillin and 100 pg/mL streptomycin 
(RPMI[Complete]). When required for experiments, cells were transferred to a 50 mL 
Falcon tube and pelleted by centrifugation at 1500 rpm in a Beckman Allegra 6R centrifuge 
for 10 min. Cells were resuspended in RPMI(Complete) and counted using a 
haemocytometer. Cells were then diluted to a concentration o f 1 x 106 cells/mL. Viruses to 
be tested were diluted in RPMI(Complete) at a concentration o f 3 x 106 pfu/mL. Cells (5 
mL) were mixed with virus (5 mL) in a 50 mL Falcon tube and incubated in a 37°C water 
bath for 60 min to infect (MOl = 3.0), gently mixing the tubes every 10 min. Following 
infection, duplicate 1 mL aliquots o f each infection were placed in 24 well plates. One 
plate was immediately stored at -80°C (time 0 sample) and the others incubated at 37°C. 
Sample plates were frozen at 24, 48, 72 or 96 h post infection. The titre o f virus in each 
sample was determined by plaque assay as described in Section 2.5.5.
2.5.8 Measuring the viability of RL-5 cells following infection with recombinant 
viruses
Viability o f infected RL-5 cells was measured by trypan blue exclusion assay. Viable cells 
do not take up trypan blue, but cells that have lost integrity (non-viable) stain blue. This 
method has been adapted from Macen et al. (1996). RL-5 cells were harvested and 
counted. Virus was added to 5 x 10 cells such that the final MOI was 10 (5 x 10 pfu) in a 
final volume o f 150 pL o f RPMI(Complete). The mixture was incubated at 37°C for 1 h in 
a microfuge tube, inverting every 20 min, and then placed in a round-bottom 96-well plate 
and incubated at 37°C in a humidified, water-jacketed incubator with 5% C02/95% air. A 
25 pL aliquot was taken at 0, 3, 6, 12 or 24 h after infection and added to 25 pL o f 0.4% 
trypan blue stain (GibcoBRL, USA). Using a haemocytometer, the total number o f viable
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(unstained) and non-viable (blue stained) cells was recorded and the percentage viability of 
cells calculated.
2.6 An i ma l  me t h o d s
2.6.1 Rabbit care and housing
Outbred domestic European rabbits (Oryctolagus cuniculus) used in this study were bred at 
the CSIRO Sustainable Ecosystems Animal House. Wild rabbits were also bred at the 
CSIRO Sustainable Ecosystems Animal House from populations captured from the wild 
near Canberra. They have been bred in captivity under specific pathogen free conditions 
for 2-4 generations. Animals were housed in an OGTR approved PC2 facility at a constant 
20°C and 12 h light / 12 h dark regime. Rabbits were fed ad libitum on standard rabbit 
pellets supplemented with fresh cabbage and lettuce leaves.
2.6.2 Collecting blood samples from rabbits and processing
Blood samples for serum (1 m l) were collected from the marginal ear vein using a 22G 
needle. The blood was stored at 4°C overnight then centrifuged at 13,000 rpm for 15 min 
and serum transferred to a fresh microfuge tube and stored at -20°C. Blood samples 
collected for isolation of peripheral blood mononuclear cells (PBMC; 10 mL) were 
collected from the marginal ear vein using a butterfly catheter (22G; Vacutainer, Australia) 
attached to a 10 mL syringe. Before blood collection, 1 mL of Heparin (1000 U/mL; 
Sigma, Australia) was drawn through the needle, catheter and syringe. Details of further 
processing are described in Section 2.7.1.
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2.6.3 Vaccination, challenge and monitoring of rabbits
Rabbits were inoculated with 50, 5000 or 10^  pfu o f vaccine virus in 100 pL o f PBS 
delivered intradermally at a site on the left thigh. Rectal temperatures were monitored 
daily, and the rabbits closely observed for any secondary signs o f infection.
To determine the protective efficacy o f vaccines in rabbits, animals were challenged with 
1000 pfu o f SLS intradermally at a site on the thigh. Rectal temperature was measured 
daily. The rabbits were closely observed for clinical signs o f myxomatosis and scored 
using a scale o f 0 to 5 (Kerr et al., 2003). The designation for each number is described in 
Table 2.5. In every experiment, animals displaying severe symptoms (clinical score o f 4.5 
to 5) and not expected to survive were euthanased by intravenous injection o f barbiturate.
2.6.4 Inoculation and tissue collection from rabbits for pathogenesis studies
To determine the dissemination o f virus in vivo, domestic or wild rabbits were inoculated 
intradermaUy with 5000 pfu of virus on the dorsal surface of the right hind foot. At 2, 4, 6, 
10 or 20 days post inoculation, groups o f three rabbits were euthanased by overdose o f 
barbiturate delivered into the marginal ear vein. The following tissues were collected: skin 
from the inoculation site (primary lesion), the right popliteal lymph node (draining lymph 
node), skin from the left hind foot (distal skin), the left popliteal lymph node (contralateral 
lymph node) and left testis. Each tissue sample was divided in half: a sample was frozen 
immediately in preweighed tubes at -80°C for virus titre determination (Section 2.6.6) and a 
sample was fixed in 10% formalin in PBS for histopathology (Section 2.6.5).
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Table 2.5 -  Myxomatosis clinical scores and the corresponding symptoms.
Score Sym ptom s
0 No clinical signs of myxomatosis.
0 to 0.5 Reaction (reddening) at the inoculation site, through to a primary 
lesion less than 2 cm in diameter.
0.5 to 1 Primary lesion greater than 2 cm in size. No secondary signs of 
myxomatosis.
1 to 2 Very mild clinical signs limited to a slight reddening and swelling of 
eyelids.
2 to 3 Mild generalised signs of myxomatosis with swollen eyelids, some 
conjunctival discharge; mild anogenital swelling. Animals still 
bright and alert.
3 to 4 Moderate clinical signs of myxomatosis characterised by swollen 
eyelids with some mucopurulent discharge (eyes 0-75% closed); 
moderate anogenital swelling; secondary lesions on face and body. 
Animal appears depressed.
4 to 5 Severe myxomatosis. Eyes closed (75-100%) by swollen eyelids and 
copious mucopurulent discharge; nasal swelling; severe anogenital 
swelling; secondary lesions on face and body; very depressed 
demeanour; laboured, snuffly breathing.
5 Severely ill, not expected to survive.
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2.6.5 Fixed tissue sections and histology
The embedding, sectioning and haematoxylin and eosin staining o f tissue sections were 
performed at the Histology Unit at the John Curtin School o f Medical Research. Formalin- 
fixed tissues were embedded in paraffin wax. Two 5 pm sections were cut from each tissue 
and mounted on superfrost microscope slides (Menzel, Germany). Sections were dewaxed 
in three changes o f xylene (BDH, Australia) for 2 min each and rehydrated through a 
graded series o f ethanol (100% to 75%). Slides were washed in water and then stained with 
Gills' N° 3 haematoxylin (BDH, Australia) for 3 min. Slides were washed in water, stained 
with 0.025% alcoholic eosin for 2 min, differentiated in two washes o f 90% ethanol and 
cleared in two washes o f xylene. Sections were mounted under a coverslip with DPX 
(Difco, Australia), examined by light microscopy using an Olympus BX40 microscope and 
photographed using an Olympus DPI 1 colour digital camera.
2.6.6 Processing of tissue samples for determination of virus titre
Tissue samples stored at -80°C (Section 2.6.4) were defrosted and weighed. Skin samples 
were minced with a scalpel blade and placed in 5 mL tubes with 4 volumes o f 1 mg/mL 
collagenase D (Sigma, Australia) in PBS and incubated at 37°C for 2-3 h, vortexing every 
30 min (Best and Kerr, 2000). After incubation, 5 volumes o f MEM(Complete) were 
added to the samples. Other tissue samples were minced with a scalpel blade, placed in a 
microfuge tube, homogenised with a microfuge tube pestle (Bioventures, USA) and then 
mixed with 9 volumes o f MEM(Complete). Both skin and other tissue samples were then 
sonicated using a Branson Sonifier 450 Cup sonicator (3 pulses o f 15 sec, maximum 
power). Samples were then diluted and plaque assayed on Vero cell monolayers to 
determine the concentration o f virus in samples, as described in Section 2.5.5, expressing 
the concentration o f virus as plaque forming units per gram o f tissue (pfu/g).
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2.6.7 PCR analysis of virus in tissue biopsies
Small samples of lesion material were collected using an 18G needle from both secondary 
and primary lesions. The material was placed in 200 pL of PBS and subjected to three 
cycles of freeze/thawing, and then sonicated. Virus was amplified by placing 50 pL of this 
material on RK13 cells in 6 -well plates and incubating for several days under MEM(F"A+). 
After freeze/thawing several times, viral DNA was extracted using the Qiagen DNAeasy 
Tissue Kit as described in Section 2.5.2, and viral DNA analysed by PCR as described in 
Section 2.5.3.3.
2.7 Me a s u r e m e n t  o f  im m u n e  r e s po n s e s  in  v a c c i n a t e d  r a b b it s  
2.7.1 In vitro antigen-specific lymphocyte proliferation assay
Peripheral blood lymphocytes (PBMC) were isolated from blood taken one week after the 
final boost of plasmid vaccine, and an antigen-specific proliferation assay performed as 
described in Han et al. (1999). Briefly, 10 mL of blood was collected from the marginal 
ear vein of rabbits into tubes containing 1000 U of heparin (Sigma, Australia) (Section 
2.6.2), and then diluted with 10 mL of RPMI-1640 without any supplemental additives. 
This was gently layered over 10 mL of Lympholyte-Rabbit (Cedarlane, Canada) and 
centrifuged at 1000 g at room temperature for 30 min in a Beckman Allegra 6 R centrifuge. 
PBMC were collected from the interface using a pasteur pipette, diluted to 20 mL with 
RPMI-1640 and centrifuged at 400 g for 15 min at 4°C to pellet cells. After removing the 
supernatant, contaminating red blood cells were lysed by the addition of 10 mL of ACK 
Shocking Buffer (155 mM NH4CI [BDH, Australia], 10 mM KHCO3 [BDH, Australia], 
0.11 mM Na2EDTA, pH 7.3) and incubated on ice for 10 min. After shocking, 20 mL of 
RPMI(Complete) was added and the cells pelleted as previously described. PBMCs were 
washed with 20 mL of RPMI(Complete) three times and then counted using a
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haemocytometer. They were resuspended in RPMI(Complete) and diluted to a final density 
o f 2 x 106 cells/mL.
Assays were performed in 96-well flat-bottomed microtiter plates (Nunc, USA). For each 
PBMC sample, at least four sets o f wells were set up in quadruplicate. Into each group o f 
four wells was placed 100 pL o f cells (2 x 105 cells) and one o f the following solutions: 
concanavalin A (10 pL o f a 5 pg/mL solution in PBS; Sigma, Australia) as a positive 
control for lymphocyte proliferation and viability; 10 pL o f PBS (negative control); 10 pL 
o f purified myxoma virus antigen (25 pg/mL in PBS; Section 2.3); 10 pL o f negative 
control antigen (25 pg/mL in PBS; Section 2.3). Cells were incubated at 37°C in a 
humidified, water-jacketed incubator in 5% CC>2/95% air for 5-6 days. Twenty-four hours 
prior to harvest, cells were pulsed with 1.0 pC i o f 3H-thymidine in 20 pL o f 
RPMI(Complete). Cells were harvested onto glass filters and ’H-thymidine incorporation 
measured as described in Section 2.4.8. The antigen-specific stimulation index was 
calculated for each animal using the formula below:
Stimulation index (SI) = [Average cpm in wells in the presence o f recombinant antigen]_
[Average cpm in wells in the presence o f negative control antigen]
The statistical significance o f each stimulation index value was determined using Fieller's 
theorem to determine the upper and lower limits o f the 95% confidence interval (Finney, 
1971). For the purposes o f this study, an SI value for which the lower lim it o f the 95% 
confidence interval was greater than 1.5 was considered a positive antigen-specific 
response.
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2.7.2 Detection of antigen-specific antibody responses in DNA-vaccinated animals
Antibody responses to M055R and M121R in DNA-vaccinated rabbits were measured 
using immunofluorescent methods as described in Section 2.4.5, except 1:50 dilutions o f 
vaccinated rabbit serum were used on pDual-55R- or pDual-121 R-transfected RK13 cells 
respectively. FITC-conjugated anti-rabbit Ig (Silenus Labs, Australia) was used as 
secondary antibody at a concentration o f 1:100. Binding o f rabbit antibody to transfected 
cells was observed under a Leitz Fluovert FS microscope. The observation o f increased 
specific fluorescence compared to pre-vaccination serum from the same rabbit was 
recorded as a positive seroconversion.
Antibody responses to M055R, M073R and M115L in vaccinated rabbits were detected 
using immunoblotting. Purified recombinant antigen (production described in Section 2.3) 
was run on a 12% SDS-PAGE gel, transferred onto a PVDF membrane and probed with 
1:200 dilutions o f vaccinated rabbit serum, using the protocol described in Section 2.2. 
Binding o f antibody was detected using FIRP-conjugated anti-rabbit lg  (Silenus Labs, 
Australia), and ECL+ Chemiluminescence kit (Amersham, UK). An increase in binding o f 
antibody to the recombinant protein band compared to pre-vaccination serum from the 
same rabbit was recorded as a positive seroconversion.
2.7.3 Enzyme-linked immunosorbent assay (ELISA)
To determine the anti-myxoma virus antibody levels in vaccine virus-infected rabbits, 
whole virus ELISA was used as described in Kerr (1997). A laboratory stock o f myxoma 
virus (strain Lausanne) was purified by ultracentrifugation. Lausanne was grown in RK13 
cells in 180 cm" tissue culture flasks and concentrated as described in Section 2.5.4, except 
the pellet was resuspended in PBS before sonication. The virus preparation was digested
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with DNAse (25 pg/mL; Sigma, Australia) and RNAse (50 pg/mL; Sigma, Australia) for 
30 min at 37°C with frequent agitation. Virus was then pelleted through a step-gradient o f 
0.54 mL o f dextran solution (10% dextran T10 [Amersham Pharmacia Biotech, Sweden], 
10 mM Tris.HCl, 1 mM EDTA, pH 8.0) over which was layered 0.56 mL o f sucrose 
solution (36% sucrose (BDH, Australia), 10 mM Tris.HCl, 1 mM EDTA, pH 8.0). The 
virus preparation was layered over the top o f this gradient and centrifuged at 250,000 g for 
20 min in a Beckman TLS-55 rotor. The pellet was resuspended in PBS and the step- 
gradient centrifugation repeated. The final pellet was resuspended in 1 mL o f PBS and 
stored at -20°C.
This stock was diluted 1:12,500 with carbonate buffer (15 mM Na2CC>3 [BDH, Australia], 
35 mM NaHCCE [BDH, Australia], pH not adjusted). This dilution was found to give a 
final OD405 reading o f 1.0 using a 1:100 dilution o f standard serum from myxoma virus- 
infected rabbits. This pooled serum was used within the lab to calibrate new stocks o f 
myxoma virus antigen. Aliquots of diluted virus (50 pL) were added to each well o f an 
Immulon 2HB ELISA plate (Immulon, USA) and incubated at 4°C overnight. The wells 
were then washed three times with PBS. The wells were then blocked with 100 pL o f 
ELISA blocking buffer (PBS containing 5% skim milk powder and 0.05% Tween 20) for 2 
h at 37°C. The plate was then washed four times with Tween-PBS (PBS containing 0.05% 
Tween 20).
Serum samples from rabbits were serially diluted from 1/100 to 1/10,2400 with ELISA 
antibody binding buffer (PBS containing 0.05% Tween 20 and 1% skim milk powder). 
Duplicate aliquots o f 50 pL were added to the prepared Immulon plates and incubated at 
37°C for 2 h. Wells were then washed six times with Tween-PBS. HRP-conjugated anti-
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rabbit Ig (Silenus Labs, Australia) was used as a secondary antibody. This was diluted 
1/100 with ELISA antibody binding buffer and 50 pL aliquots added to each well and 
incubated at 37°C for 30 min. The plate was then washed six times with Tween-PBS and 
tapped dry on paper towelling. The HRP substrate was prepared by dissolving a 10 mg 
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) [ABTS; Sigma, Australia] tablet in 10 
mL o f citrate-phosphate buffer (61.4 mM citric acid [BDH, Australia], 77 mM Na2HPC>4 
[Ajax, Australia], pH 4.0) and adding 20 pL o f 30% hydrogen peroxide solution [BDH, 
Australia]. The substrate solution (100 pL) was added to each well and incubated at room 
temperature for 10 min. The absorbance at 405 nm was then measured using a pQuant 
Plate Spectrophotometer, with OD405 values zeroed against a 1/100 dilution o f pooled sera 
from uninfected rabbits. The reciprocal o f the highest serum dilution giving an average 
absorbance above 0.1 was recorded as the anti-myxoma virus antibody titre. I f  the average 
absorbance at the lowest dilution ( 1/ 100) was less than 0.1, the rabbit was recorded as 
having an anti-myxoma virus antibody titre o f zero.
2.7.4 Plaque reduction neutralisation assay (PRNA)
The titre o f myxoma virus-neutralising antibody was measured by a plaque reduction 
neutralisation assay as described in Kerr (1997). Serum from rabbits was heated to 56°C 
for 10 min to inactivate complement prior to testing. Serum was them serially diluted from 
1/5 to 1/10240 with MEM(F'A') and 150 pL aliquots o f each dilution added to mircofuge 
tubes. A previously titred stock o f Lausanne was diluted in MEM (F'A ') to a final 
concentration o f 2000 pfu/mL, and 150 pL aliquots o f this diluted virus stock added to each 
diluted serum sample. This resulted in final serum dilutions o f 1/10 to 1/20480. A 
negative control serum was prepared by diluting pooled and heat-treated serum from 
uninfected rabbits with MEM(F'A') such that the final concentrations were 1/10 and 1/100.
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A third, serum-free negative control was also prepared. The tubes were incubated at 37°C 
for 1 h, vortexing briefly every 20 min. During this time, 6-well plates with confluent 
monolayers o f Vero cells were prepared by washing monolayers once with MEM(F’A'). 
After the incubation, 100 pL o f the virus/serum dilutions were added to wells in duplicate, 
and incubated at 37°C for 1 h, rocking the plate every 10 min. The virus/serum dilution 
was then aspirated, replaced with 2.5 mL o f MEM(Complete) and incubated for 8 days at 
37°C in a 5% COJVSVo air humidified water-jacketed incubator. Visualisation o f plaques 
was achieved as described in Section 2.5.5.
The percentage virus neutralisation at each serum dilution was calculated as follows:
% neut. = 100 Mean number o f plaques on plates with test serum X 100
jnean number o f plaques per plate on negative control plates
The 50% and 80% neutralisation titres for each serum sample were determined as the 
reciprocal o f the highest serum dilution at which greater than 50% or 80% o f plaques were 
neutralised, respectively.
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Ch apt er  3 -  Con s tr u c ti on  an d  Tes tin g  o f  DNA Vac c in es  
Ex pr es s ing  Se le c te d  My x o ma  V ir u s  An tig ens
The material presented in this chapter has been accepted for publication:
Adams, M.M., van Leeuwen, B.H. and Kerr, P.J. (2004). "Limitations o f plasmid vaccines 
to complex viruses: selected myxoma virus antigens as DNA vaccines were not protective." 
Vaccine: In press. Available online at: http://dx.doi.Org/10.1016/j.vaccine.2004.05.023
3.1 In t r o d u c t io n
The endogenous production o f antigen by DNA vaccine-transfected cells can result in a 
strong Thl-type immune response and can induce high levels o f antigen-specific CTLs, 
with demonstrated protective efficacy in many disease models (Shedlock and Weiner, 
2000). As cell-mediated responses are thought to be critical in protecting rabbits against 
myxomatosis, the ability o f DNA vaccines expressing myxoma virus antigens to protect 
rabbits from myxomatosis was investigated. The effect on vaccine efficacy o f the co-
expression o f the rabbit cytokines interleukin-2 (IL-2) and interleukin-4 (IL-4) with virus 
antigens was also investigated. In previous studies in other animal models, IL-2 cDNA co-
delivery has enhanced both cell-mediated and antibody responses to DNA immunogens and 
resulted in a skewing towards Th 1 -like responses (Pan et al., 1999). Similarly, IL-4 
expressing DNA vaccines have previously been shown to increase the seroconversion rate 
and improve antibody titres to DNA immunogens, and bias the immune response toward 
Th2 development (Pan et al., 1999). As well as a potential direct path to vaccine 
development, this study also sheds light on the possible protective antigens o f poxviruses 
and expands studies into a different model from the VV/mouse model where antigen- 
specific studies have been performed to date.
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This chapter describes the selection of myxoma virus antigens for testing as DNA vaccines, 
construction of the vaccines, in vitro testing of viral antigen expression, purification of the 
DNA vaccine plasmids and the purification of viral antigen for use in the in vitro analysis 
of antigen-specific immune responses in rabbits. The vaccines were then administered to 
domestic European rabbits (Oryctolagns cuniculus). Following vaccination, the antigen- 
specific antibody and T cell immune responses to individual myxoma virus antigens were 
determined, and the rabbits then challenged with a virulent strain of myxoma virus to assess 
the protective efficacy of the various antigen/cytokine combinations.
3.2 Re s u l t s
3.2.1 Antigen Selection
The large size of the poxvirus genome, the complexity of its structure and the unknown 
functions of many genes means that little work has been done to identify protective 
antigens of poxviruses until recently. Protective antigens have been identified from 
research undertaken using the model Orthopoxvirus, vaccinia virus (VV) (Demkowicz et 
al., 1992; Galmiche et a!., 1999; Hooper etal., 2000; Hooper et al., 2003; Lai et al., 1991b; 
Pulford et al., 2004). Most of these antigens are membrane proteins of the intracellular 
mature virion (1MV) membrane or the extracellular enveloped virion (EEV) membrane. 
The IMV membrane in VV possesses 13 integral or associated proteins -  A9L, A28L, 
A13L, A14L, A14.5, A17L, A27L, D8L, D13L, E10R, H3L, I5L and LIR (Moss, 2002). 
The EEV membrane in VV possesses five unique proteins -  A33R, A34R, F13L, A56R and 
B5R (Moss, 2002; Smith et al., 2002). Homologues of all these antigens except D8L are 
found in myxoma virus (Cameron et al., 1999).
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Eleven antigens have been shown to protect, or partially protect, mice from lethal VV 
challenge (LI R, D8L, H3L, A33R, A27L, A4L, A10L, A56R, A36R and B5R) 
(Demkowicz et al., 1992; Galmiche et al., 1999; Hooper et al., 2000; Hooper et al., 2003; 
Lai et al., 1991b; Pulford et al., 2004) or are targets of neutralising antibodies (A27L, D8L, 
LIR, H3L, A17L, B5R) (Galmiche et al., 1999; Gordon et al., 1991; Hsiao et al., 1999; 
Ichihashi et al., 1994; Rodriguez and Esteban, 1987; Wallengren et al., 2001; Wolffe et al., 
1995). These antigens were initially identified by the induction of high titres of antibody 
against these antigens during natural infection (Demkowicz et al., 1992), or by the ability 
of monoclonal antibodies directed against these antigens to neutralise virus in vitro (Lai et 
al., 1991b) or protect mice from challenge when passively administered (Hooper et al., 
2000).
Five myxoma virus antigens homologous to the VV antigens L1R, H5R, A17L, A27L and 
A33R were selected for initial screening and three more were placed on a secondary list 
(H3L, A10L and B5R). These antigens (M055R, M073R, M107L, M115L, M121R, 
M071L, M099L and M144R respectively), their known or putative functions, and the 
results of vaccination experiments are summarised in Table 3.1.
L1R (M055R), A27L (M115L) and A33R (M121R) have been demonstrated to protect 
mice from lethal challenge with VV when delivered as DNA vaccines (Galmiche et al., 
1999; Hooper et al., 2000; Hooper et al., 2003; Pulford et al., 2004). A27L and A33R have 
also been shown to confer complete protection from lethal VV challenge when delivered as 
protein vaccines (Demkowicz et al., 1992; Galmiche et al., 1999; Lai et al., 1991b). These 
results suggest that these three antigens may be excellent vaccine candidates. A17L 
(M107L) has not been studied as a vaccine, but monoclonal antibodies directed against the
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Chapter 3 -  Preparation and testing of DNA vaccines
N-terminal region of A17L were able to neutralise infection of VV (Wallengren et al., 
2001), suggesting an important role for this antigen in VV pathogenesis. For this reason, 
M107L was selected as a vaccine candidate.
The myxoma virus homologue of H5R (M073R) was selected based on research which 
suggested H5R was a highly immunogenic IMV membrane antigen and the target of potent 
neutralising antibodies (Gordon et al., 1988; Gordon et al., 1991). However, after the 
vaccination trials described in this thesis had commenced, further analysis of the literature 
revealed that H5R had been misidentified, the immunogenic antigen being the co-migrating 
35 kDa antigen, H3L (M071L) (Chertov et al.,  1991; Zinoviev et al.,  1994). It is 
interesting to note that the misidentification of H5R has been perpetuated in several later 
peer-reviewed papers and reviews (Hooper et al., 2000; Moss, 1996). As M073R 
vaccination trials had already commenced, they were completed as planned.
3.2.2 Cloning of myxoma virus genes, and construction of candidate vaccine plasmids
The vector selected for use as the DNA vaccine backbone was pDual2+ (obtained from Dr 
Scott Thomson, John Curtin School of Medical Research, Australian National University). 
This vector contains two expression cassettes derived from pcDNA3.1+, each controlled by 
a cytomegalovirus immediate-early promoter (CMV-IE) followed by a bovine growth 
hormone polyadenylation signal (BGHpA), between which is located a multiple cloning 
site (Figure 3.1). The two expression cassettes allow for the constitutive co-expression of 
two different genes from the same vaccine construct. In this study, myxoma virus genes 
were cloned into the 5’ expression cassette and cytokine genes into the other.
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Figure 3.1 - The DNA vaccine vector pDua!2+. This 4596 bp vector has two 
separate expression cassettes each containing the cytomegalovirus 
intermediate-early promoter (pCMV), a multiple cloning site (MCS) and 
bovine growth hormone polyadenylation signal (BGHpA). Each MCS 
encodes sites for different restriction enzymes as shown. Other sequences 
include the ampicillin resistance gene (AmpR) and the colicin El replicon 
(ColEl). Myxoma virus antigen genes were cloned into the first (red), and 
rabbit cytokine cDNAs into the second (blue) multiple cloning sites.
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Myxoma virus DNA was prepared from the Lausanne strain o f the virus, whose genome 
has been completely sequenced (Cameron et al., 1999). Primers were designed to amplify 
the ORFs o f the five selected genes, and to add an EcoR\ site immediately before the start 
codon, and a Xho\ site a few bases after the stop codon (Table 2.2). Pfu polymerase was 
used to amplify the antigen genes, which were then were digested with EcoR\ and Xho\ and 
cloned into the first expression cassette o f pDual2+. The constructs were sequenced, 
confirming that the nucleotide sequence o f the antigen genes was identical to the reported 
Lausanne sequence (Cameron et al., 1999) and that the orientation o f the antigen genes was 
correct with respect to the promoter sequence (data not shown).
Rabbit IL-2 and IL-4 cDNAs were individually amplified from plasmids (supplied by Dr 
Harvey Perkins, School o f Biochemistry and Molecular Biology, Australian National 
University). Primers were designed with a NheI site immediately before the start codon 
and a //m d lll site immediately after the stop codon (Table 2.2). After amplification, the 
cDNAs were digested with Nhe\ and Hin d i l l  and ligated into pDual2+. The correct 
orientation and nucleotide sequence o f the cytokine cDNA in each plasmid was confirmed 
by sequencing (data not shown).
Vaccine plasmids were constructed for each o f the five antigens containing IL-2, IL-4 or no 
cytokine. Plasmids containing IL-2 or IL-4 with no antigen gene were also prepared. 
Therefore, with the vector pDual2+, 18 vaccine plasmids were prepared. Each vaccine 
plasmid was named by the antigen and cytokine expressed; for example pDual-55R-IL2 
expresses both M055R and rabbit IL-2.
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A control plasmid expressing influenza haemagglutinin (HA) derived from the influenza 
strain A/Puerto Rico/8 was also constructed. The gene was amplified from a plasmid 
(supplied by Dr Sue McKenzie, CS1RO Sustainable Ecosystems) and cloned into the first 
expression cassette o f pDual2+. This plasmid was called pDual-HA.
3.2.3 Confirmation of antigen production in vaccine-transfected cells
To confirm that the vaccine constructs were producing each myxoma virus antigen, RK13 
cells were transfected with each o f the vaccine plasmids. Vaccine plasmid DNA was 
prepared as described in Section 2.1.3.1 and transfections performed as described in 
Section 2.4.2. These transfected cells were used in a number o f techniques to detect the 
presence o f antigen protein and antigen gene transcripts.
3.2.3.1 Immunofluorescent detection o f  antigens
Twenty-four hours after transfection, RK13 cells transfected with the plasmid vaccines 
were fixed with methanohacetone, and probed with a \ .400 dilution of polyclonal anti-
myxoma virus serum (Section 2.4.5). This serum contains antibodies to at least 20 
myxoma virus antigens, detectable on an immunoblot (data not shown).
Figure 3.2 shows RK13 cells transfected with each o f the 18 vaccine plasmids and probed 
with the polyclonal anti-myxoma virus serum. There was no specific fluorescence 
observed in cells transfected with plasmids expressing M055R, M073R or M107L (Figure 
3.2). M l 15F expression did not result in as intensely fluorescent individual cells, but there 
is an increase in fluorescent intensity when compared to pDual2+-transfected cells (Figure 
3.2, fifth  row). M121R expression resulted in intensely fluorescent, readily visible 
transfected cells (Figure 3.2, bottom row). There was a high level o f background
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pDual 2+
pDual-55R
pDual-73R
pDual-107L
Figure 3.2 - Detection o f plasmid vaccine-expressed myxoma virus antigens using 
cellular immunofluorescence. Cells transfected with plasmid vaccines were probed with 
polyclonal anti-myxoma virus serum (1:400 dilution) and anti-rabbit FITC-conjugated 
secondary antibody. Results are shown for each o f the 18 vaccine plasmids constructed, 
containing either no antigen gene (top row) or the myxoma virus antigen genes M055R 
(second row), M073R (third row), M107L (fourth row), M115L (fifth row) or M121R 
(bottom row), and co-expressing no cytokine (first column), rabbit IL-2 (middle column) 
or rabbit IL-4 (last column). Bars on images are 200 pm in length.
pDual-115L
pDual-121 R
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fluorescence even on control cells (pDual2+-transfected) which may have masked low- 
level specific fluorescence due to the expression o f the first three antigens. Alternatively, 
the polyclonal anti-myxoma virus serum used may only contain very low levels o f 
antibodies specific for M055R, M073R and M107L.
Expression o f HA from RK13 cells transfected with pDual-HA was confirmed by cellular 
immunofluorescence using 1:100 diluted serum from a rabbit vaccinated with VV 
expressing the same HA gene (VV-H A; Kerr and Jackson, 1995) (Figure 3.3). Cells 
expressing HA were observed as brightly fluorescing bodies in the cell monolayer. No 
immunofluorescence was observed on cells transfected with pDual2+.
3.2.3.2 Immunoblot detection o f myxoma virus antigens
Immunoblotting is an alternative method o f detecting expression o f proteins. Twenty-four 
hours after transfection, total cellular protein was collected from vaccine-transfected RK13 
cells by solubilisation in SDS-PAGE sample loading buffer under reducing (0.1M DTT) or 
non-reducing conditions. After separation on a SDS-PAGE gel and blotting, the membrane 
was probed with the polyclonal anti-myxoma virus serum (1:1000 dilution). Specific 
binding o f antibody was observed in the lysates o f cells transfected with pDual-M l 15L 
under both reducing and non-reducing conditions and expression o f M073R was visible 
under reducing conditions (Figure 3.4), although the intensity was not as pronounced. This 
may be due to lower anti-M073R antibody titres in the polyclonal serum, or differing 
expression levels o f the two antigens. The sizes observed for both M073R and M l 15L (37 
and 34 kDa respectively), were larger than those expected based on protein sequence (21.5 
and 21.6 kDa respectively) although this does not take into account post-translational
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Figure 3.3 - Confirmation of expression of influenza HA in RK13 cells transfected 
with pDual-HA. RK13 cells were transfected with pDual2+ (A) or pDual-HA (B) 
and probed with serum (1:100 dilution) collected from a rabbit infected with VV 
expressing the same influenza HA gene (VV-HA). Bars on images are 200 pm in 
length.
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Figure 3.4 - Detection o f plasmid vaccine-expressed myxoma virus antigens by 
immunoblot. Cells transfected with each o f the myxoma virus antigen-expressing 
plasmids (without cytokine co-expression) were grown for 24 hours, total cellular 
protein was extracted under non-reducing or reducing (0.1M DTT) conditions, 
separated on an SDS-PAGE gel, blotted onto a PVDF membrane and probed with 
polyclonal anti-myxoma virus serum (1:1000 dilution). The expression o f M115L 
(A) and M073R (B) are arrowed.
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modification. Similar increases in molecular weight were observed for the VV 
homologues, H5R (22.3 to 35 kDa) and A27L (12.6 to 14 kDa) (Johnson et al., 1993).
Specific binding of antibody to the lysates of cells transfected with pDual-55R, pDual-107L 
and pDual-121R was not observed on immunoblots. Anti-M121R antibodies in the 
polyclonal serum may not be able to bind to the protein under denaturing conditions, 
although strong specific binding was evident on methanol-acetone fixed cells (Figure 3.2). 
M055R and M107L expression was not detected using either antibody-mediated detection 
method. It was possible that the proteins were not detectable due to very low or absent 
titres of anti-M055R and anti-M107L antibodies in the polyclonal serum. However, 
another possibility is that the antigen genes are not being transcribed appropriately.
3.2.3.3 Northern analysis to detect myxoma virus antigen transcripts 
Poxviruses replicate in the cytoplasm of infected cells. A large part of the poxvirus genome 
codes for proteins required for its own replication and transcription (Moss, 2002). For this 
reason, the mRNA transcribed from the poxvirus genome is never exposed to the splicing 
machinery of the nucleus. However, in the context of a DNA vaccine, the antigen genes 
are transcribed in the nucleus under the control of the CMV-IE promoter, and therefore 
genes could potentially be inappropriately spliced. It was possible that the M055R and 
M107L genes contained splice-consensus sequences, which would result in no mature 
mRNA and therefore no protein.
The five myxoma virus candidate genes were analysed by the program GeneSplicer 
(http://www.tigr.org/tdb/GeneSplicer/gene_spl.html) which screens DNA sequences for the 
presence of potential splice-consensus sequences (Pertea et al., 2001). The entire myxoma
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virus antigen sequences cloned into pDual2+, including restriction enzyme sites and 3’ 
untranslated sequence was analysed by this program using splice-consensus sequences for 
humans, as there is no data available on rabbit splice-consensus sequences (Table 3.2). 
Although the software found several low probability potential splice sites in each gene, no 
antigen gene seemed more likely than any other to contain splice-consensus sequences. 
The highest probability donor sites, as defined by the highest scores, were found in M l 15L 
and acceptor sites in M107L (Table 3.2). These sites were only defined as Medium 
confidence. Therefore, sequence analysis did not strongly suggest the presence o f splice- 
consensus sequences in M055R and M107L.
Northern analysis was used to directly detect antigen transcripts in DNA vaccine- 
transfected cells as described in Sections 2.1.7. RK13 cells were transfected with each o f 
the vaccine plasmids and incubated for 24 hours. Total RNA was extracted, separated on 
an agarose/formaldehyde gel, blotted onto a nylon membrane and probed with DIG-labelled 
antigen DNA.
The sizes o f the open reading frames o f M073R and M121R are 622 and 567 bp 
respectively. After probing RNA extracted from cells transfected with M073R-expressing 
plasmids with randomly primed DIG-labelled M073R DNA, a distinct band o f 
approximately 850 nt was detected (Figure 3.5). RNA extracted from cells transfected with 
M 121 R-expressing vaccines was probed with randomly primed, DIG-labelled M121R 
DNA, and an approximately 800 nt product was detected (Figure 3.6). These results 
indicate that the mRNA transcripts are approximately 230 nt longer than the open reading 
frame o f the cloned gene, the extra length originating from 5’ and 3’ untranslated DNA 
generated by the CMV-IE promoter and BGH polyadenylation signal. A slightly larger
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Table 3.2 - Potential donor and acceptor splice sites in cloned myxoma virus genes as 
determined by GeneSplicer.
D onor Sites A ccep tor Sites
Gene Position3 Score0 / Position3 Score0 /
Confidence6 Confidence6
M 055R 261 3.86 / Medium 106 4.37 / Medium
7 4 7  bpb
M 073R 182 3.88 / Medium 198 5.44 / Medium
r» a  a  i b 504 5.13 / Medium
6 0 0  bp
M 107L 132 4.67 / Medium
356 10.20 / Medium
6 2 2  bp 480 2.97 / Medium
M 115L 223 4.86 / Medium 506 4.11 / Medium
5 9 2  bpb
M 121R 275 2.32 / Medium 89 2.14 / Medium
431 3.80 / Medium 433 3.27 / Medium
5 5 6  bp ]_
a -  Position refers to the nucleotide number within the submitted sequence including the £coRI site 
immediately before the start codon (start o f gene = position 7).
b -  Length of sequence submitted to GeneSplicer including restriction sites and 3' untranslated sequence 
cloned into pDual2+.
c -  The score as defined by GeneSplicer is a measure o f the probability o f the site being a true splice 
consensus sequence.
d - A high confidence donor site has a score o f greater than 14.16. Scores greater than zero are o f medium 
confidence.
e - A high confidence acceptor site has a score o f greater than 13.22. Scores greater than zero are of 
medium confidence.
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Figure 3.5 - Northern analysis of MQ73R mRNA expression in RK13 cells transfected with vaccine plasmids. 
Total RNA from RK13 cells transfected with vaccines containing the M073R gene were separated on a 
formaldehyde-agarose gel, blotted onto a nylon membrane and probed with randomly primed, DIG-labelled 
M073R DNA. A: Ethidium bromide stained agarose gel showing loading of RNA isolated from cells 
transfected with vaccine plasmids. B: After transfer to a PVDF membrane and probing with DIG-labelled 
M073R DNA, an approximately 850 nt product was detected on the autoradiograph (arrowed).
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Figure 3.6 - Northern analysis o f M 121R mRNA expression in RK13 cells transfected with vaccine plasmids. 
Total RNA from RK 13 cells transfected with vaccines containing the M 121R gene were separated on a formaldehyde- 
agarose gel, blotted onto a nylon membrane and probed with randomly primed, DIG-labelled M121R DNA. A: 
Ethidium bromide stained agarose gel showing loading o f RNA isolated from cells transfected with vaccine 
plasmids. B: After transfer to a PVDF membrane and probing with DIG-labelled M 121R DNA, an approximately 
800 nt product was detected on the autoradiograph (arrowed).
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band o f approximately 1000 nt was also observed in RNA isolated from pDual-121 R-IL4 
transfected cells; the identity o f this band is not known.
The size o f the mRNA transcript from cells transfected with vaccines expressing M055R 
(768 bp ORF) was expected to be approximately 1000 nt, which included 5' and 3' 
untranslated sequences. When RNA from cells transfected with M055R-expressing 
plasmids was probed with DIG-labelled M055R DNA, an approximately 1000 nt product 
was detected (Figure 3.7). This suggested that these cells were producing full length 
mRNA coding for M055R. The band from pDual-55R transfected cells was distinct, but in 
other lanes was not as clear, and did not reproduce well in the autoradiograph in Figure 
3.7B. The intensity o f the bands appeared to be lower than for other the other two myxoma 
virus genes -  approximately 20% o f the intensity when compared to M073R exposed for 
the same amount o f time (data not shown).
No M107L RNA was detected using Northern analysis, although several attempts were 
made (data not shown). The failure to detect M107L protein or mRNA transcripts 
suggested that this antigen was not being produced in cells transfected with M107L- 
expressing plasmid vaccines, Therefore, M 107L-expressing vaccines were not analysed 
further or used in animal vaccination experiments. Northern detection o f M115L 
transcripts was not performed as protein expression had been demonstrated by 
immunofluorescence and immunoblotting.
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Figure 3.7 - Northern analysis of M055R mRNA expression in RK13 cells transfected with vaccine 
plasmids. Total RNA from RK13 cells transfected with vaccines containing the M055R gene were 
separated on a formaldehyde-agarose gel, blotted onto a nylon membrane and probed with randomly 
primed, DIG-labelled M055R DNA. A: Ethidium bromide stained agarose gel showing loading of 
RNA isolated from cells transfected with vaccine plasmids. B: After transfer to a PVDF membrane 
and probing with DIG-labelled M055R DNA, an approximately 1000 nt product was detected on the 
autoradiograph (arrowed).
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3.2.4 Confirmation of cytokine production from vaccine-transfected cells
To confirm the expression o f rabbit 1L-2 and 1L-4 from cells transfected with vaccine 
plasmids, RK13 cells were transfected with vaccine plasmids as described in Section 2.4.2 
and examined for the presence o f the cytokines.
As no antibodies were available to detect rabbit IL-2, a bioassay able to detect rabbit IL-2 
was used (Section 2.4.8). The mouse T cell line HT-2 has an absolute dependence on IL-2 
for growth (Wadhwa et al., 1995). Rabbit IL-2 has been shown to induce the proliferation 
o f this cell line (Dr Peter Kerr, personal communication). Supernatants from RK13 cells 
transfected with IL-2-containing plasmids were able to induce high levels o f proliferation in 
HT-2 cells (Figure 3.8), and levels were equivalent between vaccines co-expressing the 
various myxoma virus antigens. This method was not quantitative for rabbit IL-2, and not 
indicative o f how much rabbit IL-2 was produced.
Expression o f rabbit interleukin 4 (IL-4) was confirmed using a polyclonal anti-peptide 
antibody directed against Helix-A o f rabbit IL-4. This anti-rabbit IL-4 antibody is able to 
detect rabbit IL-4 in both cellular immunofluorescence and immunoblotting (Kerr et a l., 
2004). As shown in Figure 3.9, there were high levels o f specific fluorescence on cell 
monolayers transfected with IL-4-expressing vaccines, indicating the expression o f rabbit 
IL-4.
3.2.5 Purification of vaccine plasmids for injection
Each vaccine plasmid was purified by two rounds o f CsCl gradient ultracentrifugation 
(Section 2.1.3.2). Generally, 7.5-10 mg o f plasmid was obtained from 4 L o f E. coll 
culture. For injection, plasmids were resuspended in normal saline, and the concentration
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Figure 3.8 - HT-2 bioassay for IL-2 production from plasmid vaccine-transfected cells. 
DNA vaccines were transfected into RK13 cells and incubated for 48 hours. 
Supernatants were collected, concentrated, and applied to the IL-2-dependent cell line 
HT-2 in a two-fold dilution series. The degree of HT-2 proliferation was measured 
using 3H-thymidine incorporation, as indicated by measured counts per minute. DNA 
vaccines expressing M055R (A), M073R (B), M115L (C) and M121R (D) are shown 
with the corresponding controls. Graph A has been enlarged to show each tested 
supernatant in detail. There was little 3H-thymidine incorporation by cells treated with 
supernatants from mock-transfected, pDual2+-transfected, pDual-IL4-transfected, 
pDual-Antigen-transfected and pDual-Antigen-IL-4-transfected cells (A-D).
Key: mock transfected - X ; pDual 2+ - ♦ ; mouse IL-2 - 4^ ; pDual-IL2 - ■ ; pDual-IL4 - 
; pDual-Antigen - • ;  pDual-Antigen-IL2 - +; pDual-Antigen-IL4 - ■.
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Figure 3.9 - Detection of rabbit IL-4 expression in cells transfected with plasmid vaccines 
using cellular immunofluorescence. IL-4 expression was detected using a polyclonal 
anti-rabbit IL-4 serum (1:100 dilution) and a FITC-conjugated secondary antibody. 
Results are shown for each of the 18 vaccine plasmids constructed containing no antigen 
gene (top row) or the myxoma virus antigen gene M055R (second row), M073R (third 
row), Ml 15L (fourth row) or M121R (bottom row), and co-expressing no cytokine (first 
column), rabbit IL-2 (middle column) or rabbit IL-4 (last column). Bars on images are 
200 pm in length.
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adjusted to 1 mg/mL. The purity o f the plasmid was confirmed by restriction enzyme 
digestion and agarose gel electrophoresis (data not shown) and absence o f endotoxin by 
Pyrotell Gel-Clot assay (Associates o f Cape Cod, USA).
3.2.6 Vaccination of rabbits
Each vaccine was administered to groups o f three male, outbred domestic rabbits. The 
vaccine plasmid (1 mg/mL in saline) was injected intramuscularly (250 pL) into each thigh 
(a total dose o f 500 pg o f plasmid DNA).
In a previous study, mice vaccinated with DNA vaccines expressing both an IM V and an 
EEV antigen were more effectively protected from lethal challenge with VV than by 
vaccination with either antigen alone (Hooper et al., 2000; Hooper et a l., 2003). To 
determine i f  vaccination with more than one myxoma virus antigen was able to elicit a 
greater protective immune response than a single antigen, groups o f three rabbits were 
vaccinated w ith both M115L (an IM V  antigen) and M121R (an EEV antigen). The 
vaccination regime was the same as for other vaccine groups, except 500 pg o f each 
plasmid was injected at each boost. M115L and M 121 R-expressing plasmids co-
expressing rabbit cytokines were also co-delivered.
To confirm that the vaccination method was able to elicit antigen-specific immune 
responses in rabbits, the plasmid expressing influenza haemagglutinin (pDual-HA) was 
administered to rabbits as described for the other DNA vaccines. This antigen is highly 
immunogenic and has elicited potent antibody and cell-mediated immune responses in a 
range o f animal species when delivered as a DNA vaccine (Bot et al., 1999; Chen et al., 
1999; Lunn et al., 1999; Operschall et al., 1999; Radu et al., 1999).
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These doses were repeated at 2, 4 and 6 weeks after the initial inoculation. No reaction was 
observed at the inoculation site after the first or subsequent doses of vaccine plasmid.
3.2.7 Challenge of rabbits with Standard Laboratory Strain (SLS) of myxoma virus
All DNA-vaccinated rabbits, except those vaccinated with pDual-HA, were challenged by 
subcutaneous injection of 1000 pfu of SLS on the thigh and monitored for clinical signs of 
myxomatosis for up to 13 days post infection (dpi). This dose is 100% lethal for domestic 
rabbits within 10 to 13 days (Robinson et al., 1999). A clinical score (CS) was recorded as 
a measure of disease progression using a scoring system between 0 and 5 (Section 2.6.3) 
which is described in Table 2.5. Rectal temperatures were recorded daily until the rabbit 
died or was euthanased.
3.2.7.1 pDual2+-vaccinated animals (negative controls)
Rabbits vaccinated with the vector alone were treated as negative controls. It was expected 
that delivery of plasmid alone should not alter the progression of disease in these animals 
after challenge with SLS. All three control animals developed severe myxomatosis. The 
clinical scores of challenged animals began to increase from 2 dpi (Figure 3.10A) when a 
reaction at the inoculation site was generally visible. By 4 dpi, reddening of the 
conjunctiva was visible on two animals followed by mucopurulent discharge and hot, 
swollen ears by 6 dpi. Symptoms rapidly progressed until 8 dpi when all three animals had 
closed eyes with severe mucopurulent discharge, some discharge from the nose, anogenital 
oedema (AGO) and secondary lesions developing on the face and body. Two animals (857 
and 847) displayed laboured and snuffly breathing (CS > 4). The control animals were 
euthanased at 9 dpi.
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Figure 3.10 - Clinical scores and rectal temperatures o f rabbits vaccinated with pDua!2+ 
(negative control) or Uriarra-HA (positive control; immune) after challenge with 1000 
pfu o f SLS. Clinical scores (A and C) and rectal temperatures (B and D) were recorded 
daily for rabbits vaccinated with pDua!2+ or Uriarra-HA.
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Rectal temperatures of pDual2+-vaccinated rabbits began to increase from 5 dpi, and were 
at 40°C or greater for all animals at 7, 8 and 9 dpi (Figure 3.1 OB).
3.2.7.2 Uriarra-HA-vaccinated (immune) animals
To observe the clinical signs of myxoma virus-immune rabbits following challenge with 
SLS, rabbits were first inoculated with the highly attenuated myxoma virus strain Uriarra- 
HA. This virus confers complete protection from myxomatosis following a very mild 
infection, generally limited to a primary lesion with secondary lesions developing in some 
animals (Kerr and Jackson, 1995; Kerr et al., 2004). This group of animals was vaccinated 
with 1000 pfu of Uriarra-HA, and challenged with SLS three weeks later. Upon challenge 
with SLS, rabbits developed a small red spot at the inoculation site within 1 dpi, and some 
rabbits developed a small, localised primary lesion, no larger than 30 mm in size. This 
lesion scabbed over, regressed, and by 8 dpi was a flat scab with little to no inflammation. 
None of the challenged animals developed secondary lesions or any symptoms beyond a 
lesion at the inoculation site (CS < 1) (Figure 3.IOC). Immune animals did not display 
sustained increases in rectal temperature following challenge (Figure 3.10D), although 
rabbit 767 had a temperature of 40°C at 2 dpi only.
3.2.7.3 M055R-vaccinated animals
The post-challenge clinical scores for M055R-vaccinated rabbits are shown in Figure 3.11. 
Clinical scores and disease progression did not appear to vary from pDual2+-vaccinated 
controls, and all animals were euthanased by 9 dpi.
The rectal temperatures of challenged animals are shown in Figure 3.11. Most animals 
showed elevated temperatures (>40°C) between 6 and 8 dpi. One pDual-55R-vaccinated
Page 93
BA
- * - 8 8 4  
■ 91 1 
-*- 8 9 5
C D
-* -9 4 2
■ 9 3 9
-* -9 4 6
- * -9 1 0  
■ 9 4 7  
- * -9 0 5
F
42  \
Time post challenge (days)
Figure 3.11 - Clinical scores and rectal temperatures of rabbits vaccinated with 
M055R-expressing DNA vaccines after challenge with 1000 pfu of SLS. Each group 
of three rabbits vaccinated with pDual-55R (A and B), pDual-55R-IL2 (C and D) or 
pDual-55R-IL4 (E and F) was observed daily. The degree of disease progression for 
each animal was recorded as a clinical score between 0 and 5 (A, C and E). Rectal 
temperatures were recorded daily (B, D and F). The final data point indicates the 
animal was euthanased or was found dead on the following day.
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animal (911) did not show an elevated temperature following challenge. However, a drop 
in temperature to 38°C was observed at 8 dpi. Several other animals showed a drop in 
temperature on day 8 or 9 post challenge. In these challenge experiments, animals that 
displayed a rapid decrease in temperature were euthanased, as previous experience has 
shown that these rabbits rarely survive for a further day (Best and Kerr, 2000).
3.2.7.4 M073R-vaccinated animals
Clinical scores for M073R-vaccinated rabbits are shown in Figure 3.12. Disease 
progression in these animals was indistinguishable from pDual2+-vaccinated animals, with 
most animals being euthanased at 9 dpi. One pDual-73R-IL4-vaccinated rabbit (924) 
displayed extremely rapid disease progression with a very large primary lesion. The 
primary lesion was 35 mm in diameter by 3 dpi, growing to 70 mm by day 7. The animal 
had facial lesions, closed eyes, extremely swollen ears and laboured breathing by 7 dpi, and 
was found dead on day 8. This case was the most severe manifestation o f myxomatosis 
observed in all 52 challenged animals during the course of this experiment.
Post-challenge rectal temperatures o f M073R-vaccinated rabbits are shown in Figure 3.12. 
Again, the profiles are more similar to pDual2+-vaccinated rabbits than immune controls, 
with most animals having a temperature o f 40°C or greater from 5 or 6 dpi until death. A 
pDual-73R-IL2-vaccinated rabbit (915) displayed a substantial increase in temperature, 
reaching above 41 °C on days 4 and 5 post infection. On day 9, the rabbit showed a drop in 
temperature to 37°C (2.5°C below normal), at which point it was euthanased.
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Figure 3.12 - Clinical scores and rectal temperatures of rabbits vaccinated with 
M073R-expressing DNA vaccines after challenge with 1000 pfu of SLS. Each group 
of three rabbits vaccinated with pDual-73R (A and B), pDual-73R-IL2 (C and D) or 
pDual-73R-IL4 (E and F) was observed daily. The degree of disease progression for 
each animal was recorded as a clinical score between 0 and 5 (A, C and E). Rectal 
temperatures were recorded daily (B, D and F). The final data point indicates the 
animal was euthanased or was found dead on the following day.
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3.2.7.5 M l 15L-vaccinated animals
Clinical scores for challenged M l 15L-vaccinated rabbits are shown in Figure 3.13. There 
is some suggestion that clinical signs were slightly delayed in M l 15L-vaccinated animals 
with respect to pDual2+-vaccinated control animals (Figure 3.13). However, it is important 
to note that the clinical score data were collected by another researcher for these challenge 
experiments, which may have affected the scoring o f the animals slightly due to emphasis 
o f various symptoms, or different diagnosis o f the severity o f symptoms. Any suggestion 
o f protection is eliminated by 8 dpi when the symptoms o f pDual2+- and M115L- 
vaccinated rabbits were indistinguishable. Both sets o f animals displayed laboured 
breathing, severe anogenital oedema, closed eyes and facial lesions.
One rabbit (705; pDual-115L-IL4-vaccinated) died a few days post-challenge from other 
causes, possibly an unrelated enteric infection. A t the time o f death, no clinical signs were 
visible. The data for this animal have not been included in Figure 3.13. The other two 
rabbits in the same challenge group exhibited disease progression similar to other M l 15L- 
vaccinated rabbits.
Most M l 15L-vaccinated rabbits had increased rectal temperatures later during the course o f 
challenge compared to rabbits vaccinated with pDual2+ (Figure 3.13). This temperature 
increase more often occurred by 7 dpi, although pDual-115L-IL2-vaccinated animals had 
temperatures o f 40°C or greater at 4 dpi. Again, several rabbits displayed a large drop in 
temperature to below 39°C on the final day (766, 667, 756 and 762) at which point the 
animals were euthanased.
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Figure 3.13 - Clinical scores and rectal temperatures of rabbits vaccinated with 
Ml 15L-expressing DNA vaccines after challenge with 1000 pfu of SLS. Each group 
of three rabbits vaccinated with pDual-115L (A and B), pDual-115L-IL2 (C and D) 
or pDual-115L-IL4 (E and F) was observed daily. The degree of disease progression 
for each animal was recorded as a clinical score between 0 and 5 (A, C and E). 
Rectal temperatures were recorded daily (B, D and F). The final data point indicates 
the animal was euthanased or was found dead on the following day.
Chapter 3 -  Preparation and testing of DNA vaccines
3.2.7.6 M121 R-vaccinated animals
The clinical signs of M 121 R-vaccinated rabbits following SLS challenge are shown in 
Figure 3.14. Most M121 R-vaccinated rabbits began to show a reaction at the inoculation 
site by 3 or 4 dpi, as opposed to animals vaccinated with pDual2+, which showed a reaction 
by 2 dpi (Figure 3.10A). There was the possibility that this group of animals did not 
receive 1000 pfu of virus due to the temporary storage of challenge virus used in this 
experiment at -20°C instead of -80°C. This may have resulted in a slight degradation of the 
virus and a lower amount of virus delivered at challenge and may explain why symptoms 
appeared a day later than controls. However, any difference is eliminated later in infection 
when all animals displayed severe symptoms of myxomatosis.
This group of animals was the First challenged in these DNA vaccination experiments. For 
this reason, they were not euthanased as early as other groups of animals, in case 
vaccination was able to offer some ability to control the infection. Three rabbits (791, 798 
and 776) were not euthanased until 12 or 13 dpi, at which point all animals were extremely 
ill with laboured breathing. Rectal temperatures of M121 R-vaccinated animals are shown 
in Figure 3.14. Many animals showed a fever with temperatures of 40°C or greater from 6 
dpi until the end of the experiment.
3.2.7.7 M115L and M121R dual-vaccinated animals
The co-administration of plasmid DNA expressing two myxoma virus antigens (Ml 15L 
and M121R), and the delivery of twice as much plasmid DNA had no effect on the course 
of disease in rabbits challenged with SLS. Rabbits vaccinated with both M115L- and 
M121R-expressing vaccines showed similar clinical signs (Figure 3.15) to those vaccinated 
with the vector pDual2+ (Figure 3.10A). All challenged animals developed severe
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Figure 3.14 - Clinical scores and rectal temperatures of rabbits vaccinated with 
M121R-expressing DNA vaccines after challenge with 1000 pfu of SLS. Each group 
of three rabbits vaccinated with pDual-121R (A and B), pDual-121R-IL2 (C and D) 
or pDual-121R-IL4 (E and F) was observed dai ly. The degree of di sease progression 
for each animal was recorded as a clinical score between 0 and 5 (A, C and E). 
Rectal temperatures were recorded daily (B, D and F). The final data point indicates 
the animal was euthanased or was found dead on the following day.
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Figure 3.15 - Clinical scores and rectal temperatures of rabbits vaccinated with 
M115L- and M121R-expressing DNA vaccines after challenge with 1000 pfu of 
SLS. Each group of three rabbits vaccinated with pDual-115L and pDual-121R (A 
and B), pDual-115L-IL2 and pDual-121R-IL2 (C and D) or pDual-115L-IL4 and 
pDual-121R-IL4 (E and F) was observed daily. The degree of disease progression 
for each animal was recorded as a clinical score between 0 and 5 (A, C and E). 
Rectal temperatures were recorded daily (B, D and F). The final data point indicates 
the animal was euthanased or was found dead on the following day.
Chapter 3 -  Preparation and testing of DNA vaccines
myxomatosis and were euthanased 8 or 9 dpi. The post-challenge rectal temperatures of 
these animals also showed a similar profile to that observed in pDual2+-vaccinated rabbits 
(Figure 3.15).
3.2.8 Measurement of anti-myxoma virus immune responses following vaccination
Antigen-specific immune responses were measured one week after the final dose of 
plasmid for DNA-vaccinated animals, and 3 weeks following infection with Uriarra-HA for 
immune control animals. Antibody responses were qualitatively measured by either 
cellular immunofluorescence or immunoblotting, and cell-mediated responses were 
measured using a lymphocyte proliferation assay.
3.2.8.1 Production o f recombinant myxoma virus antigens for use in bioassays 
The pET system (Novagen) was chosen for the production of recombinant myxoma virus 
antigens in the E. coli strain BL21(DE3) using the lila c  promoter system (Novagen, 2003; 
Studier et al., 1990). The plasmid used for the cloning of the antigen genes, pET30a+, 
contains a series of purification and identification tags which can be expressed at the N- 
terminal end of the antigens. The genes coding for each of the antigens were cloned into 
pET30a+ in frame with the 5’ sequence including the 6xHis tag that was used for later 
purification. This was achieved by removing the antigen gene from the pDual-Antigen 
plasmids as a restriction fragment and ligating it into pET30a+. The correct insertion and 
nucleotide sequence of the antigen genes were confirmed by sequencing. The plasmids 
were given the names pET-55R, pET-73R, pET-115L and pET-121R.
After propagation in E. coli DH5a, the plasmids were transformed into the producer strain 
E. coli BL21(DE3), antigen production induced and antigens purified as described in
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Section 2.3. After elution, individual fractions were screened for the presence o f the 
antigen by SDS-PAGE. Fractions containing protein were pooled, concentrated and 
resuspended in PBS. The concentration o f each antigen sample was calculated by 
comparison against Benchmark protein ladder (Invitrogen, USA). The recombinant 
proteins were diluted to 25 pg/mL with sterile PBS, and stored at -80°C.
Protein purified from bacteria w ill contain some other proteins or compounds that may 
affect the in vitro PBMC proliferation assay. For this reason, the use o f PBS as a negative 
control for the assay when using E. co//-produced antigen would not be suitable. Instead, 
E. coli BL21(DE3) was transformed with the vector pET30a+ only. When induced with 
IPTG, this plasmid codes for a 74 amino acid peptide containing all o f the residues 
preceding the antigens, including the 6xHis tag, with a molecular weight o f approximately 
8.1 kDa. This protein, named rpET, was prepared and purified in the same way as the other 
antigens and was used as a negative control antigen in lymphocyte proliferation assays.
Figure 3.16 shows samples o f eluted fractions for each recombinant antigen on Coomassie 
Blue-stained SDS-PAGE gels. The expected sizes for the recombinant antigens, including 
the addition o f the purification tags to the N-terminal region o f the protein were 31.9, 27.2, 
27.3 and 25.4 kDa for rM055R, rM073R, rM115L and rM121R respectively. The actual 
sizes were approximately 31, 33, 31 and 26 kDa. The control antigen, rpET, was expected 
to have a molecular weight o f 8.1 kDa, but appears to be approximately 10 kDa in size, 
slightly larger than expected (Figure 3.16). Although the rM073R and rM l 15L bands were 
larger than expected, they were found to specifically bind with the polyclonal anti-myxoma 
virus serum on an immunoblot (data not shown), indicating that the bands do correspond to 
myxoma virus antigens. The other antigens, rM055R and rM121R were not detectable on
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Figure 3.16 - Purification of recombinant myxoma virus antigen proteins. The 
genes encoding each of the myxoma virus antigens used in DNA vaccination 
experiments were cloned into the pET30a+ plasmid and protein production 
induced in E. coli BL21(DE3). After purification through TALON IMAC resin, 
protein (arrowed) was obtained for each antigen: M055R (A), M073R (B), 
Ml 15L (C) and M121R (D). The protein production protocol was repeated using 
an E. coli strain containing the pET30a+ vector only as a negative control, 
producing a lOkDa protein (arrowed) containing only the N-terminal purification 
tags (E).
Each of A, B, C, D and E show the coloured protein markers (Benchmark Pre- 
Stained Protein ladder) in the left lane and the Coomassie Blue-stained gel 
containing the purified antigen protein in the right lane.
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an iimnunoblot using the polyclonal anti-myxoma virus serum, as was found previously 
using antigen extracted from vaccine-transfected cells (Section 3.2.3.2). The yields 
obtained for each antigen varied significantly, as visible in Figure 3.16. Only low levels of 
rM121R were expressed, although enough protein was obtained for bioassays.
3.2.8.2 Measurement of antibody responses in DNA-vaccinated and control rabbits 
Anti-HA and anti-myxoma virus antibody responses were qualitatively measured by 
cellular immunofluorescence or immunoblotting. The detection of anti-HA, anti-M055R 
and anti-M121R antibodies was achieved by applying serum from a DNA-vaccinated rabbit 
(diluted 1:50) to RK13 cells transfected with pDual-HA, pDual-55R or pDual-121R 
respectively. An FITC-conjugated secondary antibody was then applied, and specific 
fluorescence observed. A positive antibody response was taken to be when there was an 
increase in the specific fluorescence observed on the transfected cell monolayer when 
serum collected after vaccination was compared to pre-vaccination serum. An example of a 
positive and a negative antibody response in M121R-vaccinatcd rabbits is displayed in 
Figure 3.17A.
Anti-M055R, anti-M073R and anti-M115L antibodies were detected by immunoblotting 
with recombinant myxoma virus antigens. A positive antibody response as measured by 
immunoblotting was determined as an increase in antibody binding to recombinant 
myxoma virus antigens on immunoblots of rM055R (anti-M055R responses), rM073R 
(anti-M073R responses) or rM115L (anti-M115L responses), when pre- and post-
vaccination sera were compared. Examples of positive and negative antibody responses for 
M073R- and Ml 15L-vaccinated rabbits are displayed in Figure 3.17B and C. Examples of
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Figure 3.17 - Examples o f qualitative measurement o f antibody responses in DNA- 
vaccinated rabbits. A: Anti-M121R antibody responses detected by cellular 
immunofluorescence on pDual-121R-transfected RK13 cell monolayers. B: Anti- 
M073R antibody responses detected by immunoblot using recombinant M073R 
protein (arrowed). C: A n ti-M l 15L antibody responses detected by immunoblot using 
recombinant M l 15L protein (arrowed).
Chapter 3 -  Preparation and testing of DNA vaccines
M055R-vaccinated rabbits have not been included as anti-M055R antibody was not 
detected in any serum sample using either immunoblotting or immunofluorescent methods.
3.2.8.2.1 pDual-HA vaccinated animals
Anti-HA antibody responses were detected by cellular immunofluorescence. After 4 doses 
o f pDual-HA, all three rabbits (004, 971 and 995) had readily detectable anti-HA 
antibodies, as observed by cellular immunofluorescence on pDual-HA-transfected cells 
(Figure 3.18). No immunofluorescence was observed on pDual2+ (vector only) transfected 
cells. The fluorescence intensity was lower than that observed when serum from a rabbit 
infected with VV-HA was applied to RK13 cells transfected with pDual-HA (Figure 3.18).
3.2.8.2.2 Control animals
Negative control animals were vaccinated with the vector pDual2+, following an identical 
vaccination regime as for the other DNA vaccines. The antigen-specific antibody 
responses were measured 1 week after the fmal dose o f pDua\2+. No myxoma virus- 
specific antibodies were detected in the sera collected from these rabbits (Table 3.3).
To determine the immune response to M055R, M073R, M115L and M121R in immune 
rabbits that had been infected and then recovered, six rabbits were vaccinated with Uriarra- 
HA (Kerr and Jackson, 1995). Antigen-specific antibody responses were measured 3 
weeks after inoculation with virus. Sera from all immune animals showed readily 
detectable levels o f anti-M121R, anti-M115L and anti-M073R antibodies (Table 3.3). 
However, no anti-M055R antibodies were detectable in sera from any immune animal, by 
either cellular immunofluorescence or immunoblotting.
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Figure 3.18 - Detection o f anti-HA antibody responses in pDual-HA-vaccinated 
rabbits. Rabbits were immunised with vaccinia vims expressing influenza HA 
(V V -H A ) or with pDual-HA (rabbit N° 004, 971 and 995) and serum collected 1 
week after the final vaccine dose and applied to pDual2+ or pDual-H A-transfected 
RK13 cells.
Table 3.3 -  Antibody responses to individual myxoma virus antigens in negative control rabbits 
(pDual2+-vaccinated), immune rabbits (Uriarra-HA-vaccinated) and rabbits vaccinated with DNA 
vaccines expressing myxoma virus antigens.
A n tib o d y  resp o nse  
d etec ted  ag a in s ta,b
Rabbit Vaccine M055R M073R M115L M121R
846 pDual2+ - - - -
847 pDual2+ - - - -
852 pDual2+ - - - -
767 Uriarra-HA + + +
782 Uriarra-HA - + + +
784 Uriarra-HA - + + +
786 Uriarra-HA - + + +
884 pDual-55R _
911 pDual-55R -
895 pDual-55R -
942 pDual-55R-IL2 -
939 pDual-55R-IL2 -
946 pDual-55R-IL2 -
910 pDual-55R-IL4 -
947 pDual-55R-IL4 -
905 pDual-55R-IL4 -
914 pDual-73R _
918 pDual-73R +
926 pDual-73R -
913 pDual-73R-lL2 -
915 pDual-73R-IL2 +
930 pDual-73R-IL2 +
984 pDual-73R-IL4 +
892 pDual-73R-IL4 -
924 pDual-73R-IL4 +
766 pDual-115L _
667 pDual-115L -
709 pDual-115L +
756 pDual-115L-IL2 +
751 pDual-115L-IL2 +
762 pDual-115L-IL2 -
708 pDual-115L-IL4 -
668 pDual-115L-IL4 -
705 pDual-115L-IL4 -
Table 3.3 continued
A n tib o d y  resp o nse  
d etec ted  ag a in s ta,b
Rabbit Vaccine M 055R M 073R M115L M121R
746 pDual-121R +
760 pDual-121 R -
748 pDual-121R -
791 pD ual-121R -IL2 -
798 pDual-121R -IL2 -
827 pDual-121R -IL2 +
776 pDual-121R -IL4 +
793 pDual-121R -IL4 -
774 pDual-121R -IL4 -
859 pD ua l-115L + pD u a l-121R - -
861 pDual-115L + pDual-121R - -
864 pD u a l-115L + p D u a l-121R + -
000 pD ua l-115 L -IL 2  + pD u a l-121R -IL2 - -
865 pD ua l-115L-IL2  + pDual-121R-IL2 - -
867 pD ua l-115L-IL2 + pD ual-121R -IL2 - -
850 pD ua l-115L-IL4 + p D u a l-121R -IL4 - -
855 pD ua l-115L-IL4  + pDual-121R -IL4 + +
856 pD ua l-115L-IL4 + pD ual-121R -IL4 - -
a: - : no detectable response; + : positive response.
b: An empty space indicates that responses against the antigen were not measured for the indicated rabbit.
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3.2.8.2.3 Animals vaccinated with myxoma virus antigen-expressing plasmids 
The antigen-specific antibody responses of DNA-vaccinated rabbits are shown in Table 3.3. 
No M055R-vaccinated animals had anti-M055R antibodies detectable by either 
immunoblot or cellular immunofluorescence. Five M073R-vaccinated rabbits had positive 
anti-M073R antibody responses as determined by an increase in specific binding of 
antibody to the rM073R band when post- and pre-immune sera were compared on 
immunoblots (Figure 3.17). Three M115L-vaccinated animals showed the presence of anti- 
M115L antibodies as detected by immunoblotting. Serum from three M121R-vaccinated 
animals showed slightly increased binding to RK13 cells transfected with pDual-121R.
Only two rabbits that had been vaccinated with both M115L- and M 121R-expressing 
vaccines possessed detectable anti-Ml 15L antibody responses, and one of these animals 
(855) also had very low levels of anti-M121R antibodies (Table 3.3). Therefore, 
vaccination of rabbits with two antigens and twice as much plasmid DNA did not enhance 
antigen-specific antibody responses.
The magnitude of the antigen-specific antibody response against myxoma virus antigens in 
DNA-vaccinated rabbits was less than in Uriarra-HA-vaccinated rabbits. The degree of 
antibody binding to rM073R or rMl 15L on immunoblots from DNA-vaccinated rabbit sera 
was not as high as that observed from Uriarra-HA-vaccinated rabbit sera (data not shown). 
Similarly, fluorescence intensities observed when serum from DNA-vaccinated rabbits was 
applied to RK13 cells transfected with pDual-121R (Figure 3.17) were much weaker than 
those observed when serum from hyperimmune rabbits (Figure 3.2) or Uriarra-HA-infected 
(data not shown) rabbits was applied to the same cells.
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There was no correlation between the co-expression of cytokines by DNA vaccines and the 
measured antigen-specific antibody responses. Of the 14 positive antibody responses 
recorded, four were from cytokine-free treatments, five from IL-2 treatments and five from 
IL-4 treatments.
3.2.8.3 Measurement of PBMC proliferative responses in DNA-vaccinated and control 
rabbits
Antigen-specific cell-mediated immune responses in vaccinated rabbits were measured by 
examining the antigen-specific proliferation of peripheral blood mononuclear cells (PBMC) 
isolated from rabbit blood 1 week after the final dose of vaccine plasmid, or 3 weeks after 
inoculation with Uriarra-HA for immune control animals. PBMC were pulsed with 
purified recombinant myxoma virus antigens produced in an E. coli expression system 
(Section 3.2.8.1). In Tables 3.4-3.10 are shown the measured counts per minute 5 days 
after addition of one of concanavalin A (as a positive control for T cell proliferation), PBS 
(as a negative control), the recombinant myxoma virus antigen or the negative control 
antigen rpET. Antigen-specific proliferative responses were recorded as a stimulation 
index (SI) calculated as the ratio between counts recorded in the presence of antigen and 
counts recorded in the presence of the negative control antigen (Section 2.7.1). The 
standard errors of counts were quite high with all treatments. Therefore, the statistical 
significance of each SI value was calculated using Fieller's theorem to determine the 95% 
confidence interval of the SI ratio (Finney, 1971). In Tables 3.4-3.10, a bold SI value 
indicates that the ratio was significantly greater than 1.5 {p < 0.05), the value considered a 
positive proliferative response in these experiments.
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3.2.8.3.1 pDual-HA-vaccinated animals
A sample of influenza A/Puerto Rico/8 virus was obtained from Dr Sue McKenzie (CSIRO 
Sustainable Ecosystems). As this antigen was not produced in an E. coli expression 
system, PBS was used as a negative control. To confirm that the antigen sample did not 
induce non-specific responses in isolated rabbit PBMC, it was also added to PBMC isolated 
from unvaccinated rabbits.
PBMC isolated from rabbits vaccinated with pDual-HA proliferated in response to the 
addition of influenza A/Puerto Rico/8, with SI values of between 4.49 and 4.97 (Table 3.4), 
which were all significantly greater than 2.4. SI values from unvaccinated animals were 
approximately 1.0 (Table 3.4). The addition of concanavalin A (conA), a potent non-
specific T cell mitogen, stimulated very high levels of PBMC proliferation (Table 3.4), with 
SI values of between 59 and 356 recorded. This indicates that PBMC isolated from rabbits 
were viable and capable of proliferation. Similar levels of PBMC proliferation in response 
to concanavalin A were found throughout the different groups of DN A-vaccinated rabbits.
These results, together with the antibody results shown in Figure 3.18, indicate that 
intramuscular injection of pDual2+ expressing a highly immunogenic viral antigen could 
induce cell-mediated and humoral immune responses in domestic rabbits.
3.2.8.3.2 Control animals
The SI values recorded after addition of purified myxoma virus antigens to PBMC isolated 
from rabbits vaccinated with pDual2+ were low, ranging between 0.58 to 1.29 for all four 
viral antigens (Table 3.5). This indicated there was no antigen-specific proliferation of 
pDual2+-vaccinated rabbit PBMC in the presence of the four myxoma virus antigens.
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Chapter 3 -  Preparation and testing of DNA vaccines
PBMC were isolated from Uriarra-HA infected (immune) animals 3 weeks after inoculation 
with virus and stimulated with purified myxoma virus antigens. The SI values obtained for 
each animal and each antigen are recorded in Table 3.5. Some animals displayed a very 
high background level of lymphocyte proliferation regardless of the antigen added (rabbit 
numbers 767, 782 and 784). Similar counts were observed when cells obtained from these 
rabbits were pulsed with PBS alone (Table 3.5). Routine microscopic inspection of these 
cultures did not show any bacterial infection. This very high background proliferation may 
have masked any antigen-specific proliferation induced by the addition of myxoma virus 
antigens. Of the remaining immune animals, only responses against M055R and Ml 15L 
were significantly greater than 1.5 for a single animal (Table 3.5).
3.2.8.3.3 Animals vaccinated with myxoma virus antigen-expressing plasmids 
The antigen-specific proliferation of PBMC isolated from rabbits administered DNA 
vaccines expressing myxoma virus antigens were measured 1 week after the final dose of 
vaccine plasmid. None of the M055R-vaccinated rabbits had PBMC proliferative 
responses significantly greater than 1.5 (Table 3.6). Together with the antibody responses 
shown in Table 3.3, this suggests that DNA vaccination of rabbits with M055R did not 
result in a detectable anti-M055R immune response.
Two M073R-vaccinated rabbits (930 and 924) had SI values above 2.0, but only one 
pDual-73R-IL2-vaccinated rabbit (rabbit 930) had an SI significantly greater than 1.5 
(Table 3.7). Both rabbits with SI values greater than 2.0 also had readily detectable anti- 
M073R antibodies (Table 3.3). However, other rabbits displaying positive anti-M073R 
antibody responses (rabbit numbers 918, 915 and 984) did not have significant levels of 
M073R-specific PBMC proliferation (Tables 3.3 and 3.7).
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Chapter 3 -  Preparation and testing of DNA vaccines
O f the nine rabbits vaccinated with M 115L-expressing vaccines, two showed a proliferative 
response significantly greater than 1.5, and had SI values in excess o f 4.0 (Table 3.8). 
There was no correlation between rabbits with detectable cell-mediated and humoral 
responses as both rabbits had no detectable anti-M l 15L antibodies (Table 3.3).
O f the nine rabbits vaccinated with M121R-expressing vaccines, only one showed a 
positive proliferative response to recombinant M121R protein (rabbit 760; Table 3.9), with 
an SI value o f 5.33. This value had a lower 95% confidence interval o f 3.3, the highest SI 
value recorded in these experiments. This animal did not have detectable anti-M121R 
antibodies (Table 3.3). None o f the animals vaccinated with both M l 15L- and M121R- 
expressing vaccines showed positive proliferative responses to either antigen.
As was found with antigen-specific antibody responses, there was no overall decrease or 
increase in the antigen-specific PBMC proliferative responses due to co-expression o f 
rabbit IL-2 or IL-4 by myxoma virus DNA vaccines. O f the four SI values significantly 
greater than 1.5 obtained, two were from cytokine-free treatments, one from IL-2 
treatments and one from IL-4 treatments (Tables 3.6-3.10).
3.3 D is c u s s io n
The results presented in this chapter indicate that DNA vaccines expressing the myxoma 
virus antigens M055R, M073R, M l 15L and M121R, and co-expressing the cytokines IL-2 
and IL-4, are unable to protect rabbits from lethal myxoma virus challenge. These results 
suggest that simple intramuscular DNA vaccination is unable to protect rabbits from a 
complex virus such as myxoma virus. These results also demonstrate that data obtained 
during vaccination experiments in the VV/mouse model cannot simply be extrapolated to
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Chapter 3 -  Preparation and testing of DNA vaccines
other poxvirus models, and questions the validity o f comparing the VV/mouse model with 
natural poxvirus disease models.
3.3.1 Selection of candidate antigens
Myxoma virus, like all poxviruses contains well over 100 genes, many o f which have 
unknown functions (Cameron et al., 1999). The antigen-specific responses and protective 
antigens o f poxviruses have not been studied intensively until recently, and only in the 
VV/mouse model (Demkowicz et a l., 1992; Galmiche et al., 1999; Hooper et al., 2000; 
Hooper et al., 2003; Lai et al., 1991b; Pulford et al., 2004), which was the basis for the 
selection o f genes to investigate in these experiments. These genes were selected based on 
studies where they were able to protect mice from lethal challenge with VV, or were the 
targets o f potent neutralising antibody.
In hindsight, M071L (VV H3L) and M144L (VV B5R) would have been better candidates 
to test rather than M073R (VV H5R) and M107L (VV A17L), as they had demonstrated 
ability to protect mice from challenge with VV. However, the confusion in the literature 
between the identity o f H3L and H5R was not identified until vaccines expressing M073R 
had already been administered to rabbits. It is also important to note that what were 
considered the best two candidates -  M l 15L and M121R -  were not protective either alone 
or delivered together, and thus it is perhaps unlikely that pDual2+-based vaccines 
expressing M144L or M071L would prove more effective than either o f these candidates.
3.3.2 Detection of myxoma virus antigen expression in RK13 cells
O f the five selected myxoma virus antigens, the expression o f three in RK13 cells was 
visualised using antibody-mediated methods (cellu lar immunofluorescence and
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immunoblotting) using the polyclonal anti-myxoma virus serum. The expression o f 
M121R was clearly visible by cellular immunofluorescence, but the same serum was 
unable to bind to M 121R on a Western blot. It may be that the anti-M121R antibodies in 
the polyclonal serum can only bind native protein, and are unable to bind to SDS-denatured 
M121R protein. In contrast, anti-M l 15L antibodies in the polyclonal serum were able to 
bind to M l 15L on an immunoblot under both reducing and non-reducing conditions, but 
the fluorescence observed by cellular immunofluorescence was much lower than that seen 
on cells transfected with pDual-121R. M073R was only detected by immunoblotting, 
which is a more sensitive method o f detecting antigen expression than cellular 
immunofluorescence, as the protein is concentrated as a discrete band during SDS-PAGE. 
Without a quantitative means o f measuring the expression o f antigens, it cannot be 
determined whether the four tested antigens are being expressed at the same level, or i f  the 
observed differences in intensity o f cellular fluorescence and bands on immunoblots was 
due to different levels o f antibodies in the polyclonal anti-myxoma virus serum.
M107L mRNA or protein expression was not detected. Although analysis o f M107L’s 
nucleotide sequence did not strongly suggest the presence o f a splice-consensus sequence, 
the lack o f detectable M107L mRNA indicates that expression was not occurring. I f  
M107L gene does contain a splice-consensus sequence, this would lead to inappropriate 
splicing and degradation o f M107L mRNA. There are very few reports available in the 
literature on lack o f DNA vaccine antigen expression due to inappropriate splicing, most 
likely because this data is simply not published. However, Zhou et al., (2002) found that 
cryptic splice sites in the env gene o f equine infectious anaemia virus resulted in reduced 
immune responses to the antigen during DNA vaccination studies, which were overcome 
by site-directed mutagenesis o f the cryptic splice site.
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Expression o f the VV homologue (A17L) under control o f the CMV-IE promoter in a DNA 
vaccine could not be detected (Jay Hooper, USAMRI1D, personal communication), 
suggesting that expression o f M107L and its homologues in other poxviruses may be 
dependent on the presence o f other viral antigens.
3.3.3 Measurement of antigen-specific immune responses
The PBMC proliferation assay used in these experiments measured the presence o f antigen- 
specific CD4 T cells in the blood o f vaccinated animals (Han et a l., 1999b; Han et a l., 
2000b). It would have been preferable to use an assay to measure CTL responses in 
vaccinated rabbits as CTLs are the effector cells believed to be responsible for clearance o f 
and protection from myxoma virus (Kerr and McFadden, 2002). However, there is 
currently no assay to measure CTL activity in the myxoma virus model. The use o f outbred 
rabbits in the vaccination experiments prevented the use o f standard 51Cr release assays to 
measure antigen-specific CTL responses as MHC-compatible cells lines were not available. 
Therefore, it was decided to use the lymphoproHferative assay to measure cell-mediated 
responses.
Recombinant myxoma virus antigens were used in this assay because whole virus would 
have would have resulted in the inhibition o f any antigen-specific proliferation. The 
proliferation o f rabbit lymphocytes is inhibited upon infection with myxoma virus, both 
before and after addition o f T cell mitogens such as concanavalin A (Collins, 2004). This 
effect extends to inactivated virus, which can prevent cellular proliferation, possibly 
through signals following binding o f cellular and viral receptors (Strayer et al., 1983; Peter 
Kerr, personal communication).
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The PBMC proliferation assay was quite ‘noisy’, in that high standard errors were 
recorded, often 10-30% of the mean values. These errors were recorded across all 
treatments including mitogen- and PBS-treated cells. This resulted in most SI values being 
statistically insignificant, as determined by Fieller's theorem. A similar level of noise has 
been recorded by others working with rabbit lymphocyte proliferation assays (Han et al., 
1999b; Han et al., 2000b), and it appears that the use of rabbit cells in this assay is 
inherently much noisier than when using murine cells (Demkowicz et al., 1992; Lai et al., 
1991b). Christensen et al., from whom the rabbit PBMC proliferation protocol was 
obtained (Han et al., 1999a; Han et al., 1999b) have since used delayed-type 
hypersensitivity (DTH) tests to measure cell-mediated immune responses against antigens 
delivered as DNA vaccines, and have found better correlation between observed DTH 
responses and protective efficacy in the cottontail rabbit papilloma virus (CRPV) model 
(Han et al., 2000a; Han et al., 2000b; Hu et al., 2002).
The immune responses measured against the viral antigens did not affect disease 
progression after challenge. Even animals with significant and strong SI values (SI > 4) or 
higher antibody responses showed comparable disease progression to animals with no 
detectable responses. Similar poor correlation between measured immune responses and 
protective immunity have been noted in other rabbit DNA vaccination studies (Han et al., 
2000a; Han et al., 1999b; Han et al., 2000b). Studies in cancer immunotherapy have also 
shown poor correlation between the magnitude of measured cellular immune responses and 
protective efficacy (Bellone et al., 1999). This is believed to be due to the fact that while 
low avidity T cells (T cell clones with a low binding strength between the TCR and the 
antigen peptide-loaded MHC molecule) are readily detected by in vitro assays, these cells 
have little biological activity in vivo where high avidity T cells are required (Gilboa, 1999).
Page 109
Chapter 3 -  Preparation and testing of DNA vaccines
3.3.4 Lack of cytokine efficacy
There was no observed enhancement o f antigen-specific immune responses by co-
expression o f rabbit cytokine genes in this study. Based on previous DNA vaccination 
studies in other species (mice, humans, monkeys), enhanced antibody responses in IL-4 
vaccinated rabbits and enhanced cellular responses in IL-2 vaccinated rabbits were 
expected (Pan et a l., 1999). The reason for this lack o f cytokine effect is unknown. In 
other studies, cytokines have been delivered on a separate plasmid to the antigen. The co-
expression o f cytokines from the same plasmid using a bi-cistronic vector has resulted in 
similar results to separate plasmid delivery (Chow et a l., 1997), although separate cytokine-
expressing plasmid delivery has also been shown to be more effective at eliciting CD4 T 
cell responses (Barouch et a l., 2002).
Murine GM-CSF has been used to enhance immune responses in DNA vaccinated rabbits 
using the CRPV model (Leachman et a l., 2000), but this was the first study where rabbit 
cytokine cDNAs have been used in a vaccination experiment. Recombinant myxoma 
viruses expressing rabbit IL-2 or IL-4 displayed enhanced virulence in rabbits (Junankar, 
1999; Kerr et a l., 2004), suggesting that these cytokines have potent in vivo activity. In 
other animal models, IL-2 cDNA co-delivery has enhanced cell-mediated and antibody 
responses to plasmid-delivered antigens and skewed immune responses towards Th 1 -like 
responses (Pan et a l., 1999). Similarly, IL-4 co-expression by DNA vaccines has resulted 
in increased seroconversion rates and improved antibody titres to plasmid-delivered 
antigens, and a predominantly Th2-like immune response (Pan et a l., 1999).
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3.3.5 DNA vaccines in rabbits and alternative DNA vaccination protocols
DNA vaccines have protected domestic rabbits from challenge with viruses in several 
different models including pseudorabies (Hong et al., 2002), CRPV (Christensen et a/., 
2001; Hu et al., 2002; Leachman et al., 2002) and rinderpest (Joshi et al., 2002). This 
indicates that with the correct protective antigen, rabbits can be successfully DNA 
vaccinated against pathogenic viruses, even using intramuscular injection of plasmid (Hong 
et al., 2002; Joshi et al., 2002). Alternative delivery methods such as gene-gun inoculation 
may induce a protective immune response where intramuscular injection of plasmid DNA 
does not (Han et al., 2000b).
Considerable work has been undertaken in mouse models to enhance the immune response 
to DNA immunogens. Tested variables include the location of the muscle in which the 
DNA is injected (Yokoyama et al., 1997), injection volume (Dupuis et al., 2000) and the 
use of various cytokine or immunomodulatory genes (Egan and Israel, 2002). More recent 
methods involve intradermal injection (Raz et al., 1994), intralymphatic injection (Maloy et 
al., 2001), electroporation of muscles following plasmid injection (Widera et al., 2000), the 
use of lipid carriers to enhance cellular transfection (Fischer et al., 2003) and the inclusion 
of immunostimulatory DNA sequences (CpG motifs) on the plasmid backbone or co-
injected with the plasmid (Klinman et al., 1997; Mutwiri et al., 2003). Whether any of 
these methods would enhance the protective efficacy of the tested myxoma virus DNA 
vaccines is unknown. These tests and protocol modifications are generally performed once 
an effective candidate antigen has been selected, to enhance the immune responses 
generated by the DNA vaccine. The use of M055R, M073R, Ml 15L or M121R in such an 
optimisation regime may still result in an infective vaccine if they are not key protective 
antigens for myxoma virus.
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One important factor in this study may have been injection volume. Studies o f protective 
vaccines in rabbits utilised smaller amounts o f plasmid DNA, but in greater volumes (1-2 
mL rather than 250 pL; Hong et al., 2002; Joshi et al., 2002). Smaller volumes were 
utilised in this study as such large volume injections can cause significant discomfort to 
rabbits. However, the larger volume injection also enhances drainage o f the plasmid 
solution from the injection site to the draining lymphatics where enhanced antigen 
presentation and induction o f immunity can occur. Larger injection volumes have also 
resulted in enhanced transfection o f muscle cells and immune stimulation, possibly due to 
higher hydrostatic pressure in the muscle bundle (Dupuis et a l., 2000). It was also 
suggested by Dupuis et a/., (2000) that intramuscular DNA vaccination in larger animals is 
not as effective as in mice due to the larger relative muscle to vaccine volume, resulting in a 
correspondingly lower hydrostatic pressure and rate o f cellular transfection. A comparison 
o f injection volumes in rabbits has not been performed.
3.3.6 Conclusions
These sets o f experiments demonstrate that an easily delivered plasmid DNA vaccine to 
protect rabbits from myxomatosis is not feasible at this point. Although alternative 
delivery methods or altered formulations may allow these constructed DNA vaccines to 
induce protective responses, many o f these technologies are all still lab-based methods 
which are not currently available to veterinarians.
The further screening o f other myxoma virus antigens may reveal a highly immunogenic, 
protective antigen. However, this approach is still high risk in that a single protective 
antigen may not exist, or it may be an antigen o f unknown function with little evidence 
pointing to its identity. The large scale screening o f many antigens would be time
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consuming, expensive and may not yield an effective vaccine. Therefore, it was decided to 
investigate recombinant myxoma virus strains as potential non-transmissible myxomatosis 
vaccines. Attenuated poxvirus vaccines have been highly efficacious in protecting against 
poxvirus diseases in many different models (Aspden et al., 2003; Fenner, 1993; Ngichabe 
et al., 2002; Tripathy, 1999; Tulman et al., 2002). In Chapter 4, the construction and 
testing o f several recombinant myxoma virus strains based on the Uriarra strain o f myxoma 
virus w ill be described.
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Cha pte r  4 - Co nst r uc t io n  an d  te st ing  of  My x o ma  V ir us
D ELETIO N  M U TAN TS AS C A N D ID ATE VACCINES
4.1 In t r o d u c t io n
The effectiveness o f live virus vaccines to protect against poxvirus diseases has been well 
established in many different poxvirus disease models, and attenuated vaccines are 
routinely used to protect humans and livestock from diseases such as scabby mouth disease, 
goatpox, smallpox and lumpy skin disease (Esposito and Fenner, 2002). As described in 
Section 1.5, live attenuated myxoma virus vaccines, including the antigenically related 
poxvirus, rabbit fibroma virus (RFV) and tissue culture-attenuated strains o f myxoma virus, 
are used to protect domestic rabbits against myxomatosis. These vaccines are used in 
Europe with varying degrees o f success (Marlier et al., 2000).
This chapter describes the construction o f new candidate vaccine strains by the deletion o f 
one or more key immunomodulatory genes from Uriarra. This virus was isolated from wild 
rabbits in the Canberra region o f Australia in 1953 (Mykytowycz, 1953), and the current 
strain has since been plaque purified (Russell and Robbins, 1989). This virus is o f Grade V 
virulence, with only 5% lethality in domestic rabbits, although all rabbits develop moderate 
to severe symptoms o f myxomatosis upon infection (Best and Kerr, 2000).
The genes chosen for deletion were selected based on the following criteria:
1. Their role in promoting dissemination o f the virus in vivo. Their deletion would reduce 
or eliminate the appearance o f secondary signs o f myxomatosis and secondary lesions 
which could be a site o f arthropod-borne transmission o f the vaccine virus;
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2. Their role in lesion growth and development. Their deletion would reduce the size o f 
the primary lesion, and therefore the potential area on the animal from which the virus 
could transmit;
3. Their role in suppression o f cell-mediated immune responses. Their deletion would 
enhance the host’s response to the vaccine virus and produce an infection that is rapidly 
controlled, in that virus titres in the skin do not reach transmissible titres.
The three genes selected for deletion were M010L, M011L and M007. M011L is a key 
inhibitor o f apoptosis in infected lymphocytes (Macen et al., 1996), and M010L encodes an 
epidermal growth factor homologue, which plays a key role in lesion growth and 
development (McFadden et al., 1995). Deletion o f these genes inhibited dissemination o f 
the virus to secondary sites in the animal, and the development o f the primary and 
secondary lesions (Opgenorth et al., 1992). The M010L/M011L genes, due to their 
overlapping open reading frames (ORFs) could be deleted in a single recombination event.
M007 encodes the myxoma virus y-interferon receptor homologue M-T7, a key virulence 
factor o f myxoma virus (Mossman et al., 1996b). M-T7 also binds to CC, C and CXC 
chemokines (Lalani et al., 1997). Deletion o f M-T7 from the Lausanne strain o f myxoma 
virus prevented the interruption o f cellular immune responses, not only at the sites o f viral 
replication, but in distal lymphoid organs (Mossman et al., 1996b). The overall effect was 
an enhanced cellular immune response against the virus, more efficient migration o f 
immune cells into sites o f infection and much more rapid clearance o f the virus.
It was postulated that in a vaccine, deletion o f these genes would result in a much more 
rapid and robust anti-myxoma virus immune response which would reduce the titre o f virus
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at sites of infection and result in more rapid clearance, lowering the titre of virus in the skin 
below transmissible levels.
This chapter deals with the construction, purification and testing of three myxoma virus 
candidate vaccines. The vaccines were evaluated for two characteristics -  acceptability and 
efficacy. The acceptability of the vaccine to pet rabbit owners was gauged by the severity 
of the symptoms caused by the vaccine virus, especially considering the appearance of 
secondary symptoms such as secondary lesions on the face and ears, which would not be 
acceptable in a companion animal. The protective efficacy of the vaccines was evaluated 
as the ability to protect rabbits from a lethal myxoma virus challenge. Candidate vaccine 
strains that were considered acceptable and effective were then selected for further analysis.
4.2 Re s u l t s
4.2.1 Construction of recombinant myxoma virus vaccines
4.2.1.1 Design and construction o f pKS AM 1OL/M11 Lgpt and Uriarra AM10L/M1 ILgpt 
The inactivation of the overlapping ORFs of M010L and M011L was achieved by 
homologous recombination in Uriarra infected RK13 cells with the plasmid 
pKS AM 10L/M11 Lgpt (Figure 4.1). This plasmid contains two regions of sequence 
homologous to the Uriarra genome, between which was cloned a selective marker, the E. 
coli gene xanthine guanine phosphorybosyl transferase (gpf, Richardson et a/., 1983), under 
control of the poxvirus early/late promoter, p7.5 (Davidson and Moss, 1989). This method, 
first developed by Falkner and Moss (1988), is routinely used to generate recombinant 
poxviruses. A recombination event between the plasmid and Uriarra genomic DNA results 
in a deletion of 292 bp from the genome of Uriarra, including the first 148 bp of M010L 
(57.8% of the ORF) and the last 173 bp of M011L (34.7% of the ORF), and its replacement
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Figure 4.1 - Construction of plasmid for deletion of the M010L and M011L sequences 
of myxoma virus. Short sequences (423 and 371 bp) homologous to Uriarra DNA were 
cloned by PCR using the primers (small black arrows; Table 2.3) indicated, between 
which the selective gene xanthine guanine phosphorybosyl transferase (gpt) under 
control of the poxvirus promoter p7.5, was cloned. Homologous recombination of this 
plasmid with the Uriarra genome results in a recombinant virus (Uriarra 
AM10L/M11Lgpt) with a 292 bp deletion including the first 148 bp of M010L and last 
173 bp of M011L. The positions of other primers used for the PCR screening of 
recombinant viruses (M010L-R1 and gpt-Rl) are indicated. The position of the ends of 
the homologous sequences are indicated as described in the published myxoma virus 
sequence (Genbank AF170726). Figure is not to scale.
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with the p7.5-gpt cassette, allowing for selection of recombinant virus by resistance to 
mycophenolic acid. This is a larger deletion of the open reading frames than that used in 
the construction of a Lausanne strain with inactivated MOlOLand M011L ORFs 
(Opgenorth et al., 1992), where both open reading frames were interrupted by insertion of 
the E.coli ß-galactosidase gene at a specific restriction enzyme site in the overlapping 
section of the two genes.
Following infection of RK.13 cells with Uriarra and transfection with 
pKS AM10L/M1 \Lgpt, recombinant virus was isolated by plaque purification under 
mycophenolic acid selection (Section 2.5.3). After 4 rounds of single plaque purification, a 
pure recombinant virus was obtained and named Uriarra AM 10L/M11Lgpt. The virus was 
amplified and concentrated as described in Section 2.5.4. This concentrated virus 
preparation was found to contain no wild-type virus by PCR analysis (Figure 4.2). Cloning 
and sequencing of the M010L/M011L locus of Uriarra AM10L/M1 lLgpr showed the 
sequence to be the same as the plasmid pKS AM10L/M11Lgpt, as was expected after a 
homologous recombination event between this plasmid and Uriarra genomic DNA (data not 
shown).
4.2.1.2 Design and construction o f pKS AM-T7gpt and Uriarra AM-T7gpt 
The inactivation of the two copies of the open reading frame M007 was achieved by 
homologous recombination in Uriarra-infected RK.13 cells with the plasmid pKSAM- 
T7gpt (Figure 4.3 A). This plasmid contains two regions of sequence homologous to the 3’ 
and 5’ ends of M007, between which was cloned gpt under control of the p7.5 promoter. A 
recombination event between the plasmid and the Uriarra genome would result in a 118 bp
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Figure 4.2 - PCR analysis o f Uriarra AM1QL/M11Lgpt. DNA isolated from 
the concentrated Uriarra AM 1OL/M11Lgpt virus stock was analysed by PCR 
primer pairs specific for recombinant virus (A; gpt-Rl x M012-F1, 645 bp) 
or wild type virus (B; M010L-R1 x M012L-F1, 684 bp). The plasmid 
pKS+AM10L/Ml 1Lgpt was used as a positive control for recombinant virus, 
and Uriarra genomic DNA was used as a positive control for wild type 
virus. No wild type PCR product was amplified from the Uriarra 
AM 1 OL/M 11 LgpX virus preparation (B, arrowed).
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Figure 4.3 - Construction o f  plasmids for deletion o f M007 sequences o f myxoma 
virus. A: Short sequences (307 and 320 bp) homologous to Uriarra DNA were cloned 
by PCR using the primers indicated (small black arrows; Table 2.3), between which the 
selective gene gpt under control o f the p7.5 promoter was cloned. Homologous 
recombination results in a recombinant virus (Uriarra AM -Tlgpt) with a 118 bp 
deletion in the middle o f each copy o f M007. B: In place o f the gpt gene, the ß- 
glucuronidase (gusA) gene under control o f the synthetic early/late promoter (pEL) was 
cloned as the selection marker to construct the recombinant virus Uriarra AM-T7gw5. 
The positions o f  other primers used for the PCR screening o f recombinant viruses 
(M007-R1, gpt-R l and gus-F l) are indicated. The position o f the ends o f the 
homologous sequences are indicated as described in the published myxoma virus 
sequence, Genbank A F 170726. Figure is not to scale.
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deletion in the open reading frame of M007 (15.1% of the ORF), and its replacement with 
the pl.5-gpt cassette.
Following infection of RK.13 cells with Uriarra and transfection with pKS AM-Tlgpt, 
recombinant virus was isolated by plaque purification under mycophenolic acid selection 
(Section 2.5.3). After 7 rounds of single plaque purification, a pure recombinant virus was 
obtained and named Uriarra AM-Tlgpt. The virus was amplified and concentrated as 
described in Section 2.5.4, and was found to contain no wild-type virus by PCR analysis 
(Figure 4.4). Cloning and sequencing of the M007 locus of Uriarra AM-Tlgpt showed the 
sequence to be the same as the plasmid pKS"AM-Tlgpt, as was expected after a 
homologous recombination of the plasmid sequence into the virus (data not shown).
4.2.1.3 Design and construction o f pKS AM-T7 gus and Uriarra AMI OL/M 1 ILgpt AM- 
77gus (TKO)
The construction of Uriarra AM 1OL/M \\Tgpt AM-Tlgus was achieved by homologous 
recombination in Uriarra AMI OL/M 11 LgpMnfected RK13 cells with the plasmid pKSAM- 
Tlgus (Figure 4.3B). This plasmid was the same as pKS AM-Tlgpt except for the 
replacement of the pi .5-gpt cassette with a pEL-gus cassette, containing the E. coli ß- 
glucuronidase gene {gusA) under control of the synthetic early/late poxvirus promoter pEL 
(Davidson and Moss, 1989). This method, first developed by Carroll and Moss (1995), is 
routinely used for the construction and selection of recombinant poxviruses. A 
recombination event between the genome of Uriarra AMI OL/M 11L gpt and pKS+AM-T7gzvs 
would result in an identical 118 bp deletion in the M007 ORF as found in Uriarra AM- 
Tlgpt, and its replacement with the pEL-gws cassette, allowing for the selection of 
recombinant virus by identification of plaques which stain blue in the presence of X-gluc.
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Figure 4.4 - PCR analysis of Uriarra AM-T7gpt. DNA isolated from the
concentrated Uriarra AM-Tlgpt virus stock was analysed by PCR primer pairs 
specific for recombinant virus (A; gpt-Rl x M007-F1, 603 bp) or wild type virus 
(B; M007-RI x M007-F1, 380 bp). The plasmid pKS+AM-T7g/?/1 was used as a 
positive control for recombinant virus, and Uriarra genomic DNA was used as a 
positive control for wild type virus. No wild type PCR product was amplified 
from the Uriarra AM-T7g/?t virus preparation (B, arrowed).
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Following infection o f RK13 cells with Uriarra AM 1OL/M11 Lgpt and transfection with 
pKS AM-T7gz/5, recombinant virus was isolated by single plaque purification after 
selection o f isolated plaques that stained blue in the presence o f X-gluc (Section 2.5.3.4). 
After 8 rounds o f single plaque purification, a pure recombinant virus was obtained and 
named Uriarra AMI OL/M 11L gpt AM-T7<gws, or Triple KmockOut (TKO). The virus was 
amplified and concentrated as described in Section 2.5.4, and was found to contain no 
Uriarra or Uriarra AM10L/M1 \Lgpt by PCR analysis (Figure 4.5). Cloning and 
sequencing o f the M010L/M011L and M007 loci o f TKO showed the sequence to be the 
same as the plasmids pKS AM 1 OL/M 11 Lgpt and pKS AM-T7gws respectively, as was 
expected after a homologous recombination o f the plasmid sequences into the virus (data 
not shown).
4.2.2 In vitro analysis of recombinant virus replication and protein secretion 
characteristics
Previous studies involving the deletion of M007, M011L and M010L indicated that the 
deletions had no effect on the in vitro growth characteristics o f myxoma virus in rabbit and 
primate fibroblast cells lines (Mossman et al., 1996b; Opgenorth et al., 1992). The 
attenuation o f the recombinant viruses observed in vivo was therefore attributed to 
enhanced host responses to the viruses due to the loss o f the viral immunomodulatory genes 
(Barrett et al., 2001). Several in vitro tests were performed to confirm the deletion o f the 
viral sequences in the recombinant Uriarra virus strains, and to investigate the in vitro 
growth characteristics o f the recombinant viruses compared to their parental strain, Uriarra.
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Figure 4.5 - PCR analysis of TKO. DNA isolated from the concentrated TKO 
virus stock was analysed by PCR primer pairs specific for recombinant virus (A; 
gus-Fl x M007-R2, 411 bp) or wild type virus (B; M007-RI x M007-F1, 380 bp). 
The plasmid pKS+AM-T7gw5 was used as a positive control for recombinant 
virus, and Uriarra genomic DNA was used as a positive control for wild type 
virus. No wild type PCR product was amplified from the TKO virus preparation 
(B, arrowed).
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4.2.2.1 Growth characteristics o f recombinant viruses in RK13 cells
To determine the growth characteristics of Uriarra AM10L/M11Lgpt, Uriarra AM-Tlgpt 
and TKO compared to their parental virus Uriarra, RK13 cell monolayers were infected 
with the viruses at a multiplicity of infection (MOl) of 0.1 or 3.0, and the titre of virus in 
duplicate samples determined at various time points following infection (Section 2.5.6). 
Uriarra and the recombinant viruses all had comparable growth characteristics, increasing 
in titre over time to very similar levels (Figure 4.6). It was concluded that the deletions of 
M010L, MOl 1L and M007 in Uriarra AM10L/M11Lgpt, Uriarra AM-T7g/?/ and TKO have 
no effect on virus replication in RK13 cells.
4.2.2.2 Growth o f recombinant viruses in RL-5 cells and viability o f RL-5 cells following 
infection with recombinant viruses
The deletion of MOl 1L results in a virus with reduced ability to prevent the apoptosis of 
infected lymphocytes, both in vivo and in vitro (Everett et al., 2000; Opgenorth et a/., 
1992). This resulted in reduced growth of AM011L viruses in rabbit lymphocytes, and 
decreased viability of RL-5 cells infected with AM011L myxoma viruses as observed by 
trypan blue exclusion assay (Everett et al., 2000). To confirm that the function of M011L 
had been interrupted in Uriarra AM10L/M11Lgpt and TKO, the replication of each virus in 
the rabbit lymphocyte cell line RL-5, and the effect of virus infection on RL-5 viability was 
measured.
RL-5 cells were infected with Uriarra, Uriarra AM 10L/M11 Lgpt, Uriarra AM-T7gpt or 
TKO at a MOl of 3.0 and the titre of virus determined at 24, 48 or 72 hours after infection 
(Section 2.5.7). Both Uriarra and Uriarra AM-Tlgpt replicated in RL-5 cells, with little 
difference between the two strains, increasing from approximately 2.5x106 pfu/mL to
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Figure 4.6 - Growth of recombinant viruses in RK13 cells. RK13 cells were 
infected with virus at an MOI of 0.1 (A) or 3.0 (B) and the titre of virus following 
infection determined by plaque assay. Each point represents the mean of duplicate 
samples.
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Figure 4.7 - Growth curve of vaccine candidates and Uriarra in RL-5 cells. RL-5 
cells were infected with recombinant viruses at an MOI of 3 and the titre of virus in 
duplicate samples determined every 24 hours post infection.
Key: Uriarra - ♦ ; Uriarra AM10L/M11Lgpt - ■; Uriarra AM-Tlgpt - ▲; TKO - X .
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approximately 8xl07 pfu/mL by 72 hours post infection (Figure 4.7). However, Uriarra 
AM10L/M11Lgpt and TKO only increased in titre slightly to approximately 5x1 06 pfu/mL, 
more than one log less than for Uriarra and Uriarra AM-Tlgpt.
The viability of RL-5 cells following infection at an MOI of 10 with Uriarra, Uriarra 
AM 10L/M1 \Lgpt, Uriarra AM-Tlgpt or TKO was determined by trypan blue exclusion 
assay (Section 2.5.8). The viability of Uriarra- and Uriarra AM-T7g/?Mnfected RL-5 cells 
remained high throughout the experiment, dropping to 87.6% and 82.4% respectively at 24 
hours after infection, similar to mock-infected cells at 81.3% (Figure 4.8). The viability of 
Uriarra AM10L/M1 \Lgpt- and TKO-infected RL-5 cells dropped rapidly following 
infection to 40.6 and 29.7% respectively at 24 hours after infection. This indicated that the 
viability of RL-5 cells infected with AM011L virus strains was markedly reduced compared 
to viruses with an intact M011L gene, and compares well with the results of Everett et al. 
(2000). These results, together with the replication of the recombinant viruses in RL-5 cells 
indicate that Uriarra AM 10L/M11 Lgpt and TKO do not possess an active M011L gene.
4.2.2.3 Confirmation o f deletion o f M-T7 sequence in Uriarra AM-T7gpt and TKO 
The product of the M007 gene, the IFN-y-binding protein (M-T7), is the major protein 
secreted from cells infected with myxoma virus (Upton et al., 1992). To confirm that M-T7 
protein was not produced in Uriarra AM-Tlgpt- and TKO-infected cells, RK13 cell 
monolayers were mock infected or infected with Uriarra, Uriarra AM10L/M11Lgpt, Uriarra 
AM-Tlgpt or TKO at an MOI of 1, and incubated in serum free media for 24 hours. The 
media was then concentrated as described in Section 2.4.7 and proteins separated by SDS- 
PAGE. Figure 4.9 shows the supernatants from virus-infected and mock-infected cells on 
Coomassie Blue-stained and silver-stained gels. Distinct groups of bands of 37 and 42 kDa
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Figure 4.8 - Viability of RL-5 cells following infection with recombinant myxoma 
virus strains. RL-5 cells were infected with virus at an MOI of 10 and the viability 
of duplicate samples determined by trypan blue exclusion.
Key: Mock infected - • ;  Uriarra - ♦ ;  Uriarra AM10L/M11Lgpt - ■ ; Uriarra AM- 
T lgpt - A; TKO - X .
Figure 4.9 - Analysis of supernatants from virus infected cells. After 24 hours 
incubation, the supernatants from RK13 cells infected with Uriarra, Uriarra 
AM 1OL/M11 Lgpt, Uriarra AM-Tlgpt or TKO were separated by SDS-PAGE, 
and stained with Coomassie Blue (A) or silver stained (B). In both gels, bands 
at 37 and 42 kDa (arrowed) can be seen in Uriarra and Uriarra 
AMI OL/M 1 \Lgpt supernatants. Benchmark protein markers were fractionated 
as size markers.
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can be seen in the supernatants of Uriarra- and Uriarra AM10L/M11 Lgp/-infected cells 
which are absent in the supernatants of cells infected with Uriarra AM-Tlgpt and TKO. 
The different sizes of the bands possibly indicate the M-T7 gene product is secreted with 
different levels of post-translational modification, resulting in slightly different molecular 
weights. These bands correspond with the size of the y-interferon binding protein observed 
by Mossman et al. (1996). This evidence suggests that Uriarra AM-11 gpt- and TKO- 
infected cells do not secrete the M-T7 protein.
4.2.2.4 Analysis o f Uriarra AMI 0L/M1 ILgpt plaque morphology in vitro 
During the analysis of Uriarra AM10L/M11Lgpt growth kinetics in vitro, it was discovered 
that this knockout virus had unusual plaque morphology when grown on Vero cell 
monolayers. Infected cells grown in plaque assays were usually grown for 6 days, and then 
fixed and stained with crystal violet. After 6 days of growth, the visual appearance of 
Uriarra and Uriarra AM10L/M11Lgpt plaques were identical (data not shown). However, 
after 8 days of growth, a difference was observed (Figure 4.10). The plaques formed by 
Uriarra AM10L/M11Lgpt were approximately twice the diameter of Uriarra plaques and 
exhibited a ‘comet plaque’ morphology. The large primary plaques were usually at the 
head of a series of smaller secondary plaques that formed in parallel lines ‘behind’ the 
primary plaques. This plaque morphology is typical of a poxvirus which is producing 
higher amounts of extracellular enveloped virus (EEV) particles (Smith et al., 2002).
In case the observed plaque phenotype of Uriarra AM 1OL/M11 Lgpt was caused by an 
unrelated mutation in another gene during plaque purification, the virus was re-purified 
from the original recom binant virus preparation (the original 
Uriarra/pKS AMI OL/M 11 LgpMnfection/transfection lysate). Six different plaques were
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Figure 4.10 - Plaque morphology of Uriarra AM 1OL/M11 Lgpt on Vero cells. 
Eight days after infection of monolayers, Uriarra AM 1 OL/M 11 Lgpt showed a 
different plaque morphology to its parental virus (Uriarra) with larger primary 
plaque sizes and a distinct ‘comet plaque’ morphology (arrowed). Bars on the 
images are 5 mm in length.
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picked from this preparation and purified. All six had the same plaque phenotype as the 
original isolate of Uriarra AM 10L/M11Lgpt, suggesting this phenotype is a characteristic of 
the deletion in the M010L/M011L locus of Uriarra (data not shown). The implications of 
this plaque phenotype to the vaccine’s pathogenesis will be discussed in Section 4.3.3.
4.2.3 Vaccination of rabbits with recombinant myxoma virus vaccines
4.2.3.1 Vaccination of rabbits with Uriarra AM10L/MI /Lgpt
Six male domestic rabbits of between twelve and fourteen months of age were inoculated 
with 5000 pfu of Uriarra AM10L/M11Lgpt subcutaneously on the left thigh and examined 
daily for 3 weeks. Their clinical symptoms are summarised in Table 4.1.
At 3 days post inoculation (dpi), a slight reddening of the skin was seen at the inoculation 
site, which was 2-5 mm in diameter. By 7 dpi, the inoculation site had developed into a 
distinct lesion 10-30 mm in diameter (Figure 4.11A-C), and all animals had begun to 
develop secondary lesions on the eyelids (Figure 4.1 ID and E). Secondary lesions became 
more evident on later days, especially on the eyelids, anogenital region, face and ears on all 
animals. These lesions were red in colour and no larger than 10 mm in diameter (Figure 
4.12C-F). The primary lesion ceased growing (a maximum of 20-35 mm in diameter) and 
became circumscribed by 11 to 13 dpi (Figure 4.12A and B). By 15 dpi, the lesion changed 
colour from crimson to black and developed a hard brown or black scab on its surface. The 
lesion then began to regress slightly, changing from crimson to pink at the edges. By 21 
dpi, vaccinated animals had recovered from the vaccine virus infection. The primary lesion 
was scabbed over, or the scab had come off (Figure 4.13A-C). Secondary lesions were still 
evident on many animals, although they had all scabbed over (Figure 4.13D and F) or 
regressed completely (Figure 4.13E). Thirty weeks following vaccination, scarring was
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Table 4.1 -  Clinical signs of mature domestic rabbits following vaccination with 5000 
pfu of Uriarra AM 1OL/M11Lgpt.
D a y  p o s t  
in o c u la t io n
C lin ic a l s i g n s
3 Slight reddening of skin at the inoculation site
6 Primary lesion 10-20 mm in diameter. Some animals had red 
areas on the eyelids.
7 Primary lesion 10-30 mm in diameter. Secondary lesions evident 
on eyelids of most animals.
8 Primary lesion 15-28 mm in diameter. Temperatures above 40°C. 
Secondary lesions on eyes approximately 4 mm in diameter, red in 
colour. One animal had very mild anogenital swelling.
10 Primary lesion 20-35 mm in diameter, some showing black 
haemorrhagic patches. 2/6 rabbits have temperatures above 40°C. 
Secondary lesions evident on face, ears, body or anus on all 
animals.
15 Primary lesion covered with black scab, circumscribed. 
Secondary lesions on eyes, face, ears, body scabbing over, 
regressing. Two animals (019 and 963) had a rash of small (5 
mm) secondary lesions over the body.
21 Primary lesion scab has come off. Animals fully recovered from 
infection although some scabbing and evidence of scarring at sites 
of secondary lesions.
Figure 4.11 - Rabbits 7 days following inoculation with 5000 pfu of Uriarra 
AM 1QL/M11 Lspt. Primary lesions were 10-30 mm raised pink or red lumps (A-C, 
arrowed). Red patches on the eyelids (C and D; arrowed). Bars on images are 10
mm in size.
Figure 4.12 - Rabbits 13 days following inoculation with 5000 pfu of Uriarra 
AM10L/M1 \Lgpt. Primary lesions (A and B, arrowed). Secondary lesions at distal 
sites such as the eyelids (C and D, arrowed), the anus (E, red arrow) or face (F, 
arrowed). Bars on images are 10 mm in size.
Figure 4.13 - Rabbits 21 days after inoculation with 5000 pfu of Uriarra 
AM 1QL/M11 L g p t .  Primary lesions (A-C, arrowed). Secondary lesions on the 
eyes (D and E, arrowed) or ears (F, arrowed) had scabbed over or regressed 
completely (E, arrowed). Bars on images are 10 mm in size.
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evident at the sites of secondary lesions on most animals. This scarring was evident as 
patches of lost fur or fur regrowth of a different colour (Figure 4.14).
Temperatures were recorded daily for each animal and are shown in Figure 4.15. 
Temperatures of some animals increased to over 40°C from 5 dpi and at least one animal 
had a fever every day until 20 dpi. During the 3 weeks of monitoring, all six rabbits had 
temperatures of 40°C or above for at least 2 days from 5 dpi. Rabbits 957 and 963 had 
temperatures of greater than 40°C on 10 days between 5 and 20 dpi.
4.2.3.2 Analysis o f virus isolated from secondary lesions following vaccination with 
Uriarra AM10L/M1 ILgpi
Thirteen days following vaccination, biopsies from the primary lesions and secondary 
lesions of Uriarra AM 10L/M11 Lgp/-infected rabbits were collected and used to infect 
RK13 cells in vitro. Virus was grown without mycophenolic acid selection to permit the 
replication of both recombinant and wild type viruses. From these cells, viral ÜNA was 
isolated and examined by PCR to identify wild type and recombinant virus. Uriarra 
AM10L/M11 Lgp/-specific PCR product was isolated from most sites, including secondary 
sites as indicated by the 645 bp M012L-F1 x gpt-Rl product amplified from viral DNA 
(Figure 4.16A). A Uriarra-specific, 599 bp M012L-F1 x M010L-R1 PCR product was not 
amplified from any viral DNA sample, except the Uriarra DNA control (Figure 4.16B). 
These results indicate that secondary lesion formation was the result of dissemination of 
Uriarra AM10L/M11Lgpt, and not due to a low-level contamination of wild-type Uriarra.
Page 124
Figure 4.14 - Scarring on rabbits inoculated with Uriarra AM 1OL/M11 Lgpt 30 weeks 
after vaccination. Scarring was evident where secondary lesions developed following 
inoculation with the vaccine virus (arrowed). Bars on images are 10 mm in size.
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Figure 4.15 - Rectal temperatures of rabbits following inoculation with 5000 
pfu of Uriarra AM 1OL/M11Lgpt.
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Figure 4.16 - PCR analysis o f virus isolated from primary and secondary 
lesions o f Uriarra AM10L/M11 Lgpf-vaccinated rabbits. DNA was isolated 
from virus-infected cells seeded with tissue from vaccinated rabbits (rabbits 
003, 019, 957, 960, 963 and 968) collected 13 days after vaccination and 
analysed by PCR to identity recombinant virus (A) or wild type virus (B). The 
plasmid pKS+AM 10L/M11Lgpt was used as a positive control for recombinant 
virus, and Uriarra genomic DNA was used as a positive control for wild type 
virus. A recombinant virus PCR product was amplified from most samples, 
including tissue collected from secondary lesions (panel A, 645 bp, arrow X). 
No w ild  type PCR product was amplified from any site (panel B, 684 bp, arrow 
Y).
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4.2.33 Vaccination o f rabbits with Uriarra AAf-77gpt
Six domestic male rabbits o f between twelve and nineteen months o f age were inoculated 
with 5000 pfu o f Uriarra AM-T7g/?/ and examined for 15 days. A summary o f the clinical 
signs o f these animals is displayed in Table 4.2.
Within 2-3 dpi, a reddening o f the skin was seen at the inoculation site, which developed 
into a primary lesion o f 10-25 mm diameter. By 6 dpi, this lesion had grown to 25-35 mm 
diameter and was pink to red in colour and protuberant (Figure 4.17A and B). In addition, 
red areas were seen on the eyelids o f all animals except rabbit 943 and by 6 dpi, these had 
developed into secondary lesions (Figure 4.17C-E). Lesions had begun to develop at other 
sites including the ears, anus and face (Figure 4.17F). At 8 dpi, the primary lesions were 
35-50mm in diameter, red in colour, protuberant and some had darker patches in the middle 
(Figure 4.18A-B). Secondary lesions were more evident on the eyelids, face and ears 
(Figure 4.18C-F) o f all animals except rabbit 943. By 10 dpi, the primary lesion was 
circumscribed, crimson in colour and many had haemorrhagic patches.
By 15 dpi, the primary lesions were covered in a hard black scab (Figure 4.19A and B) and 
all animals except rabbit 030 had recovered from infection. Secondary lesions had scabbed 
over or had regressed on most animals (Figure 4.19C-D). Rabbit 030 had a more severe 
and persistent infection, had lost weight and had a slightly depressed demeanour. Lesions 
were more numerous on this animal, especially on the face and eyelids (Figure 4.19E-F). 
Very mild mucopurulent discharge was observed from the right eye o f this animal (Figure 
4.19F). Rabbit 030 recovered completely from infection by 21 dpi.
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Table 4.2 -  Clinical signs o f mature domestic rabbits following vaccination with 5000 
pfu o f Uriarra kNYX-lgpt.
D ay p ost 
in o cu la tio n
C lin ica l s igns
2 Slight reddening o f skin at the inoculation site
3 Primary lesions were pink in colour, 10-25 mm in diameter.
5 Primary lesion 25-35 mm in diameter, pink, raised and firm. 
Eyelids o f 5/6 animals had developed reddening or distinct lesions. 
Two animals had temperatures above 40°C.
8 Primary lesions 35-50 mm in diameter, raised, red. Secondary 
lesions (< 8 mm diameter) on 5/6 animals on ears, anus, eyelids and 
face.
10 Primary lesions circumscribed, 35-50 mm diameter, crimson in 
colour with black centre. Secondary lesions circumscribed, red, 
some beginning to scab over. 3/6 animals with temperatures above 
40°C.
15 Primary lesions covered in hard black scab. Secondary lesions 
regressing or scabbed over. One rabbit (030) had not fully 
recovered and had lost some weight.
21 Primary lesion scab had come off. Animals fully recovered from 
infection although evidence o f scarring at sites o f secondary lesions.
Figure 4.17 - Rabbits 6 days after inoculation with 5000 pfu of Uriarra AM-T7g£>f. 
Primary lesions were at least 30-40 mm in diameter, red and protuberant (A and B, 
arrowed). Secondary lesions on the eyelids (C-E, arrowed) and face (F, arrowed). 
Bars on images are 10 mm in size.
Figure 4.18 - Rabbits 8 days after inoculation with 5000 pfu of Uriarra AM-T7g£>/. 
Primary lesions (A and B, arrowed). Secondary lesions on the eyelids and face (C-F, 
arrowed). Bars on images are 10 mm in size.
Figure 4.19 - Rabbits 15 days after inoculation with 5000 pfu of Uriarra AM- 
Tlgpt. Primary lesions (A and B, arrowed). Secondary lesions on the face, ears 
and eyes (C and D, arrowed). One rabbit (030) had persistent symptoms and 
more secondary lesions than other rabbits (E and F, arrowed). Bars on images 
are 10 mm in size.
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Temperatures for each Uriarra AM-T7<gpf-vaccinated rabbit were recorded daily. All 
rabbits except rabbit 943 had temperatures above 40°C for 1-4 days following inoculation, 
primarily between 4 and 10 dpi (Figure 4.20), and rabbit 030 had a temperature over 40°C 
at 13 and 14 dpi.
Thirty weeks following vaccination, scarring was seen at the sites of secondary lesions on 
most animals vaccinated with Uriarra AM-T1 gpt. Similar to Uriarra AM10L/M1 lLgpt- 
vaccinated rabbits, this scarring was evident as patches where fur had not regrown over 
secondary lesions, as the ‘moth-eaten’ appearance of the fur on the edges of the ears, or fur 
regrowth of a different colour (Figure 4.21).
4.2.3.4 Analysis o f virus isolated from secondary lesions following vaccination with 
Uriarra AM-T7gpt
Biopsies of primary lesion and secondary lesion material were collected from rabbits 10 
days following vaccination with Uriarra AM-T7gpr, and used to infect RK13 cells in vitro. 
As described in Section 4.2.3.2, virus was grown without mycophenolic acid selection to 
permit the replication of both recombinant and wild type viruses. Viral DNA was isolated 
and examined by PCR to identify wild type and recombinant virus. Uriarra AM-Tlgpt- 
specific PCR product was isolated from most sites including secondary lesions on the 
eyelids, ears and anus, as indicated by the 603 bp M007-F1 x gpt-Rl PCR product 
amplified from viral DNA (Figure 4.22A). A Uriarra-specific, 542 bp M008-F1 x M007- 
RI PCR product was not amplified from any viral DNA sample, except the Uriarra DNA 
control (Figure 4.22B). These results indicate that secondary lesion formation was the 
result of dissemination of Uriarra AM-Tlgpt, and not due to a low-level contamination with 
wild-type Uriarra.
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Figure 4.20 - Rectal temperatures of rabbits following inoculation with 5000 pfii 
of Uriarra AM-T7gpt.
Figure 4.21 - Scarring on Uriarra AM-T7gE>f-vaccinated rabbits following 
vaccination. Scarring was evident on rabbits 30 weeks after vaccination at the 
sites of secondary lesions on the face and ears (A-C, arrowed).
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Figure 4.22 - PCR analysis of virus isolated from primary and secondary lesions of 
Uriarra AM-T7g£>f-vaccinated rabbits. DNA isolated from virus-infected cells 
seeded with tissue from a vaccinated rabbits (rabbits 030, 934, 943, 970, 974 and 
990) taken 10 days after vaccination and analysed by PCR to identify recombinant 
virus (A) or wild type virus (B). The plasmid pKS+AM-T7g/?r was used as a positive 
control for recombinant virus, and Uriarra genomic DNA was used as a positive 
control for wild type virus. A recombinant virus PCR product was amplified from 
most samples, including tissue collected from secondary lesions (panel A, 603 bp, 
arrow X). No wild type PCR product was amplified from any site (panel B, 542 bp, 
arrow Y).
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4.2.3.5 Vaccination o f rabbits with TKO
Eighteen domestic male rabbits of between six and twelve months of age were inoculated 
with 5000 pfu of TKO and examined daily for 14 days. Vaccination experiments were 
performed in two batches. The first group of six rabbits responded very well to 
vaccination, so another twelve animals were inoculated with TKO in a second experiment. 
The clinical signs of all 18 rabbits are summarised in Table 4.3.
By 5 dpi, a lesion had developed at the inoculation site on 17 of the 18 rabbits, ranging in 
size from 8-15 mm in diameter (Figure 4.23). By 7 dpi, primary lesions were 
circumscribed and had increased in size on some rabbits with a range of 10-25 mm and 
were dark pink in colour (Figure 4.24). The lesions of some rabbits had darker centres or 
had scabbed over (Figure 4.24C and D), and by 9 dpi were covered with a scab. The 
lesions then regressed, fading to pale pink on most animals by 12 dpi (Figure 4.25). None 
of the 18 rabbits developed secondary lesions following vaccination.
The temperatures of TKO-vaccinated rabbits were recorded daily. None of the 18 animals 
had temperatures above 40°C at any point following inoculation with TKO (Figure 4.26).
4.2.4 Challenge of vaccinated rabbits with SLS
4.2.4.1 Challenge o f Uriarra AM10L/M11 Lgpt-vaccinated rabbits six weeks after 
vaccination
Six weeks after vaccination, rabbits were challenged with 1000 pfu of SFS subcutaneously 
on the right thigh. All animals developed a reddening of the skin at the challenge site by 1- 
2 days post challenge (dpc). This grew to up to 10 mm in diameter by 3-4 dpc (Figure 
4.27). By 5 dpc, skin at the inoculation site had returned to normal.
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Table 4.3 -  C lin ical signs o f mature domestic rabbits follow ing vaccination with 5000 
p fu o fT K O .
D ay p o s t 
in o c u la tio n
C lin ica l s ig ns
2 Slight reddening o f skin at the inoculation site
4 Primary lesion is 8-15 mm in diameter, slightly raised and 
pink in colour.
6 Primary lesions circumscribed, 10-25 mm diameter
10 Primary lesion scabbed over on most animals, red or pink 
in colour.
14 Animals completely recovered. No secondary lesions 
were observed on any animal during infection
Figure 4.23 - Inoculation site of rabbits 5 days after vaccination with TKO. 
Primary lesions are indicated with arrows. Bars on images are 10 mm in size.
Figure 4.24 - Inoculation site of rabbits 7 days after vaccination with TKO. 
Primary lesions were pink in colour and slightly raised (A-F, arrowed). The lesion 
of one animal had scabbed over (C). Bars on images are 10 mm in size.
Figure 4.25 - Inoculation site of rabbits 12 days after vaccination with TKO. 
Primary lesions are indicated with arrows. The primary lesions had scabbed over 
on several animals (A-C). Bars on images are 10 mm in size.
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Figure 4.26 - Rectal temperatures of rabbits following inoculation with 5000 pfu 
ofTKO.
Figure 4.27 - Uriarra AM10L/M1 lLg£>/-vaccinated rabbits 4 days following 
challenge with 1000 pfu of SLS. Rabbits had a reddening of the skin at the 
inoculation site (arrowed). Bars on images are 10 mm in size.
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There was no large increase in temperature of the challenged animals, with the temperature 
of all animals staying below 40°C (Figure 4.28).
4.2.4.2 Challenge o f Uriarra AM10L/M11 Lgpt-vaccinated rabbits 30 weeks after 
vaccination
The same six rabbits previously challenged at 6 weeks were again challenged 30 weeks 
after vaccination with 1000 pfu of SLS delivered subcutaneously on the left thigh, and 
monitored for 1 week post challenge. Within 1-2 days, all animals had a reddening at the 
inoculation site ranging in size from 5-10 mm (data not shown). Some animals showed a 
slight thickening of the skin at the inoculation site, which regressed quickly. By 5 dpc, the 
inoculation site on all animals had returned to normal.
4.2.4.3 Challenge o f Uriarra AM-T7 gpt-vaccinated rabbits six weeks after vaccination 
Rabbits that had been inoculated with Uriarra AM-T7gpt were challenged with 1000 pfu of 
SLS subcutaneously on the right thigh. All animals developed a reddening of the skin at 
the inoculation site by 1-2 dpc. This was approximately 8 mm in diameter by 5 dpc (Figure 
4.29A). By 6 dpc, skin at the inoculation site had returned to normal. Only one of the six 
rabbits developed a distinct lesion at the inoculation site (rabbit 943; Figure 4.29B). By 3 
dpc, a hard red lump had developed at the inoculation site. This lump grew to 15 mm in 
diameter. The lesion was circumscribed began to darken and by 6 dpc was covered in a 
black scab. This rabbit had not developed any secondary signs of myxomatosis upon 
vaccination with Uriarra AM-Tlgpt (Section 4.2.3.3).
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Figure 4.28 - Rectal temperatures o f Uriarra AM10L/M11 Lgp/-vacci nated rabbits 
following challenge with 1000 pfu o f SLS.
Figure 4.29 - Uriarra AM-T7g£>f-vaccinated rabbits 5 days following challenge 
with SLS. Transient reddening of the skin at the challenge site (A, arrowed). 
Rabbit 943 developed a distinct lesion at the inoculation site (B, arrowed). Bars 
on images are 10 mm in size.
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There was no large increase in the temperature of challenged animals, with the temperature 
of all animals staying below 40°C, except for an early increase in temperature to 40°C at 1 
dpc for two rabbits (970 and 974; Figure 4.30).
4.2.4.4 Challenge of Uriarra AM-T7gpt-vaccinated rabbits 30 weeks after vaccination 
The Uriarra AM-T7g/?/-vaccinated rabbits were challenged again 30 weeks after 
vaccination with 1000 pfu of SLS delivered subcutaneously on the left thigh, and 
monitored for 1 week post challenge. Within 1-2 days, all animals exhibited a reddening at 
the inoculation site which faded quickly (data not shown). By 7 dpc, the inoculation site on 
all animals had returned to normal.
4.2.4.5 Challenge ofTKO-vaccinated rabbits six weeks after vaccination
Following challenge with SLS, the 18 TKO-vaccinated rabbits could be divided into three 
groups based on the clinical signs displayed.
Six rabbits (110, 155, 114, 135, 132, 127) displayed a transient response at the inoculation 
site involving a reddening of the skin within 2 dpc, followed by fading and the skin 
returning to normal by 5 dpc (Figure 4.31C-D). This response was very similar to that 
observed when Uriarra AM10L/M1 \Lgpt- or Uriarra AM-T7g/?/-vaccinated rabbits were 
challenged with SLS (Sections 4.2.4.1-4.2.4.4).
Eight rabbits (158, 116, 115, 109, 118, 125, 124, and 120) developed a distinct lesion at the 
inoculation site following challenge. These rabbits displayed a rapid reddening of the skin 
(within 1-2 dpc) at the inoculation site. However, instead of returning to normal, the skin 
thickened and developed into a red, protuberant lesion. The lesion at the inoculation site
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Figure 4.30 - Rectal temperatures o f Uriarra AM-T7g/?/-vaccinated rabbits 
following challenge with 1000 pfu o f SLS.
Figure 4.31 - TKO-vaccinated rabbits 4 days following challenge with 1000 pfu of 
SLS. Primary lesions at the inoculation site (A and B, arrowed). Transitory 
reddening of the skin at the inoculation site (C and D, arrowed). A small secondary 
lesion on the eyelid (E, arrowed). Bars on images are 10 mm in size.
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became circumscribed and scabbed over much more rapidly than during primary 
vaccination. By 4 dpc, haemorrhagic patches were visible on most lesions (Figure 4.31 A), 
and all lesions were covered with a hard black scab by 6 dpc (Figure 4.32A and B).
Four rabbits (113, 108, 039, and 123) developed a lesion at the inoculation site (Figure 
4.3IB), as observed in the previous group o f rabbits, but also developed very small 
secondary lesions at sites including the eyelids, ears and anus (Figure 4.3IE and Figure 
4.32C-E). These secondary lesions were usually visible by 3-4 dpc - they appeared more 
rapidly than observed during infection with SLS in DNA-vaccinated rabbits (Chapter 3). 
However, the lesions also regressed or scabbed over very quickly, generally within 48 
hours o f appearance, and the rabbits had completely recovered from infection by 8-9 dpc. 
No more than 4 secondary lesions were observed on any one animal, and these were 
smaller than those seen on rabbits inoculated with Uriarra AM10L/M1 \Lgpt or Uriarra 
AM-T7gpt, being no larger than 5 mm in diameter.
Temperatures were recorded daily for all 18 rabbits and are shown in Figure 4.33. The 
temperatures have been divided into the three rabbit groups; those that did not develop a 
lesion (Figure 4.33A), those that developed a lesion at the inoculation site (Figure 4.33B) 
and those that developed secondary lesions (Figure 4.33C). Rabbits that did not develop a 
lesion had no increase in temperature above 40°C during the 8 days post challenge (Figure 
4.33 A). Three o f the rabbits that developed a lesion at the inoculation site (rabbits 124, 116 
and 118) had temperatures above 40°C for 1 or 2 days following challenge (Figure 4.33B). 
Three o f the four rabbits that developed secondary lesions had temperatures above 40°C for 
2 or 3 days following challenge (Figure 4.33C). Thus there appeared to be a correlation
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Figure 4.32 - TKO-vaccinated rabbits 7 days following challenge with 1000 pfu of 
SLS. Circumscribed and scabbed over primary lesions (A and B, arrowed). Small 
secondary lesions on the ear (C, arrowed), eyelid (D, arrowed) and anus (E, red 
arrow). Bars on images are 10 mm in size.
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Figure 4.33 - Rectal temperatures o f TKQ-vaccinated rabbits following challenge 
with 1000 pfu o f SLS. The temperatures o f rabbits which upon challenge with 
SLS developed no lesion (A), a lesion at the inoculation site only (B) or secondary 
lesions (C) were monitored for 8 days post-challenge.
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between the external clinical symptoms observed following challenge and the temperature 
o f the animals.
Due to space constraints in the PC2 animal facilities in which these experiments were 
conducted and the very high levels o f protection seen amongst rabbits vaccinated with 
Uriarra AM10L/M1 \Lgpt and Uriarra AM -T lgpt at 30 weeks after vaccination, these 18 
rabbits were not kept for re-challenge at 30 weeks.
4.2.5 Analysis of anti-myxoma virus antibody development in vaccinated rabbits 
following vaccination and challenge
4.2.5.1 ELIS As
The anti-myxoma virus ELISA antibody titre was determined for all serum samples after 
vaccination and after challenge with SLS using the method described in Kerr (1997). Anti-
myxoma virus antibodies were first detected 14 days following inoculation with vaccine 
viruses. In rabbits vaccinated with Uriarra AM10L/M1 ILgpf, titres increased rapidly and 
ranged between 6400 and 51200 by 4 weeks post vaccination (wpv) and between 6400 and 
25600 by 6 wpv (Figure 4.34A). Titres recorded in Uriarra AM-T7gp/-vaccinated rabbits 
were not as high as those in Uriarra AM10L/M11 Lgp/l-vaccinated rabbits. By 4 wpv, titres 
ranged between 6400 and 12800, falling slightly to between 1600 and 6400 by 6 wpv 
(Figure 4.34B).
Following challenge with SLS, there was no significant increase (4-fold or greater; Kerr, 
1997) in antibody titre in any o f the Uriarra AM10L/M1 \Lgpt or Uriarra AM -T lgpt 
vaccinated rabbits except for 943 (Figure 4.34). This rabbit showed a 4-fold increase in
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Figure 4.34 - ELISA anti-myxoma virus antibody titres in rabbits vaccinated 
with Uriarra AM 10L/M11 Lgpf (A) or Uriarra AM-TIgpt (B). The ELISA titre 
was determined by titration in duplicate of two-fold serial dilutions of rabbit sera 
from 1:100. The ELISA endpoint was defined as the reciprocal serum dilution 
0.1 OD405 units above the OD405 of the 1:100 negative control. An OD405 of less 
than 0.1 for a 1:100 dilution of serum was recorded as a titre of zero. Rabbits 
were challenged with SLS following sera collection at week 6 (arrows).
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titre between 1 and 2 weeks following challenge. This rabbit was also the only rabbit in 
these groups that developed a lesion at the SLS inoculation site.
The ELISA titres for TKO-vaccinated rabbits have been divided into three graphs based on 
the symptoms exhibited by these rabbits follow ing challenge with SLS (Figure 4.35). 
Following vaccination with TKO, anti-myxoma virus antibodies were first detected by 
ELISA 14 days post vaccination. Early titres (2-3 wpv) were generally lower than those 
measured in Uriarra AM 10L/M11 Lgpt- and Uriarra AM-T7g/?/l-vaccinated animals. 
However, by 6 wpv, titres were comparable with other vaccine groups with a range 
between 1600 and 6400 (Figure 4.35).
Following challenge, rabbits that did not develop a lesion showed no increase in antibody 
titre (Figure 4.35A). O f the eight rabbits which developed a lesion at the SLS inoculation 
site, four (124, 118, 116 and 109) showed a significant increase in titre following challenge 
(Figure 4.35B). A ll four rabbits which also developed secondary lesions after SLS 
infection had significant increases in anti-myxoma virus antibody titre following challenge, 
including rabbit 039 which showed a 32-fold increase in titre by 2 weeks after challenge 
(Figure 4.35C).
4.2.5.2 Plaque reduction neutralisation assay (PRNA)
The ability o f virus-specific antibody in the serum o f TKO-vaccinated rabbits to neutralise 
myxoma virus in vitro was analysed using a plaque reduction neutralisation assay, as 
described in Kerr (1997). PRNA titres were not measured for Uriarra AM10L/M11Lgpt- 
and Uriarra AM-T7g/?/-vaccinated rabbits because these vaccines were not considered 
suitable for further development. PRNA were conducted on serum from rabbits before
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Figure 4.35 - ELISA anti-myxoma virus antibody titres in rabbits vaccinated with 
TKO. The ELISA titre was determined by titration in duplicate of two fold serial 
dilutions of rabbit sera from 1:100. The ELISA endpoint was defined as the 
reciprocal serum dilution 0.1 OD405 units above the OD405 of the 1:100 negative 
control. Rabbits were challenged with SLS following sera collection at week 6 
(arrows). Rabbits which upon challenge with SLS developed no lesion (A), a lesion 
at the inoculation site only (B) or secondary lesions (C) have been graphed 
separately.
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challenge (6 wpv) and two weeks after challenge (8 wpv). The percentage plaque 
neutralisation for each serum dilution tested and the corresponding 50% and 80% plaque 
neutralisation titres were recorded for rabbits that did not develop a lesion upon challenge 
(Figure 4.36), rabbits that developed a lesion following challenge (Figure 4.37) and rabbits 
that developed secondary lesions following challenge (Figure 4.38). At 6 wpv, 50% PRNA 
titres in TKO-vaccinated rabbits ranged between 80 and 1280 (Figures 4.36-4.38), except 
for rabbit 158 which had a titre o f 10240 (Figure 4.37). There was no correlation between 
the pre-challenge PRNA titre and the severity o f symptoms exhibited by TKO-vaccinated 
rabbits following challenge with SLS.
Following challenge, only one rabbit (155) amongst those that did not develop a lesion had 
a significant (4-fold or greater; Kerr, 1997) increase in PRNA titre (Figure 4.36), although 
this animal's ELISA titre fell slightly during this time (Figure 4.35A). A greater proportion 
o f rabbits that developed a lesion at the inoculation site following challenge had increases 
in 50% PRNA titres, with five out o f eight rabbits increasing titre by 8 to 64-fold, with final 
titres o f between 320 and 10240 (Figure 4.37). Rabbit 158, which had the highest pre-
challenge titre, showed a 16-fold decrease in 50% PRNA titre (Figure 4.37). A ll rabbits 
that developed secondary lesions upon challenge had significant increases in 50% PRNA 
titres, with 4- to 128-fold increases resulting in final titres o f between 2560 and 10240 
(Figure 4.38). There was no correlation between the magnitude o f ELISA and PRNA titres 
increases following challenge with SLS.
4.3 Di s c u s s i o n
This chapter has described the construction and testing o f three candidate myxoma virus 
vaccines by the targeted inactivation o f the viral immunomodulatory genes M010L, M 011L
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Figure 4.36 - Analysis of neutralising anti-myxoma virus antibodies in the serum of 
rabbits vaccinated with TKO that did not develop a lesion following challenge with 
SLS. Neutralising antibody was measured by plaque reduction neutralisation assay 
and the percentage plaque neutralisation recorded at week 6 (A) and week 8 (B) for 
each serum dilution (two-fold from 1:40 to 1:20480). The highest reciprocal serum 
dilutions at which 50% or greater and 80% or greater of myxoma virus plaque 
formation was neutralised is recorded (C).
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Figure 4.37 - Analysis of neutralising anti-myxoma virus antibodies in the serum of 
rabbits vaccinated with TKO that developed a primary lesion only following 
challenge with SLS. Neutralising antibody was measured by plaque reduction 
neutralisation assay and the percentage plaque neutralisation recorded at week 6 
(A) and week 8 (B) for each serum dilution (two-fold from 1:40 to 1:20480). The 
highest reciprocal serum dilutions at which 50% or greater and 80% or greater of 
myxoma virus plaque formation was neutralised is recorded (C).
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Figure 4.38 - Analysis of neutralising anti-myxoma virus antibodies in the serum of 
rabbits vaccinated with TKO that developed secondary lesions following challenge 
with SLS. Neutralising antibody was measured by plaque reduction neutralisation 
assay and the percentage plaque neutralisation recorded at week 6 (A) and week 8 
(B) for each serum dilution (two-fold from 1:40 to 1:20480). The highest 
reciprocal serum dilutions at which 50% or greater and 80% or greater of myxoma 
virus plaque formation was neutralised is recorded (C).
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and M007. These vaccines were evaluated for their acceptability and efficacy. Uriarra 
AM 10L/M11 Lgpt and Uriarra AM -T lgpt induced extremely mild myxomatosis in all 
vaccinated rabbits, which was not considered acceptable for use in pet animals. TKO was 
considered acceptable, with infection limited to a small lesion at the inoculation site only, 
with no secondary lesion development in the 18 rabbits vaccinated. A ll three vaccines 
conferred complete protection from lethal challenge. A small proportion (22%) o f TKO- 
vaccinated rabbits developed very small secondary lesions upon challenge, but there were 
no clinical signs o f myxomatosis observed in any o f these animals.
The acceptability and efficacy o f the three candidate vaccines, the role o f measured virus- 
specific antibody in protection from myxoma virus challenge, and the possible role o f 
myxoma virus EEV in the pathogenesis o f Uriarra AM10L/M11Lgpt have been discussed 
below.
4.3.1 Acceptability versus efficacy in myxoma virus vaccines
The three candidate vaccines have been evaluated for acceptability and efficacy. Both 
Uriarra AM 1OL/M11 Lgpt and Uriarra AM-T7gpt were highly protective vaccines, with 
absolutely minimal symptoms o f myxomatosis upon challenge with SLS up to 30 weeks 
after vaccination. Replication o f SLS was extremely limited and cleared very rapidly, as 
exhibited by the transient reddening o f the skin at the inoculation site (Fenner et al., 1953). 
However, these viruses cannot be considered acceptable vaccines as they induced 
secondary lesions on vaccinated animals, and one o f the Uriarra AM-T7gp/-vaccinated 
rabbits developed a more persistent disease and exhibited some weight loss during 
vaccination. The secondary lesions, as well as potentially distressing for rabbit owners, are 
also sites where the virus could potentially be transmitted by arthropod vectors, increasing
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the chances o f the vaccine virus being transmissible. Also, most o f the rabbits exhibited 
scarring at sites where secondary lesions developed, visible over 30 weeks post vaccination 
and likely to be permanent.
In contrast, TKO is a more acceptable vaccine in rabbits o f this age group. The virus 
induced minimal symptoms in domestic rabbits, limited to a small primary lesion. 
However, the level o f protection conferred by TKO was less than that o f the more virulent 
vaccine viruses. Twelve out o f eighteen TKO-vaccinated rabbits exhibited a lesion at the 
challenge site, and four o f these also developed a limited number o f very small secondary 
lesions, indicating SLS replication and dissemination was occurring. However, these 
symptoms are extremely minor compared to SLS infection in non-immune rabbits, such as 
those vaccinated with pDual2+ (Chapter 3), where the virus rapidly disseminated to 
secondary sites and was lethal within 13 days. In TKO-vaccinated rabbits, the SLS 
infection was controlled and cleared extremely rapidly, as exhibited by rapid 
circumscription and scabbing o f the lesion at the inoculation site and secondary lesions, 
indicative o f potent cell-mediated clearance o f the virus in the skin. These post-challenge 
symptoms have been observed in previously infected and immune wild rabbits (Fenner et 
al., 1953; Kerr, 1997).
Although TKO does not meet the ‘ ideal’ standard for a myxomatosis vaccine established in 
Section 1.6, due to the appearance o f secondary lesions on some rabbits upon lethal 
challenge, it appears that a vaccine which does confer this complete protection from 
infection (such as Uriarra AM 10L/M11Lgpt) would be too virulent to be acceptable. There 
appears to be a small window o f opportunity where the virulence o f a live myxoma virus
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vaccine allows it to be both acceptable and effective enough to protect from more serious 
symptoms o f myxomatosis. The TKO vaccine satisfies both o f these criteria.
4.3.2 Antibody titres in vaccinated rabbits
The severity o f clinical signs observed in vaccinated rabbits following SLS challenge could 
not be predicted based on pre-challenge ELISA or PRNA titres. For example, pre-
challenge neutralising antibody titres were comparable between groups o f TKO-vaccinated 
rabbits that did not develop a lesion upon challenge and those that developed a lesion at the 
inoculation site or secondary lesions. This indicates that the level o f anti-myxoma virus 
antibody following vaccination is not the key immune mechanism that confers protection.
A large proportion (77%) o f those rabbits that developed distinct lesions at the inoculation 
site or secondary lesions, showed a significant increase in antibody levels follow ing 
challenge. The development o f a lesion is indicative o f substantial viral replication in the 
skin at the inoculation site, and the subsequent production o f viral proteins. A more 
vigorous immune response must be mounted against this infection, leading to the 
proliferation o f myxoma virus-specific memory B and T cell populations and subsequent 
increase in myxoma virus-specific antibody titres. It has previously been found that only 
50% o f immune w ild rabbits showed a significant increase in ELISA titre follow ing 
challenge with virulent myxoma virus, despite the development o f a lesion at the 
inoculation site (Kerr, 1997). The transient reddening o f the skin following challenge 
observed on rabbits vaccinated with Uriarra AM 1OL/M11 Lgpt, Uriarra AM -T lgpt and 
some rabbits vaccinated with TKO, is indicative o f very limited viral replication that is 
rapidly cleared from the skin, most like ly by virus-specific cell-mediated immune
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responses. The limited amount o f viral antigens produced did not induce the amnesiastic 
antibody response observed in other animals.
4.3.3 Role of EEV particles in myxoma virus pathogenesis
Although Uriarra AM10L/M11Lgpt cannot productively infect lymphocytes as indicated by 
its in vitro characteristics in RL-5 cells (Section 4.2.2.2), it was able to disseminate and 
cause secondary lesions at distal sites. Therefore, it appears this virus has the ability to 
disseminate to secondary sites outside o f infected lymphocytes. The pathology o f Uriarra 
AM10L/M1 \Lgpt in infected rabbits was more severe than that reported for 
LausanneAM010L/M011L, which did not induce any secondary lesions (Opgenorth et al., 
1992).
The comet plaque morphology o f Uriarra AM10L/M11Lgpt plaques on Vero cells (Figure 
4.13) suggests that this virus is producing more EEV particles than Uriarra. This plaque 
morphology is caused by the release of EEV particles from infected cells and their 
distribution to distant sites on the cell monolayer by convection currents in the media (Law 
et al., 2002). The increased dissemination o f Uriarra AM10L/M11Lgpt observed in vivo 
compared to that reported for LausanneAM010L/M011L may be due to enhanced 
production o f EEV particles from Uriarra AM 10L/M 11 Lgp/-infected cells. There is no 
published information about the role o f EEV particles in the pathogenesis o f myxoma virus, 
although they are critical for the dissemination o f VV to distal tissues in the VV/mouse 
model (Payne, 1980; Payne and Kristensson, 1985; Smith and Vanderplasschen, 1998; 
Smith et al., 2002).
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The cause o f this phenotype is currently unknown. M010L and M011L and their 
homologues in other poxviruses have no reported effects on EEV production or plaque 
phenotype. The inactivation o f MOlOLand M011L in Lausanne was mediated by the 
insertion o f the E. co/i ß-galactosidase gene in the overlapping region o f the two genes, 
with no myxoma virus sequence deleted (Opgenorth et al., 1992). The deletion in Uriarra 
AM 1OL/M11 Lgpt may have affected promoter and regulatory elements controlling the 
neighbouring gene M009L. The function o f this gene is unknown. M009 contains several 
kelch-ring motifs (Cameron et al., 1999), and kelch-like proteins in VV have demonstrated 
effects on the formation o f VV-induced cellular projections that are associated with EEV 
particles (Pires de Miranda et al., 2003). It is interesting to note that highly virulent field 
strains o f myxoma virus have been isolated in Australia with deletions in the M009L gene 
(Peter Kerr, personal communication), suggesting a possible role for this gene in viral 
pathogenesis. Further investigation o f Uriarra AM I OL/M 11L gpt and the possible role o f 
M009L and EEV in myxoma virus pathogenesis are certainly warranted.
4.3.4 Conclusions
O f the three candidate vaccines tested, only TKO can be considered acceptable. The 
appearance o f secondary lesions on almost all rabbits vaccinated with Uriarra 
AM 1 OL/M 11 Lgpt and Uriarra AM-T7gpt would not lead to an acceptable vaccine. 
Although only six animals were vaccinated with each o f the viruses in this trial, the 
potential complication rate o f such vaccines in younger and immunocompromised animals 
would most likely be unacceptable. As TKO was the only one o f the three candidate 
vaccines to pass the initial selection criteria o f acceptability and efficacy, it was selected for 
further analysis and evaluation, as described in Chapters 5 and 6.
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Cha pte r  5 -  The Pa tho ge ne sis  o f  TKO in Do mest ic
a nd Wil d  Ra bbit s
5.1 I n t r o d u c t io n
The three deletion mutant vaccines evaluated in Chapter 4 all conferred excellent protection 
from challenge with myxoma virus. However, only TKO conferred this protection without 
causing any secondary lesions or visible scarring on vaccinated rabbits. As the candidate 
vaccine with the least vaccine-induced side effects combined with good protection from 
challenge, the pathogenesis o f TKO in domestic rabbits was studied to further evaluate 
TKO's acceptability as a vaccine.
Histological analysis o f skin lesion and draining lymph node sections allowed us to 
determine what level o f tissue damage was occurring in TKO-infected rabbits. The 
measurement o f titres o f virus in the skin o f domestic rabbits allowed us to infer the 
potential transmissibility o f the TKO vaccine from a recently vaccinated domestic rabbit. 
This is because transmissibility o f myxoma virus by arthropod vectors is directly related to 
the titre o f virus in the skin (Fenner et a/., 1956). The titre o f TKO in distal tissues was 
also measured to evaluate the in vivo dissemination o f the vaccine virus.
Myxoma virus replicates to high titres in the testes o f male rabbits and the resultant 
inflammatory reactions in the testes can make males infertile (Fountain et al., 1997; Sobey 
and Turnbull, 1956). I f  TKO is to be utilised as a vaccine for farmed rabbits and 
commercial rabbit breeders, it must not adversely affect the fertility o f male breeders. In 
the work described here, the amount o f virus in the testes o f infected rabbits was measured, 
and the testes examined histologically to determine i f  there were any changes that were 
indicative o f reduced fertility.
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The pathogenesis of TKO in wild rabbits was also studied. Measurement of TKO titres in 
wild rabbit skin allowed us to infer the potential transmissibility of the virus between wild 
rabbits, and its possible establishment in wild rabbit populations. The pathology of TKO 
infection in wild rabbit skin and draining lymph nodes was also examined.
5.2 Re s u l t s
5.2.1 Pathogenesis of TKO in mature domestic rabbits
TKO virus (5000 pfu) was inoculated subcutaneously into the dorsum of the right hind foot 
of mature domestic rabbits (6-15 months old). At each of 2, 4, 6, 10 and 20 days after 
infection, a group of three rabbits was killed. Samples of skin from the inoculation site, the 
right popliteal lymph node (draining lymph node), the left popliteal lymph node 
(contralateral lymph node) and right testis were removed. Half of the tissue was fixed in 
10% formalin in PBS and prepared for histological analysis (haematoxylin and eosin 
staining), while half was frozen immediately on dry ice and used to determine the titre of 
virus in the tissue. This was the same methodology used in previous pathogenesis studies 
of Uriarra (Best et a/., 2000; Best and Kerr, 2000), allowing the use of data and histological 
sections from those experiments to be compared to those obtained here.
5.2.1.1 Titre o f TKO in domestic rabbit tissues
The skin from the inoculation site, the draining lymph node, the contralateral lymph node 
and testis were processed as described in Section 2.6.6, and the virus titres in these tissues 
determined by plaque assay, with a detection limit of 10“ pfu per gram of tissue (pfu/g). 
Figure 5.1 shows the virus titre for each rabbit in the skin at the inoculation site, the 
draining lymph node and the contralateral lymph node. Samples where a trace of virus (a 
single plaque on one of duplicate samples) was found were defined as having a titre of 50
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pfu/g (10169), and samples with no detectable virus were defined as having a titre o f 0 
pfu/g. The mean titres o f Uriarra determined by Best and Kerr (2000) have been included 
in Figure 5.1 to allow comparison o f TKO to a virus that is readily transmissible and 
disseminates to distal tissues, causing severe symptoms o f myxomatosis in domestic 
rabbits.
TKO was detected at the inoculation site in all three rabbits at 2 days post inoculation (dpi), 
with titres ranging from a trace to 9.4 x 10^  pfu/g (Figure 5.1 A). Maximum TKO titres 
were detected at 6 dpi, with a mean titre o f 1.4 x 107 pfu/g (range o f 3.5 x 106 to 4.2 x 107 
pfu/g). Two o f the three rabbits had titres above 107 pfu/g, the titre o f virus in the skin 
required for mosquito transmission o f the virus (Fenner et al., 1956). By 10 dpi, the mean 
virus titre had dropped to 1 x 10 pfu/g (range o f 5.8 x 10“ to 3 x 10 pfu/g); virus was 
undetectable by plaque assay at 20 dpi (Figure 5.1 A). In contrast, Uriarra had a peak mean
o
titre o f 4 x 10 pfu/g at 6 and 10 dpi, and at 20 dpi, mean Uriarra titres in the skin were still 
106 pfu/g (Figure 5.1 A).
TKO was detected in the draining lymph node by 2 dpi with a mean titre o f 3.2 x 10“ pfu/g 
(Figure 5.1B). Peak TKO titres were recorded at 4 dpi with a mean titre o f 1.1 x 10 pfu/g. 
TKO was still detectable in the draining lymph node at 10 dpi in two o f three rabbits. TKO 
was not detected at 20 dpi. Previously determined Uriarra titres in the draining lymph node 
o f domestic rabbits were 100-1000 times higher than TKO titres at 4, 6 and 10 dpi (Figure 
5.IB).
Titres o f TKO were lower in the contralateral lymph node than the draining lymph node, 
and generally at or just above the lim it o f detection (10" pfu/g). TKO was first detected at 4
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Figure 5.1 - Myxoma virus titres in domestic rabbit tissues following inoculation 
with 5000 pfu of TKO. Vims titres at the inoculation site (A), draining lymph node 
(B) and contralateral lymph node (C) were measured by plaque assay, with a 
detection limit of 102 pfu/g. Each open square represents an individual rabbit 
infected with TKO and killed 2, 4, 6, 10 or 20 dpi. A titre of zero indicates no virus 
was detected in the given tissue sample. A titre of 10169 pfu/g indicates that a single 
plaque (a trace) was detected on duplicate sample wells. The solid line on each 
graph represents the geometric mean titre for the three rabbits sampled at each time 
point. The dotted line represents the geometric mean titre of Uriarra (of 2 or 3 
rabbits) in the same tissues following inoculation with 100 pfu of virus, as 
determined by Best and Kerr (2000).
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dpi in two of three rabbits, with a trace of virus in one animal and a titre of 200 pfu/g in the 
other (Figure 5.1C). By 6 dpi, a trace of virus was detected in only one of three rabbits, and 
virus was not detected in the contralateral lymph node at 10 or 20 dpi. In contrast, Uriarra 
was first detected in the contralateral lymph node at 6 dpi, and titres peaked at 104 pfu/g at 
10 dpi (Figure 5.1C). Uriarra was not detected at 15 and 20 dpi in domestic rabbits.
Virus was not detected in the testes of TKO-infected domestic rabbits at 2, 4, 6, 10 or 20 
dpi (data not shown).
5.2.1.2 Tissue damage and histopathological changes in the skin and draining lymph 
node of TKO-vaccinated domestic rabbits
5.2.1.2.1 Histological appearance o f normal rabbit skin
Haematoxylin and eosin-stained sections of skin from the dorsum of the hind foot on an 
uninfected rabbit are shown in Figure 5.2. The skin of uninfected rabbits has a thin 
epidermis consisting of a layer of cells with flattened nuclei covered with keratin (Figure 
5.2A). The dermis consists of regularly packed collagen fibres and contains hair follicles 
and blood vessels (Figure 5.2). Within the dermis, many cell types can be differentiated 
based on their morphology and appearance after haematoxylin and eosin staining. The 
most common cell type in normal skin are fibroblasts (elongated darkly-stained cells; 
Figure 5.2B). Lymphocytes (10 pM round cells with very little cytoplasm) and 
polymorphonuclear cells (PMN; 15-20 pM, multilobed nuclei with dark pink-staining 
granular cytoplasm) are seen in infected skin (Figure 5.3), but these cell types are not 
common in uninfected skin. The total thickness of uninfected skin on the dorsum of the 
hind foot was between 1.5 and 2 mm on domestic rabbits.
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Figure 5.2 - Haematoxylin and eosin-stai ned skin section from the dorsum of 
the hind foot of uninfected domestic rabbits showing normal skin structure and 
cell types. A: The epidermis and upper dermis. B: The deeper dermis; blood 
vessels are surrounded by a layer of endothelial cells (arrowed). Bars on images 
are 50 pm in length. Key: E, epidermis; D, dermis; HF, hair follicle; BV, blood 
vessel; F, fibroblast. Examples of each cell type and structure are indicated.
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5.2.1.2.2 Histopathological changes in the skin at the inoculation site o f domestic rabbits 
following TKO infection
Haematoxylin and eosin-stained sections of skin at the inoculation site from three TKO- 
infected domestic rabbits at each time point were examined. Sections from Uriarra-infected 
rabbits prepared in a previous study (Best et al., 2000; Best and Kerr, 2000) were re-
examined and compared. The histological changes seen in skin at the inoculation site of 
TKO- and Uriarra-infected domestic rabbits are summarised in Table 5.1. Figures 5.3 to 
5.6 show typical histopathology sections illustrating the changes.
At 2 dpi, there were no histological changes in the skin of TKO-infected rabbits (Figure 
5.3 A). By 4 dpi, the epidermis of TKO-infected rabbits was 1.5 times thicker than normal 
(Figure 5.3B). An increased cellular infiltrate was seen throughout the dermis, consisting 
of polymorphonuclear cells with some lymphocytes and other mononuclear cells (Figure 
5.3B and C). Degradation of the regular collagen structure and purple-staining fibrin 
deposits was seen in the deeper dermis (Figure 5.3C).
By 6 dpi, the epidermis of TKO-infected rabbits at the inoculation site was 2-4 times 
thicker than normal (Figure 5.4A). There were more inflammatory cells in the upper 
dermis than at 4 dpi, consisting of mononuclear cells and polymorphonuclear cells (Figure 
5.4). Large elongated cells previously identified as myxoma cells (Best et al., 2000; Hurst, 
1937) were seen in the deeper dermis of TKO-infected rabbits (Figures 5.4B), and were 
more common in Uriarra-infected rabbits (Table 5.1).
By 10 dpi, the primary lesions of TKO-infected rabbits were 4-6 mm thick and 
approximately 20 mm in diameter. Uriarra-induced lesions were up to 60 mm in diameter
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Table 5.1 - Summary o f the histopathological changes in domestic rabbit skin following infection 
with TKO or Uriarra. Histopathological images corresponding to the information in this table are 
found in Figures 5.3-5.6.
TKO Uriarra
Two Days Post Infection
No changes No changes
Four Days Post Infection
Epiderm is 1.5 times thicker than normal; swelling o f 
epidermal cells
1.5 times thicker than normal; swelling o f 
epidermal cells
Derm is Degradation o f collagen fibres; fibrin 
deposition
Degradation o f collagen fibres
In flam m ation Increased numbers o f PMN near epidermis; 
mononuclear cells and PMN in dermis
Increased numbers o f PMN in dermis
Six Days Post Infection
Epiderm is 2-4 times thicker than normal; some 
proliferation o f epidermal cells.
3-5 times thicker than normal; proliferation o f 
epidermal cells
Derm is Oedema (skin section 2 times normal 
thickness); increased levels o f collagen 
degradation and fibrin deposition than at 4 
dpi; some myxoma cells in deeper dermis
Oedema (skin section 2 times normal 
thickness); degradation o f collagen fibres 
throughout dermis; fibrin deposition; swelling 
o f blood vessels; myxoma cells prevalent in 
deeper dermis
In flam m ation Cellular infiltrate consists o f equal numbers o f 
PMN and mononuclear cells; macrophages in 
deeper dermis; many more inflammatory cells 
than at 4 dpi
PMN infiltrate; occasional mononuclear cells
Ten Days Post Infection
Epiderm is 2 rabbits - thickening o f epidermis 3-5 times 
normal; slight swelling o f epidermal cells
1 rabbit - scabbing and complete loss o f 
epidermal cell layer,
5 times thicker than normal; proliferation and 
degradation o f cells
Derm is Oedema (skin section 3-4 times normal 
thickness); extensive degradation o f collagen 
fibres, especially near epidermis; 
proteinaceous exudate in upper dermis; no 
myxoma cells
Oedema (skin section 3-4 times normal 
thickness); extensive degradation o f collagen 
fibres and fibrin deposits throughout; myxoma 
cells in deeper dermis
In flam m ation Very intense mononuclear cell infiltrate 
throughout the dermis, dominated by 
lymphocytes. No PMN present.
Infiltrate was predominantly PMNs; 
macrophages and mononuclear cells more 
common than at 6 dpi
Tw enty Days Post Infection
Epiderm is Normal Very thick scab over the primary lesion; 
adjacent epidermis up to 10 times normal 
thickness; cellular proliferation
Derm is Almost returned to normal; slightly irregular 
collagen structure
Oedema (skin section 3-5 times normal 
thickness); highly degraded dermis; vacuoles 
in dermis with extensive fibrin deposits
Inflam m ation Slight mononuclear cell infiltrate, mostly 
lymphocytes
Intense mononuclear cell infiltrate throughout 
dermis; some PMN present
Abbreviations: PMN; polymorphonuclear cell; dpi, days post infection.
Figure 5.3 - Histopathology of the skin at the inoculation site of domestic rabbits 
infected with TKO. A: Skin at 2 days post infection. B: The epidermis and upper 
dermis at 4 days post infection. C: Inflammatory cell infiltrate, collagen 
degradation and fibrin deposits in the deeper dermis at 4 days post infection. Bars 
on images are 50 pm in length. Key: E, epidermis; BV, blood vessel; black 
arrowhead, polymorphonuclear cell; yellow arrowhead, macrophage; red arrow, 
lymphocyte. Examples of each cell type and structure are indicated
Figure 5.4 - Histopathology of the skin at the inoculation site of domestic rabbits 6 days 
after infection with TKO. A: Epidermis and upper dermis with an infiltrate of 
polymorphonuclear and mononuclear cells. B: Extensive collagen degradation, fibrin 
deposits, myxoma cells and an infiltrate of polymorphonuclear and mononuclear cells in 
the deeper dermis. Bars on images are 50 pm in length. Key: E, epidermis; BV, blood 
vessel; black arrowhead, polymorphonuclear cell; yellow arrowhead, macrophage; red 
arrow, lymphocyte; MC, myxoma cell. Examples of each cell type and structure are 
indicated.
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at this time (Best and Kerr, 2000). The epidermis o f two TKO-infected rabbits was only 
slightly thicker than at 6 dpi, and the structure o f the upper dermis was highly degraded and 
separated from the epidermis (Figure 5.5A). The third animal had a thick scab over the 
inoculation site and the dermis was filled with a dark pink-staining material and red blood 
cells (Figure 5.5B). The inflammatory infiltrate in TKO-infected rabbit skin consisted o f 
mononuclear cells, predominantly lymphocytes (Figure 5.5A), and was more intense than at 
6 dpi (Figure 5.4). In contrast, polymorphonuclear cells dominated the cellular infiltrate in 
Uriarra-infected skin at 10 dpi (Figure 5.5C). Also, the epidermis was 50% thicker than in 
TKO-infected rabbits, and contained more numerous degenerating epidermal cells (Figure 
5.5C).
By 20 dpi, the skin o f TKO-inoculated domestic rabbits had returned to normal appearance, 
although the collagen structure was still slightly irregular (Figure 5.6A) compared to 
uninfected controls (Figure 5.2). In contrast, Uriarra-infected skin was still very abnormal, 
with a very thick epidermis and an extensive inflammatory infiltrate consisting 
predominantly o f macrophages and lymphocytes, although numerous polymorphonuclear 
cells were also present (Figure 5.6B).
In summary, the histopathological changes that occurred in rabbit skin following TKO 
infection were the thickening o f the epidermis and some proliferation o f epidermal cells; 
swelling and degradation o f the dermis; the infiltration o f polymorphonuclear cells between 
4 and 6 dpi, followed by an extensive influx o f mononuclear cells including numerous 
lymphocytes at 10 dpi. By 20 dpi, the skin at the inoculation site had returned to normal 
structure and appearance. Uriarra-infected skin had a similar appearance to TKO-infected 
skin at 2, 4 and 6 dpi. However, at 10 dpi, the inflammatory infiltrate consisted
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Figure 5.5 - Histopathology of the skin at the inoculation site of domestic rabbits 10 days 
after infection with myxoma virus. Skin sections from TKO-infected rabbits (A and B). Skin 
section from a Uriarra-infected rabbit (C). A: Skin of a TKO-infected rabbit with an 
extensive mononuclear cell infiltrate in the dermis. B: Skin of a TKO-infected rabbit 
showing scabbing, haemorrhage and pink-staining proteinaceous exudate. C: Epidermis of a 
Uriarra-infected rabbit showing degrading cells (thin red arrows) and polymorphonuclear 
cells in the dermis. Bars on images are 50 pm in length. Key: E, epidermis; D, dermis; BV, 
blood vessel; black arrowhead, polymorphonuclear cell. Examples of each cell type and 
structure are indicated.
Figure 5.6 - Histopathology of the skin at the inoculation site of domestic rabbits 
20 days infection with myxoma virus. A: The epidermis and upper dermis of a 
TKO-infected rabbit. B: The epidermis and upper dermis of a Uriarra-infected 
rabbit. Bars on images are 50 pm in length. Key: E, epidermis; D dermis; HF, 
hair follicle; red arrow, lymphocyte; yellow arrowhead, macrophage; black 
arrowhead, polymorphonuclear cell. Examples of each cell type and structure are 
indicated.
Chapter 5 -  Pathogenesis of TKO
predominantly of polymorphonuclear cells, and the skin was still abnormal in structure at 
20 dpi.
5.2.1.2.3 Histological appearance of normal rabbit popliteal lymph node
Images of haematoxylin and eosin-stained uninfected rabbit popliteal lymph nodes are 
shown in Figure 5.7. The lymph node is encased within a capsule of dense connective 
tissue (Figure 5.7A and B). Uninfected lymph nodes contain large numbers of primary 
lymphoid follicles with small lymphocytes immediately beneath the capsule (Figure 5.7A). 
Secondary lymphoid follicles, consisting of a germinal centre surrounded by a mantle of 
lymphocytes, are occasionally seen in uninfected lymph nodes (Figure 5.7B). A germinal 
centre is an active B cell zone where naive B cells are activated and differentiate into 
plasma cells (MacLennan, 1994). Active germinal centres have fewer lymphocytes than 
the surrounding mantle, and therefore stain more faintly, as shown in Figure 5.7B. The 
paracortical area is located beneath the follicle-containing cortex (Figure 5.7A). This 
region contained large numbers of lymphocytes and the occasional blood vessel (Roitt, 
1997; Figure 5.7C).
5.2.1.2.4 Histopathological changes in the draining lymph node o f domestic rabbits 
following TKO infection
Haematoxylin and eosin-stained sections of the draining lymph node from three TKO- 
infected domestic rabbits at each time point were examined. Sections from Uriarra-infected 
rabbits prepared in a previous study (Best et al., 2000; Best and Kerr, 2000) were re-
examined and compared. The histological changes seen in the draining lymph node of 
TKO- and Uriarra-infected rabbits are summarised in Table 5.2. Figures 5.8 to 5.10 show 
typical histopathology sections illustrating the changes.
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Figure 5.7 - Histology of the popliteal lymph node from an uninfected rabbit. A: The 
cortex of the lymph node with primary lymphoid follicles and the paracortical area. 
B: Secondary lymphoid follicle with a germinal centre surrounded by the lymphocyte 
mantle. C: The paracortical area with abundant lymphocytes. Key: GC, germinal 
centre, M, mantle; F, primary lymphoid follicle; C, capsule; PA, paracortical area; SS, 
subcapsular sinus, BV, blood vessel. Examples of each cell type and structure are 
indicated.
Table 5.2 - A summary o f the histopathological changes in domestic rabbit draining lymph nodes 
follow ing infection with TKO or Uriarra. Histopathological images corresponding to the 
information in this table are found in Figures 5.8-5.10.
TK O Uriarra
Two Days Post Infection
C ortex Large secondary lymphoid follicles with 
distinct germinal centres; macrophages in 
mantle
Large secondary lymphoid follicles, no 
distinct germinal centres; macrophages 
throughout secondary lymphoid follicles
C ellu lar
infiltrate
PMN and eosinophilic mononuclear cells in 
the medullary sinus and cortex
PMN and eosinophilic mononuclear cells in 
the medullary sinus
P aracortex Normal Normal
Four Days Post Infection
C ortex Increase in number o f active germinal centres 
since 2 dpi
Large increase in number o f active germinal 
centres since 2 dpi, found into paracortex
C ellu lar
infiltrate
As at 4 dpi; PMN and eosinophilic 
mononuclear cells clustering in medullary 
sinus
No change
Paracortex Normal Normal
Six Days Post Infection
C ortex Numerous large active germinal centres Fewer, smaller germinal centres than in TKO- 
infected animals; large parts o f cortex highly 
depleted o f lymphocytes with extensive 
apoptosis
C ellu lar
in filtrate
No change Very intense PMN infiltrate throughout node, 
especially in medullary sinus
Paracortex Slight, localised depletion o f lymphocytes 
compared to uninfected lymph nodes
Very low density o f lymphocytes; extensive 
apoptosis visible
Ten Days Post Infection
C ortex Numerous large germinal centres containing 
mitotic and apoptotic cells; slightly depleted 
o f lymphocytes; haemorrhaging in the cortex
Fewer germinal centres than in TKO-infected 
rabbits; PMN and apoptotic cells present in 
germinal centres
C ellu lar
infiltrate
Fewer PMN seen in lymph node; 
macrophages containing apoptotic bodies seen 
in germinal centres
Fewer PMN in lymph node; some 
macrophages containing apoptotic bodies seen 
in germinal centres
Paracortex Slightly lower density o f lymphocytes 
compared to uninfected lymph nodes; 
clustering o f lymphocytes in blood vessels
Low density o f lymphocytes, though not as 
marked as at 6 dpi; no apoptosis visible 
microscopically
Twenty Days Post Infection
Cortex Numerous large active germinal centres in 
cortex
Few germinal centres; cortex depleted o f 
lymphocytes
C ellu lar
infiltrate
Normal Large numbers o f macrophages seen in all 
parts o f the lymph node
Paracortex Normal Very low density o f lymphocytes; remaining 
lymphocytes were clustered around 
macrophages
Abbreviations: PMN, polymorphonuclear cells; dpi, days post infection.
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At 2 dpi, secondary lymphoid follicles with lighter-staining germinal centres were prevalent 
in the draining lymph nodes o f TKO-infected animals. Secondary lymphoid follicles were 
also seen in lymph nodes o f Uriarra-infected rabbits, but lighter staining germinal centres 
indicative o f active B cell zones (MacLennan, 1994) were not seen. By 4 dpi, germinal 
centres were prevalent in the draining lymph nodes o f both TKO (Figure 5.8A) and Uriarra- 
infected rabbits. Many o f these germinal centres had developed dark zones, basal light 
zones and apical light zones typical o f active germinal centres (Roitt, 1997; Figure 5.8A).
At 6 dpi, the draining lymph nodes o f TKO-infected domestic rabbits had swollen to 2.5- 
3.5 times normal size with a blotchy appearance and some haemorrhagic patches. 
Numerous active germinal centres were present (Figure 5.8C). The paracortical area had a 
reduced lymphocyte density in some areas (Figure 5.8D) compared to normal lymph nodes 
(Figure 5.7C), although there was no evidence o f lymphocyte apoptosis. Most o f the 
paracortex was still densely populated with lymphocytes. In contrast, the draining lymph 
nodes o f Uriarra-infected animals were reported to be sparsely populated with lymphocytes 
throughout most o f the node, with extensive apoptosis evident throughout the cortex and 
paracortex (Best et al., 2000). Other regions o f the cortex o f these lymph nodes were still 
well populated with lymphocytes, with active germinal centres and densely populated 
mantles.
At 10 dpi, the draining lymph nodes o f TKO-infected rabbits were still 2.5-3 times normal 
size with a blotchy appearance and haemorrhagic patches. The germinal centres contained 
more lymphocytes than at 6 dpi, and both apoptotic and mitotic cells were present (Figure 
5.9B). There was haemorrhaging in the cortex in all three infected rabbits, indicated by 
erythrocytes outside o f blood vessels (data not shown). Blood vessels within the paracortex
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Figure 5.8 - Histopathology of the draining popliteal lymph node from domestic rabbits 
after TKO infection. Sections from TKO-infected rabbits at 4 dpi (A and B) and 6 dpi (C 
and D). A: Germinal centre in the lymph node at 4 dpi with distinct dark, basal light and 
apical light zones. B: Paracortex of the lymph node at 4 dpi. C: Germinal centres in the 
draining lymph node at 6 dpi. D: Paracortex of TKO-infected rabbit at 6 dpi was depleted 
of lymphocytes in some areas. Key: GC, germinal centre; M, mantle; F, primary 
lymphoid follicle; PA, paracortical area; SS, subcapsular sinus; BV, blood vessel; DZ, 
dark zone; BZ, basal light zone; AZ, apical light zone; black arrowhead, 
polymorphonuclear cell. Examples of each cell type and structure are indicated.
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Figure 5.9 - Histopathology of the draining popliteal lymph node from domestic rabbits 
10 days after myxoma virus infection. Sections from TKO-infected rabbits (A-C). 
Section from a Uriarra-infected rabbit (D). A: Draining lymph node of a TKO-infected 
rabbit. B: Higher magnification image of a germinal centre in the lymph node of a 
TKO-infected rabbit with apoptotic and mitotic cells. C: The paracortex of a TKO- 
infected rabbit with a reduced density of lymphocytes and with lymphocytes clustered in 
blood vessels. D: Draining lymph node of a Uriarra-infected rabbit was depleted of 
lymphocytes as indicated by the lack of dark purple staining compared to a TKO- 
infected rabbit (A). Some areas had darker purple staining (box). Key: GC, germinal 
centre, Cx, cortex; PA, paracortical area; MS, medullary sinus; BV, blood vessel; Ap, 
apoptotic bodies; Mi, mitotic cell. Examples of each cell type and structure are 
indicated.
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were densely packed with lymphocytes (Figure 5.9C). Lymph nodes o f Uriarra-infected 
domestic rabbits were less densely populated with lymphocytes (Figure 5.9D) compared to 
TKO-infected rabbits (Figure 5.9A) as seen by the light staining o f sections.
At 20 dpi, the draining lymph nodes o f TKO-infected rabbits had returned to a more normal 
appearance, with numerous active germinal centres (Figure 5.10A) which had clearly 
defined dark and light zones and densely populated mantles. The paracortical area was 
densely populated by lymphocytes (Figure 5.1 OB). In contrast, the lymph nodes o f Uriarra- 
infected rabbits were sparsely populated with lymphocytes as seen by the lack o f purple 
staining in lymph node sections (Figure 5 .10C). The lymphocytes remaining in these 
lymph nodes were clustered around macrophage-like cells with extensive dendritic 
processes, some appearing to contain phagocytosed apoptotic bodies (Figure 5.10D).
In summary, following infection with TKO, the draining lymph nodes o f domestic rabbits 
developed numerous secondary lymphoid follicles with active germinal centres by 2 dpi, 
there was a reduction in the density o f lymphocytes in the cortex and paracortex at 6 and 10 
dpi, but by 20 dpi, the draining lymph node appeared normal except for the presence o f 
numerous large secondary lymphoid follicles. In contrast, the draining lymph nodes o f 
Uriarra-infected rabbits did not form active germinal centres as rapidly as TKO-infected 
rabbits. At 6 dpi, extensive apoptosis was evident throughout lymph nodes. At 10 and 20 
dpi, nodes were sparsely populated with lymphocytes compared to normal lymph nodes and 
those from TKO-infected rabbits.
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Figure 5.10 - Histopathology of the draining popliteal lymph node from domestic 
rabbits 20 days after myxoma virus infection. Sections from TKO-infected rabbits (A 
and B). Sections from Uriarra-infected rabbits (C and D). A: The draining lymph node 
of a TKO-infected rabbit appears similar to normal lymph node (Figure 5.7A) except for 
more numerous secondary lymphoid follicles. B: The paracortical area of the lymph 
node from a TKO-infected rabbit. C: Draining lymph node of a Uriarra-infected rabbit. 
D: Enlargement of the boxed area in C, showing a cluster of lymphocytes surrounding 
macrophage-like cells. Key: GC, germinal centre; F, primary lymphoid follicle; PA, 
paracortical area; MS, medullary sinus; green arrow, macrophage-like cell. Examples 
of each cell type and structure are indicated.
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5.2.1.2.5 Histological analysis o f testes from TKO-infected domestic rabbits 
The development of spermatozoa in the seminiferous tubules of the testis proceeds though a 
series of stages, which are identified in a section of a normal rabbit testis in Figure 5.11A. 
Development occurs in waves through each tubule, and early and late stages of 
development are generally not evident in all tubules (Guraya, 1987). Spermatogonia are 
identified as small cells with dense chromatin and a large nuclear vacuole (Figure 5.11 A, 
SG). These enter the first stages of meiosis and change morphology into primary 
spermatocytes, distinguished as cells with coarser chromatin (Figure 5.11A, Si). The 
process of meiosis proceeds through several short-lived stages until elongated developing 
spermatozoa with darkly staining purple nuclei are formed (Figure 5.11 A, S4), and then into 
mature tailed spermatozoa with broad, pale blue staining nuclei (Figure 5.11 A; Sm). 
Developing and tailed spermatozoa were rarely observed in the same tubule. Sertoli cells 
support the developing spermatozoa (Guraya, 1987; Wheater et al., 1987).
For comparison, a histological section of testis from a Uriarra-infected rabbit 20 days after 
inoculation is shown in Figure 5.1 IB. The degeneration of the seminiferous tubules is 
evident by their reduced size compared to normal testis and the absence of developmental 
stages of spermatozoa, with only spermatogonia and Sertoli cells evident. No mature or 
developing spermatozoa were found in any tubule from these rabbits. The inflammation of 
the testis is evident by the swelling of the interstitium (the connective tissue between the 
tubules) compared to normal testis samples.
Histological analysis of testis samples from TKO-vaccinated rabbits revealed no significant 
abnormalities compared to normal testes at 2, 4, 6, 10 and 20 dpi. Figure 5.12 shows an 
example of seminiferous tubules from TKO-infected rabbits at each time after inoculation.
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Figure 5.11 - H istology o f  sem iniferous tubules o f  dom estic rabbits before and after 
Uriarra infection. A: Tubules from an uninfected rabbit showing all stages o f 
sperm atozoa developm ent. B: Tubules from a rabbit 20 days after U riarra infection. 
Key: S, Sertoli cell; SG, sperm atogonia; S,, prim ary sperm atocytes; S4, elongated 
developing sperm atozoa; Sm, m ature sperm atozoa with tails; M B, m ultinucleate body; 
M, basem ent m em brane; BV, blood vessel. Exam ples o f  each cell type and structure 
are indicated.
Figure 5.12 - Seminiferous tubules of domestic rabbits following infection with TKO. 
Tubules from rabbits 2 days (A), 4 days (B), 6 days (C), 10 days (D) and 20 days (E) 
after infection with TKO are shown. Bars on images are 50 p.m in length. Key: S, 
Sertoli cell; SG, spermatogonia; S]9 primary spermatocytes; S4, elongated developing 
spermatozoa; Sm, mature spermatozoa with tails. Examples of each cell type are 
indicated.
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At all time points, the testes of TKO-infected rabbits displayed tubules with all stages of 
spermatozoa development evident, and were indistinguishable from uninfected rabbit 
samples. There was also no evidence of inflammation or other gross histopathological 
changes in the structure or appearance of the testis or epididymis.
5.2.2 Pathogenesis of TKO in mature wild rabbits
The pathogenesis of TKO was examined in wild rabbits to determine the potential of the 
vaccine virus to be transmitted between wild rabbits and become established amongst wild 
rabbit populations in Australia. Rabbits were infected, tissues harvested, processed and 
analysed as described for domestic rabbits (Section 5.2.1). The titre of virus in the skin at 
the inoculation site, the draining popliteal lymph node and the contralateral lymph node 
were measured to examine the level of dissemination of the virus, and the potential 
transmissibility of the vaccine from an infected wild animal. The pathology of the skin at 
the inoculation site and the draining lymph node were also examined.
5.2.2.1 Titres o f virus in wild rabbit tissues
Figure 5.13 shows the virus titre for each wild rabbit in the skin at the inoculation site, the 
draining lymph node and the contralateral lymph node. Samples where a trace of virus (a 
single plaque on one of duplicate samples) was found were defined as having a titre of 50 
pfu/g (10169), and samples with no detectable virus were defined as having a titre of 0 
pfu/g. The mean titres of Uriarra determined by Best and Kerr (2000) have been included 
in Figure 5.13 to allow comparison of TKO to a field isolated virus that is readily 
transmissible between rabbits.
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TKO was detected at the inoculation site o f two out o f three wild rabbits at 2 days post 
inoculation (dpi). By 4 dpi, virus titres were at their highest levels at a mean o f 5.5 x 106 
pfu/g, with a range o f 2.2 x 106 to 1.5 x 107 pfu/g (Figure 5.13A). By 6 dpi, virus titres in 
wild rabbits were consistently lower than those measured in domestic rabbits, with titres at 
a mean o f 1.9 x 106 pfu/g. Low titres o f TKO were detected at the inoculation site o f all 
three rabbits at 10 dpi (mean titre o f 115 pfu/g) and in one o f three rabbits 20 dpi at 5 x 10"
o
pfu/g. Uriarra titres were similar to TKO titres at 2 and 4 dpi, and peaked at over 10 pfu/g 
at 6 dpi (Best and Kerr, 2000). By 20 dpi, titres were still above 106 pfu/g (Figure 5.13A).
TKO titres in the draining lymph nodes o f w ild rabbits were similar to those in domestic 
rabbits. Virus was detected in all rabbits by 2 dpi and peaked at 4 dpi with titres between 
4.5 x 10" and 3.6 x 10 ' pfu/g (Figure 5.13B). TKO was detected in two o f three rabbits at 
10 dpi with titres o f 1.5 x 102 pfu/g. At 20 dpi, TKO was detected (102 pfu/g) in one rabbit 
(Figure 5.13B) which also had detectable virus at the inoculation site (Figure 5.13A). 
Uriarra was first detected in the draining lymph node at 4 dpi with a mean titre o f 104 pfu/g. 
By 10 dpi, only a trace o f virus was detected some w ild rabbits, and Uriarra was not 
detected at 15 or 20 dpi (Figure 5.13 B).
In the contralateral lymph nodes o f wild rabbits, a trace o f TKO was detected in one rabbit 
at 2 dpi and in two rabbits at 4 dpi (mean titre o f 50 pfu/g; Figure 5.13C). At 6 dpi, TKO 
was detected in one rabbit at a titre o f 3 x 10' pfu/g, and was not detected at 10 or 20 dpi. 
Titres o f Uriarra in the contralateral lymph node were similar to TKO, with a trace o f virus 
measured in some rabbits at 6 and 10 dpi only (Figure 5.13C).
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Figure 5.13 - Myxoma virus titres in wild rabbit tissues following inoculation with 
5000 pfu of TKO. Virus titres at the inoculation site (A), draining lymph node (B) 
and contralateral lymph node (C) were measured by plaque assay, with a detection 
limit of 102 pfu/g. Each open square represents an individual rabbit infected with 
TKO and killed 2, 4, 6, 10 or 20 dpi. A titre of zero indicates no virus was detected 
in the given tissue sample. A titre of 10169 pfu/g indicates that a single plaque (a 
trace) was detected on duplicate sample wells. The solid line on each graph 
represents the geometric mean titre for the three rabbits sampled at each time point. 
The dotted line represents the geometric mean titre of Uriarra (of 2 or 3 wild 
rabbits) in the same tissues following infection with 100 pfu of virus, as determined 
by Best and Kerr (2000).
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5.2.2.2 Histopathological changes in the skin o f wild rabbits at the primary inoculation site 
following TKO infection
Haematoxylin and eosin-stained sections of the skin at the inoculation site from three TKO- 
infected wild rabbits at each time point were examined. Sections from Uriarra-infected 
wild rabbits prepared in a previous study (Best et a/., 2000; Best and Kerr, 2000) were re-
examined and compared. The histological changes seen in the skin of TKO- and Uriarra- 
infected wild rabbits are summarised in Table 5.3. Figures 5.14 to 5.16 show typical 
histopathology sections illustrating the changes.
The changes observed during TKO or Uriarra infection in wild rabbit skin were similar to 
those seen in domestic rabbits, although there were several key differences. At 4 dpi, there 
was a more intense inflammatory cell infiltrate (Figure 5.14A) than seen in domestic rabbits 
at the same time (Figure 5.3B). At 6 dpi, the inflammatory cell infiltrate was much more 
intense than that in domestic rabbits at the same time and in two of the three rabbits was 
predominantly mononuclear cells, with polymorphonuclear cells almost absent (Figure 
5.14C and D). This was similar to domestic rabbits at 10 dpi (Figure 5.5A). The pathology 
of one TKO-infected wild rabbit appeared similar to that of domestic rabbits at the same 
time point, with a predominantly polymorphonuclear cell infiltrate (Figure 5.14B).
At 10 dpi, the inflammatory infiltrate in wild rabbit skin was similar to that in domestic 
rabbit skin at the same time, with an intense mononuclear cell infiltrate throughout the 
dermis (Figure 5.15A and B). The epidermis appeared normal, though darkly stained 
(Figure 5.15A) and the collagen structure of the deeper dermis was relatively intact (Figure 
5.15B) compared to domestic animals (Figure 5.5A). In contrast, the dermis of Uriarra- 
infected wild rabbits was highly degraded, with almost no collagen in the upper dermis and
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Table 5.3 - A summary o f the histopathological changes o f wild rabbit skin following infection 
with TKO or Uriarra. Histopathological images corresponding to the information in this table are 
found in Figures 5.14-5.16.
T K O U ria rra
Two Days Post Infection
No change No change
Four Days Post Infection
Epiderm is No change No change
Derm is Degradation o f collagen fibres; fibrin 
deposition; extensive haemorrhaging in one 
rabbit
Degradation o f collagen fibres
In flam m ation Increased presence o f PMN and mononuclear 
cells near epidermis and in dermis
Slight increase in PMN and mononuclear cells 
in dermis
Six Days Post Infection
Epiderm is 2-4 times thicker than normal; some 
proliferation o f epidermal cells.
3-4 times thicker than normal; proliferation o f 
epidermal cells
Derm is Oedema (skin sections 3 times normal 
thickness); slightly increased levels o f 
collagen degradation and fibrin deposition; no 
myxoma cells
Oedema (skin sections 3 times normal 
thickness); degradation o f collagen fibres 
throughout dermis; fibrin deposition; swelling 
o f blood vessels; myxoma cells in deeper 
dermis
In flam m ation Increased cellular infiltrate consisting o f PMN 
and mononuclear cells; composition varied 
between animals
Mixed PMN and mononuclear cell infiltrate 
throughout dermis - much less than in TK.O- 
infected animals
Ten Days Post Infection
Epiderm is Normal 5 times thicker than normal; proliferation and 
degradation o f cells
Derm is Oedema (skin sections 4 times normal 
thickness); extensive degradation o f collagen 
fibres near epidermis; deeper dermis only had 
slight degradation; no myxoma cells
Oedema (skin sections 5 times normal 
thickness); extensive degradation o f collagen 
fibres, fibrin deposits throughout dermis; 
proteinaceous exudate in upper dermis; some 
myxoma cells in deeper dermis
In flam m ation Very intense mononuclear cell infiltrate 
throughout the dermis, dominated by 
lymphocytes and macrophages. No PMN 
present.
Infiltrate was predominantly mononuclear 
cells; PMN present throughout dermis
Tw enty Days Post Infection
Epiderm is Normal Very thick scab over the primary lesion; 
adjacent epidermis up to 1 Ox normal 
thickness; cellular proliferation
Derm is Almost returned to normal; slightly irregular 
collagen structure
Oedema (skin sections 6 times normal 
thickness); highly degraded dermis; vacuoles 
in dermis with extensive fibrin deposits
In flam m ation Slight mononuclear infiltrate, mostly 
lymphocytes
Intense mononuclear cell infiltrate throughout 
dermis; some PMN present
Abbreviations: PMN, polymorphonuclear cells.
Figure 5.14 - Histopathology of wild rabbit skin at the inoculation site after TKO 
infection. Skin section from a rabbit 4 days after TKO infection (A). Skin sections from 
rabbits 6 days after TKO infection (B-D). A: Skin at 4 dpi contained numerous 
lymphocytes near the epidermis. B: The epidermis and upper dermis at 6 dpi with a 
predominantly polymorphonuclear cell infiltrate. C: The epidermis and upper dermis of 
another rabbit at 6 dpi with a predominantly mononuclear cell infiltrate. D: Lymphocytes 
and macrophages adjacent to a blood vessel in the deeper dermis at 6 dpi. Bars on images 
are 50 pm in length. Key: E, epidermis; BV, blood vessel; HF, hair follicle; black 
arrowhead, polymorphonuclear cell; yellow arrowhead, macrophage; red arrow, 
lymphocyte; NF, nuclear fragment (apoptotic body). Examples of each cell type and 
structure are indicated.
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Figure 5.15 - Histopathology of wild rabbit skin at the inoculation site 10 days after 
myxoma virus infection. Skin sections from TKO-infected rabbits (A and B). Skin 
section from a Uriarra-infected rabbit (C and D). A: The epidermis and upper dermis of a 
TKO-infected rabbit. B: The deeper dermis of a TKO-infected rabbit. C: Epidermis and 
upper dermis of a Uriarra-infected rabbit. Bars on images are 50 pm in length. Key: E, 
epidermis; D, dermis; BV, blood vessel; HF, hair follicle; yellow arrowhead, macrophage; 
red arrow, lymphocyte. Examples of each cell type and structure are indicated.
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with much of the tissue filled with pink-staining material and fibrin fibres (Figure 5.15C). 
By 20 dpi, the skin of TKO-infected wild rabbits had returned to normal appearance and 
thickness (0.5-1.5 mm; Figure 5.16A). As seen in domestic rabbits, the skin of Uriarra- 
infected wild rabbits was still very abnormal and degraded, and covered by a very thick 
scab (Figure 5.16B).
5.2.2.3 Histopathological changes in the draining lymph node o f wild rabbits following 
TKO infection
Haematoxylin and eosin-stained sections of the draining lymph node from three TKO- 
infected wild rabbits at each time point were examined. Sections from Uriarra-infected 
rabbits prepared in a previous study (Best et al., 2000; Best and Kerr, 2000) were re-
examined and compared. The histological changes seen in the draining lymph node of 
TKO- and Uriarra-infected rabbits are summarised in Table 5.4.
The histopathological changes seen in the draining lymph nodes of wild rabbits infected 
with TKO or Uriarra showed a similar progression to domestic animals infected with each 
virus (Section 5.2.1.2.4). There were two major differences in the draining lymph node of 
wild rabbits compared to domestic rabbits: 1 - a reduced presence of polymorphonuclear 
cells and eosinophilic mononuclear cells at 2 dpi during both TKO and Uriarra infections 
and; 2 - very little depletion of lymphocytes in the draining lymph nodes of TKO-infected 
rabbits at any time after infection. Uriarra-infected rabbits showed some reduction in 
lymphocyte density at 6 and 10 dpi, but it was not as extensive as that seen in Uriarra- 
infected domestic rabbits, and there was no evidence of the apoptosis seen in domestic 
rabbits at 6 dpi.
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Figure 5.16 - Histopathology of wild rabbit skin at the inoculation site 20 days 
after myxoma virus infection. A: Skin section from a TKO-infected rabbit. B: 
Skin section from a Uriarra-infected rabbit that was covered by a thick scab. Bars 
on images are 50 pm in length. Key: E, epidermis; D, dermis; HF, hair follicle; 
BY, blood vessel. Examples of each cell type and structure are indicated.
Table 5.4 - A summary o f the histopathological changes o f wild rabbit draining lymph nodes 
following infection with TKO or Uriarra.
TKO Uriarra
Two Days Post Infection
C ortex Several small secondary follicles with distinct 
germinal centres
Several secondary follicles with no distinct 
germinal centres
C ellu lar
in filtrate
Normal Normal
P aracortex Normal Normal
Four Days Post Infection
C ortex Increased numbers o f secondary follicles since 
2 dpi; germinal centres darkly stained; 
haemorrhaging in the cortex
Large increase in number o f active germinal 
centres, found into paracortex
C ellu lar
in filtrate
Macrophages in cortex and subcapsular sinus Macrophages in cortex and subcapsular sinus
Paracortex Some haemorrhaging, otherwise normal Normal
Six Days Post Infection
C ortex Large secondary follicles with dark germinal 
centres
Large secondary follicles with dark germinal 
centres
C ellu lar
in filtrate
No change Increased numbers o f macrophages in 
paracortex and germinal centres
Paracortex Very slight depletion o f lymphocytes 
compared to uninfected lymph nodes; mitotic 
cells and macrophages present
Slightly lower density o f lymphocytes 
compared to uninfected lymph nodes; 
macrophages present
Ten Days Post Infection
C ortex Numerous large germinal centres throughout 
cortex and paracortex; depletion o f 
lymphocytes in germinal centres; apoptotic 
cells; macrophages with apoptotic bodies 
prevalent
Large germinal centres throughout cortex and 
paracortex; depletion o f lymphocytes in 
germinal centres; macrophages with apoptotic 
bodies present
C ellu lar
in filtrate
Macrophages in sinuses No change from 6 dpi
P aracortex Normal; macrophages present Slightly lower density o f lymphocytes 
compared to uninfected lymph nodes; more 
numerous macrophages
Tw enty Days Post Infection
C ortex Numerous large active germinal centres in 
cortex; macrophages present
Very large germinal centres; cortex depleted 
o f lymphocytes; macrophages surrounded 
secondary lymphoid follicles and within 
germinal centres
C ellu lar
in filtrate
Normal Large numbers o f macrophages in all parts o f 
the lymph node
Paracortex Normal Normal
Abbreviations: PMN, polymorphonuclear cells.
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5.3 D is c u s s io n
The pathogenesis o f TKO in domestic rabbits was studied to further evaluate the suitability 
o f the virus as a vaccine to protect domestic rabbits from myxomatosis. This study allowed 
us to evaluate the level o f tissue damage occurring in the skin and draining lymph nodes o f 
TKO-infected rabbits, the potential transmissibility o f the vaccine virus, its in vivo 
dissemination and the effects o f TKO infection on the fertility o f vaccinated male rabbits. 
The results o f this pathogenesis study w ill be discussed with respect to the suitability o f 
TKO as a vaccine for use in protecting domestic rabbits in Australia from myxomatosis.
5.3.1 The pathology of TKO infection in domestic rabbits
The histopathological changes seen in skin at the inoculation site o f TKO-infected rabbits 
were very similar to those seen following infection with the more virulent Uriarra strain o f 
myxoma virus. However, two important differences in the infection were seen. Although 
the degradation o f the dermis seen within the primary lesion during the first 10 days o f 
infection was similar with both viruses, the sizes o f the lesions were very different. TKO 
lesions were no larger than 20 mm in diameter, while Uriarra lesions were up to 60 mm in 
size - 9 times the area. Secondly, TKO-induced lesions were resolved much more rapidly 
than Uriarra-induced lesions. By 20 dpi, the skin at the inoculation site o f TKO-infected 
rabbits was o f normal structure and appearance, while Uriarra-infected skin was still 
swollen, highly degraded and contained an extensive inflammatory cell infiltrate.
There was very little pathology observed in the draining lymph node o f TKO-infected 
domestic rabbits. The histopathological changes that were observed (swelling o f the lymph 
node, formation o f germinal centres) were indicative o f a robust immune response, rather
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than the virus-induced damage seen during infection with more virulent strains o f myxoma 
virus (Best et al., 2000).
The rapid control and clearance o f TKO compared to Uriarra coincided with a change in 
the nature o f the inflammatory cell infiltrate in the skin. Between 6 and 10 dpi, the 
infiltrate in TKO-infected skin changed from predominantly polymorphonuclear cells, to an 
extensive mononuclear cell infiltrate. In this time, TKO titres in the skin dropped by a 
factor o f 10,000. In contrast, the infiltrate in Uriarra-infected skin was unchanged, 
consisting primarily o f polymorphonuclear cells. Uriarra titres were likewise unchanged. 
The exact composition o f the cellular infiltrate in TKO-infected skin cannot be confirmed 
without immunohistochemical analysis o f tissue sections to identify specific cellular 
markers. However, the morphology o f cells observed in the skin at 10 dpi indicate that 
large number o f lymphocytes were present, which most likely included virus-specific 
CTLs, as these are detectable by 4 days after infection o f mice with ectromelia virus 
(Blanden and Gardner, 1976) or sheep with VV  (Issekutz, 1984).
The deletion o f M010L, M011L and M-T7 in the genome o f the TKO vaccine virus was 
probably responsible for the changes in the magnitude and character o f the cellular infiltrate 
in TKO-infected skin, the rapid clearance o f the vaccine virus and the limited pathology in 
the draining lymph node, compared to Uriarra infection. Previous studies have shown that 
the deletion o f M011L increased the magnitude o f the inflammatory infiltrate in infected 
skin compared to wild-type virus infection (Opgenorth et a l., 1992). This was due to the 
apoptosis o f infected macrophages, normally prevented by M011L expression (Everett et 
a l., 2000), resulting in higher levels o f the pro-inflammatory cytokine IL - lß  in infected 
skin (Savill, 1997). The inability o f TKO to replicate in lymphocytes, the most common
Page 154
Chapter 5 -  Pathogenesis of TKO
cell type in the lymph node, limited the amplification o f TKO in the lymph node leading to 
reduced pathology in the draining lymph node, and the very low dissemination o f the virus 
to other tissues. Deletion o f M-T7 has been shown to increase numbers o f mononuclear 
cells including CD43 T cells aggregating at the epidermal/dermal border where virus 
replication occurred (Mossman et al., 1996b), as the chemokine gradients required for 
efficient migration o f lymphocytes were present (Laing and Secombes, 2004). A more 
robust cellular immune response was also evident in secondary lymphoid organs such as 
the lymph nodes, due to higher levels o f bioactive IFN-y (Mossman et al., 1996b). Both o f 
these effects were seen in TKO-infected skin and lymph nodes.
Although there was marked pathology in the skin o f TKO-infected rabbits, normal 
pathology was restored by 20 dpi, suggesting that TKO w ill be suitable as a vaccine for 
domestic rabbits. Once virus had been cleared from the tissue, there was no longer any 
viral antigen stimulation required for the maintenance o f an inflammatory response and the 
activity o f CTL populations (Esser et al., 2003). The inflammatory response in the skin o f 
TKO-infected domestic rabbits was rapidly curtailed between 12 and 15 dpi, visible by the 
reduced inflammation and redness o f skin at the edges o f the primary lesion and a return to 
normal skin colour (Chapter 4). This allowed a reduction in swelling, the swift repair o f 
skin tissue in the lesion and the establishment o f normal pathology by 20 dpi.
The long-term effects to the skin at the inoculation site following TKO vaccination have 
not been evaluated as the fur was removed from the inoculation site before infection. 
Secondary lesions induced by Uriarra AM 10L /M 11 Lg/?/1 and Uriarra AM-T7gp/ caused 
long-term scarring and alterations in fur regrowth (Chapter 4) and similarly unacceptable 
effects may occur at TKO-induced primary lesions. This w ill require further investigation
Page 155
Chapter 5 -  Pathogenesis of TKO
through the vaccination o f rabbits without clipping o f the fur at the inoculation site, as 
would occur in a clinical environment.
This study did not detect TKO by plaque assay in the testes o f domestic rabbits following 
infection, and histological analysis o f testes revealed no abnormalities at any time up to 20 
dpi. Therefore, it can be concluded that vaccination with 5000 pfu o f TKO does not result 
in the dissemination o f the vaccine virus to the testis, and would be highly unlikely to have 
any effect on the fertility o f male domestic rabbits.
5.3.2 Potential transmissibility of TKO in domestic and wild rabbits
There is the formal possibility that TKO could be transmitted from recently vaccinated 
domestic rabbits to w ild rabbits by arthropod vectors because two domestic rabbits had 
titres at the inoculation site greater than 107 pfu/g at 6 dpi, the level considered 
transmissible by mosquitoes (Fenner et al., 1956). However, at both 4 and 10 days, the 
titres were below this lim it, suggesting that TKO was only at transmissible levels for 3-5 
days, and possibly as little as 2 days. Previously described studies have shown that Uriarra 
had titres greater than 107 pfu/g in half o f infected rabbits at 4 dpi, and in all rabbits at 6 
and 10 dpi, having achieved maximum titres 100-fold greater than TKO (Best and Kerr, 
2000), and was readily transmissible by mosquitoes between 6 and 18 dpi (Fenner et a l., 
1952; Fenner and Ratcliffe, 1965).
TKO titres in w ild rabbits were investigated to determine i f  the virus was capable o f 
reaching transmissible titres in genetically resistant animals and could be transmitted and 
maintained amongst w ild rabbit populations. This possibility is the primary reason 
myxoma virus vaccines are not permitted in Australia (Fenner and Ross, 1994). Although
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this formal possibility exists, it is highly unlikely for three reasons. Firstly, the virus 
reached transmissible titres in only 1/3 o f rabbits at 4 dpi, and was below transmissible 
levels at both 2 and 6 dpi. Secondly, genetically resistant rabbits had an earlier, more 
intense mononuclear cell infiltrate into the inoculation site compared to domestic rabbits, 
which may have been responsible for the more rapid control o f TKO in the skin as seen by 
the lower peak titres and a drop in virus titres at 6 dpi. Thirdly, mildly attenuated viruses, 
which are virulent enough to reach high titres in the skin and disseminate to secondary skin 
sites, but are attenuated enough to allow for extended survival periods, are more successful 
in the field in Australia. This is because virus is transmissible by arthropod vectors for 
longer than virulent stains (due to the death the host) and highly attenuated strains (due to 
the clearance o f the virus). This has resulted in mildly attenuated strains o f myxoma virus 
(grade III and IV) becoming predominant in Australia (Fenner and Marshall, 1957; Kerr 
and Best, 1998). Recent studies suggest that selective advantage is shifting toward even 
more virulent (grade I and II) virus strains (Kerr et al., 2003; Saint et al., 2001). As TKO is 
only potentially transmissible in genetically resistant animals for at most 2-3 days, and in a 
small proportion o f infected animals, it is highly unlikely to successfully compete with the 
more virulent myxoma virus strains in the field and become established in w ild rabbit 
populations.
5.3.3 Conclusions
Following infection with TKO, domestic rabbits showed only mild and transient pathology 
at the inoculation site, and very little virus-induced pathology at the draining lymph node, 
suggesting that this vaccine w ill be acceptable for use in domestic rabbits. However, o f 
concern was the potential transmissibility o f the TKO virus from vaccinated domestic 
rabbits, and between wild rabbits, indicated by the ability o f the virus to reach titres o f
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greater than 107 pfu/g in the skin at the inoculation site. Although the establishment o f 
TKO in wild rabbit populations is unlikely, it remains a formal possibility, rendering TKO 
potentially unacceptable as a vaccine for use in Australia according to the criteria 
established in Section 1.6.
In the following chapter, the efficacy and acceptability o f TKO in younger animals w ill be 
described, a study that was conducted concurrently with the TKO pathogenesis study 
described in this chapter.
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Chapter 6 -  TKO vaccination of younger rabbits
C h a p t e r  6 -  E v a l u a t i o n  o f  TK O 's Sa f e t y  a n d  E f f i c a c y  
in  Y o u n g e r  D o m e s t i c  R a b b it s
6.1 In t r o d u c t io n
Concurrently with the pathogenesis study described in Chapter 5, TKO was tested in 
younger domestic rabbits (8 and 12 weeks old) to determine its safety in these age groups. 
Rabbits o f this age are a more likely target o f a commercial myxomatosis vaccine, and 
younger rabbits often have a lower tolerance for attenuated myxoma virus vaccines, 
resulting in increased incidence o f vaccine-induced disease, generalised immune 
suppression and the establishment o f potentially fatal secondary bacterial infections 
(McKercher, 1952; Vautherot et al., 1997). This chapter describes the investigation o f the 
clinical response o f 8 and 12 week old rabbits to TKO, their anti-myxoma virus antibody 
responses and the protective efficacy o f the vaccine. This has allowed us to determine i f  
TKO is suitable for use in rabbits o f this age group. The vaccine was tested at two doses. 
Twelve week old rabbits were vaccinated with 5000 or 50 pfu o f TKO, whilst eight week 
old animals were vaccinated with 50 pfu o f the vaccine virus.
6.2 Res ult s
6.2.1 Inoculation of 12 week old rabbits with 5000 pfu of TKO
6.2.1.1 Vaccination o f rabbits
Six 12 week old, male domestic rabbits were inoculated with 5000 pfu o f TKO on the left 
thigh and examined daily for 14 days following vaccination. A summary o f the clinical 
signs o f these animals is recorded in Table 6.1. This dose o f TKO had been well tolerated 
in mature rabbits with no vaccine-induced secondary lesions observed, as described in 
Chapter 4.
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Table 6.1 -  Clinical signs of 12 week old domestic rabbits following vaccination with 
5000 pfuofTK O .
D a y  p o s t  
in o c u la t io n
C lin ic a l s i g n s
2 Slight reddening of skin at the inoculation site
3 Primary lesion was a soft, pink lump 6-12 mm in diameter.
5 Primary lesion 10-20 mm in diameter, red and raised from 
surrounding skin.
7 Primary lesion 15-30 mm in diameter, red and protuberant.
Single, small secondary lesion on the edge of the ear of two rabbits 
(211 and 229).
8 Primary lesion crimson or red in colour with darker haemorrhagic 
patches forming in centre. Secondary lesions forming on the edge 
of the ears of three rabbits (237, 211 and 229). Secondary lesions 
were red, ~5 mm hard lumps.
10 Primary lesion circumscribed, 15-30 mm in diameter, scabbed 
over and haemorrhagic. Secondary lesions on 4/6 rabbits (237, 
211, 227 and 229), primarily on margins of ears. One animal 
(229) also had a lesion on the anus and one lesion on eyelid.
14 Primary lesion covered with a hard, black, concave scab, with skin 
at edges faded from red to pink in colour. Secondary lesions 
scabbed over and regressing.
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Within 3 days post infection (dpi), a reaction was seen at the inoculation site on all rabbits 
as a 6-12 mm pink lump. By 4 dpi, the primary lesion had grown to an 8-15 mm raised 
pink lump on all animals (Figure 6.1). By 9 dpi, four rabbits had several small secondary 
lesions on the edges of the ears and one of these rabbits (rabbit 229) also had a very small 
(~3 mm) secondary lesion on the eyelid, and a secondary lesion on the anus. The primary 
lesions had become circumscribed, and had haemorrhagic patches at the centre. By 12 dpi, 
the primary lesions on all animals were scabbed over and regressing slightly (Figure 6.2A 
and B), and secondary lesions had also scabbed over and begun regressing (Figure 6.2C). 
By 21 dpi, rabbits had completely recovered from infection except for residual scabbing at 
the primary lesion. These symptoms were slightly worse than those seen in mature (6-12 
month old) rabbits following vaccination with 5000 pfu of TKO (Chapter 4).
Rectal temperatures for each rabbit were recorded daily. Half of the rabbits did not show 
increases in temperature during the 14 days post vaccination (Figure 6.3). The other three 
rabbits had one day at or over 40°C, including rabbit 237 which had a temperature of 41°C 
at 6 dpi only.
6.2.1.2 SLS challenge o f rabbits vaccinated with 5000 pfu o f TKO at 12 weeks o f age 
Rabbits were challenged with 1000 pfu of SLS on the right thigh 6 weeks after TKO 
vaccination and examined for 12 days following infection. A reddening at the inoculation 
site or the development of a small (3-5 mm) lump was seen on all rabbits at 1 day post 
challenge (dpc). This developed into a distinct 7-20 mm protuberant lesion by 3 dpc 
(Figure 6.4). The lesions on several rabbits had already developed darker, haemorrhagic 
regions in the centre at this point (Figure 6.4B and C). By 6 dpc, the lesion at the 
inoculation site had either scabbed over (Figure 6.5A-C) or had begun to fade and regress
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Figure 6.1 - Inoculation sites of rabbits vaccinated with 5000 pfu of TKQ at 12 weeks of 
age, 4 days after inoculation. Primary lesions on rabbits were 8-12 mm in diameter, pink 
and slightly protuberant (A-D, arrowed). Bars on images are 10 mm in size.
Figure 6.2 - Primary and secondary lesions on rabbits vaccinated with 5000 pfu of 
TKO at 12 weeks of age, 12 days after inoculation. Representative primary lesions 10- 
25 mm in diameter and covered with a hard black scab are shown (A and B, arrowed). 
A small scabbed-over secondary lesion on the ear (C, arrowed). Bars on images are 10 
mm in size.
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Figure 6.3 - Rectal temperatures o f 12 week old rabbits following 
vaccination with 5000 pfu o f TKO.
Figure 6.4 - Challenge inoculation site on rabbits vaccinated with 5000 pfu of TKO at 
12 weeks of age, 3 days following challenge with SLS. Lesions at the site of SLS 
challenge are shown (A-D, arrowed) and haemorrhagic patches had developed in the 
centre of lesions (B and C, arrowed). Bars on images are 10 mm in size.
Figure 6.5 - Appearance of primary and secondary lesions on rabbits vaccinated with 
5000 pfu of TKO at 12 weeks of age, 6 days following challenge with SLS. Lesions at 
the inoculation site had scabbed over (A-C, arrowed), or begun to regress (D, arrowed). 
Small secondary lesion on the eyelid that had turned black and scabbed over (E, 
arrowed). Bars on images are 10 mm in size
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(Figure 6.5D). A single small (2-3 mm) secondary lesion was seen on the right eyelid of 
one rabbit (227) at 5 dpc, which had changed colour to black by 6 dpc (Figure 6.5E). By 14 
dpc, this secondary lesion had completely regressed (Figure 6.6D). Lesions at the 
inoculation site had faded with residual scab material remaining on normal coloured skin 
(Figure 6.6A and B), or had regressed completely (Figure 6.6C). Three rabbits had a rectal 
temperature above 40°C for a single day only (Figure 6.7). All rabbits survived challenge.
6.2.1.3 Analysis o f anti-myxoma virus antibody responses
The anti-myxoma virus ELISA antibody titre was determined for all serum samples after 
vaccination and following challenge with SLS (Figure 6.8). The level of myxoma virus 
neutralising antibody was determined at 6 weeks after vaccination (day of challenge) and 8 
weeks after vaccination (2 weeks post challenge) using a plaque reduction neutralisation 
assay (PRNA). The percentage neutralisation at each serum dilution and the 50% and 80% 
neutralisation titres are shown in Figure 6.9. Anti-myxoma virus antibody was first 
detected by ELISA in rabbits 2 weeks post vaccination (wpv), with titres ranging between 
800 and 3200 (Figure 6.8). By the time of challenge at 6 wpv, titres had not changed 
significantly, ranging between 1600 and 3200. At this point, 50% PRNA titres were 
between 320 and 640 (Figure 6.9).
By 2 weeks after challenge, four of the six rabbits showed a significant increase (4-fold or 
greater) in anti-myxoma virus ELISA antibody titres (Figure 6.8). Two of these rabbits 
showed an 8-fold or greater increase in ELISA titre including rabbit 227, which had 
developed a secondary lesion (Figure 6.6D). Five of the six rabbits displayed a >4-fold 
50% PRNA titre increase after challenge, with final titres ranging between 1280 and 5210
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Figure 6.6 - Appearance of primary and secondary lesions on rabbits vaccinated with 
5000 pfu of TKO at 12 weeks of age, 14 days following challenge with SLS. Lesions 
at the inoculation site had regressed with just a scab remaining (A and B, arrowed) or 
had regressed completely (C, arrowed). Secondary lesion on the eyelid of one rabbit 
had regressed completely (D, arrowed). Bars on images are 10 mm in size.
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Figure 6.7 - Rectal temperatures o f 12 week old rabbits vaccinated with 
5000 pfu o f TKO following challenge with SLS.
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Figure 6.8 - ELISA anti-myxoma virus antibody titres in rabbits vaccinated with 5000 
pfu of TKO at 12 weeks of age. The ELISA titre was determined by titration in 
duplicate of two-fold serial dilutions of rabbit sera from 1:100. The ELISA endpoint 
was defined as the reciprocal serum dilution 0.1 OD405 units above the OD405 of the 
1:100 negative control. A titre of zero was recorded when the OD405 of 1:100 diluted 
serum was less than 0.1. Rabbits were challenged with SLS following sera collection 
at week 6 (arrow).
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Figure 6.9 - Analysis of neutralising anti-myxoma virus antibodies in the serum of rabbits 
vaccirated with 5000 pfu of TKO at 12 weeks of age. Neutralising antibody was measured 
by pkque reduction neutralisation assay and the percentage plaque neutralisation recorded 
at week 6 (A) and week 8 (B) for each serum dilution (two-fold from 1:40 to 1:10240). 
The tires at which 50% or greater or 80% or greater of myxoma virus plaque formation 
was neutralised is summarised (C).
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(Figure 6.9). Increases in ELISA titre did not correlate with increases in PRNA titre after 
challenge.
6.2.2 Testing of a lower dose of TKO in 12 week old rabbits
6.2.2.1 Inoculation o f 12 week old rabbits with 50 pfu o f TKO
To determine if there was a dose-related amelioration of secondary symptoms of 
myxomatosis induced by the vaccine, a 100-fold lower dose of the virus was administered 
to 12 week old rabbits. This allowed a direct comparison between the previous experiment 
conducted with 5000 pfu of TKO. Six 12 week old male domestic rabbits were inoculated 
with 50 pfu of TKO on the left thigh, and examined for clinical signs of disease for 14 days. 
A summary of the clinical signs of these animals is recorded in Table 6.2.
Following inoculation, there was no response at the inoculation site until 4 or 5 dpi, 2-3 
days later than found following inoculation with 5000 pfu of TKO. Lesions developed into 
a raised pink lump ranging in size from 7-15 mm by 6 dpi (Figure 6.10). By 8 dpi, small 
secondary lesions (2-4 mm) were noted on the ears or nose of three rabbits (a total of four 
secondaries on all three rabbits), one less than following the larger dose of virus. As found 
after inoculation with 5000 pfu of TKO, the primary lesions on most rabbits were 
circumscribed by 10 dpi, and several exhibited haemorrhagic patches or a cream coloured 
scabby material on the surface. Lesions ranged in size from 12 to 25 mm in diameter. 
Rabbits recovered quickly from this point, and by 13 dpi, the primary lesions were scabbed 
over (Figure 6.11A-D) or were fading and regressing. Secondary lesions were hard, 
scabbed over (Figure 6.11E), and no larger than 4 mm in diameter.
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Table 6.2 -  Clinical signs of 12 week old domestic rabbits following vaccination with 50 
pfu of TKO.
D a y  p o s t  
in o c u la t io n
C lin ic a l s i g n s
4 Slight reddening of skin at the inoculation site
5 Primary lesions had developed on 5/6 rabbits, 4-12 mm in diameter, 
soft and pink in colour. One rabbit (252) had slight reddening of 
skin at the inoculation site.
7 Primary lesions were 14-20 mm in diameter, firm and red, except 
for rabbit 252 with a 5 mm pink lump.
8 Primary lesions 7-22 mm in diameter, raised, red. Secondary 
lesions on three rabbits (260, 247 and 242) on margins of ears, or on 
nose.
10 Primary lesions circumscribed, 12-25 mm diameter, crimson in 
colour, some with a black, haemorrhagic centre. Secondary lesions 
red, most beginning to scab over.
14 Primary lesion scabbed over on 4/6 rabbits and all primary and 
secondary lesions had begun to regress.
Figure 6.10 - Inoculation site of rabbits vaccinated with 50 pfu of TKO at 12 weeks of 
age, 6 days after inoculation. Primary lesions were small and pink (A and B, arrowed); 
or larger and protuberant (C and D, arrowed). Bars on images are 10 mm in size.
Figure 6.11 - Primary and secondary lesions on rabbits vaccinated with 50 pfu of 
TKO at 12 weeks of age, 13 days after inoculation. Primary lesions with a slightly 
scabby surface (A-C, arrowed). Rabbit 266 had a very small primary lesion, 
covered with a black scab (D, arrowed). Secondary lesion on the nose of a rabbit 
(E). Bars on images are 10 mm in size.
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The rectal temperatures of rabbits following inoculation are displayed in Figure 6.12. 
Temperatures remained within normal limits until 8 dpi, when two rabbits had temperatures 
of 40.1°C. These two rabbits also developed a small secondary lesion the following day, 
when temperatures returned to normal. At 13 dpi, three rabbits had temperatures of 40°C, 
although temperatures also returned to below 40°C the following day.
Overall, the clinical symptoms following inoculation with 50 pfu of TKO were 
indistinguishable from those following inoculation with 5000 pfu, except for the slight 
delay in the appearance of a reaction at the inoculation site.
6.2.2.2 SLS challenge o f  rabbits vaccinated with 50 pfu o f  TKO at 12 weeks o f  age 
Six weeks after vaccination, rabbits were challenged with 1000 pfu of SLS on the right 
thigh and examined for 8 days following infection. The symptoms following challenge 
with SLS were similar to those exhibited by rabbits that had been vaccinated with 5000 pfu 
of TKO. Twenty-four hours after challenge, a pink or red area was observed at the 
inoculation site, which developed into an 8-25 mm red, raised lesion by 3 dpc (Figure 
6.13). A single small secondary lesion was noted on the ear of one rabbit (247) at 3 dpc. 
Several lesions also had scabby material on the surface or displayed dark haemorrhagic 
patches (Figure 6.13C). By 6 dpc, the lesions at the inoculation site were circumscribed 
and covered in a hard black scab (Figure 6.14). One animal developed a large lesion at the 
inoculation site that grew to 35 mm in diameter (Figure 6.14B). This animal did not 
develop any secondary lesions. The secondary lesion on rabbit 247 was a 5 mm hard pink 
lump (Figure 6.14E). Animals recovered quickly and by 10 dpc, the only remaining 
evidence of infection was a scab at the inoculation site. All animals survived challenge 
with SLS. Rectal temperatures were monitored following challenge and are shown in
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Figure 6.12 - Rectal temperatures o f 12 week old rabbits following 
vaccination with 50 pfu o f TKO.
Figure 6.13 - Challenge inoculation site of rabbits vaccinated with 50 pfu of TKO at 12 
weeks of age, 3 days following challenge with SLS. Representative red, protuberant 
lesions are shown (A-C, arrowed). Bars on images are 10 mm in size.
Figure 6.14 - Primary and secondary lesions of rabbits vaccinated with 50 pfu of TKO 
at 12 weeks of age, 6 days following challenge with SLS. Lesions at the inoculation 
site had completely scabbed over as shown (A and B, arrowed) or developed 
haemorrhagic patches (C and D, circled). Small secondary lesion on the edge of the ear 
of rabbit 247 (E, arrowed). Bars on images are 10 mm in size.
Chapter 6 -  TKO vaccination of younger rabbits
Figure 6.15. The temperatures of most animals remained within normal limits, with two 
animals displaying temperatures of over 40°C for one or two days only.
6.2.23 Analysis o f anti-myxoma virus antibody responses
Anti-myxoma virus antibody was first detected in these rabbits at 2 wpv (Figure 6.16). 
There was no difference in the kinetics of antibody development in 12 week old rabbits 
given 50 or 5000 pfu of TKO, and by 6 wpv, all rabbits had ELISA antibody titres of 
between 1600 and 6400. At this time, PRNA titres were also comparable with rabbits that 
had received 5000 pfu of TKO (Figure 6.8), with 50% neutralisation titres of between 320 
and 1280, except for rabbit 264 that had a titre of only 40. This rabbit also had the lowest 
ELISA titre, although it was only 2-fold lower than three other animals in the group (Figure 
6.16).
In the 2 weeks following challenge, only two of the rabbits (252 and 264) showed 
significant (4-fold or greater) increases in anti-myxoma virus ELISA titres, at 4- and 16- 
fold respectively (Figure 6.16). These animals were the only ones that had temperatures 
above 40°C following challenge (Figure 6.15), and rabbit 264 had developed the largest 
lesion at the inoculation site (Figure 6.14B). Flowever, rabbit 247, which was the only 
animal in this group to develop a secondary lesion, did not show an increase in ELISA 
antibody titre (Figure 6.16). The only correlation between ELISA and PRNA titre changes 
after challenge was shown by rabbit 264, which showed a 128-fold increase in its PRNA 
titre (Figure 6.15), as well as a 16-fold increase in its ELISA titre. Rabbit 260 was the only 
other rabbit with a 4-fold or greater increase in PRNA titre but only had a 2-fold increase in 
ELISA titre following challenge (Figures 6.15 and 6.16).
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Figure 6.15 - Rectal temperatures o f rabbits vaccinated with 50 pfu of 
TKO at 12 weeks o f age, following challenge with 1000 pfu o f SLS.
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Figure 6.16 - ELISA anti-myxoma virus antibody titres in rabbits 
vaccinated with 50 pfu of TKO at 12 weeks of age. The ELISA titre was 
determined by titration in duplicate of two-fold serial dilutions of rabbit sera 
from 1:100. The ELISA endpoint was defined as the reciprocal serum 
dilution 0.1 OD405 units above the OD405 of the 1:100 negative control. A 
titre of zero was recorded when the OD405 of 1:100 diluted serum was less 
than 0.1. Rabbits were challenged with SLS following sera collection at 
week 6 (arrow).
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Figure 6.17 - Analysis of neutralising anti-myxoma virus antibodies in the serum of rabbits 
vaccinated with 50 pfu of TKQ at 12 weeks of age. Neutralising antibody was measured 
by plaque reduction neutralisation assay and the percentage plaque neutralisation recorded 
at week 6 (A) and week 8 (B) for each serum dilution (two-fold from 1:40 to 1:20480). 
The titre at which 50% or greater or 80% or greater of myxoma virus plaque formation was 
neutralised is summarised (C).
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6.2.3 Testing of TKO in 8 week old rabbits
6.2.3.1 Vaccination o f 8 week old rabbits with 50 pfu o f TKO
Since 50 pfu appeared to be an effective dose of TKO in 12 week old rabbits, the 
acceptability of TKO in 8 week old rabbits was evaluated using this lower dose, to 
determine if rabbits of this age showed more serious vaccine-induced disease. Six 8 week 
old male domestic rabbits were inoculated with 50 pfu of TKO on the left thigh, and 
examined daily for 16 days. A summary of the clinical signs of these animals is recorded in 
Table 6.3. Following inoculation, three rabbits displayed a reaction at the inoculation site 
at 3 dpi, and two rabbits at 5 dpi, initially taking the form of a reddening of the skin which 
developed into a small, pink raised lesion within 2 days.
The sixth animal in the treatment group (rabbit 256) displayed very little reaction to the 
vaccine with no response noted at the inoculation site until 6 dpi (Figure 6.18D). Figure 
6.19C shows the inoculation site at 9 dpi. This was negligible, with an 8 mm flat pink lump 
forming at the inoculation site by 12 dpi (Figure 6.20C), which regressed by 14 dpi. 
During this time, rabbit 256 did not appear to eat much food and lost weight. The animal 
was most ill and lethargic at 13 dpi, when its temperature was recorded at 38.4°C (Figure 
6.21). This illness could not be attributed to the vaccine virus infection, as clinical signs of 
myxomatosis were minimal. The rabbit quickly recovered by 15 dpi, although it was of a 
lower weight than the other animals in the treatment group.
At 6 dpi, the primary lesions of the other five rabbits were pink or red raised lumps less 
than 10 mm in diameter (three are shown in Figure 6.18A-C) and one rabbit had begun to 
develop very small secondary lesions on the ear. Eight days following vaccination, these 
five rabbits had very small secondary lesions evident on the ears or nose. Figure 6.19D and
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Table 6.3 -  Clinical signs o f 8 week old domestic rabbits following vaccination with 50 
pfu o f TKO.
Day post Clinical signs
inoculation
3 Slight reddening o f skin at the inoculation site
5 Primary lesions o f 5/6 rabbits were 8-10 mm in diameter, 
slightly raised and pink or red in colour. Rabbit 256 had 
no visible reaction at the inoculation site.
7 Primary lesions were 10-25 mm diameter, red in colour 
and protuberant. Primary lesion o f rabbit 256 was 5 mm 
in diameter and flat. Several small, red secondary lesions 
developing on ear o f rabbit 243.
8 Primary lesions were 10-20 mm in diameter, protuberant, 
pink or red in colour. Secondary lesions had developed 
on ears, nose or eyelids o f 5/6 rabbits. Rabbit 256 had 
only a very small primary lesion (5 mm) and no 
secondary lesions
10 Primary lesions had haemorrhagic patches, or were 
covered with a pale flaky scab. Secondary lesions were 
circumscribed, hard and red. Some had begun to scab 
over.
14 Primary lesions covered with hard black or brown scab. 
Secondary lesions were very hard and had begun to 
regress and scab over. Rabbit 256 had only developed a 
10 mm, flat red lesion that did not scab over and 
regressed by 20 dpi. Rabbit 256 did not develop any 
secondary lesions.
Figure 6.18 - Inoculation site of rabbits vaccinated with 50 pfu of TKO at 8 weeks of 
age, 6 days after inoculation. Representative primary lesions of four rabbits (A-D). 
Reddening of the skin at the inoculation site (A-C, arrowed). Rabbit 256 had a very 
slight reaction at the inoculation site (D, arrowed). Bars on images are 10 mm in size.
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E shows some of these lesions at 9 dpi. One rabbit (250) had at least 10 small lesions (3-6 
mm) on the ears, primarily on the edges by 9 dpi (Figure 6.19D). At this time, the primary 
lesions were circumscribed, 10-15 mm in diameter and several displayed haemorrhagic 
patches (Figure 6.19A-B). By 12 dpi, primary lesions had scabbed over and begun to 
regress (Figure 6.20A-B). Secondary lesions on the ears were still evident as small, hard 
lumps, and several had begun to scab over (Figure 6.20D-E).
Rectal temperatures of rabbits were recorded daily for each animal and are shown in Figure 
6.21. Temperatures remained within normal limits (<40°C) until 7 dpi, when four of six 
rabbits had temperatures of 40°C or greater. One rabbit (250) had a temperature of 40.7°C 
at this point. This rabbit also had the greatest number of secondary lesions (Figure 6.19D). 
By 9 dpi, temperatures had returned to normal in all rabbits except for rabbit 256.
6.2.3.2 SLS challenge o f  rabbits vaccinated with 50 pfu o f  TKO at 8 weeks o f  age 
Six weeks after vaccination, rabbits were challenged with 1000 pfu of SLS on the right 
thigh and examined daily for 9 days following infection. Within 24 hours of challenge, a 5- 
8 mm red patch was seen at the inoculation site, which by 3 dpc had developed into a red, 
protuberant lesion, 9-20 mm in diameter. Several lesions had darker, haemorrhagic patches 
(Figure 6.22). The lesions had become circumscribed by 6 dpc and most were covered with 
a hard black scab (Figure 6.23). The skin surrounding the lesions was less inflamed, and by 
10 dpc, rabbits had completely recovered from challenge with only residual scab material 
remaining at the inoculation site. No secondary lesions were noted on any animal 
following challenge, and all animals survived challenge. The rectal temperatures of rabbits 
following challenge are shown in Figure 6.24. Rabbit 255 had a slightly higher temperature 
between 2 and 5 dpc, with a temperature of 40.1°C at 5 dpc. This animal also had the
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/Figure 6.19 - Primary and secondary lesions on rabbits vaccinated with 50 pfu of 
TKO at 8 weeks of age, 9 days after inoculation. Primary lesions of three rabbits are 
shown (A-C, arrowed). On two rabbits, the primary lesion was 10-20 mm in diameter, 
red and protuberant (A and B, arrowed), with one having a haemorrhagic patch (A, 
arrowed). There was a slight reaction at the inoculation site on rabbit 256 (C). 
Secondary lesions on the ear (D, arrowed) and nose (E, arrowed). Bars on images are 
10 mm in size.
Figure 6.20 - Primary and secondary lesions on rabbits vaccinated with 50 pfu of TKO 
at 8 weeks of age, 12 days after inoculation. Representative primary lesions of five 
rabbits (A and B, arrowed) were 10-20 mm in diameter, and scabbed over as shown. 
The primary lesion of rabbit 256 was small, flat and red as shown (C, arrowed). Small 
secondary lesions on the margins of the ears of two rabbits are shown (D and E, 
arrowed). Bars on images are 10 mm in size.
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Figure 6.21 - Rectal temperatures o f 8 week old rabbits following 
vaccination with 50 pfu o f TKO.
Figure 6.22 - Challenge inoculation site of rabbits vaccinated with 50 pfu of TKO at 8 
weeks of age, 3 days following challenge with SLS. Red, protuberant lesions at the 
challenge inoculation site as shown (A-D, arrowed), some with haemorrhagic patches 
(A and C, arrowed). Bars on images are 10 mm in size.
Figure 6.23 - Challenge inoculation site of rabbits vaccinated with 50 pfu of TKQ at 8 
weeks of age, 6 days following challenge with SLS. Lesions at the inoculation site 
were covered with a hard, black scab as shown (A-D, arrowed). Bars on images are 10 
mm in size.
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Figure 6.24 - Rectal temperatures o f rabbits vaccinated with 50 pfu of 
TKO at 8 weeks o f age, following challenge with 1000 pfu o f SLS.
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largest lesion at the inoculation site (Figure 6.23B). Rabbit 254 had temperatures of over 
40°C at 3, 6 and 7 dpc. The temperatures of the other four challenged animals remained 
within normal limits.
6.2.3.3 Analysis o f anti-myxoma virus antibody responses
Anti-myxoma virus antibody was first detected by ELISA by 2 wpv, except for rabbit 256, 
which had exhibited an extremely limited response to the TKO vaccine and did not develop 
detectable anti-myxoma virus antibodies until 3 wpv (Figure 6.25). However, by the time 
of challenge at 6 wpv, anti-myxoma virus titres in this rabbit were at 1600, comparable to 
other rabbits (Figure 6.25). Eight week old rabbits tended to develop anti-myxoma virus 
antibodies slightly slower than 12 week old rabbits. At 2 wpv, titres ranged between >100 
and 400 whilst rabbits vaccinated at 12 weeks old had titres between 200 and 1600 (Figures 
6.8 and 6.16). However, by 6 wpv, the range of titres was comparable to other groups of 
animals, between 1600 and 25600 (Figure 6.25). PRNA titres (50% neutralisation) at this 
time ranged between 640 and 2560 (Figure 6.26), which was slightly higher (2-4 fold) than 
that seen in 12 week old rabbits.
In the two weeks following challenge, only two of the six rabbits (255 and 256) showed a 
significant (8-fold) increase in anti-myxoma virus antibody as measured by ELISA (Figure 
6.25). Rabbit 255 had developed the largest lesion upon challenge (Figure 6.23B). These 
two rabbits were also the only animals to show significant increases in PRNA titres, 
increasing 4-fold and 8-fold respectively (Figure 6.26). The final ELISA titres of all six 
rabbits ranged between 12800 and 25600.
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Figure 6.25 - ELISA anti-myxoma virus antibody titres in rabbits vaccinated 
with 50 pfu of TKO at 8 weeks of age. The ELISA titre was determined by 
titration in duplicate of two-fold serial dilutions of rabbit sera from 1:100. The 
ELISA endpoint was defined as the reciprocal serum dilution 0.1 OD405 units 
above the OD405 of the 1:100 negative control. A titre of zero was recorded 
when the OD405 of 1:100 diluted serum was less than 0.1. Rabbits were 
challenged with SLS following sera collection at week 6 (arrow).
P
la
qu
e 
ne
ut
ra
lis
at
io
n 
(%
)
T— C\J LO i -  CM i n  O
Reciprocal serum dilution
c N eutra lis ing  an tib o d y  titre
P re C h a llen g e  
(W eek 6)
P ost C h a llen g e  
(W eek  8)
R ab b it 50% 80% 50% 80%
250 1280 160 2560 160
267 2560 160 2560 160
254 1280 320 1280 160
255 1280 160 5120 1280
243 2560 640 5120 1280
256 640 160 5120 1280
Figure 6.26 - Analysis of neutralising anti-myxoma virus antibodies in the serum of rabbits 
vaccinated with 50 pfu of TKO at 8 weeks of age. Neutralising antibody was measured by 
plaque reduction neutralisation assay and the percentage plaque neutralisation recorded at 
week 6 (A) and week 8 (B) for each serum dilution (two-fold from 1:40 to 1:10240). The 
titre at which 50% or greater or 80% or greater of myxoma virus plaque formation was 
neutralised is summarised (C).
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6.3 Discu ssio n
6.3.1 Acceptability of TK O  vaccination in young domestic rabbits
As described in Section 1.6, the ideal myxomatosis vaccine for use in Australia would have 
the follow ing three characteristics: it should cause no illness or distress in vaccinated 
animals (acceptability), confer complete protection from challenge with myxoma virus for 
the lifetime o f the animal (efficacy) and be unable to transmit from a recently vaccinated 
rabbit to others either by direct contact or via arthropod vectors (non-transmissibility).
Although TKO was well tolerated in mature rabbits, there was an increase in the 
appearance o f very small secondary lesions when the virus was administered to 8 or 12 
weeks old rabbits. These lesions were smaller and shorter lived than those observed on 
mature rabbits vaccinated with Uriarra AM 1OL/M11Lgpt or Uriarra AM-T7gp/. Although a 
cause o f little apparent distress to the animals themselves, this may be unacceptable to the 
owners o f rabbits and there is also the potential o f long-term scarring at the sites o f 
secondary lesions. Inoculation with a 100-fold lower dose of the vaccine had little effect on 
the pathology o f TKO infection in 12 week old rabbits, except for a slight delay (2-3 days) 
in the appearance o f a reaction at the inoculation site. The incidence o f secondary lesions 
was comparable between animals that received 5000 or 50 pfu o f TKO, with three and four 
rabbits in each group, respectively, developing secondary signs o f disease.
These results are comparable to those obtained with other attenuated myxoma virus 
vaccines. Previous vaccine trials and field trials have shown an increased incidence o f 
vaccine-induced disease in younger rabbits, including those vaccinated with the French 
SG33 strain (Saurat et al., 1978; Vautherot et al., 1997). Similarly, inoculation o f newborn 
rabbits with RFV, which has no ill effects on rabbits greater than 6 weeks o f age (Fenner
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and Woodroofe, 1954; Marlier et al., 2000), has resulted in high levels o f morbidity and 
mortality including generalised disease (Duran-Reynals, 1945; Hyde and Gardner, 1939). 
However, amongst the 18 young animals vaccinated in this study, none developed any 
more serious signs o f disease than several small secondary lesions, and there was no 
evidence o f generalised immunosuppression in rabbits as young as 8 weeks old.
Although TKO induced some very small secondary lesions in 8 and 12 week old rabbits, it 
did confer complete protection from myxoma virus challenge at 6 weeks after vaccination. 
A ll TKO-vaccinated rabbits developed a lesion at the inoculation site, a higher proportion 
than found amongst mature animals (12/18 rabbits). Dissemination o f virulent challenge 
virus within the rabbits was extremely limited, with only two out o f 18 animals developing 
secondary signs o f myxomatosis. These were limited to a single, very small, secondary 
lesion on the eyelid or ear o f each. As four o f the 18 mature animals vaccinated with 5000 
pfu o f TKO developed secondary lesions, it seems that there was little difference in the 
protective efficacy o f TKO between mature and younger domestic rabbits.
Another consideration is the potential transmissibility o f TKO from younger rabbits. 
Because the pathology o f TKO infection was slightly more severe than that observed in 
mature rabbits, the virus may exceed transmissible titres for longer periods o f time, or may 
achieve higher titres for longer periods in young w ild rabbits, increasing the potential 
transmissibility o f TKO. This would require further investigation including, most 
importantly, direct insect transmission studies in younger animals to determine the actual 
risk o f TKO escape and establishment in the field.
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6.3.2 Conclusions
Although TKO was safe and effective in mature rabbits, it induced very mild secondary 
signs o f myxomatosis in younger animals, and may not be suitable for use in rabbits as 
young as 8-12 weeks old. Also, as demonstrated in Chapter 5, the titre o f virus at the 
inoculation site was above potentially transmissible levels (107 pfu/g), at least temporarily 
in mature rabbits, and in a small proportion o f w ild animals, and the formal possibility o f 
transmission o f TKO from a recently vaccinated domestic rabbit to w ild rabbits exists. 
Together, these factors indicate that TKO would not be an ideal candidate for a widely 
used, live attenuated myxomatosis vaccine.
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Cha pte r  7 -  Con str uc ti on  an d  t es t ing  o f  a r epl ic a t io n - 
de f ic ien t  MYXOMA VIRUS VACCINE
7.1 I n t r o d u c t io n
As demonstrated in Chapters 5 and 6, live virus vaccines are able to elicit excellent 
protective responses in rabbits. However, even the highly attenuated TKO vaccine 
occasionally induced very small secondary lesions in younger animals, and reached 
transmissible titres in the skin of some mature domestic rabbits. One approach that would 
prevent vaccine transmission is to use a replication-deficient virus that was capable o f 
entering host cells and expressing viral antigens following inoculation. In contrast to TKO, 
it would be unable to assemble new virus particles in vivo and increase virus titre to 
transmissible levels or disseminate to other tissues and induce disease. The production of 
viral antigens by this virus within host cells, especially professional antigen presenting 
cells, should allow the induction o f a broad range o f virus-specific host effector 
mechanisms, most importantly CTL responses, which are believed to be critical for 
protection against myxoma virus (Kerr and McFadden, 2002).
As described in Section 1.4.3, the replication-deficient VV strain MVA has proven 
effective at protecting mice from lethal VV challenge (Wyatt et al., 2004) and monkeys 
from monkeypox virus challenge (Earl et al., 2004). The use o f MVA before 
administration of a replication-competent VV vaccine also reduced the severity o f the 
lesion induced by the live VV vaccine in monkeys (Earl et al., 2004). However, live 
replication-deficient vaccines to protect against poxvirus diseases have not been evaluated 
outside of the Orthopoxvirus models of mouse/VV and monkey/monkeypox virus.
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This chapter describes the testing o f a replication-deficient myxoma virus vaccine that was 
constructed through the deletion o f the myxoma virus putative host-range gene M063R. 
The selection o f this gene was based on information provided by Professor Grant 
McFadden (John P. Robarts Research Institute, London, Ontario, Canada - provisional 
patent application 111702GM-RRI). M063R is a 20 kDa cytoplasmic protein that is 
expressed early during infection. It is one o f three adjacent genes in the myxoma virus 
genome (M062R, M063R and M064R) which all share some homology with other poxvirus 
genes including VV C7L and capripoxvirus CF8a. These genes share the conserved 
Pox_C7_F8A domain and are all predicted host-range genes. A strain o f VV not 
expressing C7L has been investigated, which exhibited limited replication in hamster Dede 
cells, but normal replication in most human cell lines (Oguiura et al., 1993), further 
suggesting a host-range function for genes with this conserved domain.
Studies using a AM063R strain o f Lausanne virus have been conducted by McFadden et al. 
(personal communications). This virus was constructed by inactivation of M063R by 
insertion o f the E. coli ß-galactosidase gene in the M063R open reading frame. This virus 
was able to infect and grow in Vero cells to similar levels as wild type virus. However, the 
AM063R virus was unable to replicate in rabbit cell lines including RK13, RL-5, Hig82 
(rabbit synovial cells) and SIRC (rabbit corneal fibroblasts). It was determined that 
expression o f late viral genes (as measured by immunoblot analysis o f Serpl expression) 
was prevented in rabbit cells infected with the AM063R virus. At a low multiplicity o f 
infection (MOI) o f 0.001, expression o f the early gene M-T7 or the late gene Serpl was not 
detected in infected RK13 cells by immunoblot analysis. At higher MOIs (1.0), a low level 
o f M-T7 expression, but no Serpl expression was detected. Similarly, when enhanced 
green fluorescent protein (EGFP) was placed under control o f an early myxoma virus
Page 172
Chapter 7 -  Construction and testing of a replication-deficient vaccine
promoter in the AM063R virus, a low level o f EGFP expression was detected in infected 
RK13 cells. However, when expressed under a synthetic late promoter, no EGFP 
expression was found (Grant McFadden, personal communication).
The function o f M063R in myxoma virus infected cells is unknown, although it may be 
involved in inhibiting the cellular response to interferons (Grant McFadden, personal 
communication). Without M063R, myxoma virus may be unable to productively infect 
rabbit cells due to the induction o f interferon-response genes. An abortive infection, 
apparently specific for rabbit cells is induced (although some early gene expression does 
occur) due to the cessation o f host cell biosynthetic activity. Interestingly, inoculation o f 
rabbits with 1000 pfu o f this replication-deficient strain o f Lausanne conferred complete 
protection from challenge with virulent myxoma virus 15 days after vaccination (Grant 
McFadden, personal communication).
In this chapter, 1 w ill describe the construction and testing of a myxoma virus Uriarra strain 
with a deletion in the M063R open reading frame to evaluate the safety and efficacy o f a 
replication-deficient vaccine using the myxoma virus/rabbit poxvirus disease model. This 
virus strain was analysed to confirm its replication-deficient nature, and tested for its 
acceptability and protective efficacy against lethal myxoma virus challenge as a single dose 
vaccine, and as part o f a boosting regimen with either a second dose o f the replication- 
deficient virus or TKO.
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7.2 Resul ts
7.2.1 Design and construction of pKS+AM063Rg/?/&Ms and Uriarra AM063Rg/?/&//s
The inactivation o f the M063R open reading frame (ORF) was achieved by homologous 
recombination in Uriarra-infected Vero cells with the plasmid pKS AM063Rgptgus (Figure 
7.1). This plasmid contains two regions o f sequence homologous to the Uriarra genome, 
between which was cloned a selective marker, the gpt-gusA fusion gene (Cao and Upton, 
1997) under the control o f the synthetic early/late poxvirus promoter (Davidson and Moss, 
1989). A recombination event between the Uriarra genomic DNA and the plasmid results 
in a deletion o f 498 bp in the middle o f the M063R gene (54.2% o f the ORF), and its 
replacement with the pEL-gpt-gusA cassette, allowing for selection o f the recombinant 
virus by resistance to mycophenolic acid, and screening for recombinant plaques by blue 
staining in the presence o f X-gluc (Section 2.5.3.4).
As the recombinant virus was predicted to be unable to productively infect rabbit cells 
including the RK13 cell line, the initial virus/plasmid recombination was performed in 
Vero cell monolayers. Isolation o f single recombinant viral plaques was conducted by 
infecting monolayers o f the primate cell line BSC-1 with this recombinant virus 
preparation, and selecting viral plaques that stained blue in the presence o f X-gluc. BSC-1 
cells were used because plaques were evident on the cell monolayer as clusters o f cells 
rather than the holes in the monolayer that form on Vero cell monolayers. This made 
staining and picking o f isolated recombinant plaques easier. After six rounds o f plaque 
purification, four recombinant virus clones were recovered. To determine i f  these clones 
contained any w ild type virus, they were examined by PCR. RK13 or Vero cell 
monolayers were infected with the viruses at an MOI o f 0.1 and incubated for 72 hours. 
Viral DNA was isolated and subjected to two PCR analyses - one pair o f primers (M063R-
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Figure 7.1 - Construction of plasmid for deletion of M063R sequences of myxoma 
virus. Sequences (349 and 376 bp) homologous to the 3’ and 5’ ends of M063R were 
cloned by PCR from the genome of Uriarra using the primers indicated (small black 
arrows, Table 2.3). The gpt-gusA fusion gene was cloned between these sequences 
under poxvirus synthetic early/late promoter (pEL) control. Homologous 
recombination of this plasmid with the Uriarra genome results in a recombinant virus 
(Uriarra AM063Rg/?^gw5') with a 498 bp deletion in the middle of M063R. The 
positions of other primers used for the PCR screening of recombinant viruses (M063R- 
F l, gpt-Rl and gus-Fl) are indicated. The position of the ends of the homologous 
sequences are indicated as described in the published myxoma virus sequence, 
Genbank AF170726. Figure is not to scale.
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FI x M064R-R1) was used to amplify wild type DNA only, whilst a second pair (M062R- 
F1 x gpt-R l) was used to amplify recombinant viral DNA only. Only recombinant virus 
PCR product (440 bp) was amplified from all four virus preparations (Figure 7.2). The 
infection o f RK13 cell monolayers was included, as these cells would have preferentially 
amplified wild type virus that was capable o f replication in rabbit cell lines. Isolate #C10 
was selected for further analysis and named Uriarra AM063Rgptgus. Cloning and 
sequencing o f the M063R locus showed sequence to be the same as that o f the plasmid 
pKS AM063Rgy?/gzys, indicating that a homologous recombination event between the 
plasmid and Uriarra genomic DNA had resulted in the loss o f 54.2% o f the M063R ORF.
7.2.2 In vitro growth characteristics of Uriarra AM063Rgpfgws in RK13 and Vero 
cells
To compare the growth kinetics o f Uriarra (wild type) and Uriarra AM063Rg/?/gws, Vero 
and RK13 cell monolayers were infected with viruses at a MOI o f 0.1 or 3.0, and the titre 
o f virus determined at time points following infection (Section 2.5.6). Uriarra and Uriarra 
AM063Rg/?rgws had comparable growth characteristics in Vero cells, increasing in titre to 
very similar levels (Figure 7.3). However, Uriarra AM063Rg/?/gws did not increase in titre 
over the observed time period when grown in RK13 cells. A t a MOI o f 0.1, the titre 
dropped from 2.9x104 pfu/mL to 2.6x10’ pfu/mL by 48 hours post infection (hpi), and 
increased slightly to 1.85xl04 pfu/mL by 96 hpi, whilst Uriarra titres increased to 2.4x107 
pfu/mL by 72 hpi (Figure 7.3A). A similar pattern was observed at a MOI o f 3.0, where 
Uriarra and Uriarra AM063Rg/?fgws exhibited very similar growth patterns in Vero cells. 
However, whilst Uriarra grown in RK13 cells increased from 3.9x10" pfu/mL to 5.68x106 
pfu/mL by 72 hpi, Uriarra AM063Rg/?fgw.s' decreased in titre to 1.2x10" pfu/mL by 36 hpi 
and remained lower than original titres during the course o f the experiment (Figure 7.3B).
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Figure 7.2 - PCR analysis o f Uriarra AM063Rg77/‘g7/.s'. DNA was 
isolated from four clones o f Uriarra AM063Rg/?/g«s (C2, CIO, C23 and 
C25) that had been grown for 3 days on Vero or RK13 cell monolayers 
and analysed by PCR to identify the presence o f recombinant virus or 
wild type virus. The plasmid pKS+AM063Rg/?rgws was used as a 
positive control for recombinant virus, and Uriarra genomic DNA was 
used as a positive control for w ild  type virus. A recombinant virus PCR 
product (440 bp) was amplified from all virus preparations except 
Uriarra. Wild type PCR product (660 bp) was amplified from the 
Uriarra control only.
8Time post infection (hours)
0 20 40 60 80 100
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Figure 7.3 - Growth o f Uriarra and Uriarra AM063Rg^g^5 in Vero and RK13 
cell monolayers. Vero or RK13 cell monolayers were infected with Uriarra or 
Uriarra AM063Rgpfgws at an MOI o f 0.1 (A ) or 3.0 (B), and the titre o f virus in 
duplicate samples was determined up to 96 hours post infection.
Key: ♦  - Uriarra in Vero; ■  - Uriarra AM063R,g/?fgws in Vero; ▲ - Uriarra in 
RK13; X - Uriarra AM063R<gpfgws in RK13.
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These data suggest that Uriarra AM063Rg/?fgws is unable to replicate in RK13 cells in vitro , 
although replication in Vero cells was very similar to its parental virus, Uriarra.
7.2.3 Expression of intermediate/late genes in Uriarra AM063Rg/tfgws-infected RK13 
and Vero cells
Monolayers o f Vero or RK13 cells were infected with Uriarra or Uriarra AM063Rgp(gws at 
a MOI o f 1 and incubated for 24 hours before fixing with methanofacetone. The 
monolayers were probed with the monoclonal antibody 3B6E4, specific for an unknown 
intermediate or late-expressed myxoma virus protein, the expression o f which is inhibited i f  
viral DNA replication is inhibited (Peter Kerr, personal communication). The staining o f 
infected Vero cell monolayers appeared similar regardless o f the infecting virus, with 
intensely fluorescent cells observed across the monolayer (Figure 7.4C and E). Uriarra- 
infected RK13 cell monolayers also exhibited a high level o f fluorescence, with almost all 
cells on the monolayer possessing an intense fluorescence throughout the cytoplasm 
(Figure 7.4D), although fluorescence intensity appeared lower than in infected Vero cells 
(Figure 7.4C). However, Uriarra AM063Rg/?/gws-infected RK13 cell monolayers exhibited 
a reduced fluorescence intensity, with most cells staining poorly with a patchy appearance, 
and with approximately ha lf o f the cells on the monolayer staining no more intensely 
(Figure 7.4F) than uninfected control cells (Figure 7.4B).
These data suggests that the intermediate/late myxoma virus protein is being expressed in at 
least some Uriarra AM063Rg/Vgws-infected RK13 cells, although the amount o f protein 
produced is generally less than in Vero cells or RK13 cells infected with Uriarra, and many 
cells do not appear to express the protein.
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Figure 7.4 - Immunofluorescent detection of myxoma virus antigen in infected cells. 
Vero cell monolayers were mock infected (A), infected with Uriarra (C) or Uriarra 
AMOöSRgprgws (E) at an MOI of 1. RK13 cell monolayers were mock infected (B), 
infected with Uriarra (D) or Uriarra AM063Rgptgus (F) at an MOI of 1. After 24 
hours, cells were fixed and probed with the monoclonal antibody 3B6E4, specific for 
an intermediate or late myxoma virus antigen. All photos were taken at 40X 
magnification.
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7.2.4 Vaccination of rabbits with Uriarra AM063Rg/?/&//,s and protective efficacy 
against SLS challenge
7.2.4.1 Vaccination o f rabbits
Six domestic rabbits of 10-13 months of age were vaccinated with 100,000 pfu of Uriarra 
AM063Rg/?/gws intradermally on the left thigh, and examined daily for 2 weeks following 
vaccination. A summary of the clinical signs of rabbits is recorded in Table 7.1. There was 
no reaction at the inoculation site of most rabbits (Figure 7.5A-D), apart from a slight 
pinkness of the skin of one rabbit (Figure 7.5E), until 5 days post inoculation (dpi), when a 
small pink lump formed on all rabbits, ranging in size from 3-5 mm. By 7 dpi, this lump 
was slightly protuberant, pink or red in colour and up to 15 mm in diameter (Figure 7.6). 
The appearance of the lesion had not changed significantly over the next 7 days except for a 
reduction in size and a brown scab forming over it on two of the rabbits. By 14 dpi, the 
lesion was a smaller (<10 mm) hard lump, which had faded in colour to pink (Figure 7.7). 
By 21 dpi, the lesion had resolved completely on all rabbits. There were no secondary 
lesions or other signs of disease observed on any animal following vaccination. The rectal 
temperatures of all animals remained within normal limits (38.9-39.9°C) over the 14 days 
during which temperatures were monitored (Figure 7.8).
7.2.4.2 Challenge o f rabbits with SLS
Six weeks after vaccination, all Uriarra AM063Rg/?/gws-vaccinated rabbits were challenged 
with 1000 pfu of SLS intradermally on the left thigh, and examined for signs of disease for 
14 days. The clinical signs of rabbits following challenge are summarised in Table 7.2. 
Within 24 hours of challenge, a pink lump was seen at the inoculation site, ranging in size 
from 8-12 mm in diameter. By 3 days post challenge (dpc), these lesions had increased in 
size up to 25 mm, and were quite protuberant (Figure 7.9); some lesions were dark crimson
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Table 7.1 -  Clinical signs o f mature domestic rabbits fo llow ing vaccination with 100,000 
pfu o f Uriarra AM063Rg/?(gws.
D ay post 
ino cu la tio n
C lin ica l s ig ns
2 No reaction at the inoculation site
3 Pinkness to skin at the inoculation site o f one rabbit (183)
5 Pink lump (3-5 mm) at inoculation site
7 Red or pink raised lump, 8-15 mm in diameter
14 Hard lump at inoculation site, 8-10 mm. Black or brown scab on 2 
animals.
21 No lesion. Slightly darker skin at inoculation site.
Figure 7.5 - Inoculation site of rabbits vaccinated with 100,000 pfu of Uriarra 
AM063Rg£>te^s 3 days after inoculation. There was no reaction observed at the 
inoculation site (arrowed) on any rabbit at this time point, except for a slight 
pinkness on one rabbit (E, arrowed). Each image position corresponds to the same 
rabbit in Figures 7.6 and 7.7. Bars on images are 10 mm in size.
Figure 7.6 - Primary lesion of rabbits vaccinated with 100,000 pfu of Uriarra 
AM063Rg£>tez/s, 7 days after inoculation. The inoculation site of all rabbits had 
developed a small (5-15 mm) raised pink lump (A-F, arrowed). Bars on images 
are 10 mm in size.
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Figure 7.7 - Primary lesion of rabbits vaccinated with 100,000 pfu of Uriarra 
AM063RggygE/s, 14 days after inoculation. The primary lesions were raised, pink 
or red lumps no larger than 10 mm in diameter (A-F, arrowed). Some lesions had 
scabbed over (A, E). Bars on images are 10 mm in size.
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Figure 7.8 - Rectal temperatures o f rabbits following vaccination w ith 
100,000 pfu o f Uriarra AM 063Rgp^5.
Table 7.2 -  Clinical signs of Uriarra AM063Rg/?/gz/s-vaccinated rabbits following 
challenge with SLS.
D a y  p o s t  
in o c u la t io n
C lin ic a l s i g n s
1 Pink lesion at the inoculation site, 8-12 mm diameter.
3 Red or crimson protuberant lesion, 15-25 mm diameter.
5 Lesions at the inoculation site 20-40 mm in diameter, black in 
colour. Secondary lesions on 5/6 rabbits on eyelids, body, ears 
and/or face. All animals had a temperature of >40°C.
7 Lesions at the inoculation site were protuberant and covered by a 
hard black scab, 25-40 mm diameter. More numerous secondary 
lesions; all had turned black in colour, though still swollen and hard; 
5-10 mm in diameter; located on eyelids, ears, anus, scrotum, body, 
face or nostrils. 4/6 animals had a temperature of >40°C.
8 Rabbits 187 and 184 had developed snuffly breathing, 
mucopurulent discharge from nostrils and mild anogenital swelling. 
3/6 animals had a temperature of >40°C.
9 Rabbits 187, 184 and 154 had snuffly breathing, mucopurulent 
discharge and/or bleeding from nostrils, temperature of >40°C and 
mild anogenital swelling. All secondary lesions were black and had 
begun regressing. Two animals (176 and 179) recovered except for 
hard black scabs over inoculation site lesion and secondary lesions.
13 Lesions at the inoculation site covered with hard, black, concave 
scabs. Breathing of rabbits 187 and 154 were clear; anogenital 
swelling had regressed. These animals had lost some weight.
Rabbit 184 still had slight mucopurulent discharge from nostrils and 
snuffly breathing, though much improved since day 9.
21 All animals recovered, although some appear 'ratty' with lumpy, 
misshapen ears, and numerous black scabs on body and face.
Figure 7.9 - Uriarra AM063Rg£>/gas-vaccinated rabbits, 3 days following challenge 
with 1000 pfu of SLS. Lesions at the inoculation site were between 15 and 25 mm 
in diameter, protuberant and pink or red in colour (A-E, arrowed). Lesions on some 
rabbits had developed a dark crimson or black colour in the centre (B and D, 
arrowed). Bars on images are 10 mm in size.
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in colour (Figure 7.9D). At 5 dpc, all lesions at the inoculation site were black in colour or 
exhibited black patches, and most rabbits had developed small, red secondary lesions on the 
eyelids, ears or body. By 7 dpc, the lesions at the inoculation site ranged in size from 20 to 
40 mm (Figure 7.10A and B). Secondary lesions had developed on all animals at sites 
including the eyelids, nose, mouth, body, anus or scrotum (Figure 7.10C-H). Most 
secondary lesions were small (no larger than 5 mm in diameter) and had progressed from 
crimson swellings to flat black lesions surrounded by crimson-coloured inflamed skin, 
within 24-48 hours o f appearance (Figure 7.10D-H). Secondary lesions were evident on 
the bodies o f three animals, and these lesions were generally larger than at other sites, 
usually 10 mm in diameter (Figure 7.10G).
By 8 dpc, two rabbits (187 and 184) had developed slightly snuffly breathing associated 
with nasal discharge and bleeding from lesions in the nostrils, and a third rabbit (154) 
developed snuffly breathing at 9 dpc. These three animals also exhibited mild anogenital 
swelling. Two animals (176 and 179) had shown improvement and by 10 dpc had 
recovered completely except for residual scabs at the sites o f small secondary lesions and 
the lesion at the inoculation site.
By 13 dpc, most rabbits had recovered from challenge, however scabby black lesions were 
evident at many sites o f the body although the surrounding skin was pink (Figure 7.11), and 
rabbits which had exhibited mucopurulent discharge from the nose still had crusty material 
surrounding the nostrils (Figure 7.1 IF). Some animals also had a slight watery discharge 
from the eyes (Figure 7.1 ID). One rabbit (187) still had slightly snuffly breathing and two 
had lost some weight over the preceding 5 days (187, 154). Other symptoms o f disease 
such as anogenital swelling had regressed completely.
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Figure 7.10 - Uriarra AM063Rg£>rgas-vaccinated rabbits, 7 days after challenge 
with lOOOpfuof SLS. Representative primary lesions (A and B, arrowed) were 
protuberant, black and haemorrhagic. Crimson or black secondary lesions on the 
eyelids (C and D, arrowed), mouth and nose (E and F, arrowed), body (G, 
arrowed), and scrotum (H, arrowed). Bars on images are 10 mm in size.
Figure 7.11 - Uriarra AM063Rgp^5-vaccinated rabbits, 13 days after challenge 
with lQQQpfuof SLS. Representative primary lesions (A and B, arrowed) were 
covered with black scabs with pink skin at the edges. Secondary lesions covered 
with black scabs on the eyes (C, E, F, arrowed), nose (E, F, arrowed), face (D, 
arrowed), body (G, arrowed) and anus (H, arrowed). Bars on images are 10 mm in
size.
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All rabbits had rectal temperatures over 40°C at 2 dpc, with all except 154 falling below 
40°C at 3 dpc before increasing again at 4 dpc (Figure 7.12). Over the course of infection, 
rabbits had a temperature of 40°C or greater on at least 4 days. Animals that showed the 
most severe disease symptoms (187, 184, 154) had fevers for longer periods, with rabbit 
187 having a fever for 8 days from 4-11 dpc. By 12 dpi, the temperatures of all animals 
had fallen below 40°C.
In summary, the degree of secondary signs of myxomatosis following challenge varied 
from a few very small secondary lesions on the ears of one rabbit (179), more numerous 
secondary lesions (176, 183), to more severe signs of myxomatosis including mucopurulent 
discharge from the nasal passages, mild obstruction of the respiratory tract resulting in 
snuffly breathing, and mild anogenital swelling (154, 184 and 187). However, by 2 weeks 
after lethal challenge, even the rabbits with moderate symptoms of myxomatosis had 
improved, and by 21 dpi had completely recovered from SLS infection. All rabbits 
survived challenge, and the symptoms exhibited were very mild in comparison to SLS 
challenge of non-immune rabbits such as those vaccinated with pDual2+ (Section 3.2.7.1).
7.2.4.3 Analysis o f anti-myxoma virus antibody development in Uriarra AM063Rgp\.gws>- 
vaccinated rabbits
The anti-myxoma virus ELISA antibody titre was determined for all serum samples after 
vaccination and challenge and are shown in Figure 7.13. Anti-myxoma virus antibody 
capable of neutralising myxoma virus in vitro was analysed using a plaque reduction 
neutralisation assay (PRNA) for serum samples taken before challenge (6 weeks after 
vaccination) and 2 weeks after challenge (8 weeks after vaccination). The percentage
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Figure 7.12 - Rectal temperatures o f rabbits vaccinated with Uriarra AM063Rgg>fgas 
following challenge with SLS.
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plaque neutralisation for each serum dilution tested and the corresponding 50% and 80% 
plaque neutralisation titres are shown for each rabbit in Figure 7.14.
Following inoculation with 100,000 pfu o f Uriarra AM063Rg/?/lgz/,s', all rabbits had 
detectable antibody, with titres o f 100 or 200 measured after 2 weeks post vaccination 
(wpv) (Figure 7.13), although titres o f some rabbits returned to zero for some time before 
challenge. Very low levels o f neutralising antibody were recorded at 6 wpv, with 
neutralisation o f only 0-35% o f virus in serum diluted 1/10 (Figure 7.14A).
After challenge, rabbits had very large and rapid increases in ELISA titres with 32- to 64- 
fold increases observed within 7 days o f challenge, and 128- to 512-fold increases to 
between 12800 and 51200 over 14 days (Figure 7.14). Similarly, PRNA titres o f all rabbits 
measured 2 weeks after SLS challenge had increased significantly, with 50% neutralisation 
titres ranging from 640 to >20480, and 80% neutralisation titres between 160 and 10240 
(Figure 7.14B and C).
7.2.5 Use of Uriarra A M 063Rgptgus in a boosting regimen
Uriarra AM063Rg/?/gr/5 provided complete protection against lethal disease following SLS 
challenge six weeks after vaccination, although half o f the challenged rabbits exhibited 
mild to moderate symptoms o f myxomatosis. Therefore, the use o f this replication- 
deficient vaccine was also evaluated as part o f a boosting regimen by boosting Uriarra 
AM063Rg7?/lgws-vaccinated rabbits with another dose o f Uriarra AM063Rgp/gws', to 
determine i f  this was able to elicit greater levels o f protective immunity in domestic rabbits. 
Boosting o f rabbits with the TKO vaccine w ill be evaluated in Section 7.2.6, though the
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Figure 7.13 - ELISA anti-myxoma virus antibody titres in rabbits vaccinated 
with Uriarra AM063Rg£>fgas. The ELISA titre was determined by titration in 
duplicate o f two fold serial dilutions o f rabbit sera from 1:100. The ELISA 
endpoint was defined as the reciprocal serum dilution 0.1 OD405 units above the 
OD405 o f the 1:100 negative control. An OD405 o f less than 0.1 for a 1:100 
dilution o f serum was recorded as a titre o f zero. Rabbits were challenged with 
SLS following sera collection at week 6 (arrow).
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Figure 7.14 - Analysis of neutralising anti-myxoma virus antibodies in the serum of 
rabbits vaccinated with Uriarra AM063Rgpfgas. Neutralising antibody was 
measured by plaque reduction neutralisation assay and the percentage plaque 
neutralisation recorded at week 6 (A) and week 8 (B) for each serum dilution (two-
fold from 1:10 to 1:20480). The highest reciprocal serum dilution at which 50% or 
greater or 80% or greater of myxoma virus plaque formation was neutralised is 
summarised (C).
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initial vaccination o f these rabbits with Uriarra AM063Rg/?/gws has been described in 
Section 7.2.5.1.
7.2.5.1 Vaccination with Uriarra AM063Rgptgus
Twelve 12 week old domestic rabbits were inoculated with 100,000 pfu o f Uriarra 
AM063Rg/?/gw5 intradermally on the left thigh and monitored daily for 14 days. The 
clinical signs exhibited by these twelve rabbits following inoculation were very similar to 
those o f mature rabbits vaccinated with Uriarra AM063Rg/?fgws' (Table 7.1; Figures 7.5- 
7.7). No reaction beyond a slight pinkness at the skin o f the inoculation site was observed 
for any rabbit before 5 dpi. At 6 dpi, all rabbits had a slightly raised, pink lump at the 
inoculation site which, over the next several days, grew to a slightly protuberant, 20 mm 
red lesion. By 10 dpi, most lesions were dark red in colour and two developed small black 
scabs at the centre. The primary lesions regressed, and by 17 dpi, most had regressed 
completely or a small pink lump remained at the inoculation site. No secondary lesions 
were seen on any rabbit following vaccination with Uriarra AM063Rg/?rgws.
Rectal temperatures o f rabbits remained within normal limits following inoculation o f 
Uriarra AM063Rg/?rgw5, except for two rabbits (281 and 293) which had rectal 
temperatures o f 40°C for one day only (Figure 7.15).
Six o f these rabbits were later boosted with Uriarra AM063Rgp/gws (Section 7.2.5.2), and 
the other six boosted with TKO (Section 7.2.6).
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Figure 7.15 - Rectal temperatures o f 12 week old rabbits following vaccination 
with 100,000 pfu o f Uriarra AM063Rgg>/g^5. These animals were were divided 
into two groups based on the virus boost to be used four weeks after inoculation 
with Uriarra AM063Rg/?rgws. Panel A shows the six rabbits to be boosted with 
Uriarra AM063Rg/?/gws' and Panel B shows the six rabbits to be boosted with 
TKO.
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7.2.5.2 Boosting rabbits with Uriarra AM063Rgptgus
Four weeks after inoculation with Uriarra AM063Rg/?/gw^, six of the twelve rabbits were 
boosted with 100,000 pfu of Uriarra AM063Rg/?/gws intradermally on the right thigh and 
monitored daily for 10 days. The symptoms exhibited upon boosting were very similar to 
those after the first dose of Uriarra AM063Rg/?/gws, except for a rapid response at the 
inoculation site, where within 24 hours, a 6-12 mm pink lump had developed on all rabbits. 
By 3 days post boosting (dpb), this had grown in size to an 8-15 mm raised pink lesion 
(Figure 7.16), which changed in colour to red on some animals by 6 dpb (Figure 7.17). By 
9 dpb, the lesion had completely regressed on all rabbits, with only a small residual scab 
remaining on two animals. The rectal temperatures of Uriarra AM063Rgp/gw5-boosted 
rabbits remained below 40°C following the boost (Figure 7.18).
7.2.5.3 Challenge o f Uriarra AM063Rgptgus- boosted rabbits with SLS
T he six Uriarra AM063Rgpfgz/s-boosted rabbits were challenged with 1000 pfu of SLS at a 
site on the back above the left thigh 6 weeks after boosting, and examined daily for 14 days 
following challenge. The clinical signs of these animals are summarised in Table 7.3. 
Within 24 hours, all rabbits had developed a raised red lesion 10 mm in diameter at the 
inoculation site. At 2 dpc, the lesion had developed a black, haemorrhagic centre on two 
rabbits (281 and 286). By 3 dpc, the lesions were 15-30 mm in diameter and had developed 
black centres on all rabbits (Figure 7.19). Small secondary lesions (<5 mm) distal from the 
skin surrounding the inoculation site were evident at 5 dpc on only two of the six 
challenged rabbits (282 and 288), at the edges of the ears and face. Only five small 
secondary lesions were noted on each of these animals during the course of infection. The 
secondary lesion on the ear of one rabbit at 6 dpc is shown in Figure 7.20E.
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Figure 7.16 - Uriarra AM063Rgp^5-vaccinated rabbits boosted with 100,000 pfu of 
Uriarra AMQ63Rgp/g^, 3 days after inoculation. Lesions at the inoculation site were 
8-15 mm in diameter and pink or red in colour as shown (A-D, arrowed). Bars on 
images are 10 mm in size.
Figure 7.17 - Uriarra AM063Rg£>/gE/s-vaccinated rabbits boosted with 100,000 pfu of 
Uriarra AM063Rg/7/g;/.s, 6 days after boosting. The lesion on one rabbit had scabbed 
over and regressed (A, arrowed). Other lesions were 10 mm in dimeter and pink or red 
in colour as shown (B and C, arrowed). Bars on images are 10 mm in size.
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Figure 7.18 - Rectal temperatures o f Uriarra AM063Rg/?/gMs-vaccinated 
rabbits fo llow ing boosting with 100,000 pfu o f Uriarra AM063RgE>/gas.
Table 7.3 -  Clinical signs of Uriarra AM063Rg£>fgws,-boosted rabbits following challenge 
with SLS.
D a y  p o s t  
in o c u la t io n
C lin ic a l s i g n s
l Pink lesion at the inoculation site, 10 mm diameter
3 Lesion at the inoculation site 15-30 mm diameter with 
black, haemorrhagic centres
5 Lesion at the inoculation site 15-35 mm diameter 
circumscribed and black. Secondary lesions on ears or 
face of rabbits 282 and 288.
10 Lesion at the inoculation site covered with a hard, black, 
concave scab. Secondary lesions regressing covered with 
1 black scab.
Figure 7.19 - Rabbits boosted with Uriarra AM063Rg£>tei/s, 3 days after challenge 
with 1000 pfu of SLS. Lesions at the inoculation site were 15-30 mm in diameter, 
protuberant with haemorrhagic or black centres as shown (A-D, arrowed). Bars on 
images are 10 mm in size.
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By 6 dpc, the primary lesions on all animals were 15-35 mm in diameter and covered with a 
hard black scab (Figure 7.20A-D). Some lesions were not circumscribed but were irregular 
around the edges with what appeared to be smaller lesions (approximately 5-10 mm) 
developing at the perimeter o f the primary lesion (Figure 7.20A and C). Two rabbits had 
also developed 10 mm crimson or purple lesions on the skin surrounding the primary 
lesion, and rabbit 281 had developed a large (30x20 mm) purple, bruise-like lesion 10 cm 
above the primary. Secondary lesions on the ears and face were covered with black scabby 
material, although the surrounding skin was swollen and coloured red or crimson (Figure 
7.20E).
By 9 dpc, animals had recovered completely except for residual black scabs at sites o f 
lesions. The skin colour immediately surrounding the lesion at the inoculation site had 
faded to a pink colour (Figure 7.21). Secondary lesions surrounding the primary lesion and 
at distal sites had also regressed except for black scabby material at the surface (Figure 
7.21 B, D and F). The appearance of rabbits did not change significantly before the end o f 
the experiment at 15 dpc (Figure 7.22). None o f the Uriarra AM063Rg/?/gws,-boosted 
rabbits developed any serious symptoms o f myxomatosis such as mucopurulent discharge 
from the eyes or nose, laboured breathing or anogenital swelling following SLS challenge.
The rectal temperature o f each rabbit was recorded daily following SLS challenge and are 
shown in Figure 7.23. Only two o f the six rabbits had temperatures o f 40°C or above 
following challenge including 278 which had a temperature o f 41.1 °C at 3 dpc only, and 
rabbit 288 which had temperatures o f 40°C and above at 1,2, 4 and 5 dpc.
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Figure 7.20 - Rabbits boosted with Uriarra AM063Rg/?/gr/.s, 6 days after challenge 
with 1000 pfu of SLS. Black scabbed-over lesions at the inoculation site (A-D, 
black arrows). Some lesions had smaller lesions developing at the perimeter (A 
and C, red arrows). A small secondary lesion on the ear that was covered with a 
black scab (E, arrowed). Bars on images are 10 mm in size.
Figure 7.21 - Rabbits boosted with Uriarra AM063Rgpfgas, 9 days after challenge 
with 1000 pfu of SLS. Lesions at the inoculation site were covered with a hard, 
black, concave scab (A-E, black arrows) Small, black secondary lesions on the skin 
near the primary lesion (B and D, red arrows) or the ears (E, arrowed). Bars on 
images are 10 mm in size.
BFigure 7.22 - Rabbits boosted with Uriarra A M 063R g^g^, 15 days after challenge 
with lQQOpfuof SLS. Lesions at the inoculation site covered by hard black scabs 
(A and B, arrowed). Secondary lesions covered with black scabs (C, arrowed). Bars 
on images are 10 mm in size.
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Figure 7.23 - Rectal temperatures o f Uriarra AMQ63Rgg>/g^ 5-vaccinated 
rabbits boosted with Uriarra AM063R,g£>/gas, following challenge with 1000 
pfu o f SLS.
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7.2.5.4 Analysis o f anti-myxoma virus antibody development in Uriarra AM?63/?gptgus- 
boosted rabbits
The anti-myxoma virus ELISA antibody titre was determined for all serum samples after 
vaccination, boosting and challenge, and are shown in Figure 7.24. Antibody capable of 
neutralising myxoma virus in vitro was analysed using PRNA for serum samples taken 
before the Uriarra AM063Rg/?/gws boost (4 wpv), 2 weeks after boosting (6 wpv), before 
challenge (10 wpv) and 2 weeks after challenge (12 wpv). The percentage plaque 
neutralisation for each serum dilution tested and the corresponding 50% and 80% plaque 
neutralisation titres are shown for each rabbit in Figure 7.25.
Only two rabbits out of six had anti-myxoma virus antibody detectable by ELISA by 4 wpv 
(Figure 7.24), and there were only very low levels of virus-neutralising antibody as 
detected by PRNA (Figure 7.25A). In contrast, all mature rabbits vaccinated with Uriarra 
AM063Rg/?/g«s' had anti-myxoma virus antibody as detected by ELISA, for at least one 
week before challenge (Figure 7.13). After boosting with Uriarra AM063Rg/?rgws', all six 
rabbits showed significant increases (4-fold or greater) in ELISA antibody titre with 16- to 
32-fold increases within 1 week of boosting, with titres ranging between 800 and 3200, and 
rabbit 278 increased to 6400 at 6 wpv (Figure 7.24). After boosting, titres in some rabbits 
(278 and 282) dropped slightly, and by the time of challenge, titres ranged between 200 and 
800. Similar increases in PRNA titres following boosting were recorded for all rabbits 
except rabbit 282 which still had very low virus-neutralisation activity (Figure 7.25B), 
although this increased by 10 wpv, with virus neutralisation in 1/10 diluted serum 
increasing from 3% to 57% (Figure 7.25 B and C). The 50% PRNA titres of other rabbits at 
2 weeks after boosting ranged between 10 and 160, with no correlation with the recorded 
ELISA titres (Figure 7.25E). PRNA titres fell 2- to 4-fold by 10 wpv (Figure 7.25C).
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Figure 7.24 - ELISA anti-myxoma virus antibody titres in rabbits vaccinated with 
Uriarra AM063RgE>fgas and boosted with Uriarra AM063Rg^>^5. The ELISA 
titre was determined by titration in duplicate o f two fold serial dilutions o f rabbit 
sera from 1:100. The ELISA endpoint was defined as the reciprocal serum 
dilution 0.1 OD405 units above the OD405 o f the 1:100 negative control. An OD405 
o f less than 0.1 for a 1:100 dilution o f serum was recorded as a titre o f zero. At 
week 4, rabbits were boosted with 105 pfu o f Uriarra AM063Rg/?/gws' (open arrow) 
and challenged with SLS at week 10 (closed arrow).
Figure 7.25 - Analysis of neutralising anti-myxoma virus antibodies in the serum of 
rabbits vaccinated with Uriarra AM063Rg£>teas and boosted with Uriarra 
AMQ63Rgp/g ,^v. Neutralising antibody was measured by plaque reduction 
neutralisation assay and the percentage plaque neutralisation recorded before 
boosting (week 4, A), after boosting (week 6, B), before challenge (week 10, C) and 
after challenge (week 12, D) for each serum dilution (two-fold from 1:10 to 
1:20480). The highest reciprocal serum dilutions at which 50% or greater and 80% 
or greater of myxoma virus plaque formation was neutralised is summarised (E).
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The ELISA and PRNA titres o f all Uriarra AM063Rg/?/g«s-boosted rabbits increased 
significantly following challenge with SLS, with 8- to 32-fold increases in ELISA titre 
within 1 week (Figure 7.24), and 32- to 512-fold increases in 50% PRNA titres by 2 weeks 
after challenge (Figure 5.25D and E). At 12 wpv, 1 rabbit (284) had a final anti-myxoma 
virus antibody titre o f 3200, and the remaining rabbits had a titre o f 12800 or 25600. At 
this time, the 50% PRNA titre o f rabbit 284 was only 320, whilst the other animals had 
titres o f between 1280 and 10240 (Figure 7.25E). There was no clear correlation between 
the magnitude o f increase in ELISA titre following challenge and the development o f 
secondary lesions, although rabbits that did develop secondary lesions upon challenge (282 
and 288) had the highest increases in 50% PRNA titre (512-fold).
7.2.5.5 Summary
Following inoculation with Uriarra AM063Rg/?/gws', 12 week old rabbits showed a very 
similar reaction to mature rabbits, developing a small lesion at the inoculation site only, that 
was completely resolved by 21 dpi. There was very little anti-myxoma virus antibody 
(ELISA titre < 100) measured in rabbits following the first dose o f vaccine. The response 
upon boosting was similar to that seen during the initial vaccination, although the lesion at 
the inoculation site developed and regressed more rapidly. A ll rabbits showed significant 
increases in anti-myxoma virus antibody titres following boosting.
Uriarra AM063Rg/?/gws-boosted rabbits showed very high levels o f resistance to challenge 
with SLS, exhibiting clinical signs similar to those seen in rabbits vaccinated with TKO. 
Infection was limited to a lesion at the challenge inoculation site only on four rabbits, while 
two rabbits developed five small secondary lesions each on the face or ears. Following
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challenge, all animals showed large increases (16-fold or greater) in anti-myxoma virus 
antibody titres.
7.2.6 Boosting Uriarra AM063Rg/?/£«s-vaccinated rabbits with TKO
7.2.6.1 Boosting rabbits with TKO
Four weeks after inoculation with Uriarra AM063Rg/?fgw*s' (Section 7.2.5.1), six o f the 12 
rabbits were boosted with 50 pfu o f TKO intradermally on the right thigh and examined 
daily for 10 days. The clinical signs o f these rabbits following boosting are summarised in 
Table 7.4. Unlike rabbits boosted with Uriarra AM063Rg/?fgws, there was not an 
immediate reaction at the inoculation site on all rabbits. By 3 dpb, five rabbits had 
developed a slight reddening at the inoculation site or a small, soft pink lesion (Figure 
7.26A and B) and one had no observable reaction (Figure 7.26C). This last rabbit began to 
develop a small lesion at 4 dpb. By 6 dpb, the slight reddening o f the skin o f TKO-boosted 
rabbits had developed into a small red or pink lesion, 5-15 mm in diameter on most rabbits 
(Figure 7.27A-C). The diameter o f the lesion at the inoculation site at 6 days after boosting 
with TKO (mean = 10.7 mm) was significantly lower than seen on naive 12 week old 
rabbits inoculated with 50 pfu o f TKO (mean = 17.3 mm; p  = 0.177). The exception was 
rabbit 290, which had developed a larger 20x30 mm lesion, which was covered by a hard 
black scab (Figure 7.27D). When this animal was excluded from the data set, the 
difference in TKO-induced lesion diameters was more significant (mean = 5.52 mm; p  < 
0.01).
By 10 dpb, the lesion had regressed completely on three animals (285, 293 and 275) or had 
scabbed over on two others (289 and 291). The larger lesion on rabbit 290 had also begun 
to regress slightly, and was covered with a hard black concave scab. No secondary lesions
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Table 7.4 -  Clinical signs of Uriarra AM063Rg/?fgws-vaccinted rabbits following 
boosting with 50 pfu of TKO.
D a y  p o s t C lin ic a l s i g n s
in o c u la t io n
l Slight reddening of skin at the inoculation site of rabbit 
293 and 290 only
3 5-8 mm raised pink lesion on 5 rabbits. Rabbit 275 had 
no reaction at the inoculation site.
5 Lesion at the inoculation site of 5/6 rabbits, crimson- 
coloured, 6-25 mm diameter. Darker patches on lesion of 
rabbit 290. Lesion on rabbit 285 had regressed.
7 Lesion of rabbit 290 was 20x30 mm, covered with a hard 
black scab. Other lesions were 5-15 mm in diameter, 
hard crimson lumps. No lesions on rabbits 285 and 275.
10 No lesion on rabbits 285, 275 or 293. A scabbed over, 
protuberant lesion (8-30 mm) on rabbits 290, 291 and 
289. No secondary lesions on any animal.
Figure 7.26 - Uriarra AM063Rgp/gas-vaccinated rabbits boosted with 50 pfu of TKO, 
3 days after inoculation. Reddening of the skin at the inoculation site as shown (A and 
B, arrowed). No reaction at the inoculation site on one rabbit (C, arrowed). Bars on 
images are 10 mm in size.
Figure 7.27 - Uriarra AM063Rgprg^ vaccinated rabbits boosted with 50 pfu of TKO, 
6 days after inoculation. Lesions that had regressed to a small pink or red lump (A and 
B, arrowed). Larger (10-30 mm) lesions that were circumscribed or scabbed over (C 
and D, arrowed). Bars on images are 10 mm in size.
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were noted on any rabbit following inoculation with TKO. The rectal temperatures o f 
TKO-boosted rabbits remained below 40°C for the 10 days following boosting (Figure 
7.28).
7.2.6.2 Challenge o f TKO-boosted rabbits with SLS
The six TKO-boosted rabbits were challenged with 1000 pfu o f SLS at a site on the back 
above the left thigh 6 weeks after boosting, and examined for 14 days following challenge. 
The clinical symptoms o f these animals are summarised in Table 7.5. Within 24 hours o f 
SLS inoculation, a 5-15 mm pink or red raised lesion had developed at the inoculation site 
which had increased in size to 20-35 mm by 3 dpc, and were dark red in colour with black 
haemorrhagic regions on three o f the rabbits (Figure 7.29). At 4 dpc, small secondary 
lesions began to develop on two rabbits (289 and 285). By 5 dpc, three rabbits (285, 293 
and 289) had very large lesions at the inoculation site, in excess o f 30 mm, which were 
highly protuberant and haemorrhagic, and these rabbits had also developed small (5-10 
mm) crimson secondary lesions on the eyelids, genitals, ears and face. One other rabbit 
(275) had developed small (5 mm) black secondary lesions on the lips and ears.
By 6 dpc, the infection in one rabbit (290) had almost resolved, with a black scab covering 
a 20 mm lesion at the inoculation site (Figure 7.30C), and no secondary lesions evident. 
Two other rabbits (291 and 275) only had only 15-20 mm primary lesions (Figure 7.30A) 
and rabbit 275 had developed several very small secondary lesions. These animals had 
recovered by 9 dpc, except for black scabs at the inoculation site and secondary lesions 
(Figure 7.31 A and B). The other three rabbits had lesions at the inoculation site 40-55 mm 
in diameter (Figure 7.30B, rabbit 293) and numerous secondary lesions on the eyelids, ears, 
body, nose and genitals (Figure 7.30D-H). The secondary lesions on these rabbits were
Page 187
Te
m
pe
ra
tu
re
 (
°C
) -■ -2 9 1
38.8
Time post boosting (days)
Figure 7.28 - Rectal temperatures o f Uriarra AM063Rgg>to/s-vaccinated 
rabbits following boosting with 50 pfu o f TKO.
Table 7.5 -  Clinical signs o f TKO-boosted rabbits following challenge with SLS.
D ay p o s t 
in o cu la tio n
C lin ica l s igns
l Pink, lesion at the inoculation site, 5-15 mm diameter
3 Red, protuberant lesion 20-35 mm in diameter; black, 
haemorrhagic patches on lesions o f 3 rabbits. 2/6 rabbits had 
temperatures o f >40°C.
4 Lesions at the inoculation site 21-35 mm diameter; black scab 
on lesion o f rabbits 291 and 290. Secondary lesions on eyelid 
or ears o f rabbits 289 and 285. 2/6 rabbits had temperatures o f 
>40°C.
5 Lesion at the inoculation site o f rabbit 290 regressing, covered 
with a hard black scab. Lesions o f rabbits 291 and 275 
circumscribed, scabbed over. Lesions at the inoculation site o f 
rabbits 285, 289 and 293 were 25-35 mm diameter, 
protuberant, black and haemorrhagic. Secondary lesions on 
4/6 rabbits on ears, eyelids, nostrils, anus, mouth. 4/6 rabbits 
had temperatures o f >40°C.
7 Rabbit 290 and 291 recovered. Rabbits 275 had only a few 
small, black secondary lesions. Lesions at the inoculation site 
o f rabbits 285, 289 and 293 were 40-60 mm in diameter, highly 
protuberant, bleeding or haemorrhagic. Numerous secondary 
lesions at secondary sites, m ild mucopurulent discharge from 
conjunctivae, m ild anogenital swelling. 3/6 rabbits had 
temperatures o f >40°C.
8 As at day 7, except rabbits 289 and 293 had developed snuffly 
breathing and mucopurulent discharge from the nose. Lesions 
at the inoculation site covered w ith a thin black scab; lesion o f 
rabbit 289 was bleeding. Secondary lesions covered by black 
scabby material except for on rabbit 293 - lesions still crimson 
and swollen. 3/6 rabbits had temperatures o f >40°C.
10 Rabbit 285 recovering, though still had slight mucopurulent 
discharge from conjunctivae; no anogenital swelling. 
Breathing o f rabbit 293 clear. Rabbit 289 had obstructed 
breathing and most secondary lesions were not black; 
anogenital swelling apparent. 2/6 rabbits had temperatures o f 
>40°C.
12 Lesions at the inoculation site covered with hard black scabs. 
Rabbit 289 had recovered since day 10, though airways still 
slightly obstructed; other symptoms resolving; secondary 
lesions covered with black scabs; temperature still >40°C.
15 A ll rabbits recovered. Rabbits 285, 293 and 289 appear 'ratty' 
w ith lumpy, misshapen ears, and numerous black scabs on 
body and face.
AFigure 7.29 - Rabbits boosted with TKO, 3 days after challenge with 1000 pfu of 
SLS. Lesions at the inoculation site were red or crimson (A, C, and E, arrowed) or 
had developed black, haemorrhagic patches (B and D, arrowed). Bars on images are 
10 mm in size.
Figure 7.30 - Rabbits boosted with TKO, 6 days after challenge with 1000 pfu of 
SLS. Lesions at the inoculation site were covered with a hard black scab (A-C, 
arrowed) and up to 50 mm in diameter (B, arrowed). Secondary lesions on the 
eyelids (D-G, arrowed), nose (G, arrowed) and ears (H, arrowed). Bars on 
images are 10 mm in size.
Chapter 1 -  Construction and testing of a replication-deficient vaccine
generally black in the centre and surrounded by crimson skin, except for rabbit 293 whose 
secondary lesions were red or crimson in colour with no black, haemorrhagic regions. 
Rabbits 289 and 293 had also developed a clear discharge from the conjunctivae and 
developed slightly snuffly breathing at 8 dpc.
By 9 dpc, the breathing o f these two rabbits was more obstructed and the discharge from 
the conjunctivae and nostrils was thicker and mucoid, and lesions inside the nostrils were 
bleeding slightly (Figure 7.3IF). The lesions at the inoculation site were circumscribed, 
highly protuberant, haemorrhagic and bleeding in places (Figure 7.31C and D). Rabbit 285 
had begun to recover, although had lost some weight over the previous 3 days and had a 
clear discharge from the left eye (Figure 7.3IE). Secondary lesions on the three more 
severely affected rabbits were black or haemorrhagic, although the surrounding skin was 
dark crimson in colour (Figure 7.31F-H). The breathing o f rabbits 293 and 289 was normal 
at 10 and 13 dpc, respectively.
By 15 dpc all lesions at the inoculation site were covered with a hard black scab, and the 
surrounding skin had returned to normal (Figure 7.32A) or pale pink in colour (Figure 
7.32B and C). Secondary lesions had regressed leaving black scabby material only (Figure 
7.32D and E). The clearance o f larger secondary lesions at the margins o f the ears resulted 
in a moth eaten appearance to the edges o f the ears due to the loss o f pieces o f skin (Figure 
7.32F).
Rectal temperatures o f rabbits were recorded each day following challenge and are shown 
in Figure 7.33. Rabbits 291, 275 and 290 did not have temperatures over 40°C for more 
than 1 day following challenge. Rabbits 285, 293 and 289 that showed more severe
Page 188
Figure 7.31 - Rabbits boosted with TKO, 9 days after challenge with 1000 pfu 
of SLS. Lesions at the inoculation site with residual black scab (A and B, 
arrowed). Very large lesions that were haemorrhagic and bleeding (C and D, 
arrowed). Secondary lesions on the nose (E and F, black arrows), eyes (G, 
arrowed) and ears (H, arrowed) were covered in scabby material, or 
haemorrhagic. Discharge and bleeding from the nostrils of rabbit 293 (F, white 
arrows). Bars on images are 10 mm in size.

Figure 7.32 - Rabbits boosted with TKO, 15 days after challenge with 1000 pfu of SLS. 
Lesions at the inoculation site were covered by a residual scab (A-C, arrowed). 
Secondary lesions such as those on the nose and face (D and E, arrowed) had resolved to 
black scabs. A secondary lesion on the ear of rabbit 293 resulted in the loss of a 4 mm 
piece of tissue from the edge of the ear (F, arrowed). Bars on images are 10 mm in size.
T
em
p
er
at
u
re
 (
°C
) ■«-291
38.5
Time post challenge (days)
Figure 7.33 - Rectal temperatures o f Uriarra AM063Rgg>/g^-vaccinated 
rabbits boosted with TKO, following challenge with 1000 pfu o f SLS.
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symptoms had temperatures over 40°C for 7, 9 and 9 days respectively, including several 
days above 41 °C.
In summary, two of the TKO-boosted rabbits (290 and 291) did not develop secondary 
lesions, including rabbit 290 which had developed the largest lesion following boosting 
with TKO (Figure 7.27D). One rabbit (275) developed only a few very small secondary 
lesions on the ears and eyelids following challenge. The symptoms of these three rabbits 
following SLS challenge were similar to animals that had received a single dose of TKO 
(Chapters 4 and 6) or had received two doses of Uriarra AM063Rgp/gws (Section 1.2.53). 
Three rabbits (293, 289 and 285) developed numerous, small secondary lesions on the 
eyelids, anus, nose, face or ears as well as more serious complications of myxomatosis such 
as mild laboured breathing, mild anogenital swelling, fever and some weight loss. 
However, at no point were these three rabbits seriously debilitated, being moderately ill for 
no more than 6 days. The symptoms exhibited by these rabbits were comparable to those 
exhibited by rabbits that had received a single dose of Uriarra AM063Rgptgus (Section 
7.2.4.2).
7.2.63 Analysis o f anti-myxoma virus antibody responses in TKO-boosted rabbits 
The anti-myxoma virus ELISA antibody titre was determined for all serum samples after 
vaccination, boosting and challenge, and are shown in Figure 7.34. Antibody capable of 
neutralising myxoma virus in vitro was analysed using PRNA for serum samples taken 
before the TKO boost (4 wpv), 2 weeks after boosting (6 wpv), before challenge (10 wpv) 
and 2 weeks after challenge (12 wpv). The percentage plaque neutralisation for each serum 
dilution tested and the corresponding 50% and 80% plaque neutralisation titres are shown 
for each rabbit in Figure 7.35.
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As was found with other groups o f rabbits, only low titres o f anti-myxoma virus antibody 
were detected following inoculation with 100,000 pfu o f Uriarra AM063R<g/?/gws. Only 
two rabbits (289 and 293) had detectable titres (100) by 4 wpv (Figure 7.34). PRNA titres 
were similarly very low. Only sera from rabbits 289 and 275 had any detectable virus- 
neutralising activity at 4 wpv (Figure 7.35A).
Following boosting with TKO, three rabbits (291, 289 and 290) had significant increases in 
ELISA titre over 2 weeks, with titres at 6 wpv o f 1600, 1600 and 400 respectively (Figure 
7.34). Rabbit 290, which developed the largest lesion following TKO inoculation, had a 
rapid increase in ELISA titre from <100 to 1600 within 7 days o f boosting, before 
stabilising at 3200 at 7 wpv. Three rabbits (285, 275 and 293) did not have significant 
increases in antibody titre and by the time o f challenge at 10 wpv, no anti-myxoma virus 
antibody could be detected in their serum by ELISA (Figure 7.34). Sera from rabbits 291,
289 and 290 also had increases in virus-neutralising activity between 4 and 6 wpv, with 
50% PRNA titres of between 40 and 640 (Figure 7.35B). As with ELISA results, rabbit
290 had the highest 50% PRNA titre o f 640 at 6 wpv (Figure 7.35E) falling to 320 at 10 
wpv (Figure 5.35C and E). Rabbits 291 and 290 showed similar slight drops in titre by 10 
wpv (Figure 5.35C and E). Sera from rabbits 285, 275 and 293 had very little virus- 
neutralising activity at 6 or 10 wpv (Figure 7.35B and C). In contrast, increases in ELISA 
and neutralising antibody titres were seen in all rabbits boosted with Uriarra 
AM063Rg/?r<gws' (Figures 7.24 and 7.25), or challenged with SLS (Figures 7.13 and 7.14).
A ll TKO-boosted rabbits had significant increases (4-fold or greater) in ELISA and PRNA 
antibody titres following challenge with SLS at 10 wpv (Figures 7.34 and 7.35). Rabbits
291 and 290, which did not develop secondary lesions after challenge had smaller increases
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Figure 7.34 - ELISA anti-myxoma virus antibody titres in rabbits vaccinated with 
Uriarra AMOöSRgpfgMs and boosted with TKO. The ELISA titre was determined 
by titration in duplicate of two fold serial dilutions of rabbit sera from 1:100. The 
ELISA endpoint was defined as the reciprocal serum dilution 0.1 OD405 units 
above the OD405 of the 1:100 negative control. An OD405 of less than 0.1 for a 
1:100 dilution of serum was recorded as a titre of zero. At week 4, rabbits were 
boosted with 50 pfu of TKO (open arrow) and challenged with SLS at week 10 
(closed arrow).
Figure 7.35 - Analysis of neutralising anti-myxoma virus antibodies in the serum of 
rabbits vaccinated with Uriarra AM063Rg/7fei/s and boosted with TKO. 
Neutralising antibody was measured by plaque reduction neutralisation assay and 
the percentage plaque neutralisation recorded before boosting (week 4, A), after 
boosting (week 6, B), before challenge (week 10, C) and after challenge (week 12, 
D) for each serum dilution (two-fold from 1:10 to 1:20480). The highest reciprocal 
serum dilutions at which 50% or greater and 80% or greater of myxoma virus 
plaque formation was neutralised is summarised (E).
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285 < 10 < 10 < 10 < 10 < 10 < 10 10240 1280
291 < 10 < 10 160 40 80 < 10 640 160
289 < 10 < 10 40 < 10 10 < 10 >20480 >20480
290 < 10 < 10 640 20 320 40 1280 320
275 < 10 < 10 < 10 < 10 < 10 < 10 5120 320
293 < 10 < 10 < 10 < 10 < 10 < 10 >20480 1280
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than other rabbits (16- and 4-fold increases over 14 days, respectively), and their titres at 
the time o f challenge were significantly higher than the other rabbits in the experimental 
group. Rabbits 285, 289 and 293 which developed the most severe symptoms o f 
myxomatosis following SLS challenge showed very large increases in titre in the two 
weeks following challenge (1024-, 512- and 512-fold increases respectively), and had titres 
ranging from 25600 to 102400 (Figure 7.34). Rabbit 289, which had exhibited the most 
severe symptoms following challenge had virus neutralisation levels o f 86% at a serum 
dilution o f 1/20480 (Figure 5.35D) and an ELISA titre o f 102400, the highest recorded 
anti-myxoma virus antibody titres in this study. A ll rabbits in this group had ELISA titres 
in excess o f 12800 (Figure 7.34) and 50% PRNA titres o f between 640 and >20480 at 12 
wpv (Figure 7.35D and E).
7.2.6.4 Summary
Boosting with TKO did not result in consistent responses amongst Uriarra AM063Rgp/gz/s- 
vaccinated rabbits. Responses ranged from a transient reddening at the inoculation site to a 
large protuberant lesion similar to that which developed on naive rabbits (Chapters 4 and 
6). Changes in anti-myxoma virus antibody responses after boosting were directly related 
to the response upon boosting, with rabbits that developed a distinct TKO-induced lesion 
showing larger increases in antibody titres.
Following SLS challenge, TKO-boosted rabbits could be divided into two groups. Three 
rabbits did not develop symptoms o f myxomatosis, with infection limited to a primary 
lesion and/or several small secondary lesions, similar to that seen in TKO-vaccinated and 
Uriarra AM063Rgp/gws-boosted rabbits. These rabbits had developed a distinct lesion at 
the inoculation site upon boosting with TKO. The other three rabbits developed mild
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clinical myxomatosis that was similar to that observed in some rabbits that had received a 
single dose o f Uriarra AM063Rg/ggws. These rabbits did not develop a distinct lesion upon 
boosting with TK.O, or had developed a small, rapidly resolved lesion. A ll TKO-boosted 
rabbits had significant increases in anti-myxoma virus antibody titres following challenge, 
with the magnitude o f the increase directly related to the severity o f symptoms observed 
upon challenge.
7.3 D is c u s s io n
In this chapter I have described the construction and testing o f a replication-deficient 
myxoma virus vaccine, Uriarra AM063Rg/ggws. This is the first reported evaluation o f the 
protective efficacy o f a homologous, replication-deficient vaccine against a lethal poxvirus 
disease outside o f Orthopoxvirus models, and has demonstrated the efficacy o f a 
replication-deficient, and therefore non-transmissible myxoma virus vaccine against 
myxomatosis. Uriarra AM063Rg/?/gz/5 conferred complete protection against lethal 
myxoma virus challenge, and good protection against clinical disease. When boosted with 
another dose o f Uriarra AM063Rg/?/gws, rabbits had greater resistance to lethal SLS 
challenge, comparable to that seen in TKO-vaccinated rabbits. Boosting with TKO did not 
consistently offer greater levels o f protection than a single dose o f Uriarra AM063Rg/?/gws.
The growth and protein expression characteristics o f the virus, the acceptability and 
efficacy o f Uriarra AM063Rg/?/g?/s vaccination compared to replication-competent 
vaccines, and the role o f virus-specific antibody and cell-mediated immune responses in 
protecting against SLS challenge have been discussed below.
Chapter 7 -  Construction and testing of a replication-deficient vaccine
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7.3.1 Growth and protein expression characteristics of Uriarra AM063Rgptgus
Uriarra AM063Rgp/gz« was unable to replicate within RK13 cells in vitro, suggesting that 
this recombinant virus would have similarly poor replicative ability in other rabbit cell lines 
and rabbit cells in vivo, as demonstrated by McFadden et al (personal communication). 
However, unlike the results o f McFadden et al., we have demonstrated readily detectable 
expression o f an intermediate or late gene in Uriarra AM063Rg/?^w5-infected RK13 cells 
using the monoclonal antibody 3B6E4. The specific target o f this antibody has not been 
determined. Expression o f the target protein was not detected in myxoma virus-infected 
cells at 4 hours after infection, but was detected at 6 hours after infection, and expression o f 
this protein was prevented in infected cells treated with cytosine arabinoside, an inhibitor o f 
DNA synthesis (Peter Kerr, personal communication). These two results suggest that the 
target protein is an intermediate or late gene, whose expression occurs during or after viral 
DNA replication (Moss, 1990; Moss, 2002). However, despite the low-level expression o f 
this gene and presumably other intermediate and late genes, new virus is not produced, 
indicating that the replication cycle o f Uriarra AM063Rgp/gws in RK13 cells is aborted at 
some stage before virus assembly.
The expression o f late genes in Uriarra AM063Rg/?/gws-infected rabbit cells, without 
associated production o f progeny virus, allows a broader range o f myxoma virus antigen 
production in vivo and a greater array o f antigenic epitopes to be exposed to the rabbit’s 
immune system than i f  virus gene expression is limited to early genes only. There is 
currently little information available regarding the protective antigens o f poxviruses, so the 
ability o f this virus to express as diverse a range o f viral antigens as possible, without 
concurrent viral replication, w ill enhance its potential immunogenicity and efficacy.
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7.3.2 Acceptability and efficacy of Uriarra AIM063Rgptgus vaccination and boosting
Vaccination with Uriarra AM063R^/?/gw5 was much more acceptable than vaccination with 
the replication-competent vaccines tested, including the highly attenuated TKO vaccine, 
where the primary lesion haemorrhages and leaves a hard black scab at the inoculation site. 
In contrast, the lesion induced by Uriarra AM063Rg/?/gws, both during the first vaccination 
and after boosting, was small and resolved very quickly, often without residual scabbing. 
The uniformity o f responses and reactions in mature and 12 week old rabbits following 
Uriarra AM063Rg/?/gws vaccination suggests that this dose o f virus would be similarly 
acceptable in rabbits younger than 12 weeks old. However, the long-term effects o f 
scarring at the inoculation site requires further investigation. As Uriarra AM063Rg/?/gws is 
incapable o f dissemination, it cannot cause secondary lesions and possible scarring at distal 
skin sites such as the ears, as may occur following TKO vaccination o f younger rabbits 
(Chapter 6).
The reaction at the inoculation site o f Uriarra AM063Rg/?rgws-vaccinated rabbits was seen 
2-3 days later than following inoculation with a 50-fold lower dose o f TKO. The timing o f 
these changes coincide with the appearance o f antigen-specific CTLs observed in the 
draining lymph node during VV infections in rats (Zinkernagel et a l 1977) and sheep 
(Issekutz, 1984; Issekutz, 1985), suggesting that the observed reaction was due to an influx 
o f virus-specific lymphocytes into the skin with associated inflammation, rather than the 
virus-induced tissue damage and inflammation caused by a replication-competent virus.
Uriarra AM063Rg/ggws conferred excellent levels o f protection from SLS challenge, with 
only a third o f rabbits developing more than very mild secondary signs o f infection. 
Although the symptoms exhibited these animals were more severe than preferred for an
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‘ ideal’ vaccine, it is unlikely that rabbits would succumb to SLS challenge. The symptoms 
were very mild compared to infection o f naive rabbits with SLS (Best and Kerr, 2000; 
Robinson et al., 1999). Rabbits that developed the most severe manifestations o f disease 
were still very well protected from challenge, and at no point were seriously debilitated, 
remaining active and alert at all times.
The efficacy o f Uriarra AM063Rg/?fgws was drastically improved by boosting, with much 
greater levels o f protection than that observed in rabbits that had received only a single 
dose o f the replication-deficient vaccine. This level o f efficacy was comparable to a single 
inoculation o f TKO, with only two o f the six rabbits showing dissemination o f the virus to 
secondary sites and all animals protected from any other manifestations o f myxomatosis.
It would be interesting to investigate the effect o f higher doses o f Uriarra AM063Rg/?/gw5 
on the levels o f antigen-specific responses induced, and the subsequent level o f protective
o
efficacy against SLS challenge. MVA has been delivered at doses o f up to 10 pfu, and the 
induction o f virus-specific immune responses (antibody and CD8 T cells) and 
corresponding protective efficacy against lethal VV challenge was dose-dependant (Wyatt 
et al., 2004). The dose o f Uriarra AM063Rg/?/gws' delivered (lCf pfu) was selected as it was 
the maximum achievable without also injecting large amounts o f Vero cell debris, with 
unknown effects on the infection. The delivery o f higher doses o f Uriarra AM063Rg/ggws 
would require higher concentrations o f the virus than those obtained during these studies. 
This could be achieved by ultracentrifugal purification o f virus, the optimisation o f virus 
growth conditions in Vero cells such as the use o f roller bottles, or evaluating other cells 
lines that may be capable o f producing higher titres o f virus.
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7.3.3 Efficacy of boosting with TK O
The dose o f TKO used to boost rabbits in these experiments may have been too low to 
produce consistent boosting o f anti-myxoma virus immune responses. It was selected as it 
was believed 50 pfu would reduce the incidence o f dissemination o f the vaccine virus to 
secondary sites in Uriarra AM063Rg/?rgw.s,-vaccinated rabbits, but would be high enough to 
provide a significant boost to immunity. TKO replication in most rabbits was limited at the 
inoculation site as indicated by the rapid circumscription o f the lesion and its small size on 
most rabbits. TKO-induced lesion size and severity in Uriarra AM063Rg/?/gws-vaccinated 
rabbits was significantly lower than seen on naive rabbits. Similarly, a reduction in live 
VV-induced lesion size and severity was observed in monkeys previously vaccinated with a 
single dose o f MVA (Earl et al., 2004).
The very rapid control o f TKO replication resulted in low levels o f antigen synthesis in 
most rabbits and poor boosting o f anti-myxoma virus immune responses. Similarly, the 
level o f protection from SLS challenge in TKO-boosted rabbits was not consistently as high 
as that observed in Uriarra AM063Rgpfgws-boosted animals, and was comparable to a 
single dose o f Uriarra AM063Rg/?/gws in mature animals. The only animals to be 
completely protected from dissemination o f the challenge virus were those that developed 
large lesions after TKO boosting. However, similar levels o f protection were observed in 
animals inoculated with TKO alone. This suggests that although previous vaccination with 
Uriarra AM063Rg/?rg£/s resulted in a reduction in the severity o f TKO-induced symptoms 
in some rabbits, these animals were not provided with a boost in protection from SLS 
challenge. Further evaluation o f TKO boosting using larger doses o f the virus is warranted, 
to determine i f  more consistent boosting o f protection can be obtained without a concurrent 
increase in the severity o f the TKO-induced lesion or dissemination to secondary sites.
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7.3.4 Production of anti-myxoma virus antibody following vaccination and boosting, 
and the correlation with protection
Inoculation with 105 pfu o f Uriarra AM063Rg/?^w5 did not elicit high levels o f anti-
myxoma virus antibody as was found after inoculation with TKO. This low level o f 
antibody may be due to two factors. Firstly, the replication-deficient nature o f the vaccine 
results in much lower levels o f antigen production in vivo than inoculation with replication- 
competent viruses. Secondly, the poor expression o f late myxoma virus proteins including 
IM V and EEV membrane proteins (Cameron et al., 1999; Moss, 2002), may have resulted 
in only weak antibody responses against these targets o f virus neutralisation. The ELISA 
titres would be similarly lower as the antigen used to coat the ELISA plates was intact IM V 
particles purified by ultracentrifugation, therefore consisting primarily o f exposed IM V 
antigens.
Boosting o f Uriarra AM063Rg/?rgws-vaccinated rabbits with another dose o f the virus 
resulted in significant and rapid (within 7 days) increases in serum antibody titres. This 
indicated that all rabbits possessed myxoma virus-specific B cells primed by the first dose 
o f vaccine that resulted in a potent secondary antibody response, as naive rabbits vaccinated 
with replication-competent viruses do not display detectable antibody before 10-14 dpi 
(Chapters 4 and 6; Best and Kerr, 2000; Fenner and Ratcliffe, 1965). In contrast, boosting 
with TKO did not consistently result in increases in antibody titre. Those rabbits which did 
show increases in antibody titre were those that had developed larger TKO-induced lesions, 
suggesting that a greater amount o f TKO replication and a more robust secondary immune 
response had occurred. Clearly, the very low level viral replication in some rabbits was not 
sufficient to generate a potent secondary antibody response.
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These results support the premise that circulating neutralising antibody does not play a 
significant role in protection, as there was very little present at the time o f challenge in 
many animals. This suggests that Uriarra AM063Rg/?fgws-vacinated animals possessed a 
pool o f primed virus-specific CTLs and memory T cells capable o f rapid expansion and 
control o f the infection within a few days o f challenge. The rapid infiltration o f 
lymphocytes into the inoculation site is evident by the immediate reaction observed (within 
24 hours), and the swift circumscription and haemorrhaging o f the lesion. Without an 
accurate means o f measuring myxoma virus-specific cell mediated immune responses, we 
cannot determine and compare the magnitude o f cell-mediated immune responses generated 
following inoculation with Uriarra AM063Rg/tfgws and after boosting. However, the high 
levels o f protection observed in the absence o f neutralising antibody suggests that cell- 
mediated mechanisms generated follow ing vaccination with the replication-deficient 
vaccine were primarily responsible for the initial control o f the infection at the inoculation 
site, and protection from myxomatosis.
7.3.5 Conclusions
The results presented in this chapter indicate that the deletion o f a single open reading 
frame from Uriarra was capable o f generating a safe, acceptable and non-transmissible 
replication-deficient myxoma virus vaccine, that could protect domestic rabbits from 
myxomatosis following challenge with a virulent virus. A single dose o f K f  pfu o f the 
virus conferred high levels o f protection that were enhanced by a boost with the same 
vaccine. Although the symptoms exhibited by rabbits following challenge with SLS were 
more severe than observed in animals vaccinated with replication-competent vaccines, none 
o f the challenged animals exhibited severe myxomatosis or were seriously debilitated. 
Together with the very mild reaction following inoculation and the non-transmissible
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nature o f this replication-deficient vaccine virus, Uriarra AM063Rg/?fgz^ can be considered 
an excellent candidate vaccine for further development.
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C h a p t e r  8  -  G e n e r a l  D i s c u s s io n
This thesis has evaluated three poxvirus vaccination strategies using infection o f European 
rabbits with myxoma virus as a natural poxvirus disease model. The key findings o f this 
study were:
1. Intramuscularly injected DNA vaccines expressing selected myxoma virus IM V  and 
EEV membrane antigens were not able to protect rabbits from lethal myxoma virus 
challenge;
2. Live, attenuated myxoma virus vaccines confer excellent protection from challenge, but 
can cause extremely mild secondary signs o f infection in young rabbits, and can reach 
potentially transmissible titres in the skin o f vaccinated rabbits;
3. Replication-deficient myxoma virus vaccines can confer protection from challenge, but 
require boosting to achieve protection equivalent to live attenuated vaccines.
Both TKO and Uriarra AM063Rgpfgus conferred excellent protection from lethal myxoma 
virus challenge. The acceptability and efficacy o f these two vaccines with respect to the 
criteria for an "ideal" myxomatosis vaccine established in Section 1.6 w ill be discussed, as 
well as the role o f antibody and cell-mediated immune responses in protection from 
myxoma virus challenge, and future directions for the development o f these candidate 
myxomatosis vaccines for use in Australia.
8.1 A comparison of TKO and Uriarra AM063Rgp/&ws as myxomatosis vaccines
The acceptability o f TKO and Uriarra AM063Rgp/gws can be gauged by comparing the 
pathogenesis o f these two viruses in domestic rabbits. Figure 8.1 shows a comparison o f 
models for the pathogenesis o f virulent myxoma virus (Best et al., 2000; Best and Kerr,
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2000), TKO (Chapter 5) and the hypothesised pathogenesis o f Uriarra AM063Rg/?/gws. In 
contrast to the uncontrolled, lethal SLS infection (Figure 8.1 A; Best and Kerr, 2000), 
infection with TKO is rapidly controlled. However, TKO can replicate to potentially 
transmissible titres in the skin o f domestic rabbits, and disseminates to distal skin sites in a 
majority o f 8 and 12 week old rabbits (Figure 8.IB). Although TKO appears to be safer 
than commercially available myxoma virus vaccines (Gorski et al., 1994; McKercher and 
Saito, 1964; Saurat et al., 1978), these results render the vaccine unacceptable for use in 
Australia according to the criteria established in Section 1.6.
Uriarra AM063Rg/?fgws is the most acceptable vaccine for use in domestic rabbits. The 
inability o f this virus to replicate and disseminate within the vaccinated rabbit means it 
cannot cause any secondary symptoms o f myxomatosis or transmit to another animals 
(Figure 8.1C). However, in contrast to TKO vaccination, a single dose o f Uriarra 
AM063Rg/?/gz/s raises only low levels o f virus-specific immune responses, presumably due 
to the comparatively low level o f antigen synthesis in vivo. However, the rapid 
inflammatory response and large increases in anti-myxoma virus antibody seen 
immediately following boosting indicate that potent anti-myxoma virus memory (primed 
memory B and T cells) are generated by a single dose o f Uriarra AM063Rg/?rgws.
The efficacy o f TKO and Uriarra AM063Rg/?fgws vaccination against lethal myxoma virus 
challenge can be compared by considering the pathogenesis o f SLS infection in vaccinated 
rabbits. Figure 8.2 compares the pathogenesis o f SLS in TKO-vaccinated rabbits (Figure 
8.2A), Uriarra AM063Rg/?fgz/s-vaccinated rabbits (Figure 8.2B) and rabbits that were 
boosted with a second dose o f Uriarra AM063Rgpfgws (Figure 8.2C). Vaccination with 
TKO induced moderate to high titres o f anti-myxoma virus antibody and, most likely, high
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Chapter 8 - General Discussion
levels o f anti-myxoma virus T cells (Figure 8.2A), conferring excellent protection from 
challenge. In contrast, a single dose of Uriarra AM063Rg/?/gws, although conferring 
complete protection from death, did not prevent the dissemination of the challenge virus 
and the onset of mild to moderate myxomatosis (Figure 8.2B). This level of protection is 
better than that conferred by commercially available RFV-based vaccines (Marlier et al., 
2000). The protective efficacy of Uriarra AM063Rg/ggws is drastically improved by 
boosting (Figure 8.2C), with measured immune responses and post-challenge clinical signs 
similar to those of rabbits that had received a single dose of TKO (Figure 8.2A). Although 
the need for multiple doses of a vaccine to obtain protective immunity is economically 
undesirable for farmed rabbits, amongst companion animals, safety is considered of 
paramount importance, and multiple doses of vaccines or annual boosters are commonly 
administered (Carter and Carmichael, 2003).
The protective efficacy of Uriarra AM063Rg/?/gws vaccination in the absence o f anti-
myxoma antibody indicates an important role for cell-mediated immune responses in 
protection from myxoma virus challenge. This is further supported by the rapid decline in 
protective efficacy seen following vaccination with a AM063R myxoma virus strain, from 
complete protection at 2 weeks after vaccination (Grant McFadden, personal 
communication) to moderate protection at 6 weeks. Numbers o f virus-specific CTLs 
decline by up to 95% within 2 weeks o f virus clearance as virus-specific effector CTLs 
undergo apoptosis during the maturation of memory T cell populations (Esser et al., 2003; 
Wherry and Ahmed, 2004), as observed in poxvirus disease models (Issekutz, 1984; 
Issekutz, 1985; Zinkemagel et al., 1977). A rapid immune response was indicated by the 
early inflammation at the inoculation site of all animals following challenge. However, the 
population of effector T cells had contracted since two weeks after vaccination and were
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not sufficient to completely control viral replication and dissemination, but controlled the 
virulent infection before the onset of severe myxomatosis. A second dose of the 
replication-deficient vaccine was able to boost anti-myxoma virus immune responses to the 
point where they were able to control virus replication at the inoculation site, with only 
limited challenge virus dissemination.
The results of this study suggest that replication-deficient poxvirus vaccines offer the best 
combination of safety and efficacy amongst the tested vaccination strategies. The efficacy 
of two doses of Uriarra AM063Rg/?/gw,s' was comparable to TKO and other live myxoma 
virus vaccines (Gorski et al., 1994; Jacotot et al., 1967; Marlier et al., 2000; McKercher 
and Saito, 1964; Saurat et al., 1978), with the added benefit of complete non- 
transmissibility and safety in younger rabbits. Replication-deficient poxvirus vaccines may 
be effective at combating veterinary poxvirus diseases of economic importance such as the 
capripoxviruses, orf and fowlpox. The targeted deletion of homologues of M063R and/or 
critical intracellular interferon response-resistance factors such as K1L and E3L (Alsonso et 
al., 2000; Mclnnes et al., 1998; Tulman et al., 2002), to produce homologous virus strains 
incapable of replication within the host may offer the best option for safer poxvirus 
vaccines.
The ability of live virus vaccines, whether replication-competent (with a single dose) or 
deficient (with multiple doses) to induce cell-mediated immune responses and neutralising 
antibody against a broad range of viral antigens offers the best chance of inducing long-
term protective systemic immunity to poxvirus challenge. Further investigation using 
mouse models of poxvirus diseases may reveal vaccination strategies that are capable of 
conferring complete immunity from lethal poxvirus challenge through the induction of
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narrowly targeted, specific immune responses, such as CD4 - or CD8-restricted responses 
directed against single antigens or epitopes, or neutralising antibody directed against 
specific viral antigens. However, the restricted range o f immune responses induced by 
such vaccination strategies in inbred mouse models is artificial, and does not take into 
account the diverse responses and immunogenetics o f outbred populations.
8.2 Further development of Uriarra AM063Rg/7/£ws for use as a myxomatosis vaccine 
in Australia
From this study, the most promising candidate vaccine for use in Australia is the 
replication-deficient vaccine Uriarra AM063Rg/?fgws. This vaccine possesses the optimal 
combination o f acceptability and efficacy, and its replication-deficient nature eliminates the 
possibility o f transmission to wild animals. Long-term efficacy trials are currently under 
way to evaluate how long protection from challenge is maintained after two doses o f 
Uriarra AM063Rg/?/g«s. Further investigation and characterisation o f this vaccine should 
include:
• Testing o f higher doses o f Uriarra AMQ63Rg/7^g^ and alternative delivery routes. 
M VA is more immunogenic when delivered intramuscularly than intradermally (Munz 
et al., 1993), while NYVAC is more effective when delivered intradermally (Belyakov 
et a l., 2003; Tartaglia et a l., 1992). The high density o f professional antigen presenting 
cells in the dermis that can be directly infected by myxoma virus (Best et a l., 2000) may 
make this the optimal injection site, although it does lim it the injection volume, and 
therefore the viral dose, that can be injected compared to intramuscular injection. As 
these cells are central to the induction o f the immune response and the transport o f viral 
antigens to the regional lymph node (Banchereau and Steinman, 1998), the early
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infection o f these cells may explain the efficacy o f the replication-deficient vaccine 
despite overall lower levels o f viral antigen synthesis.
• Effects o f maternally transferred antibody on vaccine efficacy. Maternally transferred 
antibody can offer protection from lethal myxoma virus challenge to a small proportion 
o f young rabbits (Fenner and Marshall, 1954), and is likely to interfere with the efficacy 
o f a highly attenuated vaccine virus infection, preventing the induction o f full protective 
immunity. Anti-myxoma virus antibody could not be detected by ELISA in young wild 
rabbits born to immune does by 6 weeks after birth (Kerr, 1997) or by PRNA and 
complement fixation assay at 7 weeks after birth (Fenner and Marshall, 1954; Fenner 
and Ratcliffe, 1965). This suggests that 8 weeks o f age may be the ideal time to 
vaccinate young rabbits born to immune does with Uriarra AM063Rgptgus, but w ill 
require direct testing.
• Detailed histological analysis o f rabbit skin fo llow ing Uriarra AMQ63Rg/7/g^5 
inoculation and after SLS challenge. This may reveal important information regarding 
the events that result in induction o f immunity follow ing vaccination with the 
replication-deficient virus, and the early events involved in protective immunity upon 
challenge. Immunohistochemical analysis can be used to identify specific cell types 
(CD8 and CD4 T cells, B cells and macrophages) in the skin during vaccination and 
challenge, and answer questions regarding the specific cell types in the lesion.
8.3 Final Summary
The myxoma virus/European rabbit model has provided a means o f investigating the
efficacy o f various novel vaccination strategies against a lethal, naturally transmitted
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poxvirus in the species at risk. The results presented here suggest that replication-deficient 
poxvirus vaccines offer the most promising, highly protective, extremely safe and non- 
transmissible alternative to currently available poxvirus vaccines. Uriarra AM063Rg/?/gws 
is an excellent candidate vaccine for further development for use in protecting domestic 
rabbits in Australia from myxomatosis.
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Appendix - Media, buffers and solutions
A p p e n d i x  -  M e d i a , b u f f e r s  a n d  s o l u t i o n s
Bacterial Growth Media
Luria-Bertcmi (LB) Broth
Tryptone 
Yeast Extract 
NaCl
10g
5 g
10g
Dissolve in 1 L of MQ EEO and autoclave.
LB Agar
As for LB broth, adding 15 g/L of agar before autoclaving.
Ampicillin
Add filter-sterilised ampicillin-sodium (100 g/L) to cooled broth or agar to a final 
concentration of 100 pg/mL.
Kanamycin
Add filter-sterilised kanamycin (30 g/L) to cooled broth or agar to a final 
concentration of 30 pg/mL
IPTG / X-Gal Plates
Add 20 pL each of X-Gal and IPTG solutions (20 mg/mL each) and spread onto the 
plate.
Piasmid Preparation
1 OX STE Buffer
1 M NaCl
100 mM Tris.HCl pH 8.0 
10 mM EDTA pH 8.0
Solution I
50 mM glucose
25 mM Tris.HCl pH 8.0
10 mM EDTA pH 8.0
Sterilised by autoclaving. Stored at 4°C
Solution II
0.2 M NaOH 
1% SDS
freshly prepared from sterile stock solutions (10% SDS, 3 M NaOH) before use.
Solution III
5 M CH3COOK 
Glacial acetic acid 
Water
60 mL
11.5 mL
28.5 mL
Prepared from sterile stock solutions and stored at 4°C
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TE Buffer
1 M Tris.HCl pH 8.0 200 pL
0.5 M EDTA pH 8.0 1 mL
Make up to 100 mL with MilliQ water and autoclave
Agarose Gel Electrophoresis
20X TAE Buffer
Tris Base 96.9 g
EDTA 5.86 g
Dissolve in 800 mL of MilliQ water. Adjust pH to 8.0 with glacial acetic acid and 
make up to a final volume of 1 L with water.
Agarose Gel Loading Buffer
Glycerol 1.2 mL
10 pg/mL Bromophenol blue 2.8 mL
MilliQ water 1 mL
RNA Gels and Northern Hybridisation
DEPC-Treated Water 
2 L water
2 mL DEPC (Sigma)
Mix and leave at room temperature for 30 minutes. Autoclave.
1 OX RNA Gel Buffer
200 mM triethanolamine 
50 mM EDTA 
Adjust pH to 7.4.
Deionised formamide
500 mL formamide (Sigma)
50 g Amberlite MBI Resin
Mix for 20 minutes, then filter to remove resin.
RNA Sample Buffer
1 mL deionised formamide 
200 pL 10X RNA Gel Buffer 
300 pL 37% formaldehyde
RNA Gel Electrophoresis Buffer
50 mL 10X RNA Gel Buffer 
80 mL 37% formaldehyde 
370 mL DEPC-treated water
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30XSSC
4.5 M Na3-citrate 
450 mM NaCl
Adjust pH to 7.0. Add 1 mL of DEPC per litre of solution, mix and leave at room 
temperature for 30 minutes. Autoclave.
High-SDS Hybridisation Solution
De-ionised Formamide 25 mL
30X SSC 8.3 mL
1 M Sodium Phosphate (pH 7.0) 2.5 mL
SDS 3.5 g
10X Blocking Solution (Roche) 10 mL
10% N-laurylsarcosine in H2O 
Heat to 65°C until clear.
500 pL
2X Wash Solution 
2X SSC 
0.1% SDS
0.5X Wash Solution 
0.5X SSC 
0.1% SDS
0.2X Wash Solution 
0.2X SSC 
0.1X SDS
Maleic Acid Buffer
0.1 M maleic acid 
0.15 M NaCl 
Adjust pH to 7.5
Antibody Wash Buffer
Maleic Acid Buffer plus 0.3% Tween 20
Antibody Blocking/Hybridisation Buffer 
9 parts Maleic Acid Buffer 
1 part 10X Blocking Solution (Roche)
SDS-PAGE and Western Blotting
4XSDS-PAGE Stacking Gel Buffer 
0.5 M Tris.HCl (pH 6.8)
0.4 % SDS
4XSDS-PAGE Resolving Gel Buffer 
1.5 M Tris.HCl (pH 8.8)
0.4 % SDS
Page 209
Appendix - Media, buffers and solutions
SDS-PAGE Running Buffer
Tris Base 1.45 g
Glycine 7.2 g
SDS 0.5 g
Dissolve in 500 inL of MQ H20 . Do not adjust pH. 
2XSDS-PAGE Gel Loading Buffer
0.5 M Tris.HCl pH 6.8 1 mL
Glycerol 0.8 mL
10% SDS 1.6 mL
2.5% Bromophenol blue 130 |iL
MilliQ H20 3.7 mL
For reducing conditions add:
1 M DTT 800 pL
Coomassie Blue Staining Solution 
250 mL methanol 
50 mL glacial acetic acid 
250 mL MilliQ Water 
1 g Coomassie Blue powder
Destaining Solution
300 mL ethanol
125 mL glacial acetic acid
875 mL MilliQ water
Fixative-1 (Silver Stain)
40% methanol 
10% glacial acetic acid 
50% MilliQ water
Fixative-2 (Silver Stain)
40% methanol 
5% glacial acetic acid 
55% MilliQ water
Oxidiser Solution (Silver Stain)
10 mL Oxidiser Solution Concentrate (Bio-Rad) 
90 mL MilliQ water
Silver Reagent (Silver Stain)
10 mL Silver Reagent Concentrate (Bio-Rad)
90 mL MilliQ water
Developer Solution (Silver Stain)
32 g Developer Powder (Bio-Rad)
1 L MilliQ water
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Stop Solution (Silver Stain) 
5% glacial acetic acid 
95% MilliQ water
Electrotransfer Buffer 
25 mM Tris.HCl 
192 mM Glycine 
0.1% SDS 
15% methanol
TBS
NaCl 8 g
KC1 0.2 g
Tris Base 3 g
Dissolve in 800 mL of MQ H2 O and adjust pH to 8.0 with HC1. Make up to 1 L 
with MQ H2 O and autoclave.
Tween-TBS (TTBS)
TBS 1 L
Tween 20 1 mL
Blocking Buffer (Blotto)
TBS' 100 mL
Skim milk powder (Diploma) 10 g
Antibody Buffer 
TBS 
TTBS
Skim milk powder
100 mL 
100 mL
2 g
Recombinant Protein Purification (TALON IMAC Resin)
Extraction/Wash Buffer
50 mM Sodium Phosphate 
300 mM NaCl
Imidazole Wash Buffer
50 mM Sodium Phosphate 
300 mM NaCl 
15 mM Imidazole
Elution Buffer
50 mM Sodium Phosphate 
300 mM NaCl 
150 mM Imidazole
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Mammalian Cell Tissue Culture
Mouse Tonicity Salts
NaCl ’ 11.7 g
Na-Pyruvate 2.2 g
Monothiolglycerol 124 pL
Make up to 200 mL with MilliQ water and filter sterilise. Store at -20°C.
RPMI-1640 (No Additives)
10.4 g RPMI-1640 powder (Sigma)
2.2 g NaHC03
Dissolve in 1000 mL of MilliQ water and filter sterilise. Store at 4°C. If not used 
within 2 weeks, supplement with 5 mL of 200 mM L-glutamine.
RPMI( Complete)
RPMI-1640 (No Additives) 500 mL
Foetal Calf Serum (FCS) 50 mL
Penicillin (60 mg/mL) / Streptomycin (100 mg/mL) 500 pL
Amphotericin B (250 pg/mL) 1 mL
ß-mercaptoethanol (0.175%) 1 mL
RPMI (for growth ofHT-2 Cells)
RPMI(Complete) 550 mL
Mouse Tonicity Salts 5 mL
Mouse IL-2 (produced in Hi5 cells) 500 pL
Minimal Essential Medium (MEM FA ')
9.5 g Minimal Essential Medium powder (Gibco-lnvitrogen)
2.2 g NaHC03
Dissolve in 1000 mL of MilliQ water, and filter sterilise. Store at 4°C. If not used 
within 2 weeks, supplement with 5 mL of 200mM L-glutamine.
MEM(F A +)
To 500mL of MEM(F'A'), add:
500 pL Penicillin (60 mg/mL) / Streptomycin (100 mg/mL)
1 mL amphotericin B (250 pg/mL)
MEM(Complete)
To 500 mL of MEM(F'A+), add:
50 mL of Foetal Calf Serum
MEM(Selective)
To 10 mL of MEM(F'A+), add:
Mycophenolic acid in ethanol (10 mg/mL) 10 pL
Xanthine in 0.1 M NaOH (10 mg/mL) 250 pL
lOOx HAT supplement in Milli Q water 100 pL
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Trypsin Diluent
NaCl 8 g
KC1 0.4 g
Na2HP04.12H20  0.15 g
KH2P04 0.06 g
K2EDTA 0.109 g
NaHC03 0.5 g
Dissolve in 1 L of MilliQ water and adjust pH to 7.2. Autoclave.
ACK Shocking Buffer
NH4C1 8.29 g
K.HCO3 1 g
Na2EDTA 37.2 mg
Dissolve in 1 L of MilliQ water and adjust pH to 7.3. Autoclave.
Phosphate Buffered Saline (PBS)
NaCl 8 g
KH2P04 0.24 g
Na2HP04 1.44 g
KC1 0.2 g
Make up to 1 L with water and sterilise by autoclaving.
Methanol: A cetone
50 mL methanol 
50 mL acetone
ELISA
Carbonate Buffer
Na2C 03 1.59 g
NaHCC)3 2.93 g
Dissolve in 1 L MilliQ water and store at 4°C.
ELISA Blocking Buffer 
PBS with:
5% skim milk powder 
0.05% Tween 20
Tween-PBS
PBS 1 L
Tween 20 5 mL
ELISA Antibody Binding Buffer 
100 mL Tween-PBS 
lg skim milk powder
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Citrate Phosphate Buffer
1 M citric acid (pH4.0) 3.07 mL
1 M Na2H P04 (pH 4.0) 3.85 mL
Make up to 50 mL with MilliQ water.
HRP Substrate Solution
10 mL Citrate Phosphate Buffer 
1 ABTS substrate tablet (Sigma, Australia) 
20 pL 30% H20 2
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